<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Donepezil for dementia due to Alzheimer's disease - Birks, JS - 2018 | Cochrane Library</title> <meta content="Donepezil for dementia due to Alzheimer's disease - Birks, JS - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Donepezil for dementia due to Alzheimer's disease - Birks, JS - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001190.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Donepezil for dementia due to Alzheimer's disease" name="citation_title"/> <meta content="Jacqueline S Birks" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="jacqueline.birks@csm.ox.ac.uk" name="citation_author_email"/> <meta content="Richard J Harvey" name="citation_author"/> <meta content="Deakin University and Private Practice" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD001190.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/06/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Alzheimer Disease [*drug therapy]; Cholinesterase Inhibitors [*therapeutic use]; Cognition [drug effects]; Cognition Disorders [drug therapy]; Donepezil; Indans [*therapeutic use]; Nootropic Agents [*therapeutic use]; Piperidines [*therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001190.pub3&amp;doi=10.1002/14651858.CD001190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="jU9oKp1Y";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001190\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001190\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","hr","fr","ja","fa","de"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001190.pub3",title:"Donepezil for dementia due to Alzheimer\u0027s disease",firstPublishedDate:"Jun 18, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001190.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001190.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001190.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001190.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001190.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001190.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001190.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001190.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001190.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001190.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>36597 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001190.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-sec-0156"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-sec-0065"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-sec-0148"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/appendices#CD001190-sec-0161"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/table_n/CD001190StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/table_n/CD001190StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Donepezil for dementia due to Alzheimer's disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/information#CD001190-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Jacqueline S Birks</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001190.pub3/information#CD001190-cr-0003">Richard J Harvey</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/information/en#CD001190-sec-0180">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 June 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001190.pub3">https://doi.org/10.1002/14651858.CD001190.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001190-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001190-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001190-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001190-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001190-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001190-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001190-abs-0001" lang="en"> <section id="CD001190-sec-0001"> <h3 class="title" id="CD001190-sec-0001">Background</h3> <p>Alzheimer's disease is the most common cause of dementia in older people. One approach to symptomatic treatment of Alzheimer's disease is to enhance cholinergic neurotransmission in the brain by blocking the action of the enzyme responsible for the breakdown of the neurotransmitter acetylcholine. This can be done by a group of drugs known as cholinesterase inhibitors. Donepezil is a cholinesterase inhibitor. </p> <p>This review is an updated version of a review first published in 1998.</p> </section> <section id="CD001190-sec-0002"> <h3 class="title" id="CD001190-sec-0002">Objectives</h3> <p>To assess the clinical efficacy and safety of donepezil in people with mild, moderate or severe dementia due to Alzheimer's disease; to compare the efficacy and safety of different doses of donepezil; and to assess the effect of donepezil on healthcare resource use and costs. </p> </section> <section id="CD001190-sec-0003"> <h3 class="title" id="CD001190-sec-0003">Search methods</h3> <p>We searched Cochrane Dementia and Cognitive Improvement’s Specialized Register, MEDLINE, Embase, PsycINFO and a number of other sources on 20 May 2017 to ensure that the search was as comprehensive and up‐to‐date as possible. In addition, we contacted members of the Donepezil Study Group and Eisai Inc. </p> </section> <section id="CD001190-sec-0004"> <h3 class="title" id="CD001190-sec-0004">Selection criteria</h3> <p>We included all double‐blind, randomised controlled trials in which treatment with donepezil was administered to people with mild, moderate or severe dementia due to Alzheimer's disease for 12 weeks or more and its effects compared with those of placebo in a parallel group of patients, or where two different doses of donepezil were compared. </p> </section> <section id="CD001190-sec-0005"> <h3 class="title" id="CD001190-sec-0005">Data collection and analysis</h3> <p>One reviewer (JSB) extracted data on cognitive function, activities of daily living, behavioural symptoms, global clinical state, quality of life, adverse events, deaths and healthcare resource costs. Where appropriate and possible, we estimated pooled treatment effects. We used GRADE methods to assess the quality of the evidence for each outcome. </p> </section> <section id="CD001190-sec-0006"> <h3 class="title" id="CD001190-sec-0006">Main results</h3> <p>Thirty studies involving 8257 participants met the inclusion criteria of the review, of which 28 studies reported results in sufficient detail for the meta‐analyses. Most studies were of six months' duration or less. Only one small trial lasted 52 weeks. The studies tested mainly donepezil capsules at a dose of 5 mg/day or 10 mg/day. Two studies tested a slow‐release oral formulation that delivered 23 mg/day. Participants in 21 studies had mild to moderate disease, in five studies moderate to severe, and in four severe disease. Seventeen studies were industry funded or sponsored, four studies were funded independently of industry and for nine studies there was no information on source of funding. </p> <p>Our main analysis compared the safety and efficacy of donepezil 10 mg/day with placebo at 24 to 26 weeks of treatment. Thirteen studies contributed data from 3396 participants to this analysis. Eleven of these studies were multicentre studies. Seven studies recruited patients with mild to moderate Alzheimer's disease, two with moderate to severe, and four with severe Alzheimer's disease, with a mean age of about 75 years. Almost all evidence was of moderate quality, downgraded due to study limitations. </p> <p>After 26 weeks of treatment, donepezil compared with placebo was associated with better outcomes for cognitive function measured with the Alzheimer's Disease Assessment Scale‐Cognitive (ADAS‐Cog, range 0 to 70) (mean difference (MD) ‐2.67, 95% confidence interval (CI) ‐3.31 to ‐2.02, 1130 participants, 5 studies), the Mini‐Mental State Examination (MMSE) score (MD 1.05, 95% CI 0.73 to 1.37, 1757 participants, 7 studies) and the Severe Impairment Battery (SIB, range 0 to 100) (MD 5.92, 95% CI 4.53 to 7.31, 1348 participants, 5 studies). Donepezil was also associated with better function measured with the Alzheimer's Disease Cooperative Study activities of daily living score for severe Alzheimer's disease (ADCS‐ADL‐sev) (MD 1.03, 95% CI 0.21 to 1.85, 733 participants, 3 studies). A higher proportion of participants treated with donepezil experienced improvement on the clinician‐rated global impression of change scale (odds ratio (OR) 1.92, 95% CI 1.54 to 2.39, 1674 participants, 6 studies). There was no difference between donepezil and placebo for behavioural symptoms measured by the Neuropsychiatric Inventory (NPI) (MD ‐1.62, 95% CI ‐3.43 to 0.19, 1035 participants, 4 studies) or by the Behavioural Pathology in Alzheimer's Disease (BEHAVE‐AD) scale (MD 0.4, 95% CI ‐1.28 to 2.08, 194 participants, 1 study). There was also no difference between donepezil and placebo for Quality of Life (QoL) (MD ‐2.79, 95% CI ‐8.15 to 2.56, 815 participants, 2 studies). </p> <p>Participants receiving donepezil were more likely to withdraw from the studies before the end of treatment (24% versus 20%, OR 1.25, 95% CI 1.05 to 1.50, 2846 participants, 12 studies) or to experience an adverse event during the studies (72% vs 65%, OR 1.59, 95% 1.31 to 1.95, 2500 participants, 10 studies). </p> <p>There was no evidence of a difference between donepezil and placebo for patient total healthcare resource utilisation. </p> <p>Three studies compared donepezil 10 mg/day to donepezil 5 mg/day over 26 weeks. The 5 mg dose was associated with slightly worse cognitive function on the ADAS‐Cog, but not on the MMSE or SIB, with slightly better QoL and with fewer adverse events and withdrawals from treatment. Two studies compared donepezil 10 mg/day to donepezil 23 mg/day. There were no differences on efficacy outcomes, but fewer participants on 10 mg/day experienced adverse events or withdrew from treatment. </p> </section> <section id="CD001190-sec-0007"> <h3 class="title" id="CD001190-sec-0007">Authors' conclusions</h3> <p>There is moderate‐quality evidence that people with mild, moderate or severe dementia due to Alzheimer's disease treated for periods of 12 or 24 weeks with donepezil experience small benefits in cognitive function, activities of daily living and clinician‐rated global clinical state. There is some evidence that use of donepezil is neither more nor less expensive compared with placebo when assessing total healthcare resource costs. Benefits on 23 mg/day were no greater than on 10 mg/day, and benefits on the 10 mg/day dose were marginally larger than on the 5 mg/day dose, but the rates of withdrawal and of adverse events before end of treatment were higher the higher the dose. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001190-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001190-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001190-abs-0015">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001190-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001190-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001190-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001190-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD001190-abs-0012">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001190-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001190-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001190-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001190-abs-0005" lang="en"> <h3>Donepezil for people with dementia due to Alzheimer's disease</h3> <p><b>Review question</b> </p> <p>What effects (benefits or harms) does donepezil have on people with dementia due to Alzheimer's disease? </p> <p><b>Background</b> </p> <p>Alzheimer's disease is the most common cause of dementia. As the disease progresses, people lose the ability to remember, communicate, think clearly and perform the activities of daily living. Their behaviour may also change. In severe Alzheimer's disease people lose the ability to care for themselves. </p> <p>The most commonly used treatment for Alzheimer's disease are medicines known as acetylcholinesterase inhibitors. Donepezil is one of these medicines. It is taken as a pill once a day. </p> <p>In Alzheimer's disease, one of the changes in the brain is a reduced number of nerve cells called cholinergic neurones. These are nerve cells that signal to other cells using a chemical called acetylcholine. Acetylcholinesterase inhibitors, such as donepezil, work by preventing acetylcholine from being broken down. This may improve the symptoms of dementia. However, acetylcholine is also found elsewhere in the body and so drugs of this type may have unwanted effects. </p> <p><b>Review methods</b> </p> <p>In this review we examined evidence about benefits and harms from studies that compared donepezil, taken for at least 12 weeks, to placebo (a dummy pill), or that compared different doses of donepezil. The studies had to be double‐blind and randomised, that is, the decision whether people taking part got donepezil or placebo had to be made randomly and neither they nor the researchers should have known which treatment they were getting while the trial was going on. This was to make the comparison as unbiased, or fair, as possible. We searched for studies up to May 2017. We assessed the quality of all the studies we included. When it was sensible to do so, we analysed the results of studies together to get an overall result. </p> <p><b>Key results</b> </p> <p>We included 30 studies with 8257 participants. Most of the people in the studies had mild or moderate dementia due to Alzheimer's disease, but in nine studies they had moderate or severe dementia. Almost all of the studies lasted six months or less. The majority of the studies were known to have been funded by the manufacturer of donepezil. </p> <p>We found that people with Alzheimer's disease who took 10 mg of donepezil a day for six months did slightly better than people taking placebo, on scales measuring their cognitive function (e.g. thinking and remembering), how well they could manage their daily activities, and the overall impression of a trained researcher. We did not find any effect on behaviour or quality of life. </p> <p>People taking donepezil were more likely than those taking placebo to report side effects and to drop out of the studies. Most side effects were described as mild. Nausea, vomiting and diarrhoea were most common. </p> <p>Comparing 5 mg of donepezil a day with 10 mg/day, people on 5 mg had fewer side effects, but did slightly less well on cognitive function tests. A higher dose (23 mg/day) offered no advantages and was associated with more side effects. </p> <p>There is some evidence that use of donepezil is neither more nor less expensive than placebo when total health care costs are taken into account. </p> <p><b>Quality of the evidence</b> </p> <p>In general, we thought that the quality of the evidence was moderate. The main factor reducing our confidence was concern that the results of some studies might have been biased by the way they were done. We cannot be sure that the results apply to treatment longer than six months. </p> <p><b>Conclusions</b> </p> <p>After six months of treatment, there are benefits of donepezil that are large enough to measure in studies. It is associated with side effects that are mainly mild, but that may cause people to stop treatment. </p> <p>Being able to stabilise cognitive performance or ability to maintain activities of daily living may be important clinically. In terms of total healthcare costs the use of donepezil appears cost neutral. However, there does not appear to be an effect on quality of life. More data are still required from longer‐term clinical studies examining measures of disease progression or time to needing full time care. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001190-sec-0156" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001190-sec-0156">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001190-sec-0224">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001190-sec-0156"></div> <h3 class="title" id="CD001190-sec-0157">Implications for practice</h3> <section id="CD001190-sec-0157"> <p>In people with mild, moderate or severe dementia due to Alzheimer's disease treated for periods of 12, 24 and 52 weeks, donepezil at a dose of 10 mg/day produced improvements in cognitive function, measuring ‐2.9 points as a weighted mean (95% confidence interval (CI) ‐3.6 to ‐2.2), in the midrange of the 70‐point ADAS‐Cog Scale (moderate‐quality evidence). Study clinicians, blind to other measures, rated global clinical state more positively in treated participants. Benefits of treatment were also seen on measures of activities of daily living and behaviour. Benefits on the 10 mg/day dose were only marginally larger than on the 5 mg/day dose. </p> </section> <h3 class="title" id="CD001190-sec-0158">Implications for research</h3> <section id="CD001190-sec-0158"> <p>Important emerging issues are the economic effectiveness of the cholinesterase inhibitors. It would be helpful to see long‐term randomised studies of treatments that examine real‐world economic outcomes, such as cost of care, effects on markers of biological disease progression and the time to and need for institutionalisation. Unfortunately, given the proven clinical efficacy of donepezil it is hard to see how long‐term, placebo‐controlled randomised studies with economic primary outcomes could now be ethically undertaken. </p> <p>Further important issues are duration of treatment, the severity of dementia and the effects of withdrawal at the end of the treatment period. As this review has evolved, the evidence of effectiveness of treatment has now been extended to 52 weeks, but effectiveness for some patients may not end at this point. Randomised studies of treatment involving the use of placebos over many years are unlikely to be either a practical or ethical option. Other robust trial designs will be needed to help establish the maximum duration of treatment, and the indicators that treatment is no longer beneficial. There is no evidence to suggest that the effects of donepezil are any less for those with severe dementia. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001190-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001190-sec-0036"></div> <div class="table" id="CD001190-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Donepezil 10 mg/day compared with placebo for dementia due to Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Donepezil 10 mg/day compared with placebo for dementia due to Alzheimer's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with Alzheimer's disease </p> <p><b>Settings:</b> worldwide </p> <p><b>Intervention:</b> donepezil 10 mg/day for 24 to 26 weeks </p> <p><b>Comparison:</b> placebo for 24 to 26 weeks </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Donepezil 10 mg/day</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 26 weeks using ADAS‐Cog)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil group was 2.67 lower (3.31 to 2.02 lower) than in the placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1130<br/> (5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADAS‐Cog score has a maximum of 70 points, the lower score in the donepezil group indicates greater improvement </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 26 weeks using MMSE)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil group was 1.05 higher (0.73 to 1.37 higher) than in the placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1757<br/> (7 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE has a maximum score of 30 points, a lower score indicates greater impairment. Treatment effect was in favour of donepezil. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Activities of daily living</b> (change from baseline at 26 weeks measured using the ADCS)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention group was<br/> 1.03 higher (0.21 to 1.85 higher) than in the placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>733<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher score indicates greater improvement.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinician‐rated global impression tests</b> </p> <p>(improved compared with baseline, measured using CIBIC‐plus at 24‐26 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>331 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>487 per 1000 (432 to 542)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.92</b> (1.54 to 2.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1674<br/> (6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behavioural symptoms</b> </p> <p>(change from baseline at 26 weeks measured using the NPI)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean score in the intervention group was 1.62 lower ( 3.43 lower to 0.19 higher) than in the placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1035</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A lower score indicates greater improvement. There was no significant difference between the 2 groups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment</b> </p> <p>(as measured by withdrawals from trial before end of treatment at 26 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>248 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>291 per 1000 (256 to 331)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.25</b> (1.05 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2846</p> <p>(12 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals were significantly more frequent in the donepezil group compared with placebo group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incidence of adverse events</b> </p> <p>(at least one adverse event by 26 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>780 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>849 per 1000 (822 to 874)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.59</b> (1.31 to 1.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2500 (10 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were significantly more frequent in the donepezil group compared with placebo group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life of participants</b> </p> <p>(change from baseline at 26 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean score was 2.79 lower (8.15 lower to 2.56 higher) than in the placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>815 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A higher svcore indicates greater improvement.There was no significant difference between the 2 groups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The <b>assumed risk is the weighted average across studies</b> . The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ADAS‐Cog</b> : Alzheimer's Disease Assessment Scale‐Cognitive; <b>ADCS</b> : Alzheimer's Disease Cooperative Study; <b>CI:</b> confidence interval; <b>CIBIC</b> : Clinician's Interview‐Based Impression of Change; <b>MMSE</b> : Mini‐Mental State Examination; <b>NPI</b> : Neuropsychiatric Inventory; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>All statistics are based on the analyses of the intention to treat last observation carried forward (ITT‐LOCF) population. Although using the ITT population in the analyses for studies in degenerative conditions can be criticised as substitution of the LOCF when a patients is lost before end point may enhance the outcome, in this review the results of the analyses of the population who completed the study were similar to the ITT results and did not alter our conclusions.<br/> <sup>2</sup>Downgraded one level due to the risk of bias due to lack of information on allocation concealment and on the blinding of outcome assessment. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001190-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Donepezil 23 mg/day compared with donepezil 10 mg/day for dementia due to Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Donepezil 23 mg/day compared with donepezil 10 mg/day for dementia due to Alzheimer's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with Alzheimer's disease </p> <p><b>Settings:</b> worldwide </p> <p><b>Intervention:</b> donepezil 23 mg/day for 24 weeks </p> <p><b>Comparison:</b> donepezil 10 mg/day for 24 weeks </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Donepezil 10 mg/day</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Donepezil 23 mg/day</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 24 weeks using SIB)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil 23 mg/day group was 1.05 higher (0.15 lower to 2.25 higher) than in the donepezil 10 mg/day group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1704</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SIB has a maximum score of 100 points, a lower score indicates greater impairment.There was no significant difference between the 2 groups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 24 weeks using MMSE)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil 23 mg/day group was 0.20 higher (0.33 lower to 0.73 higher) than in the donepezil 10 mg/day group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1370</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE has a maximum score of 30 points, a lower score indicates greater impairment. There was no significant difference between the 2 groups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Activities of daily living</b> </p> <p>(change from baseline at 24 weeks using the ADCS‐ADL‐sev)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil 23 mg/day group was 0 higher (1.18 lower to 1.18 higher) than in the donepezil 10 mg/day group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1396</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between the 2 groups</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinician‐rated global impression test</b> </p> <p>(improved compared with baseline assessed using CIBIC‐plus at 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>212 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>210 per 1000</b><br/> (173 to 253) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.99</b> (0.78 to 1.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1704<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between the 2 groups</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment</b> </p> <p>(as measured by withdrawals from trial before end of treatment at 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>172 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b><br/> (248 to 348) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.02</b> (1.59 to 2.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1818<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of adverse events</b> </p> <p>(at least one adverse event by 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>624 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>732 per 1000</b><br/> (690 to 771) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.65</b> (1.34 to 2.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1785<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ADCS‐ADL‐sev</b> : Alzheimer's Disease Cooperative Study‐Activities of Daily Living Scale (severe version); <b>CI:</b> confidence interval; <b>CIBIC</b> : Clinician's Interview‐Based Impression of Change; <b>MMSE</b> : Mini‐Mental State Examination; <b>OR:</b> odds ratio; <b>SIB</b>: Severe Impairment Battery </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>All statistics are based on the analyses of the intention to treat last observation carried forward (ITT‐LOCF) population. Although using the ITT population in the analyses for studies in degenerative conditions can be criticised as substitution of the LOCF when a patients is lost before end point may enhance the outcome, in this review the results of the analyses of the population who completed the study were similar to the ITT results and did not alter our conclusions.<br/> <sup>2</sup>Downgraded one level due to the risk of bias due to lack of information on the blinding of outcome assessment. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001190-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Donepezil 10 mg/day compared with donepezil 5 mg/day for dementia due to Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Donepezil 10 mg/day compared with donepezil 5 mg/day for dementia due to Alzheimer's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with Alzheimer's disease </p> <p><b>Settings</b>: worldwide </p> <p><b>Intervention</b>: donepezil 10 mg/day </p> <p><b>Comparison:</b> *donepezil 5 mg/day </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Donepezil 5 mg/day</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Donepezil 10 mg/day</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 24 weeks using ADAS‐Cog)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil 10 mg/day group was 1.05 lower (1.80 lower to 0.30 lower) than in the donepezil 5 mg/day group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>818<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADAS‐Cog score has a maximum of 70 points, the lower score in the donepezil 10 mg/day group indicates greater improvement </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 24 weeks using MMSE)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil 10 mg/day group was 0.15 higher (‐0.55 to 0.85 higher) than in the donepezil 5 mg/day group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE has a maximum score of 30 points, a lower score indicates greater impairment.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinician‐rated global impression test</b> </p> <p>(improved compared with baseline assessed using CIBIC‐plus at 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>246 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>291 per 1000</b><br/> (235 to 353) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.26</b> (0.94 to 1.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>981 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment</b> </p> <p>(as measured by withdrawals from trial before end of treatment at 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>183 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>272 per 1000</b><br/> (217 to 333) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.67</b> (1.24 to 2.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1052</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of adverse events</b> </p> <p>(at least one adverse event by 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>785per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>851 per 1000</b><br/> (796 to 893) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.56</b> (1.07 to 2.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>741 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ADAS‐Cog</b> : Alzheimer's Disease Assessment Scale‐Cognitive; <b>CI:</b> confidence interval; <b>CIBIC</b> : Clinician's Interview‐Based Impression of Change; <b>MMSE</b> : Mini‐Mental State Examination; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>All statistics are based on the analyses of the intention to treat last observation carried forward (ITT‐LOCF) population. Although using the ITT population in the analyses for studies in degenerative conditions can be criticised as substitution of the LOCF when a patients is lost before end point may enhance the outcome, in this review the results of the analyses of the population who completed the study were similar to the ITT results and did not alter our conclusions.<br/> <sup>2</sup>Downgraded one level due to the risk of bias due to lack of information on the blinding of outcome assessment and of blinding of participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001190-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Donepezil 10 mg/day compared with placebo for people with severe dementia due to Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Donepezil 10 mg/day compared with placebo for people with severe dementia due to Alzheimer's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with severe Alzheimer's disease </p> <p><b>Settings</b>: worldwide </p> <p><b>Intervention:</b> donepezil 10 mg/day for 24 weeks </p> <p><b>Comparison</b>: placebo for 24 weeks </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Donepezil 10 mg/day</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 26 weeks using MMSE)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil group was 0.97 higher (0.56 higher to 1.38 higher) than in the placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1102<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE has a maximum score of 30 points, a lower score indicates greater impairment. Treatment effect was in favour of donepezil. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 24 weeks using SIB)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil 10 mg/day group was 5.92 higher (4.53 higher to 7.31 higher) than in the placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1348</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SIB has a maximum score of 100 points, a lower score indicates greater impairment.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinician‐rated global impression tests</b> </p> <p>(improved compared with baseline, measured using CIBIC‐Plus at 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>274 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>402 per 1000</b><br/> (331 to 478) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.78 (1.31 to 2.43)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>755 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Activities of daily living</b> </p> <p>(change from baseline at 24 weeks using the ADCS‐ADL‐sev)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil 10 mg/day group was 1.03 higher 0.21 higher to 1.85 higher) than in the placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>733<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher score indicates greater improvement.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment</b> </p> <p>(as measured by withdrawals from trial before end of treatment at 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>187 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>233 per 1000</b><br/> (190 to 282) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.32</b> (1.02 to 1.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1396</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals significantly more frequent in the donepezil group compared with placebo group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of adverse events</b> </p> <p>(at least one adverse event by 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>616 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>718 per 1000</b><br/> (664 to 767) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.59</b> (1.23 to 2.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1396</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events significantly more frequent in the donepezil group compared with placebo group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ADCS‐ADL‐sev</b> : Alzheimer's Disease Cooperative Study‐Activities of Daily Living Scale (severe version); <b>CI:</b> confidence interval; <b>CIBIC</b> : Clinician's Interview‐Based Impression of Change; <b>MMSE</b> : Mini‐Mental State Examination; <b>OR:</b> odds ratio; <b>SIB</b>: Severe Impairment Battery </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>All statistics are based on the analyses of the intention to treat last observation carried forward (ITT‐LOCF) population. Although using the ITT population in the analyses for studies in degenerative conditions can be criticised as substitution of the LOCF when a patients is lost before end point may enhance the outcome, in this review the results of the analyses of the population who completed the study were similar to the ITT results and did not alter our conclusions.<br/> <sup>2</sup> Downgraded one level due to the risk of bias due to lack of information on allocation concealment and on the blinding of outcome assessment. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001190-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001190-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001190-sec-0188">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD001190-sec-0037"></div> <section id="CD001190-sec-0038"> <h3 class="title" id="CD001190-sec-0038">Description of the condition</h3> <p>Dementia is a syndrome of acquired deficits in multiple domains of cognition severe enough to interfere with everyday life and not due to impaired consciousness or the effects of a systemic illness (<a href="./references#CD001190-bbs2-0118" title="ChertkowH , FeldmanHF , JacovaC , MassoudF . Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. Alzheimer's Research &amp; Therapy2013;5(Supplement 1):S1. ">Chertkow 2013</a>). Memory is usually the most severely affected domain initially. Progression is evident as increasing impairment of memory, developing gradually into a global impairment of cognition, including orientation, language, judgement, perceptual ability and praxis (the ability to carry out complex actions). These cognitive impairments are accompanied by progressive deterioration in ability to carry out activities of daily living, and often by the appearance of challenging behaviours and other psychiatric features. The clinical course is associated with growing disability and dependency on carers. A characteristic feature of the disease is a widely variable rate of progression in different patients (<a href="./references#CD001190-bbs2-0140" title="RitchieCW , RussTC , BanerjeeS , BarberB , BoadenA , FoxNC , HolmesC , IsaacsJD , LeroiI , LovestoneS , NortonM , O'BrienJ , PearsonJ , PerryR , PickettJ , WaldmanAD , WongWL , RossorMN , BurnsA . The Edinburgh Consensus: preparing for the advent of disease‐modifying therapies for Alzheimer's disease.. Alzheimers Research &amp; Therapy2017;9:85. ">Ritchie 2017</a>). </p> <p>Alzheimer's disease is the most common cause of dementia, and may be involved in as many as 80% of cases. It is a primary degenerative disease of the brain of unknown cause, which leads to dementia of insidious onset, most commonly in later life. The characteristic brain pathology includes progressive loss of neurons and the development in the brain of amyloid plaques and neurofibrillary tangles (<a href="./references#CD001190-bbs2-0142" title="RyanNS , RossorMN , FoxNC . Alzheimer's disease in the 100 years since Alzheimer's death.. Brain2015;138(Pt 12):3816‐21. ">Ryan 2015</a>). </p> <p>This review is an updated version of a review first published in 1998.</p> </section> <section id="CD001190-sec-0039"> <h3 class="title" id="CD001190-sec-0039">Description of the intervention</h3> <p>Donepezil (Aricept, E2020) is a second‐generation cholinesterase inhibitor (<a href="./references#CD001190-bbs2-0135" title="LeeJH , JeongSK , KimBC , ParkKW , DashA . Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance.. Acta Neurologica Scandinavica2015;131(5):259‐67. ">Lee 2015</a>). The drug was developed by Eisai and received approval from the United States Food and Drug Administration (FDA) in 1996, and from the European Medicines Agency (EMA) in 1997. In most countries it is approved for the treatment of mild or moderate dementia due to Alzheimer's disease. However, in several countries, including the USA, Canada and Japan, it is also approved for use in severe dementia due to Alzheimer's disease. Donepezil is available in tablet form. Liquid and transdermal formulations have also been developed, but are not marketed in all countries. The recommended oral dose is 5 mg once a day initially, increasing to 10 mg once a day after at least one month of treatment. In 2010 the FDA approved a 23 mg, once‐a‐day tablet of donepezil. Two other cholinesterase inhibitors (rivastigmine and galantamine) are also available. </p> </section> <section id="CD001190-sec-0040"> <h3 class="title" id="CD001190-sec-0040">How the intervention might work</h3> <p>Acetylcholine is an important neurotransmitter associated with memory, and abnormalities in cholinergic neurons (including cell loss) are prominent among the pathological changes in the brains of people with Alzheimer's disease. One approach to lessening the impact of these abnormalities is to inhibit the breakdown of acetylcholine in synapses, thereby enhancing cholinergic neurotransmission. Donepezil does this by reversibly inhibiting the enzyme acetylcholinesterase (<a href="./references#CD001190-bbs2-0135" title="LeeJH , JeongSK , KimBC , ParkKW , DashA . Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance.. Acta Neurologica Scandinavica2015;131(5):259‐67. ">Lee 2015</a>). </p> </section> <section id="CD001190-sec-0041"> <h3 class="title" id="CD001190-sec-0041">Why it is important to do this review</h3> <p>Large multicentre studies have been completed. Donepezil has received approval for use in more than 90 countries, including all the member states of the European Union and in the USA. It is important to assess the safety and efficacy of this intervention in a systematic review (<a href="./references#CD001190-bbs2-0142" title="RyanNS , RossorMN , FoxNC . Alzheimer's disease in the 100 years since Alzheimer's death.. Brain2015;138(Pt 12):3816‐21. ">Ryan 2015</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001190-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001190-sec-0042">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001190-sec-0193">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001190-sec-0042"></div> <p>To assess the clinical efficacy and safety of donepezil in people with mild, moderate or severe dementia due to Alzheimer's disease; to compare the efficacy and safety of different doses of donepezil; and to assess the effect of donepezil on healthcare resource use and costs. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001190-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001190-sec-0043">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001190-sec-0194">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001190-sec-0043"></div> <section id="CD001190-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001190-sec-0045"> <h4 class="title">Types of studies</h4> <p>We included all unconfounded, randomised, double‐blind studies of people with dementia due to Alzheimer's disease in which treatment with donepezil was administered for 12 weeks or longer and compared with a placebo group, or in which two doses of donepezil were compared. We excluded studies with a withdrawal design, (i.e. studies in which participants already stable on donepezil treatment were randomised to placebo or continuing donepezil treatment), studies in which the allocation to treatment or control was not randomised, or in which treatment allocation was not concealed. This is because prior knowledge of treatment allocation may lead to biased participant allocation (<a href="./references#CD001190-bbs2-0144" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273:408‐12. ">Schulz 1995</a>). </p> </section> <section id="CD001190-sec-0046"> <h4 class="title">Types of participants</h4> <p>The participants in studies to be included were diagnosed with probable Alzheimer's disease according to internationally accepted criteria such as <a href="./references#CD001190-bbs2-0133" title="World Health Organization. The ICD‐10 classification of mental and behavioural disorders: clinical description and diagnostic guidelines. Geneva: World Health Organisation, Division of Mental Health, 1992. ">ICD‐10</a>, the Diagnostic and Statistical Manual of Mental Disorders (DSM IV) (<a href="./references#CD001190-bbs2-0114" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington DC: APA, 1987:American Psychiatric Association. ">APA 1987</a>) and Communicative Disorders and Stroke ‐ Alzheimer's Disease and Related Disorders Association (NINCDS‐ADRDA) (<a href="./references#CD001190-bbs2-0136" title="McKhannG , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology1984;4:939‐44. ">McKhann 1984</a>). </p> </section> <section id="CD001190-sec-0047"> <h4 class="title">Types of interventions</h4> <p>Donepezil of any formulation and dose given for at least 12 weeks, compared with placebo or with an alternative formulation or dose of donepezil. </p> </section> <section id="CD001190-sec-0048"> <h4 class="title">Types of outcome measures</h4> <p>The primary outcomes of interest were as follows.</p> <p> <ul id="CD001190-list-0001"> <li> <p>Cognitive function (as measured by psychometric tests)</p> </li> <li> <p>Activities of daily living</p> </li> <li> <p>Behavioural disturbance</p> </li> <li> <p>Clinical global impression</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Effect on carer</p> </li> <li> <p>Dependency (such as institutionalisation)</p> </li> <li> <p>Death</p> </li> <li> <p>Acceptability of treatment as measured by withdrawal from trial</p> </li> <li> <p>Safety as measured by the incidence of adverse effects (including side effects) leading to withdrawal </p> </li> <li> <p>Safety as measured by the overall incidence of adverse effects</p> </li> <li> <p>Direct and indirect costs</p> </li> </ul> </p> <p>We noted physiological outcomes, such as plasma levels, changes on functional imaging or electroencephalogram (EEG) changes but did not assess them, as they are not primarily measures of efficacy. </p> </section> </section> <section id="CD001190-sec-0049"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001190-sec-0050"> <h4 class="title">Electronic searches</h4> <p>We identified the studies from a search of <a href="http://www.medicine.ox.ac.uk/alois" target="_blank">ALOIS</a> ‐ Cochrane Dementia and Cognitive Improvement's Specialized Register on 20 May 2017 using the search terms: donepezil, aricept, "E 2020", E‐2020 and E2020. </p> <p>ALOIS is maintained by Cochrane Dementia and Cognitive Improvement's Information Specialist, and contains studies in the areas of dementia prevention, dementia treatment and cognitive enhancement in healthy people. The studies in the Specialized Register are identified from: </p> <p> <ul id="CD001190-list-0002"> <li> <p>monthly searches of a number of major healthcare databases: MEDLINE, Embase, Cinahl, Psycinfo and Lilacs; </p> </li> <li> <p>monthly searches of a number of trials registers: the World Health Organization (WHO) portal (which covers ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register; the German Clinical Trials Register; the Iranian Registry of Clinical Trials and the Netherlands National Trials Register, plus others); </p> </li> <li> <p>quarterly searches of The Cochrane Library’s Central Register of Controlled Trials (CENTRAL); and </p> </li> <li> <p>six‐monthly searches of the grey literature source: ISI Web of Science Core Collection</p> </li> </ul> </p> <p>To view a list of all sources searched for ALOIS see <a href="http://www.medicine.ox.ac.uk/alois/content/about-alois" target="_blank">About ALOIS</a> on the ALOIS website. </p> <p>Details of the search strategies used for the retrieval of reports of studies from the healthcare databases, CENTRAL can be viewed in the ‘Methods used in reviews’ section within the editorial information about the <a href="http://mrw.interscience.wiley.com/cochrane/clabout/articles/DEMENTIA/frame.html" target="_blank">Dementia and Cognitive Improvement Group</a>. </p> <p>The Information Specialist performed additional searches in many of the sources listed above to ensure that the search for the review was as up‐to‐date and as comprehensive as possible. For a full list of sources searched and view the search strategies used for each source see <a href="./appendices#CD001190-sec-0162">Appendix 1</a>. </p> </section> <section id="CD001190-sec-0051"> <h4 class="title">Searching other resources</h4> <p>We performed an additional Internet search using Copernic 2000 on 21 and 22 June 2005 using trial names and numbers. No new studies were found other than the ones that had already been found in the update search of the CDCIG Register on 12 June 2005; we did find additional references to existing studies. We searched Eisai/Pfizer, FDA, EMEA and NICE websites. </p> </section> </section> <section id="CD001190-sec-0052"> <h3 class="title" id="CD001190-sec-0052">Data collection and analysis</h3> <section id="CD001190-sec-0053"> <h4 class="title">Selection of studies</h4> <p>We discarded irrelevant publications, based on the title of the publication and the abstract. In the presence of any suggestion that an article could be relevant, we retrieved it for further assessment. </p> <p>We independently reviewed the studies for inclusion from the culled citation list.</p> </section> <section id="CD001190-sec-0054"> <h4 class="title">Data extraction and management</h4> <p>One review author (JSB) extracted data from the published reports. The summary statistics required for each trial and each outcome for continuous data were the mean change from baseline, the standard deviation of the mean change, and the number of participants for each treatment group at each assessment. We defined the baseline assessment as the latest available assessment prior to randomisation, but no longer than two months before. Where changes from baseline were not reported, we extracted the mean, standard deviation and the number of participants in each treatment group at each time point if available, and we calculated the required summary statistics. In this case, we assumed a zero correlation between the measurements at baseline and assessment time. This method overestimates the standard deviation of the change from baseline, but this conservative approach is considered to be preferable in a meta‐analysis. The outcomes measured in studies of dementia and cognitive impairment often arise from ordinal rating scales. Where the rating scales used in the studies had a reasonably large number of categories (more than 10) we treated the data as continuous outcomes arising from a normal distribution. For binary data, we sought the number in each treatment group and the numbers experiencing the outcome of interest. </p> <p>We sought data on every person assessed for each outcome measure. The reported analyses were performed on an intention‐to‐treat (ITT) basis, which included all participants who were randomised to treatment, assessed at baseline, received at least one dose of the study drug, and had at least one post‐baseline assessment. The ITT population consisted of those who provided complete data at endpoint regardless of compliance (the observed cases, OC) plus the LOCF population, (the last observation carried forward on double‐blind treatment ), for whom the last observation on double‐blind treatment was carried forward to endpoint. The study authors analysed these data in the endpoint analyses, which were the primary analyses and are described as ITT‐LOCF. To allow a completers' analysis, we sought the data, 'on‐treatment' or the data of those who completed the trial, and we indicated them as such. </p> <p>We did not use data from 'open‐label' follow‐on phases after the randomised study to assess safety or efficacy. </p> </section> <section id="CD001190-sec-0055"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We conducted the 'Risk of bias' assessment using the standard recommended approach for studies included in Cochrane Reviews (<a href="./references#CD001190-bbs2-0131" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). The Cochrane Collaboration 'Risk of bias' tool assesses the following domains: </p> <p> <ul id="CD001190-list-0003"> <li> <p>sequence generation</p> </li> <li> <p>allocation concealment</p> </li> <li> <p>blinding of participants and study personnel</p> </li> <li> <p>blinding of outcomes assessment</p> </li> <li> <p>incomplete outcome data</p> </li> <li> <p>selective outcome reporting</p> </li> <li> <p>other bias</p> </li> </ul> </p> <p>We made a judgement about the risk of bias in each domain, assigning it to one of three categories, high, low, or unclear risk of bias, basing our assessments on the criteria for making judgements that are listed in section 8.5 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001190-bbs2-0131" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>)<i>.</i> The criteria focus on whether the risk is of importance (that is, whether the presence of the risk could have an important impact on the results of the trial) rather than whether a risk of bias is present or not. </p> <p>If insufficient detail was reported to make a judgement, we usually considered this as an unclear risk of bias. We also used an 'unclear' judgement in situations where it was clear what happened in the trial but its likely impact on the results was not known. </p> </section> <section id="CD001190-sec-0056"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes the estimate of treatment effect of the intervention was the Peto odds ratio (OR) together with 95% confidence interval (CI). </p> <p>For continuous data the measure of treatment effect was the mean difference (MD) if only one study was included, or the weighted mean difference (WMD) if more than one study was included with 95% CI. When the pooled studies used different rating scales to measure the same outcome, then the measure of treatment effect was the standardised mean difference, which is the absolute mean difference divided by the pooled standard deviation. </p> </section> <section id="CD001190-sec-0057"> <h4 class="title">Unit of analysis issues</h4> <p>The review only included parallel‐group studies with individual patients randomised. There were no unit of analysis issues. </p> </section> <section id="CD001190-sec-0058"> <h4 class="title">Dealing with missing data</h4> <p>We made no attempt at data imputation, except for the estimation of standard deviations for continuous data using the methods detailed in section 7.7.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001190-bbs2-0130" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>Where possible we reported ITT analyses. We conducted sensitivity analyses to compare methods of dealing with missing data. </p> </section> <section id="CD001190-sec-0059"> <h4 class="title">Assessment of heterogeneity</h4> <p>Before pooling data we assessed potential differences between the included studies in the types of participants, interventions or control used. We did not plan any subgroup analyses. </p> <p>We assessed heterogeneity between the studies using the Chi<sup>2</sup> test (with a significance level set at P &lt; 0.10) and the I<sup>2</sup> statistic (<a href="./references#CD001190-bbs2-0129" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>), which calculates the percentage of variability due to heterogeneity rather than to chance, with I<sup>2</sup> values over 50% suggesting substantial heterogeneity (<a href="./references#CD001190-bbs2-0121" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf ofthe Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> </section> <section id="CD001190-sec-0060"> <h4 class="title">Assessment of reporting biases</h4> <p>We compared outcomes reported for a trial with its protocol where possible, to examine whether all of the study's pre‐specified outcomes had been reported. </p> </section> <section id="CD001190-sec-0061"> <h4 class="title">Data synthesis</h4> <p>The duration of the studies varied. If we considered the range too great to combine all studies into one meta‐analysis, we divided the data into smaller time periods and conducted a separate meta‐analysis for each period. Studies could contribute data to more than one time period if they had made multiple assessments. </p> <p>We have presented overall estimates of the treatment difference. In all cases we have presented the overall estimate from a fixed‐effect model and performed tests for heterogeneity using a standard Chi<sup>2</sup> statistic and I<sup>2</sup> statistic. </p> </section> <section id="CD001190-sec-0062"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We examined heterogeneity both visually and using the I<sup>2</sup> statistic (<a href="./references#CD001190-bbs2-0121" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf ofthe Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> </section> <section id="CD001190-sec-0063"> <h4 class="title">Sensitivity analysis</h4> <p>This review sought to analyse data using ITT data wherever possible. Some studies reported both an ITT analysis that included all participants randomised and a per protocol analysis. The ITT analyses often involve data imputation techniques such as LOCF for participants who did not complete the study. We investigated the impact of different ways of dealing with missing data using a sensitivity analysis of ITT and per protocol analyses. We tabulated these results and discussed any important discrepancies. </p> <section id="CD001190-sec-0064"> <h5 class="title">Presentation of results: 'Summary of findings' table</h5> <p>We used the GRADE approach (<a href="https://archie.cochrane.org/sections/documents/view?version=z1602010812541197910774077420849%26format=REVMAN#REF-Guyatt-2011" target="_blank">Guyatt 2011</a>) to describe our confidence in key effect estimates and presented them in 'Summary of findings' tables as recommended by Cochrane (<a href="./references#CD001190-bbs2-0145" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , AklE , et al. on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R,Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017</a>). The GRADE approach rates the overall quality of evidence contributing to an effect estimate as high, moderate, low or very low, taking into account risk of bias in the included studies, inconsistency between studies, imprecision in the effect estimate, indirectness with respect to the review question, and possible publication bias. We produced 'Summary of findings' tables for the comparison of donepezil (10 mg/day) versus placebo, for the comparison of donepezil (10 mg/day) versus donepezil (5 mg/day), for the comparison of donepezil (10 mg/day) versus placebo for severe Alzheimer's disease, and for the comparison of donepezil (10 mg/day) versus donepezil (23 mg/day). We included the following key outcomes in the 'Summary of findings' tables: cognitive function, activities of daily living, behavioural symptoms, clinician‐rated global impression, acceptability of treatment, incidence of adverse events and quality of life. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001190-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001190-sec-0065"></div> <section id="CD001190-sec-0066"> <h3 class="title">Description of studies</h3> <section id="CD001190-sec-0067"> <h4 class="title">Results of the search</h4> <p>The updated searches performed in January 2015, November 2015, November 2016 and May 2017 retrieved a total of 5653 references. After de‐dulication and a first assessment based on titles and abstracts by the CDCIG information specialist, we were left with 106 references. We read the full texts of 16 references from the January and November 2015 searches. Of these, 14 references were related to two studies suitable for inclusion, and two reported studies that we excluded. From the other two searches, November 2016 and May 2017, we read the full texts of four references. Of these, two were additional references for studies already included, and two were new studies to be included, see <a href="#CD001190-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD001190-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram for searches conducted in January 2015, November 2016 and May 2017" data-id="CD001190-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for searches conducted in January 2015, November 2016 and May 2017</p> </div> </div> </div> </section> <section id="CD001190-sec-0068"> <h4 class="title">Included studies</h4> <p>We have summarised the characteristics of the 30 included studies in <a href="./references#CD001190-sec-0186" title="">Characteristics of included studies</a>. </p> <p>We have summarised Important details of study design (number of participants, duration of follow‐up, mean Mini‐Mental State Examination (MMSE) of participants at baseline and description of interventions) in <a href="#CD001190-tbl-0005">Table 1</a>, the outcome measures in <a href="#CD001190-tbl-0006">Table 2</a>, and the objectives of the studies in <a href="#CD001190-tbl-0007">Table 3</a>. </p> <div class="table" id="CD001190-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of included studies at baseline</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration (weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age<br/> (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% female</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean MMSE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose mg/day donepezil</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Phase</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0007" title="HommaA , ImaiY , HariguchiS , HasegawaK , KameyamaM , NishimuraT . Late phase II clinical study of acetyl cholinesterase inhibitor E2020 in patients with Alzheimer‐type dementia. Clinical Evaluation1998;26(2):251‐84. ">Homma 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3, 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0008" title="HommaA , TakedaM , ImaiY , UdakaF , HasegawaK , KameyamaM , et al. E2020 Study Group. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24‐week, multicenter, double‐blind, placebo‐controlled study in Japan. Dementia and Geriatric Cognitive Disorders2000; Vol. 11, issue 6:299‐313. ">Homma 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0020" title="FriedhoffLT , IeniJR , RogersSL , PrattRD . Donepezil provides long‐term clinical benefits for patients with Alzheimer's Disease. Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum;1998 July 12‐16, Glasgow, Scotland1998:ABSTRACT REF: PW11017. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Correlation between the clinical efficacy of donepezil HCL (E2020) and red blood cell (RBC) acetylcholinesterase (ACHE) inhibition in patients with Alzheimer's disease. Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5‐8, San Diego. UK: Medical Education Network, 1997; Vol. 2:6‐7. RogersS , PerdomoC , FriedhoffL . Clinical benefits are maintained during long‐term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 September 30‐October 4, Venice1995a. [MEDLINE: SR‐HANDSRCH] RogersSL , DoodyRS , PrattRD , IeniJR . Long‐term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open‐label study. European Neuropsychopharmacology2000; Vol. 10, issue 3:195‐203. RogersSL , FriedhoffLT . E2020 improves cognition and quality of life in patients with mild to moderate Alzheimers Disease: results of a phase II trial. Proceedings of the 46th Annual meeting of the American Academy of Neurology. 1994 May 1‐7, Washington DC1994; Vol. 44, issue Suppl 2:A165. RogersSL , Friedhoff LT and the Donepezil Study Group. The Efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double‐blind, placebo‐controlled trial. Dementia1996;7:293‐303. ">Rogers 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1, 3, 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0028" title="TuneL , TiseoP , HoffmanJ , PerdomoC , VotawJ , RogersS , et al. PET in AD: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer's disease: results of a 24‐week study. 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 February 23‐26 San Francisco. 2001. TuneL , TiseoPJ , IeniJ , PerdomoC , PrattRD , VotawJR , et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24‐week, double‐blind, placebo‐controlled study. American Journal of Geriatric Psychiatry2003;11(2):169‐77. TuneLE , TiseoPJ , HoffmanJM , PerdomoCA , VotowJR , RogersSL , et al. Functional brain activity in Alzheimer's disease. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐ June 4, Toronto. 1998:NR345. [MEDLINE: SR‐HANDSRCH] ">Tune 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0013" title="Anon . No title. Eisai Inc. KrishnanKR , CharlesHC , DoraiswamyPM , MintzerJ , WeislerR , YuX , et al. Randomized, placebo‐controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. The American Journal of Psychiatry2003;160(11):2003‐11. ">Krishnan 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0025" title="Anon . No title. Eisai Inc. ">Study 205</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0021" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. PrattRD , PerdomoCA , IeniJK . Long‐term safety and tolerability of donepezil: results from a phase iii extension trial of patients with mild to moderately severe Alzheimer's disease. European Journal of Neurology1999;6(Suppl 3):116. [MEDLINE: SR‐HANDSRCH] RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyRS , MohsRC , FriedhoffLT , the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine1998;158:1021‐31. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego. 1997. ">Rogers 1998a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5, 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0022" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. Erratum: a 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613‐620)). Neurology2001; Vol. 57, issue 11:2153. FriedhoffLT , RogersL . Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease ‐ results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston. Neurology1997;48(3):A100. FriedhoffLT , RogersSL . Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17, Vienna, Austria1997. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis. European Journal of Neurology1997;4(Suppl 1):S9. RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyR , MohsR , FriedhoffLT . E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30‐week phase III trial. Neurology1996;46:A217 S14.001 ARI‐8. RogersSL , DoodyR , MohsR , FriedhoffT , Donepezil Study Group. E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30‐week trial. Unpublished paper1996b. RogersSL , FarlowMR , DoodyRS , MohsR , FriedhoffLT , Donepezil Study Group. A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998;50(1):136‐45. RogersSL , FriedhoffLT , FarlowMR , DoodyRS , MohsR . Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply]. Neurology1999; Vol. 52, issue 1:218‐19. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego1997. ">Rogers 1998b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5, 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0003" title="BayerAJ , RossorM , HeckerJ , GauthierS , BurnsA , PetiteH , et al. International Donepezil Study Group. Donepezil improves functional activity in patients with Alzheimer's disease. 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12‐16, Glasgow, Scotland. 1998. [MEDLINE: SR‐HANDSRCH] BurnsA , GauthierS , PerdomoC . Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(8):806‐12. BurnsA , RossorM , HeckerJ , GauthierS , PetitH , MöllerH‐J , et al. International Donepezil Study Group. The effects of donepezil in Alzheimer's disease ‐ results from a multinational trial. Dementia and Geriatric Cognitive Disorders1999;10(3):237‐44. GauthierS , RosserM , HeckerJ , PetiteH , RogersS , MohrE , et al. Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐June 4, Toronto, Canada1998. [MEDLINE: SR‐HANDSRCH] GauthierS , RossorM , HeckerJ . Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 15‐18 1998. PrattRD , GauthierS , BurnsA , PerdomoCA . Donepezil provides long‐term clinical benefits for patients with Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington. 2000. ">Burns 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5, 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0026" title="Anon . No title. Eisai Inc. ">Study 306</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0027" title="SteinmanMA , CovinskyKE , TariotPN , CummingsJL , KatzIR , MintzerJ , et al. Donepezil for nursing home patients with dementia: a reinterpretation of the evidence. Journal of the American Geriatrics Society2003;51(1):132‐33. TariotP , CummingsJL , KatzIR , PerdomoCA , WhalenE , SovelMA , et al. Donepezil was well‐tolerated and enhanced cognition in nursing home patients with Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. TariotP , PerdomoCA , WhalenE , SovelMA , SchamEM . Age is not a barrier to donepezil treatment of Alzheimer's disease in the long‐term care setting. International Psychogeriatrics1999;11(Supplement 1):134. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomised, double‐blind, placebo‐controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2003;51(1):133‐4. ">Tariot 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0017" title="EbellM . Does donepezil help patients with moderate Alzheimer's dementia preserve their ability to function independently?. Evidence Based Practice2002. MohsR , DoodyR , MorrisJ , IeniJ , PerdomoC , PrattR , et al. Donepezil preserves activities of daily living in Alzheimer's disease patients: results from a one‐year placebo‐controlled functional survival study. Neurology2000;54(Suppl 3):A415. MohsR , DoodyR , MorrisJ , IeniJ , RogersS , PerdomoC , et al. Donepezil preserves functional status and improves cognition in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Journal of the American Geriatrics Society2000;48(8):S46. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled attrition study. Journal of the European College of Neuropsychopharmacology1999;9(Suppl 5):S328. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Quality Research in Dementia Conference; 2000 November 19‐22, London. 2000. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoC , et al. 312 Study Group. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients [Erratum]. Neurology2001; Vol. 57, issue 10:1942. [MEDLINE: http://www.lww.com] MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients. Neurology2001;57(3):481‐8. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illinois. 2000. [MEDLINE: SR‐HANDSRCH] PrattR , MohsR , DoodyR , MorrisJ , RogersS , IeniJ , et al. Donepezil preserves functional status in Alzheimer's disease patients results from a 1‐year prospective placebo controlled functional study. Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden2000:178. ">Mohs 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0002" title="BlackS , LiHL , McRaeT , RichardsonS . Treatment of severe Alzheimer's disease with donepezil: results from a 24‐week, multinational, randomized, double‐blind, placebo‐controlled trial. Neurology2006;66(5):A347. BlackS , LiHonglang , McRaeT , RichardsonS . Donepezil treatment of severe Alzheimer's disease: results from a 24‐week, multinational, randomized, double‐blind, placebo controlled trial. Poster Presented at the Geneva Springfield ConferenceApril 2006. BlackSE , DoodyR , LiH , McRaeT , JamborKM , XuY , et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology2007;69(5):459‐69. Pfizer . E2020‐A001‐315: a 24 week multinational RCT evaluating the efficacy and safety of donepezil in severe AD. www.marc.soton.ac.uk/Research%20Page.htm. RichardsonS . A 24 week, multicenter, randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of donepezil hydrochloride (E2020) in patients with severe Alzheimer's disease followed by a 12 week open‐label extension period. www.clinicaltrials.gov/ct/show/NCT000964732004. ">Black 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia, Canada, France, UK, USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0024" title="SeltzerB , ZolnouniP , NunezM , GoldmanR , KumarD , IeniJ , et al. Erratum: efficacy of donepezil in early‐stage alzheimer disease: a randomized placebo‐controlled trial (Archives of Neurology (December 2004) 61 (1852‐1856)). Archives of Neurology2005;62(5):825. SeltzerB , ZolnouniP , NunezM , GoldmanR , KumarD , IeniJ , et al. Donepezil 402 Study Group. Efficacy of donepezil in early‐stage Alzheimer disease. Archives of Neurolology2004;61:1852‐6. ">Seltzer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0001" title="AD2000 Collaborative Group. Long‐term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double‐blind trial. Lancet2004;363:2105‐15. BenthamP , GrayR , HillR , SellwoodE , CourtneyC . Twelve week response to cholinesterase inhibitors dose not predict future benefit the AD2000 trial experience. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:337. LendonCL . Determination of responses to anticholinesterase therapy in the treatment of Alzheimer's disease. 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden: Abstract No 1287. 2002. RobertsN . A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease (AD2000). National Research Register2001. SchneiderLS . AD2000: donepezil in Alzheimer's disease. Lancet2004;363(9427):2100‐1. WaghrayS . AD2000 A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease. National Research Register2000. [MEDLINE: http://www.doh.gov.uk/nrr.htm] ">AD2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5, 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0014" title="RobertP , LebertF , GoniS , TouchonJ , VincentS , ARIAL Study Investigators Collaborative Group. The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. Quality Research in Dementia; 19‐22 November, 2000, London. 2000. RobertPH , LebertF , GoniS , TouchonJ , ARIAL Study Investigators Collaborative Group. The impact of caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">Lebert 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0004" title="CummingsJL , GeldmacherD , FarlowM , SabbaghM , ChristensenD , BetzP . High‐dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. CNS Neuroscience &amp; Therapeutics2013;19(5):294‐301. DoodyRS , GeldmacherDS , FarlowMR , SunY , MolineM , MackellJ . Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate‐to‐severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dementia and Geriatric Cognitive Disorders2012;33(2‐3):164‐73. DoodyRS , RamosH , FaisonW , ZouH . Efficacy and safety of donepezil 23 mg/d vs. donepezil 10 mg/d in patients with moderate to severe Alzheimer's disease: impact of concomitant memantine use. Journal of the American Geriatrics Society 2011 Annual Scientific meeting of the American Geriatrics Society, National Harbor, MD, USA2011. FarlowM , RichardsonS , MackellJ , SunY . Long‐term safety and tolerability of donepezil 23 MG in patients with moderate‐to‐severe Alzheimer's disease: an 18‐month analysis. Alzheimer's and Dementia 2011 Alzheimer's Association International Conference, Paris, France. 2011. FarlowM , VelosoF , MolineM , YardleyJ , Brand‐SchieberE , BibbianiF , et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurology2011;11:57. FarlowMR , SallowayS , TariotPN , YardleyJ , MolineML , WangQ , et al. Effectiveness and tolerability of high‐dose (23 mg/d) versus standard‐dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24‐week, randomized, double‐blind study. Clinical Therapeutics2010;32(7):1234‐51. FerrisS , CummingsJ , ChristensenD , DoodyR , FarlowM , SabbaghM , et al. Donepezil 23 MG/D for moderate to severe Alzheimer's disease: assessing subdomains of the Severe Impairment Battery. Journal of Nutrition, Health and Aging 5th Conference Clinical Trials on Alzheimer's Disease, Monte Carlo, Monaco. 2012. FerrisS , CummingsJ , ChristensenD , DoodyR , FarlowM , SabbaghM , et al. Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimer's Research &amp; Therapy2013;5:12. FerrisS , MacKellJ , BaiZ , SunY . Effect of donepezil 23 mg/day on language function in patients with moderate‐to‐severe Alzheimer's disease (AD): subgroup analysis of united states (U.S.)‐based patients. Alzheimer's Association International Conference 2012 Vancouver, BC Canada. 2012. FerrisSH , SchmittFA , SaxtonJ , RichardsonS , MackellJ , SunY , et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimer's Research &amp; Therapy2011;3(3):22. HanS‐H , LeeJ‐H , KimSY , ParkKW , ChenC , TripathiM , et al. Donepezil 23 mg in Asian patients with moderate‐to‐severe Alzheimer's disease. Acta Neurologica Scandinavica2017;135(2):252‐56. SabbaghM , CummingsJ , ChristensenD , DoodyR , FarlowM , LiuL , et al. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatrics2013;13:56. SabbaghM , CummingsJ , ChristensenD , DoodyR , FarlowM , MacKellJ , et al. Evaluating the cognitive effects of donepezil 23 MG/D in moderate and severe Alzheimer's disease: a patient subgroup analysis. Journal of Nutrition, Health and Aging 5th Conference Clinical Trials on Alzheimer's Disease, Monte Carlo, Monaco. 2012. SabbaghM , HanS , KimS , NaH‐R , LeeJ‐H , KandiahN , et al. Clinical recommendations for the use of donepezil 23 mg in moderate‐to‐severe Alzheimer's disease in the Asia‐Pacific region. Dementia and Geriatric Cognitive Disorders Extra2016;6:382‐95. TariotP , SallowayS , YardleyJ , MackellJ , MolineM . Long‐term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease. BMC Research Notes2012;5:283. TariotP , YardleyJ , MolineM , Brand‐SchieberE , ZouH , TimothyH , et al. Long‐term safety and tolerability of high dose donepezil (23 mg/day) in moderate to severe Alzheimer's disease: a 12‐month open‐label study. Neuropsychopharmacology 49th Annual Conference of the American College of Neuropsychopharmacology, Miami Beach, FL, USA. 2010. ">Farlow 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10, 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia, Canada, France</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0006" title="HegerlU , MerglR , HenkelV , GallinatJ , KotterG , Muller SiechenederF , et al. Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia. Journal of Clinical Psychopharmacology2003;23(2):214‐6. ">Hegerl 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germany</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0009" title="HommaA , ArimotoI , KaidojiK , OhbayashiT , OzawaH . Treatment of severe Alzheimer's disease with donepezil: results from a 24 week, parallel, placebo‐controlled study in Japan. 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, July 2006. 2006. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24‐week, double‐blind, placebo‐controlled, randomized trial. Geriatric Cognitive Disorders2008;25(5):399‐407. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Long‐term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52‐week, open‐label, multicenter, extension study in Japan. Dementia and Geritatric Congitive Disorders2009;27(3):232‐9. ">Homma 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5, 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0010" title="HommaA , AtarashiH , KubotaN , NakaiK , TakaseT . Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in Japanese patients with severe Alzheimer's disease: a randomized, double‐blind trial. Journal of Alzheimer's disease2016;52(1):345‐57. ">Homma 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10, 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0012" title="JiaJP , WeiCB , JiaLF , TangY , LiangJH , ZhouAH , et al. Efficacy and safety of donepezil in Chinese patients with severe Alzheimer's disease: a randomized controlled trial. Journal of Alzheimer's disease2017;56(4):1495‐504. ">Jia 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0011" title="HowardRJ , JuszczakE , BallardCG , BenthamP Brown RG , BullockR , et al. CALM‐AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine2007;357(14):1382‐92. PelosiA . Donepezil is no more effective than placebo for agitation in people with Alzheimer's disease. Evidence‐Based Mental Health2008;11(3):84. ">Howard 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>England, UK</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0015" title="Maher‐EdwardsG , DixonR , HunterJ , GoldM , HoptonG , JacobsG , et al. SB‐742457 and donepezil in Alzheimer's disease: a randomized, placebo‐controlled study. International Journal of Geriatric Psychiatry2011;26(5):536‐44. Maher‐EdwardsG , Zvartau‐HindM , DaviesJ , AlexanderK , SchronenJ , BoswellD , et al. Effects of 6‐month monotherapy treatment with the 5HT6 receptor antagonist SB 742457 or donepezil in subjects with mild‐to‐moderate Alzheimer's disease. Alzheimer's Association International Conference, Paris, France. 2011. ">Maher‐Edwards 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Austria, Bulgaria, Chile, Estonia, Germany, The Russian Federation, Slovakia, UK</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0016" title="KorczynAD . Comments on the article by Mazza et al. concerning Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study. European Journal of Neurology2007;14(9):e9. MazzaM , CapuanoA , BriaAP , MazzaS . Letter to the editor. European Journal of Neurology2007;14(9):e10. MazzaM , CapuanoA , BriaP , MazzaS . Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study. European Journal of Neurology2006;13(9):981‐85. ">Mazza 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0018" title="MoraesW , PoyaresD , Sukys‐ClaudinoL , GuilleminaultC , TufikS . Donepezil improves obstructive sleep apnoea in Alzheimer disease: a double‐blind, placebo‐controlled study. Chest2008;133(3):677‐83. MoraesW , Sukys‐ClaudinoL , PoyaresD , GuilleminaultC , TufikS . Donepezil improves oxygen desaturation in patients with alzheimer's disease and obstructive sleep apnoea. Sleep Medicine2006;7(S47):368. ">Moraes 2006a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0019" title="MoraesW dos S , PoyaresDR , GuilleminaultC , RamosLR , BertolucciPH , TufikS . The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double‐blind placebo‐controlled study. Sleep2006;29(2):199‐205. ">Moraes 2006b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0029" title="EngedalK , SoininenH , VerheyF , WaldemarG , WinbladB , WimoA , et al. Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000; Vol. 10, issue Suppl 3:S368. [MEDLINE: SR‐HANDSRCH] MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a one year, double‐blind, randomized trial. Journal of the American Geriatrics Society2001; Vol. 49, issue 4:S131. MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. Donepezil reduces the time caregivers spend providing care: results of a one‐year, double‐blind, randomized trial in patients with mild to moderate Alzheimer's disease. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23‐26, San Francisco2001. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Long term benefits of donepezil on ADLs in AD patients. Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:171. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Donepezil Nordic Study Group. Response to donepezil is not predicted by apolipoprotein E genotype and/or gender. World Alzheimer Congress; 2000 July 9‐13, Washington. 2000. WaldemarG , WinbladB , EngedalK , SoininenH , Donepezil Nordic Study Group et al. Benefits of donepezil on cognition, function and/or neuropsychiatric symptoms in patients with Alzheimers disease over one year. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WaldemarG , WinbladB , EngedalK , SoininenHS , VerheyFR , WimoA , et al. Donepezil Nordic Study Group. Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year. Neurology2000;54(Suppl 3):A470. WimoA . Erratum: an economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial (Dementia and Geriatric Cognitive Disorders (2003) 15 (44‐54)). Dementia and Geriatric Cognitive Disorders2003; Vol. 16, issue 2:102. WimoA , WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , et al. Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial. Dementia and Geriatric Cognitive Disorders2003;15(1):44‐54. WimoA , WinbladB , MasteyV . An economic evaluation of donepezil in mild to moderate Alzheimers disease: results of a one‐year, double‐blind, randomized trial. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WimoA , WinbladB , MasteyV , HaglundA , HertzmanP , MiceliR , et al. An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one‐year, double‐blind, randomized trial. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illionois. 2000. [MEDLINE: SR‐HANDSRCH] WinbladB . Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:164. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , WetterholmAL , ZhangR , HaglundA , SubbiahP . Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. International Psychogeriatrics1999;11(Supplement 1):138. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. A 1‐year, randomized, placebo‐controlled study of donepezil in patients with mild to moderate AD. Neurology2001;57(3):489‐95. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. Donepezil enhances global function and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. Quality Research in Dementia Conference; 2000 Nov 19‐22, London. 2000. WinbladB , WimoA , EngedalK , SoininenH , VerheyF , WaldemarG , et al. 3‐year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia and Geriatric Cognitive Disorders2006;21(5‐6):353‐63. ">Winblad 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0023" title="SchindlerR , Corey‐BloomJ , DoodyR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4‐7, 2004. 2004. SchindlerR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. Neurobiology of Aging2004;25(S2):195. ">Schindler 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10,20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0030" title="BatsmanS , MinthonL , EerikssonS , KilanderL , Jansson‐BlixtC , WetterholmA , et al. Study design and baseline patients characteristics in a randomized controlled trial of the efficacy and tolerability of donepezil in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. ErikssonS , WinbladB , KilanderL , BatsmanS , Jansson‐BlixtC , WetterholmA , et al. Efficacy of donepezil on secondary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. JelicV , HaglundA , KowalskiJ , LangworthS , WinbladB . Donepezil treatment of severe Alzheimer's disease in nursing home settings. Dementia and Geriatric Cognitive Disorders2008;26(5):458‐46. KilanderL , WinbladB , MinthonL , BatsmanS , Jansson‐BlixtC , CronlundA , et al. Donepezil is well tolerated in patients with severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MarderK . Donepezil in patients with severe Alzheimer's disease: double‐blind parallel‐group, placebo controlled study. Current Neurology and Neuroscience Reports2006;6(5):364‐73. OpieLH . Donepezil for severe Alzheimer's disease. Lancet2006;368:361‐2. WinbladB . Donepezil for severe Alzheimer's disease ‐ author's reply. Lancet2006;368(9533):362. WinbladB . Severe Alzheimer's disease: benefits of donepezil therapy. International Psychogeriatrics2006;18(5):S25‐S31. WinbladB , KilanderL , ErikssonS , MinthonL , BåtsmanS , WetterholmA , et al. for the Severe Alzheimer’s Disease Study Group. Donepezil in patients with severe Alzheimer’s disease: double‐blind, parallel‐group, placebo‐controlled study. Lancet2006;367(9156):1057‐65. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansoon‐BlixtC , WetterholmA , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansson‐BlixtC , WetterholmAL , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. International Psychogeriatrics2005;18(S1):S25‐S31. ">Winblad 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sweden</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>MMSE</b>: Mini‐Mental State Examination </p> </div> </div> <div class="table" id="CD001190-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcome measures</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MMSE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ADAS‐Cog</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CDR‐SB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CIBIC‐plus</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0007" title="HommaA , ImaiY , HariguchiS , HasegawaK , KameyamaM , NishimuraT . Late phase II clinical study of acetyl cholinesterase inhibitor E2020 in patients with Alzheimer‐type dementia. Clinical Evaluation1998;26(2):251‐84. ">Homma 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MENFIS, Crichton, FGIR, GIR, OSR, GUR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0008" title="HommaA , TakedaM , ImaiY , UdakaF , HasegawaK , KameyamaM , et al. E2020 Study Group. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24‐week, multicenter, double‐blind, placebo‐controlled study in Japan. Dementia and Geriatric Cognitive Disorders2000; Vol. 11, issue 6:299‐313. ">Homma 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MENFIS, Japanese‐CGIC, Crichton</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0020" title="FriedhoffLT , IeniJR , RogersSL , PrattRD . Donepezil provides long‐term clinical benefits for patients with Alzheimer's Disease. Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum;1998 July 12‐16, Glasgow, Scotland1998:ABSTRACT REF: PW11017. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Correlation between the clinical efficacy of donepezil HCL (E2020) and red blood cell (RBC) acetylcholinesterase (ACHE) inhibition in patients with Alzheimer's disease. Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5‐8, San Diego. UK: Medical Education Network, 1997; Vol. 2:6‐7. RogersS , PerdomoC , FriedhoffL . Clinical benefits are maintained during long‐term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 September 30‐October 4, Venice1995a. [MEDLINE: SR‐HANDSRCH] RogersSL , DoodyRS , PrattRD , IeniJR . Long‐term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open‐label study. European Neuropsychopharmacology2000; Vol. 10, issue 3:195‐203. RogersSL , FriedhoffLT . E2020 improves cognition and quality of life in patients with mild to moderate Alzheimers Disease: results of a phase II trial. Proceedings of the 46th Annual meeting of the American Academy of Neurology. 1994 May 1‐7, Washington DC1994; Vol. 44, issue Suppl 2:A165. RogersSL , Friedhoff LT and the Donepezil Study Group. The Efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double‐blind, placebo‐controlled trial. Dementia1996;7:293‐303. ">Rogers 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0028" title="TuneL , TiseoP , HoffmanJ , PerdomoC , VotawJ , RogersS , et al. PET in AD: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer's disease: results of a 24‐week study. 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 February 23‐26 San Francisco. 2001. TuneL , TiseoPJ , IeniJ , PerdomoC , PrattRD , VotawJR , et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24‐week, double‐blind, placebo‐controlled study. American Journal of Geriatric Psychiatry2003;11(2):169‐77. TuneLE , TiseoPJ , HoffmanJM , PerdomoCA , VotowJR , RogersSL , et al. Functional brain activity in Alzheimer's disease. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐ June 4, Toronto. 1998:NR345. [MEDLINE: SR‐HANDSRCH] ">Tune 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI, functional brain activity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0013" title="Anon . No title. Eisai Inc. KrishnanKR , CharlesHC , DoraiswamyPM , MintzerJ , WeislerR , YuX , et al. Randomized, placebo‐controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. The American Journal of Psychiatry2003;160(11):2003‐11. ">Krishnan 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hippocampal volumes and brain concentrations of N‐acetylaspartate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0025" title="Anon . No title. Eisai Inc. ">Study 205</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0021" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. PrattRD , PerdomoCA , IeniJK . Long‐term safety and tolerability of donepezil: results from a phase iii extension trial of patients with mild to moderately severe Alzheimer's disease. European Journal of Neurology1999;6(Suppl 3):116. [MEDLINE: SR‐HANDSRCH] RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyRS , MohsRC , FriedhoffLT , the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine1998;158:1021‐31. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego. 1997. ">Rogers 1998a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0022" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. Erratum: a 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613‐620)). Neurology2001; Vol. 57, issue 11:2153. FriedhoffLT , RogersL . Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease ‐ results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston. Neurology1997;48(3):A100. FriedhoffLT , RogersSL . Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17, Vienna, Austria1997. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis. European Journal of Neurology1997;4(Suppl 1):S9. RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyR , MohsR , FriedhoffLT . E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30‐week phase III trial. Neurology1996;46:A217 S14.001 ARI‐8. RogersSL , DoodyR , MohsR , FriedhoffT , Donepezil Study Group. E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30‐week trial. Unpublished paper1996b. RogersSL , FarlowMR , DoodyRS , MohsR , FriedhoffLT , Donepezil Study Group. A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998;50(1):136‐45. RogersSL , FriedhoffLT , FarlowMR , DoodyRS , MohsR . Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply]. Neurology1999; Vol. 52, issue 1:218‐19. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego1997. ">Rogers 1998b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0003" title="BayerAJ , RossorM , HeckerJ , GauthierS , BurnsA , PetiteH , et al. International Donepezil Study Group. Donepezil improves functional activity in patients with Alzheimer's disease. 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12‐16, Glasgow, Scotland. 1998. [MEDLINE: SR‐HANDSRCH] BurnsA , GauthierS , PerdomoC . Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(8):806‐12. BurnsA , RossorM , HeckerJ , GauthierS , PetitH , MöllerH‐J , et al. International Donepezil Study Group. The effects of donepezil in Alzheimer's disease ‐ results from a multinational trial. Dementia and Geriatric Cognitive Disorders1999;10(3):237‐44. GauthierS , RosserM , HeckerJ , PetiteH , RogersS , MohrE , et al. Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐June 4, Toronto, Canada1998. [MEDLINE: SR‐HANDSRCH] GauthierS , RossorM , HeckerJ . Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 15‐18 1998. PrattRD , GauthierS , BurnsA , PerdomoCA . Donepezil provides long‐term clinical benefits for patients with Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington. 2000. ">Burns 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IDDD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0026" title="Anon . No title. Eisai Inc. ">Study 306</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0027" title="SteinmanMA , CovinskyKE , TariotPN , CummingsJL , KatzIR , MintzerJ , et al. Donepezil for nursing home patients with dementia: a reinterpretation of the evidence. Journal of the American Geriatrics Society2003;51(1):132‐33. TariotP , CummingsJL , KatzIR , PerdomoCA , WhalenE , SovelMA , et al. Donepezil was well‐tolerated and enhanced cognition in nursing home patients with Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. TariotP , PerdomoCA , WhalenE , SovelMA , SchamEM . Age is not a barrier to donepezil treatment of Alzheimer's disease in the long‐term care setting. International Psychogeriatrics1999;11(Supplement 1):134. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomised, double‐blind, placebo‐controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2003;51(1):133‐4. ">Tariot 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI‐NH</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0017" title="EbellM . Does donepezil help patients with moderate Alzheimer's dementia preserve their ability to function independently?. Evidence Based Practice2002. MohsR , DoodyR , MorrisJ , IeniJ , PerdomoC , PrattR , et al. Donepezil preserves activities of daily living in Alzheimer's disease patients: results from a one‐year placebo‐controlled functional survival study. Neurology2000;54(Suppl 3):A415. MohsR , DoodyR , MorrisJ , IeniJ , RogersS , PerdomoC , et al. Donepezil preserves functional status and improves cognition in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Journal of the American Geriatrics Society2000;48(8):S46. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled attrition study. Journal of the European College of Neuropsychopharmacology1999;9(Suppl 5):S328. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Quality Research in Dementia Conference; 2000 November 19‐22, London. 2000. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoC , et al. 312 Study Group. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients [Erratum]. Neurology2001; Vol. 57, issue 10:1942. [MEDLINE: http://www.lww.com] MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients. Neurology2001;57(3):481‐8. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illinois. 2000. [MEDLINE: SR‐HANDSRCH] PrattR , MohsR , DoodyR , MorrisJ , RogersS , IeniJ , et al. Donepezil preserves functional status in Alzheimer's disease patients results from a 1‐year prospective placebo controlled functional study. Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden2000:178. ">Mohs 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADFACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0002" title="BlackS , LiHL , McRaeT , RichardsonS . Treatment of severe Alzheimer's disease with donepezil: results from a 24‐week, multinational, randomized, double‐blind, placebo‐controlled trial. Neurology2006;66(5):A347. BlackS , LiHonglang , McRaeT , RichardsonS . Donepezil treatment of severe Alzheimer's disease: results from a 24‐week, multinational, randomized, double‐blind, placebo controlled trial. Poster Presented at the Geneva Springfield ConferenceApril 2006. BlackSE , DoodyR , LiH , McRaeT , JamborKM , XuY , et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology2007;69(5):459‐69. Pfizer . E2020‐A001‐315: a 24 week multinational RCT evaluating the efficacy and safety of donepezil in severe AD. www.marc.soton.ac.uk/Research%20Page.htm. RichardsonS . A 24 week, multicenter, randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of donepezil hydrochloride (E2020) in patients with severe Alzheimer's disease followed by a 12 week open‐label extension period. www.clinicaltrials.gov/ct/show/NCT000964732004. ">Black 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>x</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB, ADCS‐ADL‐sev, NPI, CBQ, RUSP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0024" title="SeltzerB , ZolnouniP , NunezM , GoldmanR , KumarD , IeniJ , et al. Erratum: efficacy of donepezil in early‐stage alzheimer disease: a randomized placebo‐controlled trial (Archives of Neurology (December 2004) 61 (1852‐1856)). Archives of Neurology2005;62(5):825. SeltzerB , ZolnouniP , NunezM , GoldmanR , KumarD , IeniJ , et al. Donepezil 402 Study Group. Efficacy of donepezil in early‐stage Alzheimer disease. Archives of Neurolology2004;61:1852‐6. ">Seltzer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMBT, apathy scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0001" title="AD2000 Collaborative Group. Long‐term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double‐blind trial. Lancet2004;363:2105‐15. BenthamP , GrayR , HillR , SellwoodE , CourtneyC . Twelve week response to cholinesterase inhibitors dose not predict future benefit the AD2000 trial experience. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:337. LendonCL . Determination of responses to anticholinesterase therapy in the treatment of Alzheimer's disease. 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden: Abstract No 1287. 2002. RobertsN . A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease (AD2000). National Research Register2001. SchneiderLS . AD2000: donepezil in Alzheimer's disease. Lancet2004;363(9427):2100‐1. WaghrayS . AD2000 A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease. National Research Register2000. [MEDLINE: http://www.doh.gov.uk/nrr.htm] ">AD2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>entry to institutional care, BADLS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0014" title="RobertP , LebertF , GoniS , TouchonJ , VincentS , ARIAL Study Investigators Collaborative Group. The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. Quality Research in Dementia; 19‐22 November, 2000, London. 2000. RobertPH , LebertF , GoniS , TouchonJ , ARIAL Study Investigators Collaborative Group. The impact of caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">Lebert 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI, BADLS, GHQ‐30, institutionalisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0004" title="CummingsJL , GeldmacherD , FarlowM , SabbaghM , ChristensenD , BetzP . High‐dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. CNS Neuroscience &amp; Therapeutics2013;19(5):294‐301. DoodyRS , GeldmacherDS , FarlowMR , SunY , MolineM , MackellJ . Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate‐to‐severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dementia and Geriatric Cognitive Disorders2012;33(2‐3):164‐73. DoodyRS , RamosH , FaisonW , ZouH . Efficacy and safety of donepezil 23 mg/d vs. donepezil 10 mg/d in patients with moderate to severe Alzheimer's disease: impact of concomitant memantine use. Journal of the American Geriatrics Society 2011 Annual Scientific meeting of the American Geriatrics Society, National Harbor, MD, USA2011. FarlowM , RichardsonS , MackellJ , SunY . Long‐term safety and tolerability of donepezil 23 MG in patients with moderate‐to‐severe Alzheimer's disease: an 18‐month analysis. Alzheimer's and Dementia 2011 Alzheimer's Association International Conference, Paris, France. 2011. FarlowM , VelosoF , MolineM , YardleyJ , Brand‐SchieberE , BibbianiF , et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurology2011;11:57. FarlowMR , SallowayS , TariotPN , YardleyJ , MolineML , WangQ , et al. Effectiveness and tolerability of high‐dose (23 mg/d) versus standard‐dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24‐week, randomized, double‐blind study. Clinical Therapeutics2010;32(7):1234‐51. FerrisS , CummingsJ , ChristensenD , DoodyR , FarlowM , SabbaghM , et al. Donepezil 23 MG/D for moderate to severe Alzheimer's disease: assessing subdomains of the Severe Impairment Battery. Journal of Nutrition, Health and Aging 5th Conference Clinical Trials on Alzheimer's Disease, Monte Carlo, Monaco. 2012. FerrisS , CummingsJ , ChristensenD , DoodyR , FarlowM , SabbaghM , et al. Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimer's Research &amp; Therapy2013;5:12. FerrisS , MacKellJ , BaiZ , SunY . Effect of donepezil 23 mg/day on language function in patients with moderate‐to‐severe Alzheimer's disease (AD): subgroup analysis of united states (U.S.)‐based patients. Alzheimer's Association International Conference 2012 Vancouver, BC Canada. 2012. FerrisSH , SchmittFA , SaxtonJ , RichardsonS , MackellJ , SunY , et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimer's Research &amp; Therapy2011;3(3):22. HanS‐H , LeeJ‐H , KimSY , ParkKW , ChenC , TripathiM , et al. Donepezil 23 mg in Asian patients with moderate‐to‐severe Alzheimer's disease. Acta Neurologica Scandinavica2017;135(2):252‐56. SabbaghM , CummingsJ , ChristensenD , DoodyR , FarlowM , LiuL , et al. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatrics2013;13:56. SabbaghM , CummingsJ , ChristensenD , DoodyR , FarlowM , MacKellJ , et al. Evaluating the cognitive effects of donepezil 23 MG/D in moderate and severe Alzheimer's disease: a patient subgroup analysis. Journal of Nutrition, Health and Aging 5th Conference Clinical Trials on Alzheimer's Disease, Monte Carlo, Monaco. 2012. SabbaghM , HanS , KimS , NaH‐R , LeeJ‐H , KandiahN , et al. Clinical recommendations for the use of donepezil 23 mg in moderate‐to‐severe Alzheimer's disease in the Asia‐Pacific region. Dementia and Geriatric Cognitive Disorders Extra2016;6:382‐95. TariotP , SallowayS , YardleyJ , MackellJ , MolineM . Long‐term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease. BMC Research Notes2012;5:283. TariotP , YardleyJ , MolineM , Brand‐SchieberE , ZouH , TimothyH , et al. Long‐term safety and tolerability of high dose donepezil (23 mg/day) in moderate to severe Alzheimer's disease: a 12‐month open‐label study. Neuropsychopharmacology 49th Annual Conference of the American College of Neuropsychopharmacology, Miami Beach, FL, USA. 2010. ">Farlow 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB, ADCS‐ADL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB, CIBIS, DAD, NPI, FRS, CSS, CAUST, SF‐36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0006" title="HegerlU , MerglR , HenkelV , GallinatJ , KotterG , Muller SiechenederF , et al. Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia. Journal of Clinical Psychopharmacology2003;23(2):214‐6. ">Hegerl 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hand‐motor function</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0009" title="HommaA , ArimotoI , KaidojiK , OhbayashiT , OzawaH . Treatment of severe Alzheimer's disease with donepezil: results from a 24 week, parallel, placebo‐controlled study in Japan. 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, July 2006. 2006. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24‐week, double‐blind, placebo‐controlled, randomized trial. Geriatric Cognitive Disorders2008;25(5):399‐407. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Long‐term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52‐week, open‐label, multicenter, extension study in Japan. Dementia and Geritatric Congitive Disorders2009;27(3):232‐9. ">Homma 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB, ADCS‐ADL‐sev, BEHAVE‐ADL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0010" title="HommaA , AtarashiH , KubotaN , NakaiK , TakaseT . Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in Japanese patients with severe Alzheimer's disease: a randomized, double‐blind trial. Journal of Alzheimer's disease2016;52(1):345‐57. ">Homma 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0012" title="JiaJP , WeiCB , JiaLF , TangY , LiangJH , ZhouAH , et al. Efficacy and safety of donepezil in Chinese patients with severe Alzheimer's disease: a randomized controlled trial. Journal of Alzheimer's disease2017;56(4):1495‐504. ">Jia 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0011" title="HowardRJ , JuszczakE , BallardCG , BenthamP Brown RG , BullockR , et al. CALM‐AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine2007;357(14):1382‐92. PelosiA . Donepezil is no more effective than placebo for agitation in people with Alzheimer's disease. Evidence‐Based Mental Health2008;11(3):84. ">Howard 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMAI, NPI NPI‐D SIB</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0015" title="Maher‐EdwardsG , DixonR , HunterJ , GoldM , HoptonG , JacobsG , et al. SB‐742457 and donepezil in Alzheimer's disease: a randomized, placebo‐controlled study. International Journal of Geriatric Psychiatry2011;26(5):536‐44. Maher‐EdwardsG , Zvartau‐HindM , DaviesJ , AlexanderK , SchronenJ , BoswellD , et al. Effects of 6‐month monotherapy treatment with the 5HT6 receptor antagonist SB 742457 or donepezil in subjects with mild‐to‐moderate Alzheimer's disease. Alzheimer's Association International Conference, Paris, France. 2011. ">Maher‐Edwards 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DAD, NPI, ACQLI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0016" title="KorczynAD . Comments on the article by Mazza et al. concerning Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study. European Journal of Neurology2007;14(9):e9. MazzaM , CapuanoA , BriaAP , MazzaS . Letter to the editor. European Journal of Neurology2007;14(9):e10. MazzaM , CapuanoA , BriaP , MazzaS . Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study. European Journal of Neurology2006;13(9):981‐85. ">Mazza 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SKT, CGIC</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0018" title="MoraesW , PoyaresD , Sukys‐ClaudinoL , GuilleminaultC , TufikS . Donepezil improves obstructive sleep apnoea in Alzheimer disease: a double‐blind, placebo‐controlled study. Chest2008;133(3):677‐83. MoraesW , Sukys‐ClaudinoL , PoyaresD , GuilleminaultC , TufikS . Donepezil improves oxygen desaturation in patients with alzheimer's disease and obstructive sleep apnoea. Sleep Medicine2006;7(S47):368. ">Moraes 2006a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0019" title="MoraesW dos S , PoyaresDR , GuilleminaultC , RamosLR , BertolucciPH , TufikS . The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double‐blind placebo‐controlled study. Sleep2006;29(2):199‐205. ">Moraes 2006b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0029" title="EngedalK , SoininenH , VerheyF , WaldemarG , WinbladB , WimoA , et al. Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000; Vol. 10, issue Suppl 3:S368. [MEDLINE: SR‐HANDSRCH] MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a one year, double‐blind, randomized trial. Journal of the American Geriatrics Society2001; Vol. 49, issue 4:S131. MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. Donepezil reduces the time caregivers spend providing care: results of a one‐year, double‐blind, randomized trial in patients with mild to moderate Alzheimer's disease. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23‐26, San Francisco2001. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Long term benefits of donepezil on ADLs in AD patients. Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:171. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Donepezil Nordic Study Group. Response to donepezil is not predicted by apolipoprotein E genotype and/or gender. World Alzheimer Congress; 2000 July 9‐13, Washington. 2000. WaldemarG , WinbladB , EngedalK , SoininenH , Donepezil Nordic Study Group et al. Benefits of donepezil on cognition, function and/or neuropsychiatric symptoms in patients with Alzheimers disease over one year. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WaldemarG , WinbladB , EngedalK , SoininenHS , VerheyFR , WimoA , et al. Donepezil Nordic Study Group. Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year. Neurology2000;54(Suppl 3):A470. WimoA . Erratum: an economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial (Dementia and Geriatric Cognitive Disorders (2003) 15 (44‐54)). Dementia and Geriatric Cognitive Disorders2003; Vol. 16, issue 2:102. WimoA , WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , et al. Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial. Dementia and Geriatric Cognitive Disorders2003;15(1):44‐54. WimoA , WinbladB , MasteyV . An economic evaluation of donepezil in mild to moderate Alzheimers disease: results of a one‐year, double‐blind, randomized trial. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WimoA , WinbladB , MasteyV , HaglundA , HertzmanP , MiceliR , et al. An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one‐year, double‐blind, randomized trial. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illionois. 2000. [MEDLINE: SR‐HANDSRCH] WinbladB . Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:164. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , WetterholmAL , ZhangR , HaglundA , SubbiahP . Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. International Psychogeriatrics1999;11(Supplement 1):138. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. A 1‐year, randomized, placebo‐controlled study of donepezil in patients with mild to moderate AD. Neurology2001;57(3):489‐95. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. Donepezil enhances global function and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. Quality Research in Dementia Conference; 2000 Nov 19‐22, London. 2000. WinbladB , WimoA , EngedalK , SoininenH , VerheyF , WaldemarG , et al. 3‐year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia and Geriatric Cognitive Disorders2006;21(5‐6):353‐63. ">Winblad 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GBS, PDS, NPI, GDS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0023" title="SchindlerR , Corey‐BloomJ , DoodyR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4‐7, 2004. 2004. SchindlerR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. Neurobiology of Aging2004;25(S2):195. ">Schindler 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TEAE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0030" title="BatsmanS , MinthonL , EerikssonS , KilanderL , Jansson‐BlixtC , WetterholmA , et al. Study design and baseline patients characteristics in a randomized controlled trial of the efficacy and tolerability of donepezil in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. ErikssonS , WinbladB , KilanderL , BatsmanS , Jansson‐BlixtC , WetterholmA , et al. Efficacy of donepezil on secondary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. JelicV , HaglundA , KowalskiJ , LangworthS , WinbladB . Donepezil treatment of severe Alzheimer's disease in nursing home settings. Dementia and Geriatric Cognitive Disorders2008;26(5):458‐46. KilanderL , WinbladB , MinthonL , BatsmanS , Jansson‐BlixtC , CronlundA , et al. Donepezil is well tolerated in patients with severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MarderK . Donepezil in patients with severe Alzheimer's disease: double‐blind parallel‐group, placebo controlled study. Current Neurology and Neuroscience Reports2006;6(5):364‐73. OpieLH . Donepezil for severe Alzheimer's disease. Lancet2006;368:361‐2. WinbladB . Donepezil for severe Alzheimer's disease ‐ author's reply. Lancet2006;368(9533):362. WinbladB . Severe Alzheimer's disease: benefits of donepezil therapy. International Psychogeriatrics2006;18(5):S25‐S31. WinbladB , KilanderL , ErikssonS , MinthonL , BåtsmanS , WetterholmA , et al. for the Severe Alzheimer’s Disease Study Group. Donepezil in patients with severe Alzheimer’s disease: double‐blind, parallel‐group, placebo‐controlled study. Lancet2006;367(9156):1057‐65. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansoon‐BlixtC , WetterholmA , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansson‐BlixtC , WetterholmAL , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. International Psychogeriatrics2005;18(S1):S25‐S31. ">Winblad 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADCS‐ADL‐sev, SIB, CGIC, NPI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The descriptions of the scales and tests appears in <a href="./appendices#CD001190-sec-0163">Appendix 2</a>. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>ACQLI</b> : Alzheimer Carer's Quality of Life Instrument; <b>ADAS‐Cog</b> : Alzheimer's Disease Assessment Scale;<b>ADCS‐ADL‐sev</b> : Alzheimer's Disease Cooperative Study‐Activities of Daily Living Scale (severe version); <b>ADFACS</b> : AD Functional Assessment and Change Score; <b>ADL</b> : Activities of Daily Living; <b>aRSS</b> : abridged Relative's Stress Scale; <b>BADLS</b> : Bristol Activities of Daily Living Scale; <b>BEHAVE‐ADL</b> : Behavioural Pathology in Alzheimer's Disease Activities of Daily Living; <b>CAUST</b> : Canadian Utilization of Services Tracking; <b>CBQ</b> : Caregiver Burden Questionnaire; <b>CDR‐SB</b> : Clinical Dementia Scale, sum of boxes; <b>CGIC</b> : Clinician's Global Impression of Change; <b>CIBIC+</b> : Clinician's Interview‐Based Impression of Change;<b>CIBIS:</b> Clinician's Interview‐based Impression of Severity<b>, CMAI</b> : Cohen‐Mansfield Agitation Inventory; CSS: Caregiver Stress Scale, CMBT: Computerized Memory Battery Test, <b>DAD</b> : Disability Assessment for Dementia; FRS: Functional Rating Scale, <b>GBS</b> : Gottfries, Brane and Steen scale; <b>GDS</b> : Geriatric Depression Scale; <b>GHQ‐30</b> : General Health Questionnaire; <b>IDDD</b> : Interview for Deterioration in Daily living in Dementia scale; <b>MENFIS</b> : Mental Function Impairment Scale; <b>MMSE</b> : Mini Mental State Examination; <b>NOSGER</b> : Nurses' Observation Scale for Geriatric Patients; <b>NPI</b> : Neuropsychiatric Instrument; <b>NPI‐D</b> : Neuropsychiatric Inventory Distress scale; <b>NPI‐NH</b> : Neuropsychiatric Inventory Nursing Home version <b>PDS</b> : Progressive Deterioration Scale; <b>QoL</b> : Quality of Life; <b>RUSP</b> : Resources Utilisation for Severe Alzheimer's Disease Patients; <b>SF‐36</b> : Short Form ‐ 36; <b>SKT</b> : Syndrom Kurz Test; <b>SIB</b> : Severe Impairment Battery; <b>TEAE</b>: treatment‐emergent adverse event </p> </div> </div> <div class="table" id="CD001190-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Study objectives</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Objectives</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0001" title="AD2000 Collaborative Group. Long‐term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double‐blind trial. Lancet2004;363:2105‐15. BenthamP , GrayR , HillR , SellwoodE , CourtneyC . Twelve week response to cholinesterase inhibitors dose not predict future benefit the AD2000 trial experience. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:337. LendonCL . Determination of responses to anticholinesterase therapy in the treatment of Alzheimer's disease. 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden: Abstract No 1287. 2002. RobertsN . A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease (AD2000). National Research Register2001. SchneiderLS . AD2000: donepezil in Alzheimer's disease. Lancet2004;363(9427):2100‐1. WaghrayS . AD2000 A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease. National Research Register2000. [MEDLINE: http://www.doh.gov.uk/nrr.htm] ">AD2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"We aimed to determine whether donepezil produces worthwhile improvements in disability, dependency, behavioural and psychological symptoms, carers’ psychological wellbeing, or delay in institutionalisation. If so, which patients<br/> benefit, from what dose, and for how long?" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0002" title="BlackS , LiHL , McRaeT , RichardsonS . Treatment of severe Alzheimer's disease with donepezil: results from a 24‐week, multinational, randomized, double‐blind, placebo‐controlled trial. Neurology2006;66(5):A347. BlackS , LiHonglang , McRaeT , RichardsonS . Donepezil treatment of severe Alzheimer's disease: results from a 24‐week, multinational, randomized, double‐blind, placebo controlled trial. Poster Presented at the Geneva Springfield ConferenceApril 2006. BlackSE , DoodyR , LiH , McRaeT , JamborKM , XuY , et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology2007;69(5):459‐69. Pfizer . E2020‐A001‐315: a 24 week multinational RCT evaluating the efficacy and safety of donepezil in severe AD. www.marc.soton.ac.uk/Research%20Page.htm. RichardsonS . A 24 week, multicenter, randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of donepezil hydrochloride (E2020) in patients with severe Alzheimer's disease followed by a 12 week open‐label extension period. www.clinicaltrials.gov/ct/show/NCT000964732004. ">Black 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the safety and efficacy of donepezil for severe Alzheimer disease (AD)."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0003" title="BayerAJ , RossorM , HeckerJ , GauthierS , BurnsA , PetiteH , et al. International Donepezil Study Group. Donepezil improves functional activity in patients with Alzheimer's disease. 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12‐16, Glasgow, Scotland. 1998. [MEDLINE: SR‐HANDSRCH] BurnsA , GauthierS , PerdomoC . Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(8):806‐12. BurnsA , RossorM , HeckerJ , GauthierS , PetitH , MöllerH‐J , et al. International Donepezil Study Group. The effects of donepezil in Alzheimer's disease ‐ results from a multinational trial. Dementia and Geriatric Cognitive Disorders1999;10(3):237‐44. GauthierS , RosserM , HeckerJ , PetiteH , RogersS , MohrE , et al. Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐June 4, Toronto, Canada1998. [MEDLINE: SR‐HANDSRCH] GauthierS , RossorM , HeckerJ . Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 15‐18 1998. PrattRD , GauthierS , BurnsA , PerdomoCA . Donepezil provides long‐term clinical benefits for patients with Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington. 2000. ">Burns 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the efficacy and safety of once‐daily administration of donepezil at doses of 5 and 10 mg versus placebo in a large, multinational cohort of patients with mild‐moderately severe Alzheimer's disease" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0004" title="CummingsJL , GeldmacherD , FarlowM , SabbaghM , ChristensenD , BetzP . High‐dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. CNS Neuroscience &amp; Therapeutics2013;19(5):294‐301. DoodyRS , GeldmacherDS , FarlowMR , SunY , MolineM , MackellJ . Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate‐to‐severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dementia and Geriatric Cognitive Disorders2012;33(2‐3):164‐73. DoodyRS , RamosH , FaisonW , ZouH . Efficacy and safety of donepezil 23 mg/d vs. donepezil 10 mg/d in patients with moderate to severe Alzheimer's disease: impact of concomitant memantine use. Journal of the American Geriatrics Society 2011 Annual Scientific meeting of the American Geriatrics Society, National Harbor, MD, USA2011. FarlowM , RichardsonS , MackellJ , SunY . Long‐term safety and tolerability of donepezil 23 MG in patients with moderate‐to‐severe Alzheimer's disease: an 18‐month analysis. Alzheimer's and Dementia 2011 Alzheimer's Association International Conference, Paris, France. 2011. FarlowM , VelosoF , MolineM , YardleyJ , Brand‐SchieberE , BibbianiF , et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurology2011;11:57. FarlowMR , SallowayS , TariotPN , YardleyJ , MolineML , WangQ , et al. Effectiveness and tolerability of high‐dose (23 mg/d) versus standard‐dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24‐week, randomized, double‐blind study. Clinical Therapeutics2010;32(7):1234‐51. FerrisS , CummingsJ , ChristensenD , DoodyR , FarlowM , SabbaghM , et al. Donepezil 23 MG/D for moderate to severe Alzheimer's disease: assessing subdomains of the Severe Impairment Battery. Journal of Nutrition, Health and Aging 5th Conference Clinical Trials on Alzheimer's Disease, Monte Carlo, Monaco. 2012. FerrisS , CummingsJ , ChristensenD , DoodyR , FarlowM , SabbaghM , et al. Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimer's Research &amp; Therapy2013;5:12. FerrisS , MacKellJ , BaiZ , SunY . Effect of donepezil 23 mg/day on language function in patients with moderate‐to‐severe Alzheimer's disease (AD): subgroup analysis of united states (U.S.)‐based patients. Alzheimer's Association International Conference 2012 Vancouver, BC Canada. 2012. FerrisSH , SchmittFA , SaxtonJ , RichardsonS , MackellJ , SunY , et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimer's Research &amp; Therapy2011;3(3):22. HanS‐H , LeeJ‐H , KimSY , ParkKW , ChenC , TripathiM , et al. Donepezil 23 mg in Asian patients with moderate‐to‐severe Alzheimer's disease. Acta Neurologica Scandinavica2017;135(2):252‐56. SabbaghM , CummingsJ , ChristensenD , DoodyR , FarlowM , LiuL , et al. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatrics2013;13:56. SabbaghM , CummingsJ , ChristensenD , DoodyR , FarlowM , MacKellJ , et al. Evaluating the cognitive effects of donepezil 23 MG/D in moderate and severe Alzheimer's disease: a patient subgroup analysis. Journal of Nutrition, Health and Aging 5th Conference Clinical Trials on Alzheimer's Disease, Monte Carlo, Monaco. 2012. SabbaghM , HanS , KimS , NaH‐R , LeeJ‐H , KandiahN , et al. Clinical recommendations for the use of donepezil 23 mg in moderate‐to‐severe Alzheimer's disease in the Asia‐Pacific region. Dementia and Geriatric Cognitive Disorders Extra2016;6:382‐95. TariotP , SallowayS , YardleyJ , MackellJ , MolineM . Long‐term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease. BMC Research Notes2012;5:283. TariotP , YardleyJ , MolineM , Brand‐SchieberE , ZouH , TimothyH , et al. Long‐term safety and tolerability of high dose donepezil (23 mg/day) in moderate to severe Alzheimer's disease: a 12‐month open‐label study. Neuropsychopharmacology 49th Annual Conference of the American College of Neuropsychopharmacology, Miami Beach, FL, USA. 2010. ">Farlow 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"The objective of this study was to compare the effectiveness and safety profile of high‐dose donepezil (23 mg/day) and standard dose donepezil (10 mg/day) in patients with moderate to severe AD" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To investigate the efficacy and safety of donepezil in patients with moderate to severe AD" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0006" title="HegerlU , MerglR , HenkelV , GallinatJ , KotterG , Muller SiechenederF , et al. Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia. Journal of Clinical Psychopharmacology2003;23(2):214‐6. ">Hegerl 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the effects of donepezil on hand motor function in patients with mild‐moderate AD" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0007" title="HommaA , ImaiY , HariguchiS , HasegawaK , KameyamaM , NishimuraT . Late phase II clinical study of acetyl cholinesterase inhibitor E2020 in patients with Alzheimer‐type dementia. Clinical Evaluation1998;26(2):251‐84. ">Homma 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate efficacy, safety and the optimal dose of E2020 in patients with mild to moderate Alzheimer‐type dementia" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0008" title="HommaA , TakedaM , ImaiY , UdakaF , HasegawaK , KameyamaM , et al. E2020 Study Group. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24‐week, multicenter, double‐blind, placebo‐controlled study in Japan. Dementia and Geriatric Cognitive Disorders2000; Vol. 11, issue 6:299‐313. ">Homma 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the efficacy and safety of donepezil hydrochloride (donepezil) at 5mg/day in patients with mild to moderately Alzheimer's disease for 24 weeks" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0009" title="HommaA , ArimotoI , KaidojiK , OhbayashiT , OzawaH . Treatment of severe Alzheimer's disease with donepezil: results from a 24 week, parallel, placebo‐controlled study in Japan. 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, July 2006. 2006. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24‐week, double‐blind, placebo‐controlled, randomized trial. Geriatric Cognitive Disorders2008;25(5):399‐407. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Long‐term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52‐week, open‐label, multicenter, extension study in Japan. Dementia and Geritatric Congitive Disorders2009;27(3):232‐9. ">Homma 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"A 24‐week, randomized, parallel‐group, double‐blind placebo‐controlled study was conducted to evaluate the efficacy and tolerability of donepezil in severe Alzheimer’s disease (AD)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0010" title="HommaA , AtarashiH , KubotaN , NakaiK , TakaseT . Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in Japanese patients with severe Alzheimer's disease: a randomized, double‐blind trial. Journal of Alzheimer's disease2016;52(1):345‐57. ">Homma 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To demonstrate the superiority of SR 23 mg/day donepezil over IR 10 mg/day donepezil in Japanese patients with<br/> severe AD (SAD)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0011" title="HowardRJ , JuszczakE , BallardCG , BenthamP Brown RG , BullockR , et al. CALM‐AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine2007;357(14):1382‐92. PelosiA . Donepezil is no more effective than placebo for agitation in people with Alzheimer's disease. Evidence‐Based Mental Health2008;11(3):84. ">Howard 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"The primary question was whether donepezil is better than placebo in the management of agitation that is inappropriate for, or has not responded to, a psychosocial treatment." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0012" title="JiaJP , WeiCB , JiaLF , TangY , LiangJH , ZhouAH , et al. Efficacy and safety of donepezil in Chinese patients with severe Alzheimer's disease: a randomized controlled trial. Journal of Alzheimer's disease2017;56(4):1495‐504. ">Jia 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To examine the effects of donepezil on N‐acetylaspartate concentration and hippocampal volume in patients with mild‐moderate AD" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0013" title="Anon . No title. Eisai Inc. KrishnanKR , CharlesHC , DoraiswamyPM , MintzerJ , WeislerR , YuX , et al. Randomized, placebo‐controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. The American Journal of Psychiatry2003;160(11):2003‐11. ">Krishnan 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"The authors examined the effect of the acetylcholinesterase inhibitor donepezil on magnetic resonance markers<br/> of neurodegeneration in Alzheimer’s disease." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0014" title="RobertP , LebertF , GoniS , TouchonJ , VincentS , ARIAL Study Investigators Collaborative Group. The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. Quality Research in Dementia; 19‐22 November, 2000, London. 2000. RobertPH , LebertF , GoniS , TouchonJ , ARIAL Study Investigators Collaborative Group. The impact of caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">Lebert 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD2000 is a large, simple, ‘real‐life’ trial that aims to produce reliable evidence on the value of donepezil (Aricept®) in routine practice </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0015" title="Maher‐EdwardsG , DixonR , HunterJ , GoldM , HoptonG , JacobsG , et al. SB‐742457 and donepezil in Alzheimer's disease: a randomized, placebo‐controlled study. International Journal of Geriatric Psychiatry2011;26(5):536‐44. Maher‐EdwardsG , Zvartau‐HindM , DaviesJ , AlexanderK , SchronenJ , BoswellD , et al. Effects of 6‐month monotherapy treatment with the 5HT6 receptor antagonist SB 742457 or donepezil in subjects with mild‐to‐moderate Alzheimer's disease. Alzheimer's Association International Conference, Paris, France. 2011. ">Maher‐Edwards 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"This exploratory study was designed to estimate the effects of donepezil and SB‐742457 in a current day setting and population using a study design similar to those employed in two pivotal studies with donepezil (<a href="./references#CD001190-bbs2-0022" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. Erratum: a 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613‐620)). Neurology2001; Vol. 57, issue 11:2153. FriedhoffLT , RogersL . Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease ‐ results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston. Neurology1997;48(3):A100. FriedhoffLT , RogersSL . Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17, Vienna, Austria1997. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis. European Journal of Neurology1997;4(Suppl 1):S9. RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyR , MohsR , FriedhoffLT . E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30‐week phase III trial. Neurology1996;46:A217 S14.001 ARI‐8. RogersSL , DoodyR , MohsR , FriedhoffT , Donepezil Study Group. E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30‐week trial. Unpublished paper1996b. RogersSL , FarlowMR , DoodyRS , MohsR , FriedhoffLT , Donepezil Study Group. A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998;50(1):136‐45. RogersSL , FriedhoffLT , FarlowMR , DoodyRS , MohsR . Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply]. Neurology1999; Vol. 52, issue 1:218‐19. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego1997. ">Rogers 1998b</a>, <a href="./references#CD001190-bbs2-0003" title="BayerAJ , RossorM , HeckerJ , GauthierS , BurnsA , PetiteH , et al. International Donepezil Study Group. Donepezil improves functional activity in patients with Alzheimer's disease. 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12‐16, Glasgow, Scotland. 1998. [MEDLINE: SR‐HANDSRCH] BurnsA , GauthierS , PerdomoC . Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(8):806‐12. BurnsA , RossorM , HeckerJ , GauthierS , PetitH , MöllerH‐J , et al. International Donepezil Study Group. The effects of donepezil in Alzheimer's disease ‐ results from a multinational trial. Dementia and Geriatric Cognitive Disorders1999;10(3):237‐44. GauthierS , RosserM , HeckerJ , PetiteH , RogersS , MohrE , et al. Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐June 4, Toronto, Canada1998. [MEDLINE: SR‐HANDSRCH] GauthierS , RossorM , HeckerJ . Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 15‐18 1998. PrattRD , GauthierS , BurnsA , PerdomoCA . Donepezil provides long‐term clinical benefits for patients with Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington. 2000. ">Burns 1999</a>)" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0016" title="KorczynAD . Comments on the article by Mazza et al. concerning Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study. European Journal of Neurology2007;14(9):e9. MazzaM , CapuanoA , BriaAP , MazzaS . Letter to the editor. European Journal of Neurology2007;14(9):e10. MazzaM , CapuanoA , BriaP , MazzaS . Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study. European Journal of Neurology2006;13(9):981‐85. ">Mazza 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To assess the efficacy of Ginkgo biloba special extract in patients with dementia of the Alzheimer type in slowing down the disease's progression and patient's cognitive impairment compared with donepezil and placebo" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0017" title="EbellM . Does donepezil help patients with moderate Alzheimer's dementia preserve their ability to function independently?. Evidence Based Practice2002. MohsR , DoodyR , MorrisJ , IeniJ , PerdomoC , PrattR , et al. Donepezil preserves activities of daily living in Alzheimer's disease patients: results from a one‐year placebo‐controlled functional survival study. Neurology2000;54(Suppl 3):A415. MohsR , DoodyR , MorrisJ , IeniJ , RogersS , PerdomoC , et al. Donepezil preserves functional status and improves cognition in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Journal of the American Geriatrics Society2000;48(8):S46. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled attrition study. Journal of the European College of Neuropsychopharmacology1999;9(Suppl 5):S328. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Quality Research in Dementia Conference; 2000 November 19‐22, London. 2000. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoC , et al. 312 Study Group. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients [Erratum]. Neurology2001; Vol. 57, issue 10:1942. [MEDLINE: http://www.lww.com] MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients. Neurology2001;57(3):481‐8. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illinois. 2000. [MEDLINE: SR‐HANDSRCH] PrattR , MohsR , DoodyR , MorrisJ , RogersS , IeniJ , et al. Donepezil preserves functional status in Alzheimer's disease patients results from a 1‐year prospective placebo controlled functional study. Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden2000:178. ">Mohs 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To examine the effects of donepezil compared with placebo on the preservation of function in<br/> patients with AD over a 1‐year period" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0018" title="MoraesW , PoyaresD , Sukys‐ClaudinoL , GuilleminaultC , TufikS . Donepezil improves obstructive sleep apnoea in Alzheimer disease: a double‐blind, placebo‐controlled study. Chest2008;133(3):677‐83. MoraesW , Sukys‐ClaudinoL , PoyaresD , GuilleminaultC , TufikS . Donepezil improves oxygen desaturation in patients with alzheimer's disease and obstructive sleep apnoea. Sleep Medicine2006;7(S47):368. ">Moraes 2006a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"This study evaluates the effects of donepezil on obstructive sleep apnea in patients with<br/> Alzheimer disease." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0019" title="MoraesW dos S , PoyaresDR , GuilleminaultC , RamosLR , BertolucciPH , TufikS . The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double‐blind placebo‐controlled study. Sleep2006;29(2):199‐205. ">Moraes 2006b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Examine the effects of donepezil on sleep and rapid eye movement (REM) sleep electroencephalogram (EEG) in patients with Alzheimer disease, using polysomnography" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0020" title="FriedhoffLT , IeniJR , RogersSL , PrattRD . Donepezil provides long‐term clinical benefits for patients with Alzheimer's Disease. Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum;1998 July 12‐16, Glasgow, Scotland1998:ABSTRACT REF: PW11017. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Correlation between the clinical efficacy of donepezil HCL (E2020) and red blood cell (RBC) acetylcholinesterase (ACHE) inhibition in patients with Alzheimer's disease. Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5‐8, San Diego. UK: Medical Education Network, 1997; Vol. 2:6‐7. RogersS , PerdomoC , FriedhoffL . Clinical benefits are maintained during long‐term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 September 30‐October 4, Venice1995a. [MEDLINE: SR‐HANDSRCH] RogersSL , DoodyRS , PrattRD , IeniJR . Long‐term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open‐label study. European Neuropsychopharmacology2000; Vol. 10, issue 3:195‐203. RogersSL , FriedhoffLT . E2020 improves cognition and quality of life in patients with mild to moderate Alzheimers Disease: results of a phase II trial. Proceedings of the 46th Annual meeting of the American Academy of Neurology. 1994 May 1‐7, Washington DC1994; Vol. 44, issue Suppl 2:A165. RogersSL , Friedhoff LT and the Donepezil Study Group. The Efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double‐blind, placebo‐controlled trial. Dementia1996;7:293‐303. ">Rogers 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the efficacy and safety of donepezil in patients with mild to moderately severe Alzheimer's disease and to examine the relationships between plasma donepezil concentration, red blood cell acetylcholinesterase activity and clinical response" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0021" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. PrattRD , PerdomoCA , IeniJK . Long‐term safety and tolerability of donepezil: results from a phase iii extension trial of patients with mild to moderately severe Alzheimer's disease. European Journal of Neurology1999;6(Suppl 3):116. [MEDLINE: SR‐HANDSRCH] RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyRS , MohsRC , FriedhoffLT , the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine1998;158:1021‐31. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego. 1997. ">Rogers 1998a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"The present phase I11 study was undertaken to further evaluate the efficacy and safety of donepezil at dosage levels of 5 and 10 mg/d versus placebo in patients with mild to moderate AD" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0022" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. Erratum: a 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613‐620)). Neurology2001; Vol. 57, issue 11:2153. FriedhoffLT , RogersL . Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease ‐ results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston. Neurology1997;48(3):A100. FriedhoffLT , RogersSL . Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17, Vienna, Austria1997. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis. European Journal of Neurology1997;4(Suppl 1):S9. RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyR , MohsR , FriedhoffLT . E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30‐week phase III trial. Neurology1996;46:A217 S14.001 ARI‐8. RogersSL , DoodyR , MohsR , FriedhoffT , Donepezil Study Group. E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30‐week trial. Unpublished paper1996b. RogersSL , FarlowMR , DoodyRS , MohsR , FriedhoffLT , Donepezil Study Group. A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998;50(1):136‐45. RogersSL , FriedhoffLT , FarlowMR , DoodyRS , MohsR . Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply]. Neurology1999; Vol. 52, issue 1:218‐19. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego1997. ">Rogers 1998b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"This phase 3 study was 1 of 2 pivotal trials undertaken to establish the efficacy and safety of using donepezil in patients with mild to moderately severe Alzheimer disease" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0023" title="SchindlerR , Corey‐BloomJ , DoodyR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4‐7, 2004. 2004. SchindlerR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. Neurobiology of Aging2004;25(S2):195. ">Schindler 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To determine the safety and tolerability of treatment with 15 or 20 mg/day donepezil in mild to moderate AD" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0024" title="SeltzerB , ZolnouniP , NunezM , GoldmanR , KumarD , IeniJ , et al. Erratum: efficacy of donepezil in early‐stage alzheimer disease: a randomized placebo‐controlled trial (Archives of Neurology (December 2004) 61 (1852‐1856)). Archives of Neurology2005;62(5):825. SeltzerB , ZolnouniP , NunezM , GoldmanR , KumarD , IeniJ , et al. Donepezil 402 Study Group. Efficacy of donepezil in early‐stage Alzheimer disease. Archives of Neurolology2004;61:1852‐6. ">Seltzer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the efficacy of donepezil in patients with early‐stage Alzheimer disease"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0025" title="Anon . No title. Eisai Inc. ">Study 205</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the effect of donepezil on visuospatial attention in Alzheimer's disease patients" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0026" title="Anon . No title. Eisai Inc. ">Study 306</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the utility of APo‐E subtype in predicting response to treatment with donepezil in Alzheimer's disease patients" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0027" title="SteinmanMA , CovinskyKE , TariotPN , CummingsJL , KatzIR , MintzerJ , et al. Donepezil for nursing home patients with dementia: a reinterpretation of the evidence. Journal of the American Geriatrics Society2003;51(1):132‐33. TariotP , CummingsJL , KatzIR , PerdomoCA , WhalenE , SovelMA , et al. Donepezil was well‐tolerated and enhanced cognition in nursing home patients with Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. TariotP , PerdomoCA , WhalenE , SovelMA , SchamEM . Age is not a barrier to donepezil treatment of Alzheimer's disease in the long‐term care setting. International Psychogeriatrics1999;11(Supplement 1):134. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomised, double‐blind, placebo‐controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2003;51(1):133‐4. ">Tariot 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the safety and efficacy of donepezil in the management of patients with Alzheimer’s disease (AD) residing in nursing home facilities." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0028" title="TuneL , TiseoP , HoffmanJ , PerdomoC , VotawJ , RogersS , et al. PET in AD: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer's disease: results of a 24‐week study. 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 February 23‐26 San Francisco. 2001. TuneL , TiseoPJ , IeniJ , PerdomoC , PrattRD , VotawJR , et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24‐week, double‐blind, placebo‐controlled study. American Journal of Geriatric Psychiatry2003;11(2):169‐77. TuneLE , TiseoPJ , HoffmanJM , PerdomoCA , VotowJR , RogersSL , et al. Functional brain activity in Alzheimer's disease. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐ June 4, Toronto. 1998:NR345. [MEDLINE: SR‐HANDSRCH] ">Tune 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"This study evaluated the effects of donepezil on functional brain activity in patients with AD." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0029" title="EngedalK , SoininenH , VerheyF , WaldemarG , WinbladB , WimoA , et al. Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000; Vol. 10, issue Suppl 3:S368. [MEDLINE: SR‐HANDSRCH] MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a one year, double‐blind, randomized trial. Journal of the American Geriatrics Society2001; Vol. 49, issue 4:S131. MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. Donepezil reduces the time caregivers spend providing care: results of a one‐year, double‐blind, randomized trial in patients with mild to moderate Alzheimer's disease. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23‐26, San Francisco2001. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Long term benefits of donepezil on ADLs in AD patients. Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:171. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Donepezil Nordic Study Group. Response to donepezil is not predicted by apolipoprotein E genotype and/or gender. World Alzheimer Congress; 2000 July 9‐13, Washington. 2000. WaldemarG , WinbladB , EngedalK , SoininenH , Donepezil Nordic Study Group et al. Benefits of donepezil on cognition, function and/or neuropsychiatric symptoms in patients with Alzheimers disease over one year. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WaldemarG , WinbladB , EngedalK , SoininenHS , VerheyFR , WimoA , et al. Donepezil Nordic Study Group. Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year. Neurology2000;54(Suppl 3):A470. WimoA . Erratum: an economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial (Dementia and Geriatric Cognitive Disorders (2003) 15 (44‐54)). Dementia and Geriatric Cognitive Disorders2003; Vol. 16, issue 2:102. WimoA , WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , et al. Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial. Dementia and Geriatric Cognitive Disorders2003;15(1):44‐54. WimoA , WinbladB , MasteyV . An economic evaluation of donepezil in mild to moderate Alzheimers disease: results of a one‐year, double‐blind, randomized trial. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WimoA , WinbladB , MasteyV , HaglundA , HertzmanP , MiceliR , et al. An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one‐year, double‐blind, randomized trial. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illionois. 2000. [MEDLINE: SR‐HANDSRCH] WinbladB . Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:164. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , WetterholmAL , ZhangR , HaglundA , SubbiahP . Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. International Psychogeriatrics1999;11(Supplement 1):138. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. A 1‐year, randomized, placebo‐controlled study of donepezil in patients with mild to moderate AD. Neurology2001;57(3):489‐95. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. Donepezil enhances global function and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. Quality Research in Dementia Conference; 2000 Nov 19‐22, London. 2000. WinbladB , WimoA , EngedalK , SoininenH , VerheyF , WaldemarG , et al. 3‐year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia and Geriatric Cognitive Disorders2006;21(5‐6):353‐63. ">Winblad 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the long‐term clinical efficacy and safety of donepezil versus placebo over 1 year in patients with mild to moderate AD." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0030" title="BatsmanS , MinthonL , EerikssonS , KilanderL , Jansson‐BlixtC , WetterholmA , et al. Study design and baseline patients characteristics in a randomized controlled trial of the efficacy and tolerability of donepezil in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. ErikssonS , WinbladB , KilanderL , BatsmanS , Jansson‐BlixtC , WetterholmA , et al. Efficacy of donepezil on secondary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. JelicV , HaglundA , KowalskiJ , LangworthS , WinbladB . Donepezil treatment of severe Alzheimer's disease in nursing home settings. Dementia and Geriatric Cognitive Disorders2008;26(5):458‐46. KilanderL , WinbladB , MinthonL , BatsmanS , Jansson‐BlixtC , CronlundA , et al. Donepezil is well tolerated in patients with severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MarderK . Donepezil in patients with severe Alzheimer's disease: double‐blind parallel‐group, placebo controlled study. Current Neurology and Neuroscience Reports2006;6(5):364‐73. OpieLH . Donepezil for severe Alzheimer's disease. Lancet2006;368:361‐2. WinbladB . Donepezil for severe Alzheimer's disease ‐ author's reply. Lancet2006;368(9533):362. WinbladB . Severe Alzheimer's disease: benefits of donepezil therapy. International Psychogeriatrics2006;18(5):S25‐S31. WinbladB , KilanderL , ErikssonS , MinthonL , BåtsmanS , WetterholmA , et al. for the Severe Alzheimer’s Disease Study Group. Donepezil in patients with severe Alzheimer’s disease: double‐blind, parallel‐group, placebo‐controlled study. Lancet2006;367(9156):1057‐65. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansoon‐BlixtC , WetterholmA , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansson‐BlixtC , WetterholmAL , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. International Psychogeriatrics2005;18(S1):S25‐S31. ">Winblad 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Our aim was to assess the eff ect of donepezil on cognition and activities of daily living in patients with severe Alzheimer’s disease living in nursing homes ran by trained staff ." </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>AD</b> : Alzheimer's disease; <b>SAD</b> : severe Alzheimer's disease;; <b>REM:</b> rapid eye movement </p> </div> </div> <section id="CD001190-sec-0069"> <h5 class="title">Design, participants, sample sizes and interventions</h5> <p>Only randomised, double‐blind, placebo‐controlled studies, or studies comparing different doses of donepezil were included in this review. All included studies were described as randomised and double‐blind, but further details on the randomisation and blinding were not always reported. </p> <p>All included studies have been reported since 1996.</p> <section id="CD001190-sec-0070"> <h6 class="title">Studies published in 2001 or earlier</h6> <p>Eleven studies were reported in 2001 or earlier.</p> <p>Of these, six studies (<a href="./references#CD001190-bbs2-0007" title="HommaA , ImaiY , HariguchiS , HasegawaK , KameyamaM , NishimuraT . Late phase II clinical study of acetyl cholinesterase inhibitor E2020 in patients with Alzheimer‐type dementia. Clinical Evaluation1998;26(2):251‐84. ">Homma 1998</a>; <a href="./references#CD001190-bbs2-0020" title="FriedhoffLT , IeniJR , RogersSL , PrattRD . Donepezil provides long‐term clinical benefits for patients with Alzheimer's Disease. Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum;1998 July 12‐16, Glasgow, Scotland1998:ABSTRACT REF: PW11017. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Correlation between the clinical efficacy of donepezil HCL (E2020) and red blood cell (RBC) acetylcholinesterase (ACHE) inhibition in patients with Alzheimer's disease. Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5‐8, San Diego. UK: Medical Education Network, 1997; Vol. 2:6‐7. RogersS , PerdomoC , FriedhoffL . Clinical benefits are maintained during long‐term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 September 30‐October 4, Venice1995a. [MEDLINE: SR‐HANDSRCH] RogersSL , DoodyRS , PrattRD , IeniJR . Long‐term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open‐label study. European Neuropsychopharmacology2000; Vol. 10, issue 3:195‐203. RogersSL , FriedhoffLT . E2020 improves cognition and quality of life in patients with mild to moderate Alzheimers Disease: results of a phase II trial. Proceedings of the 46th Annual meeting of the American Academy of Neurology. 1994 May 1‐7, Washington DC1994; Vol. 44, issue Suppl 2:A165. RogersSL , Friedhoff LT and the Donepezil Study Group. The Efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double‐blind, placebo‐controlled trial. Dementia1996;7:293‐303. ">Rogers 1996</a>; <a href="./references#CD001190-bbs2-0021" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. PrattRD , PerdomoCA , IeniJK . Long‐term safety and tolerability of donepezil: results from a phase iii extension trial of patients with mild to moderately severe Alzheimer's disease. European Journal of Neurology1999;6(Suppl 3):116. [MEDLINE: SR‐HANDSRCH] RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyRS , MohsRC , FriedhoffLT , the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine1998;158:1021‐31. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego. 1997. ">Rogers 1998a</a>; <a href="./references#CD001190-bbs2-0022" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. Erratum: a 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613‐620)). Neurology2001; Vol. 57, issue 11:2153. FriedhoffLT , RogersL . Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease ‐ results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston. Neurology1997;48(3):A100. FriedhoffLT , RogersSL . Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17, Vienna, Austria1997. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis. European Journal of Neurology1997;4(Suppl 1):S9. RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyR , MohsR , FriedhoffLT . E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30‐week phase III trial. Neurology1996;46:A217 S14.001 ARI‐8. RogersSL , DoodyR , MohsR , FriedhoffT , Donepezil Study Group. E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30‐week trial. Unpublished paper1996b. RogersSL , FarlowMR , DoodyRS , MohsR , FriedhoffLT , Donepezil Study Group. A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998;50(1):136‐45. RogersSL , FriedhoffLT , FarlowMR , DoodyRS , MohsR . Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply]. Neurology1999; Vol. 52, issue 1:218‐19. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego1997. ">Rogers 1998b</a>; <a href="./references#CD001190-bbs2-0003" title="BayerAJ , RossorM , HeckerJ , GauthierS , BurnsA , PetiteH , et al. International Donepezil Study Group. Donepezil improves functional activity in patients with Alzheimer's disease. 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12‐16, Glasgow, Scotland. 1998. [MEDLINE: SR‐HANDSRCH] BurnsA , GauthierS , PerdomoC . Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(8):806‐12. BurnsA , RossorM , HeckerJ , GauthierS , PetitH , MöllerH‐J , et al. International Donepezil Study Group. The effects of donepezil in Alzheimer's disease ‐ results from a multinational trial. Dementia and Geriatric Cognitive Disorders1999;10(3):237‐44. GauthierS , RosserM , HeckerJ , PetiteH , RogersS , MohrE , et al. Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐June 4, Toronto, Canada1998. [MEDLINE: SR‐HANDSRCH] GauthierS , RossorM , HeckerJ . Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 15‐18 1998. PrattRD , GauthierS , BurnsA , PerdomoCA . Donepezil provides long‐term clinical benefits for patients with Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington. 2000. ">Burns 1999</a>; <a href="./references#CD001190-bbs2-0029" title="EngedalK , SoininenH , VerheyF , WaldemarG , WinbladB , WimoA , et al. Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000; Vol. 10, issue Suppl 3:S368. [MEDLINE: SR‐HANDSRCH] MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a one year, double‐blind, randomized trial. Journal of the American Geriatrics Society2001; Vol. 49, issue 4:S131. MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. Donepezil reduces the time caregivers spend providing care: results of a one‐year, double‐blind, randomized trial in patients with mild to moderate Alzheimer's disease. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23‐26, San Francisco2001. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Long term benefits of donepezil on ADLs in AD patients. Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:171. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Donepezil Nordic Study Group. Response to donepezil is not predicted by apolipoprotein E genotype and/or gender. World Alzheimer Congress; 2000 July 9‐13, Washington. 2000. WaldemarG , WinbladB , EngedalK , SoininenH , Donepezil Nordic Study Group et al. Benefits of donepezil on cognition, function and/or neuropsychiatric symptoms in patients with Alzheimers disease over one year. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WaldemarG , WinbladB , EngedalK , SoininenHS , VerheyFR , WimoA , et al. Donepezil Nordic Study Group. Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year. Neurology2000;54(Suppl 3):A470. WimoA . Erratum: an economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial (Dementia and Geriatric Cognitive Disorders (2003) 15 (44‐54)). Dementia and Geriatric Cognitive Disorders2003; Vol. 16, issue 2:102. WimoA , WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , et al. Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial. Dementia and Geriatric Cognitive Disorders2003;15(1):44‐54. WimoA , WinbladB , MasteyV . An economic evaluation of donepezil in mild to moderate Alzheimers disease: results of a one‐year, double‐blind, randomized trial. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WimoA , WinbladB , MasteyV , HaglundA , HertzmanP , MiceliR , et al. An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one‐year, double‐blind, randomized trial. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illionois. 2000. [MEDLINE: SR‐HANDSRCH] WinbladB . Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:164. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , WetterholmAL , ZhangR , HaglundA , SubbiahP . Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. International Psychogeriatrics1999;11(Supplement 1):138. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. A 1‐year, randomized, placebo‐controlled study of donepezil in patients with mild to moderate AD. Neurology2001;57(3):489‐95. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. Donepezil enhances global function and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. Quality Research in Dementia Conference; 2000 Nov 19‐22, London. 2000. WinbladB , WimoA , EngedalK , SoininenH , VerheyF , WaldemarG , et al. 3‐year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia and Geriatric Cognitive Disorders2006;21(5‐6):353‐63. ">Winblad 2001</a>) were designed to evaluate the efficacy and safety of donepezil in people with mild to moderately severe dementia due to Alzheimer's disease and one study (<a href="./references#CD001190-bbs2-0027" title="SteinmanMA , CovinskyKE , TariotPN , CummingsJL , KatzIR , MintzerJ , et al. Donepezil for nursing home patients with dementia: a reinterpretation of the evidence. Journal of the American Geriatrics Society2003;51(1):132‐33. TariotP , CummingsJL , KatzIR , PerdomoCA , WhalenE , SovelMA , et al. Donepezil was well‐tolerated and enhanced cognition in nursing home patients with Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. TariotP , PerdomoCA , WhalenE , SovelMA , SchamEM . Age is not a barrier to donepezil treatment of Alzheimer's disease in the long‐term care setting. International Psychogeriatrics1999;11(Supplement 1):134. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomised, double‐blind, placebo‐controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2003;51(1):133‐4. ">Tariot 2001</a>), was designed to examine efficacy, safety and tolerability in the management of very elderly residents with Alzheimer's disease in nursing homes, particularly the effect of donepezil on neuropsychiatric manifestations. <a href="./references#CD001190-bbs2-0020" title="FriedhoffLT , IeniJR , RogersSL , PrattRD . Donepezil provides long‐term clinical benefits for patients with Alzheimer's Disease. Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum;1998 July 12‐16, Glasgow, Scotland1998:ABSTRACT REF: PW11017. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Correlation between the clinical efficacy of donepezil HCL (E2020) and red blood cell (RBC) acetylcholinesterase (ACHE) inhibition in patients with Alzheimer's disease. Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5‐8, San Diego. UK: Medical Education Network, 1997; Vol. 2:6‐7. RogersS , PerdomoC , FriedhoffL . Clinical benefits are maintained during long‐term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 September 30‐October 4, Venice1995a. [MEDLINE: SR‐HANDSRCH] RogersSL , DoodyRS , PrattRD , IeniJR . Long‐term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open‐label study. European Neuropsychopharmacology2000; Vol. 10, issue 3:195‐203. RogersSL , FriedhoffLT . E2020 improves cognition and quality of life in patients with mild to moderate Alzheimers Disease: results of a phase II trial. Proceedings of the 46th Annual meeting of the American Academy of Neurology. 1994 May 1‐7, Washington DC1994; Vol. 44, issue Suppl 2:A165. RogersSL , Friedhoff LT and the Donepezil Study Group. The Efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double‐blind, placebo‐controlled trial. Dementia1996;7:293‐303. ">Rogers 1996</a>, <a href="./references#CD001190-bbs2-0021" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. PrattRD , PerdomoCA , IeniJK . Long‐term safety and tolerability of donepezil: results from a phase iii extension trial of patients with mild to moderately severe Alzheimer's disease. European Journal of Neurology1999;6(Suppl 3):116. [MEDLINE: SR‐HANDSRCH] RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyRS , MohsRC , FriedhoffLT , the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine1998;158:1021‐31. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego. 1997. ">Rogers 1998a</a>, <a href="./references#CD001190-bbs2-0022" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. Erratum: a 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613‐620)). Neurology2001; Vol. 57, issue 11:2153. FriedhoffLT , RogersL . Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease ‐ results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston. Neurology1997;48(3):A100. FriedhoffLT , RogersSL . Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17, Vienna, Austria1997. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis. European Journal of Neurology1997;4(Suppl 1):S9. RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyR , MohsR , FriedhoffLT . E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30‐week phase III trial. Neurology1996;46:A217 S14.001 ARI‐8. RogersSL , DoodyR , MohsR , FriedhoffT , Donepezil Study Group. E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30‐week trial. Unpublished paper1996b. RogersSL , FarlowMR , DoodyRS , MohsR , FriedhoffLT , Donepezil Study Group. A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998;50(1):136‐45. RogersSL , FriedhoffLT , FarlowMR , DoodyRS , MohsR . Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply]. Neurology1999; Vol. 52, issue 1:218‐19. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego1997. ">Rogers 1998b</a>, <a href="./references#CD001190-bbs2-0003" title="BayerAJ , RossorM , HeckerJ , GauthierS , BurnsA , PetiteH , et al. International Donepezil Study Group. Donepezil improves functional activity in patients with Alzheimer's disease. 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12‐16, Glasgow, Scotland. 1998. [MEDLINE: SR‐HANDSRCH] BurnsA , GauthierS , PerdomoC . Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(8):806‐12. BurnsA , RossorM , HeckerJ , GauthierS , PetitH , MöllerH‐J , et al. International Donepezil Study Group. The effects of donepezil in Alzheimer's disease ‐ results from a multinational trial. Dementia and Geriatric Cognitive Disorders1999;10(3):237‐44. GauthierS , RosserM , HeckerJ , PetiteH , RogersS , MohrE , et al. Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐June 4, Toronto, Canada1998. [MEDLINE: SR‐HANDSRCH] GauthierS , RossorM , HeckerJ . Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 15‐18 1998. PrattRD , GauthierS , BurnsA , PerdomoCA . Donepezil provides long‐term clinical benefits for patients with Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington. 2000. ">Burns 1999</a> and <a href="./references#CD001190-bbs2-0027" title="SteinmanMA , CovinskyKE , TariotPN , CummingsJL , KatzIR , MintzerJ , et al. Donepezil for nursing home patients with dementia: a reinterpretation of the evidence. Journal of the American Geriatrics Society2003;51(1):132‐33. TariotP , CummingsJL , KatzIR , PerdomoCA , WhalenE , SovelMA , et al. Donepezil was well‐tolerated and enhanced cognition in nursing home patients with Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. TariotP , PerdomoCA , WhalenE , SovelMA , SchamEM . Age is not a barrier to donepezil treatment of Alzheimer's disease in the long‐term care setting. International Psychogeriatrics1999;11(Supplement 1):134. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomised, double‐blind, placebo‐controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2003;51(1):133‐4. ">Tariot 2001</a> were all supported by Eisai Inc. The <a href="./references#CD001190-bbs2-0029" title="EngedalK , SoininenH , VerheyF , WaldemarG , WinbladB , WimoA , et al. Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000; Vol. 10, issue Suppl 3:S368. [MEDLINE: SR‐HANDSRCH] MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a one year, double‐blind, randomized trial. Journal of the American Geriatrics Society2001; Vol. 49, issue 4:S131. MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. Donepezil reduces the time caregivers spend providing care: results of a one‐year, double‐blind, randomized trial in patients with mild to moderate Alzheimer's disease. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23‐26, San Francisco2001. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Long term benefits of donepezil on ADLs in AD patients. Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:171. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Donepezil Nordic Study Group. Response to donepezil is not predicted by apolipoprotein E genotype and/or gender. World Alzheimer Congress; 2000 July 9‐13, Washington. 2000. WaldemarG , WinbladB , EngedalK , SoininenH , Donepezil Nordic Study Group et al. Benefits of donepezil on cognition, function and/or neuropsychiatric symptoms in patients with Alzheimers disease over one year. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WaldemarG , WinbladB , EngedalK , SoininenHS , VerheyFR , WimoA , et al. Donepezil Nordic Study Group. Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year. Neurology2000;54(Suppl 3):A470. WimoA . Erratum: an economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial (Dementia and Geriatric Cognitive Disorders (2003) 15 (44‐54)). Dementia and Geriatric Cognitive Disorders2003; Vol. 16, issue 2:102. WimoA , WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , et al. Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial. Dementia and Geriatric Cognitive Disorders2003;15(1):44‐54. WimoA , WinbladB , MasteyV . An economic evaluation of donepezil in mild to moderate Alzheimers disease: results of a one‐year, double‐blind, randomized trial. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WimoA , WinbladB , MasteyV , HaglundA , HertzmanP , MiceliR , et al. An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one‐year, double‐blind, randomized trial. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illionois. 2000. [MEDLINE: SR‐HANDSRCH] WinbladB . Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:164. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , WetterholmAL , ZhangR , HaglundA , SubbiahP . Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. International Psychogeriatrics1999;11(Supplement 1):138. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. A 1‐year, randomized, placebo‐controlled study of donepezil in patients with mild to moderate AD. Neurology2001;57(3):489‐95. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. Donepezil enhances global function and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. Quality Research in Dementia Conference; 2000 Nov 19‐22, London. 2000. WinbladB , WimoA , EngedalK , SoininenH , VerheyF , WaldemarG , et al. 3‐year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia and Geriatric Cognitive Disorders2006;21(5‐6):353‐63. ">Winblad 2001</a> was supported by Pfizer Inc. It is not clear how <a href="./references#CD001190-bbs2-0007" title="HommaA , ImaiY , HariguchiS , HasegawaK , KameyamaM , NishimuraT . Late phase II clinical study of acetyl cholinesterase inhibitor E2020 in patients with Alzheimer‐type dementia. Clinical Evaluation1998;26(2):251‐84. ">Homma 1998</a> was supported. <a href="./references#CD001190-bbs2-0020" title="FriedhoffLT , IeniJR , RogersSL , PrattRD . Donepezil provides long‐term clinical benefits for patients with Alzheimer's Disease. Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum;1998 July 12‐16, Glasgow, Scotland1998:ABSTRACT REF: PW11017. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Correlation between the clinical efficacy of donepezil HCL (E2020) and red blood cell (RBC) acetylcholinesterase (ACHE) inhibition in patients with Alzheimer's disease. Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5‐8, San Diego. UK: Medical Education Network, 1997; Vol. 2:6‐7. RogersS , PerdomoC , FriedhoffL . Clinical benefits are maintained during long‐term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 September 30‐October 4, Venice1995a. [MEDLINE: SR‐HANDSRCH] RogersSL , DoodyRS , PrattRD , IeniJR . Long‐term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open‐label study. European Neuropsychopharmacology2000; Vol. 10, issue 3:195‐203. RogersSL , FriedhoffLT . E2020 improves cognition and quality of life in patients with mild to moderate Alzheimers Disease: results of a phase II trial. Proceedings of the 46th Annual meeting of the American Academy of Neurology. 1994 May 1‐7, Washington DC1994; Vol. 44, issue Suppl 2:A165. RogersSL , Friedhoff LT and the Donepezil Study Group. The Efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double‐blind, placebo‐controlled trial. Dementia1996;7:293‐303. ">Rogers 1996</a> was described as a phase II study, and <a href="./references#CD001190-bbs2-0021" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. PrattRD , PerdomoCA , IeniJK . Long‐term safety and tolerability of donepezil: results from a phase iii extension trial of patients with mild to moderately severe Alzheimer's disease. European Journal of Neurology1999;6(Suppl 3):116. [MEDLINE: SR‐HANDSRCH] RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyRS , MohsRC , FriedhoffLT , the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine1998;158:1021‐31. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego. 1997. ">Rogers 1998a</a>, <a href="./references#CD001190-bbs2-0022" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. Erratum: a 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613‐620)). Neurology2001; Vol. 57, issue 11:2153. FriedhoffLT , RogersL . Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease ‐ results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston. Neurology1997;48(3):A100. FriedhoffLT , RogersSL . Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17, Vienna, Austria1997. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis. European Journal of Neurology1997;4(Suppl 1):S9. RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyR , MohsR , FriedhoffLT . E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30‐week phase III trial. Neurology1996;46:A217 S14.001 ARI‐8. RogersSL , DoodyR , MohsR , FriedhoffT , Donepezil Study Group. E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30‐week trial. Unpublished paper1996b. RogersSL , FarlowMR , DoodyRS , MohsR , FriedhoffLT , Donepezil Study Group. A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998;50(1):136‐45. RogersSL , FriedhoffLT , FarlowMR , DoodyRS , MohsR . Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply]. Neurology1999; Vol. 52, issue 1:218‐19. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego1997. ">Rogers 1998b</a>, <a href="./references#CD001190-bbs2-0003" title="BayerAJ , RossorM , HeckerJ , GauthierS , BurnsA , PetiteH , et al. International Donepezil Study Group. Donepezil improves functional activity in patients with Alzheimer's disease. 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12‐16, Glasgow, Scotland. 1998. [MEDLINE: SR‐HANDSRCH] BurnsA , GauthierS , PerdomoC . Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(8):806‐12. BurnsA , RossorM , HeckerJ , GauthierS , PetitH , MöllerH‐J , et al. International Donepezil Study Group. The effects of donepezil in Alzheimer's disease ‐ results from a multinational trial. Dementia and Geriatric Cognitive Disorders1999;10(3):237‐44. GauthierS , RosserM , HeckerJ , PetiteH , RogersS , MohrE , et al. Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐June 4, Toronto, Canada1998. [MEDLINE: SR‐HANDSRCH] GauthierS , RossorM , HeckerJ . Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 15‐18 1998. PrattRD , GauthierS , BurnsA , PerdomoCA . Donepezil provides long‐term clinical benefits for patients with Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington. 2000. ">Burns 1999</a> and <a href="./references#CD001190-bbs2-0027" title="SteinmanMA , CovinskyKE , TariotPN , CummingsJL , KatzIR , MintzerJ , et al. Donepezil for nursing home patients with dementia: a reinterpretation of the evidence. Journal of the American Geriatrics Society2003;51(1):132‐33. TariotP , CummingsJL , KatzIR , PerdomoCA , WhalenE , SovelMA , et al. Donepezil was well‐tolerated and enhanced cognition in nursing home patients with Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. TariotP , PerdomoCA , WhalenE , SovelMA , SchamEM . Age is not a barrier to donepezil treatment of Alzheimer's disease in the long‐term care setting. International Psychogeriatrics1999;11(Supplement 1):134. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomised, double‐blind, placebo‐controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2003;51(1):133‐4. ">Tariot 2001</a> as phase III studies. </p> <p>These studies had many features in common. They were all multicentre, parallel‐group studies. Four studies were based in the USA, two in Europe and one in Japan. All studies compared donepezil with placebo. </p> <p>These seven studies made a diagnosis for probable Alzheimer's disease according to NINCDS‐ADRDA criteria, with participants also fitting DSM‐III‐R illness categories 290.00 or 290.10 in six studies. <a href="./references#CD001190-bbs2-0020" title="FriedhoffLT , IeniJR , RogersSL , PrattRD . Donepezil provides long‐term clinical benefits for patients with Alzheimer's Disease. Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum;1998 July 12‐16, Glasgow, Scotland1998:ABSTRACT REF: PW11017. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Correlation between the clinical efficacy of donepezil HCL (E2020) and red blood cell (RBC) acetylcholinesterase (ACHE) inhibition in patients with Alzheimer's disease. Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5‐8, San Diego. UK: Medical Education Network, 1997; Vol. 2:6‐7. RogersS , PerdomoC , FriedhoffL . Clinical benefits are maintained during long‐term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 September 30‐October 4, Venice1995a. [MEDLINE: SR‐HANDSRCH] RogersSL , DoodyRS , PrattRD , IeniJR . Long‐term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open‐label study. European Neuropsychopharmacology2000; Vol. 10, issue 3:195‐203. RogersSL , FriedhoffLT . E2020 improves cognition and quality of life in patients with mild to moderate Alzheimers Disease: results of a phase II trial. Proceedings of the 46th Annual meeting of the American Academy of Neurology. 1994 May 1‐7, Washington DC1994; Vol. 44, issue Suppl 2:A165. RogersSL , Friedhoff LT and the Donepezil Study Group. The Efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double‐blind, placebo‐controlled trial. Dementia1996;7:293‐303. ">Rogers 1996</a>, <a href="./references#CD001190-bbs2-0021" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. PrattRD , PerdomoCA , IeniJK . Long‐term safety and tolerability of donepezil: results from a phase iii extension trial of patients with mild to moderately severe Alzheimer's disease. European Journal of Neurology1999;6(Suppl 3):116. [MEDLINE: SR‐HANDSRCH] RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyRS , MohsRC , FriedhoffLT , the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine1998;158:1021‐31. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego. 1997. ">Rogers 1998a</a>, <a href="./references#CD001190-bbs2-0022" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. Erratum: a 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613‐620)). Neurology2001; Vol. 57, issue 11:2153. FriedhoffLT , RogersL . Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease ‐ results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston. Neurology1997;48(3):A100. FriedhoffLT , RogersSL . Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17, Vienna, Austria1997. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis. European Journal of Neurology1997;4(Suppl 1):S9. RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyR , MohsR , FriedhoffLT . E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30‐week phase III trial. Neurology1996;46:A217 S14.001 ARI‐8. RogersSL , DoodyR , MohsR , FriedhoffT , Donepezil Study Group. E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30‐week trial. Unpublished paper1996b. RogersSL , FarlowMR , DoodyRS , MohsR , FriedhoffLT , Donepezil Study Group. A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998;50(1):136‐45. RogersSL , FriedhoffLT , FarlowMR , DoodyRS , MohsR . Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply]. Neurology1999; Vol. 52, issue 1:218‐19. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego1997. ">Rogers 1998b</a>, <a href="./references#CD001190-bbs2-0003" title="BayerAJ , RossorM , HeckerJ , GauthierS , BurnsA , PetiteH , et al. International Donepezil Study Group. Donepezil improves functional activity in patients with Alzheimer's disease. 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12‐16, Glasgow, Scotland. 1998. [MEDLINE: SR‐HANDSRCH] BurnsA , GauthierS , PerdomoC . Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(8):806‐12. BurnsA , RossorM , HeckerJ , GauthierS , PetitH , MöllerH‐J , et al. International Donepezil Study Group. The effects of donepezil in Alzheimer's disease ‐ results from a multinational trial. Dementia and Geriatric Cognitive Disorders1999;10(3):237‐44. GauthierS , RosserM , HeckerJ , PetiteH , RogersS , MohrE , et al. Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐June 4, Toronto, Canada1998. [MEDLINE: SR‐HANDSRCH] GauthierS , RossorM , HeckerJ . Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 15‐18 1998. PrattRD , GauthierS , BurnsA , PerdomoCA . Donepezil provides long‐term clinical benefits for patients with Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington. 2000. ">Burns 1999</a> and the <a href="./references#CD001190-bbs2-0029" title="EngedalK , SoininenH , VerheyF , WaldemarG , WinbladB , WimoA , et al. Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000; Vol. 10, issue Suppl 3:S368. [MEDLINE: SR‐HANDSRCH] MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a one year, double‐blind, randomized trial. Journal of the American Geriatrics Society2001; Vol. 49, issue 4:S131. MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. Donepezil reduces the time caregivers spend providing care: results of a one‐year, double‐blind, randomized trial in patients with mild to moderate Alzheimer's disease. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23‐26, San Francisco2001. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Long term benefits of donepezil on ADLs in AD patients. Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:171. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Donepezil Nordic Study Group. Response to donepezil is not predicted by apolipoprotein E genotype and/or gender. World Alzheimer Congress; 2000 July 9‐13, Washington. 2000. WaldemarG , WinbladB , EngedalK , SoininenH , Donepezil Nordic Study Group et al. Benefits of donepezil on cognition, function and/or neuropsychiatric symptoms in patients with Alzheimers disease over one year. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WaldemarG , WinbladB , EngedalK , SoininenHS , VerheyFR , WimoA , et al. Donepezil Nordic Study Group. Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year. Neurology2000;54(Suppl 3):A470. WimoA . Erratum: an economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial (Dementia and Geriatric Cognitive Disorders (2003) 15 (44‐54)). Dementia and Geriatric Cognitive Disorders2003; Vol. 16, issue 2:102. WimoA , WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , et al. Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial. Dementia and Geriatric Cognitive Disorders2003;15(1):44‐54. WimoA , WinbladB , MasteyV . An economic evaluation of donepezil in mild to moderate Alzheimers disease: results of a one‐year, double‐blind, randomized trial. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WimoA , WinbladB , MasteyV , HaglundA , HertzmanP , MiceliR , et al. An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one‐year, double‐blind, randomized trial. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illionois. 2000. [MEDLINE: SR‐HANDSRCH] WinbladB . Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:164. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , WetterholmAL , ZhangR , HaglundA , SubbiahP . Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. International Psychogeriatrics1999;11(Supplement 1):138. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. A 1‐year, randomized, placebo‐controlled study of donepezil in patients with mild to moderate AD. Neurology2001;57(3):489‐95. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. Donepezil enhances global function and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. Quality Research in Dementia Conference; 2000 Nov 19‐22, London. 2000. WinbladB , WimoA , EngedalK , SoininenH , VerheyF , WaldemarG , et al. 3‐year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia and Geriatric Cognitive Disorders2006;21(5‐6):353‐63. ">Winblad 2001</a> measured the severity of the disease using the MMSE scale, and recruited participants with mild to moderate dementia (MMSE 10‐26). <a href="./references#CD001190-bbs2-0027" title="SteinmanMA , CovinskyKE , TariotPN , CummingsJL , KatzIR , MintzerJ , et al. Donepezil for nursing home patients with dementia: a reinterpretation of the evidence. Journal of the American Geriatrics Society2003;51(1):132‐33. TariotP , CummingsJL , KatzIR , PerdomoCA , WhalenE , SovelMA , et al. Donepezil was well‐tolerated and enhanced cognition in nursing home patients with Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. TariotP , PerdomoCA , WhalenE , SovelMA , SchamEM . Age is not a barrier to donepezil treatment of Alzheimer's disease in the long‐term care setting. International Psychogeriatrics1999;11(Supplement 1):134. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomised, double‐blind, placebo‐controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2003;51(1):133‐4. ">Tariot 2001</a> recruited participants with MMSE between 5 and 26, inclusive, and consequently the mean MMSE at baseline (14.4) was lower than that in the other studies. <a href="./references#CD001190-bbs2-0007" title="HommaA , ImaiY , HariguchiS , HasegawaK , KameyamaM , NishimuraT . Late phase II clinical study of acetyl cholinesterase inhibitor E2020 in patients with Alzheimer‐type dementia. Clinical Evaluation1998;26(2):251‐84. ">Homma 1998</a> did not use the MMSE. <a href="./references#CD001190-bbs2-0007" title="HommaA , ImaiY , HariguchiS , HasegawaK , KameyamaM , NishimuraT . Late phase II clinical study of acetyl cholinesterase inhibitor E2020 in patients with Alzheimer‐type dementia. Clinical Evaluation1998;26(2):251‐84. ">Homma 1998</a>, <a href="./references#CD001190-bbs2-0020" title="FriedhoffLT , IeniJR , RogersSL , PrattRD . Donepezil provides long‐term clinical benefits for patients with Alzheimer's Disease. Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum;1998 July 12‐16, Glasgow, Scotland1998:ABSTRACT REF: PW11017. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Correlation between the clinical efficacy of donepezil HCL (E2020) and red blood cell (RBC) acetylcholinesterase (ACHE) inhibition in patients with Alzheimer's disease. Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5‐8, San Diego. UK: Medical Education Network, 1997; Vol. 2:6‐7. RogersS , PerdomoC , FriedhoffL . Clinical benefits are maintained during long‐term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 September 30‐October 4, Venice1995a. [MEDLINE: SR‐HANDSRCH] RogersSL , DoodyRS , PrattRD , IeniJR . Long‐term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open‐label study. European Neuropsychopharmacology2000; Vol. 10, issue 3:195‐203. RogersSL , FriedhoffLT . E2020 improves cognition and quality of life in patients with mild to moderate Alzheimers Disease: results of a phase II trial. Proceedings of the 46th Annual meeting of the American Academy of Neurology. 1994 May 1‐7, Washington DC1994; Vol. 44, issue Suppl 2:A165. RogersSL , Friedhoff LT and the Donepezil Study Group. The Efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double‐blind, placebo‐controlled trial. Dementia1996;7:293‐303. ">Rogers 1996</a>, <a href="./references#CD001190-bbs2-0021" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. PrattRD , PerdomoCA , IeniJK . Long‐term safety and tolerability of donepezil: results from a phase iii extension trial of patients with mild to moderately severe Alzheimer's disease. European Journal of Neurology1999;6(Suppl 3):116. [MEDLINE: SR‐HANDSRCH] RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyRS , MohsRC , FriedhoffLT , the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine1998;158:1021‐31. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego. 1997. ">Rogers 1998a</a>, <a href="./references#CD001190-bbs2-0022" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. Erratum: a 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613‐620)). Neurology2001; Vol. 57, issue 11:2153. FriedhoffLT , RogersL . Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease ‐ results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston. Neurology1997;48(3):A100. FriedhoffLT , RogersSL . Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17, Vienna, Austria1997. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis. European Journal of Neurology1997;4(Suppl 1):S9. RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyR , MohsR , FriedhoffLT . E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30‐week phase III trial. Neurology1996;46:A217 S14.001 ARI‐8. RogersSL , DoodyR , MohsR , FriedhoffT , Donepezil Study Group. E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30‐week trial. Unpublished paper1996b. RogersSL , FarlowMR , DoodyRS , MohsR , FriedhoffLT , Donepezil Study Group. A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998;50(1):136‐45. RogersSL , FriedhoffLT , FarlowMR , DoodyRS , MohsR . Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply]. Neurology1999; Vol. 52, issue 1:218‐19. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego1997. ">Rogers 1998b</a>, and <a href="./references#CD001190-bbs2-0003" title="BayerAJ , RossorM , HeckerJ , GauthierS , BurnsA , PetiteH , et al. International Donepezil Study Group. Donepezil improves functional activity in patients with Alzheimer's disease. 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12‐16, Glasgow, Scotland. 1998. [MEDLINE: SR‐HANDSRCH] BurnsA , GauthierS , PerdomoC . Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(8):806‐12. BurnsA , RossorM , HeckerJ , GauthierS , PetitH , MöllerH‐J , et al. International Donepezil Study Group. The effects of donepezil in Alzheimer's disease ‐ results from a multinational trial. Dementia and Geriatric Cognitive Disorders1999;10(3):237‐44. GauthierS , RosserM , HeckerJ , PetiteH , RogersS , MohrE , et al. Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐June 4, Toronto, Canada1998. [MEDLINE: SR‐HANDSRCH] GauthierS , RossorM , HeckerJ . Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 15‐18 1998. PrattRD , GauthierS , BurnsA , PerdomoCA . Donepezil provides long‐term clinical benefits for patients with Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington. 2000. ">Burns 1999</a> required a Clinical Dementia Rating (CDR) of 1 (mild) or 2 (moderate) at screening and baseline. </p> <p>The list of exclusions was quite extensive and consistent across the phase II and III studies. Patients were excluded if they had insulin‐dependent diabetes mellitus or other endocrine disorder, asthma, obstructive pulmonary disease or clinically significant uncontrolled gastrointestinal hepatic or cardiovascular diseases. Patients known to be hypersensitive to cholinesterase inhibitors or who had taken tacrine or other investigational medicines within one month of baseline were excluded. Concomitant medications such as anticholinergics, anticonvulsants, antidepressants and antipsychotics were not allowed. Drugs with central nervous system (CNS) activity were prohibited or partially restricted. The participants included in <a href="./references#CD001190-bbs2-0027" title="SteinmanMA , CovinskyKE , TariotPN , CummingsJL , KatzIR , MintzerJ , et al. Donepezil for nursing home patients with dementia: a reinterpretation of the evidence. Journal of the American Geriatrics Society2003;51(1):132‐33. TariotP , CummingsJL , KatzIR , PerdomoCA , WhalenE , SovelMA , et al. Donepezil was well‐tolerated and enhanced cognition in nursing home patients with Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. TariotP , PerdomoCA , WhalenE , SovelMA , SchamEM . Age is not a barrier to donepezil treatment of Alzheimer's disease in the long‐term care setting. International Psychogeriatrics1999;11(Supplement 1):134. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomised, double‐blind, placebo‐controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2003;51(1):133‐4. ">Tariot 2001</a> were on average older than in the other studies, and were more likely to have comorbid illness. They were required to have reported at a frequency of several times a week at least one symptom from the Neuropsychiatric Inventory Nursing Home version (NPI‐NH). </p> <p>The <a href="./references#CD001190-bbs2-0029" title="EngedalK , SoininenH , VerheyF , WaldemarG , WinbladB , WimoA , et al. Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000; Vol. 10, issue Suppl 3:S368. [MEDLINE: SR‐HANDSRCH] MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a one year, double‐blind, randomized trial. Journal of the American Geriatrics Society2001; Vol. 49, issue 4:S131. MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. Donepezil reduces the time caregivers spend providing care: results of a one‐year, double‐blind, randomized trial in patients with mild to moderate Alzheimer's disease. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23‐26, San Francisco2001. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Long term benefits of donepezil on ADLs in AD patients. Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:171. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Donepezil Nordic Study Group. Response to donepezil is not predicted by apolipoprotein E genotype and/or gender. World Alzheimer Congress; 2000 July 9‐13, Washington. 2000. WaldemarG , WinbladB , EngedalK , SoininenH , Donepezil Nordic Study Group et al. Benefits of donepezil on cognition, function and/or neuropsychiatric symptoms in patients with Alzheimers disease over one year. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WaldemarG , WinbladB , EngedalK , SoininenHS , VerheyFR , WimoA , et al. Donepezil Nordic Study Group. Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year. Neurology2000;54(Suppl 3):A470. WimoA . Erratum: an economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial (Dementia and Geriatric Cognitive Disorders (2003) 15 (44‐54)). Dementia and Geriatric Cognitive Disorders2003; Vol. 16, issue 2:102. WimoA , WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , et al. Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial. Dementia and Geriatric Cognitive Disorders2003;15(1):44‐54. WimoA , WinbladB , MasteyV . An economic evaluation of donepezil in mild to moderate Alzheimers disease: results of a one‐year, double‐blind, randomized trial. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WimoA , WinbladB , MasteyV , HaglundA , HertzmanP , MiceliR , et al. An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one‐year, double‐blind, randomized trial. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illionois. 2000. [MEDLINE: SR‐HANDSRCH] WinbladB . Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:164. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , WetterholmAL , ZhangR , HaglundA , SubbiahP . Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. International Psychogeriatrics1999;11(Supplement 1):138. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. A 1‐year, randomized, placebo‐controlled study of donepezil in patients with mild to moderate AD. Neurology2001;57(3):489‐95. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. Donepezil enhances global function and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. Quality Research in Dementia Conference; 2000 Nov 19‐22, London. 2000. WinbladB , WimoA , EngedalK , SoininenH , VerheyF , WaldemarG , et al. 3‐year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia and Geriatric Cognitive Disorders2006;21(5‐6):353‐63. ">Winblad 2001</a> published an economic valuation of donepezil. </p> <p>The doses used in the phase III studies were within the range shown to be clinically useful and reasonably well tolerated in the earlier studies. Treatment was once daily. When the dose of donepezil was 5 mg/day or less, the participants began with the full dose; with 10 mg/day the initial dose was 5 mg/day for one week followed by the full dose for <a href="./references#CD001190-bbs2-0021" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. PrattRD , PerdomoCA , IeniJK . Long‐term safety and tolerability of donepezil: results from a phase iii extension trial of patients with mild to moderately severe Alzheimer's disease. European Journal of Neurology1999;6(Suppl 3):116. [MEDLINE: SR‐HANDSRCH] RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyRS , MohsRC , FriedhoffLT , the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine1998;158:1021‐31. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego. 1997. ">Rogers 1998a</a>, <a href="./references#CD001190-bbs2-0022" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. Erratum: a 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613‐620)). Neurology2001; Vol. 57, issue 11:2153. FriedhoffLT , RogersL . Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease ‐ results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston. Neurology1997;48(3):A100. FriedhoffLT , RogersSL . Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17, Vienna, Austria1997. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis. European Journal of Neurology1997;4(Suppl 1):S9. RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyR , MohsR , FriedhoffLT . E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30‐week phase III trial. Neurology1996;46:A217 S14.001 ARI‐8. RogersSL , DoodyR , MohsR , FriedhoffT , Donepezil Study Group. E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30‐week trial. Unpublished paper1996b. RogersSL , FarlowMR , DoodyRS , MohsR , FriedhoffLT , Donepezil Study Group. A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998;50(1):136‐45. RogersSL , FriedhoffLT , FarlowMR , DoodyRS , MohsR . Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply]. Neurology1999; Vol. 52, issue 1:218‐19. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego1997. ">Rogers 1998b</a> and <a href="./references#CD001190-bbs2-0003" title="BayerAJ , RossorM , HeckerJ , GauthierS , BurnsA , PetiteH , et al. International Donepezil Study Group. Donepezil improves functional activity in patients with Alzheimer's disease. 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12‐16, Glasgow, Scotland. 1998. [MEDLINE: SR‐HANDSRCH] BurnsA , GauthierS , PerdomoC . Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(8):806‐12. BurnsA , RossorM , HeckerJ , GauthierS , PetitH , MöllerH‐J , et al. International Donepezil Study Group. The effects of donepezil in Alzheimer's disease ‐ results from a multinational trial. Dementia and Geriatric Cognitive Disorders1999;10(3):237‐44. GauthierS , RosserM , HeckerJ , PetiteH , RogersS , MohrE , et al. Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐June 4, Toronto, Canada1998. [MEDLINE: SR‐HANDSRCH] GauthierS , RossorM , HeckerJ . Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 15‐18 1998. PrattRD , GauthierS , BurnsA , PerdomoCA . Donepezil provides long‐term clinical benefits for patients with Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington. 2000. ">Burns 1999</a>. For the two later studies, <a href="./references#CD001190-bbs2-0027" title="SteinmanMA , CovinskyKE , TariotPN , CummingsJL , KatzIR , MintzerJ , et al. Donepezil for nursing home patients with dementia: a reinterpretation of the evidence. Journal of the American Geriatrics Society2003;51(1):132‐33. TariotP , CummingsJL , KatzIR , PerdomoCA , WhalenE , SovelMA , et al. Donepezil was well‐tolerated and enhanced cognition in nursing home patients with Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. TariotP , PerdomoCA , WhalenE , SovelMA , SchamEM . Age is not a barrier to donepezil treatment of Alzheimer's disease in the long‐term care setting. International Psychogeriatrics1999;11(Supplement 1):134. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomised, double‐blind, placebo‐controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2003;51(1):133‐4. ">Tariot 2001</a> and the <a href="./references#CD001190-bbs2-0029" title="EngedalK , SoininenH , VerheyF , WaldemarG , WinbladB , WimoA , et al. Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000; Vol. 10, issue Suppl 3:S368. [MEDLINE: SR‐HANDSRCH] MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a one year, double‐blind, randomized trial. Journal of the American Geriatrics Society2001; Vol. 49, issue 4:S131. MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. Donepezil reduces the time caregivers spend providing care: results of a one‐year, double‐blind, randomized trial in patients with mild to moderate Alzheimer's disease. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23‐26, San Francisco2001. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Long term benefits of donepezil on ADLs in AD patients. Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:171. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Donepezil Nordic Study Group. Response to donepezil is not predicted by apolipoprotein E genotype and/or gender. World Alzheimer Congress; 2000 July 9‐13, Washington. 2000. WaldemarG , WinbladB , EngedalK , SoininenH , Donepezil Nordic Study Group et al. Benefits of donepezil on cognition, function and/or neuropsychiatric symptoms in patients with Alzheimers disease over one year. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WaldemarG , WinbladB , EngedalK , SoininenHS , VerheyFR , WimoA , et al. Donepezil Nordic Study Group. Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year. Neurology2000;54(Suppl 3):A470. WimoA . Erratum: an economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial (Dementia and Geriatric Cognitive Disorders (2003) 15 (44‐54)). Dementia and Geriatric Cognitive Disorders2003; Vol. 16, issue 2:102. WimoA , WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , et al. Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial. Dementia and Geriatric Cognitive Disorders2003;15(1):44‐54. WimoA , WinbladB , MasteyV . An economic evaluation of donepezil in mild to moderate Alzheimers disease: results of a one‐year, double‐blind, randomized trial. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WimoA , WinbladB , MasteyV , HaglundA , HertzmanP , MiceliR , et al. An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one‐year, double‐blind, randomized trial. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illionois. 2000. [MEDLINE: SR‐HANDSRCH] WinbladB . Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:164. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , WetterholmAL , ZhangR , HaglundA , SubbiahP . Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. International Psychogeriatrics1999;11(Supplement 1):138. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. A 1‐year, randomized, placebo‐controlled study of donepezil in patients with mild to moderate AD. Neurology2001;57(3):489‐95. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. Donepezil enhances global function and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. Quality Research in Dementia Conference; 2000 Nov 19‐22, London. 2000. WinbladB , WimoA , EngedalK , SoininenH , VerheyF , WaldemarG , et al. 3‐year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia and Geriatric Cognitive Disorders2006;21(5‐6):353‐63. ">Winblad 2001</a>, the time on 5 mg/day was four weeks, before increasing to 10 mg/day. The forced titration schemes were blinded. <a href="./references#CD001190-bbs2-0007" title="HommaA , ImaiY , HariguchiS , HasegawaK , KameyamaM , NishimuraT . Late phase II clinical study of acetyl cholinesterase inhibitor E2020 in patients with Alzheimer‐type dementia. Clinical Evaluation1998;26(2):251‐84. ">Homma 1998</a> and <a href="./references#CD001190-bbs2-0020" title="FriedhoffLT , IeniJR , RogersSL , PrattRD . Donepezil provides long‐term clinical benefits for patients with Alzheimer's Disease. Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum;1998 July 12‐16, Glasgow, Scotland1998:ABSTRACT REF: PW11017. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Correlation between the clinical efficacy of donepezil HCL (E2020) and red blood cell (RBC) acetylcholinesterase (ACHE) inhibition in patients with Alzheimer's disease. Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5‐8, San Diego. UK: Medical Education Network, 1997; Vol. 2:6‐7. RogersS , PerdomoC , FriedhoffL . Clinical benefits are maintained during long‐term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 September 30‐October 4, Venice1995a. [MEDLINE: SR‐HANDSRCH] RogersSL , DoodyRS , PrattRD , IeniJR . Long‐term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open‐label study. European Neuropsychopharmacology2000; Vol. 10, issue 3:195‐203. RogersSL , FriedhoffLT . E2020 improves cognition and quality of life in patients with mild to moderate Alzheimers Disease: results of a phase II trial. Proceedings of the 46th Annual meeting of the American Academy of Neurology. 1994 May 1‐7, Washington DC1994; Vol. 44, issue Suppl 2:A165. RogersSL , Friedhoff LT and the Donepezil Study Group. The Efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double‐blind, placebo‐controlled trial. Dementia1996;7:293‐303. ">Rogers 1996</a> were dose‐finding studies. </p> <p>Four other studies were published in 2001 or before (<a href="./references#CD001190-bbs2-0014" title="RobertP , LebertF , GoniS , TouchonJ , VincentS , ARIAL Study Investigators Collaborative Group. The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. Quality Research in Dementia; 19‐22 November, 2000, London. 2000. RobertPH , LebertF , GoniS , TouchonJ , ARIAL Study Investigators Collaborative Group. The impact of caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">Lebert 1999</a>; <a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a>; <a href="./references#CD001190-bbs2-0008" title="HommaA , TakedaM , ImaiY , UdakaF , HasegawaK , KameyamaM , et al. E2020 Study Group. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24‐week, multicenter, double‐blind, placebo‐controlled study in Japan. Dementia and Geriatric Cognitive Disorders2000; Vol. 11, issue 6:299‐313. ">Homma 2000</a>; <a href="./references#CD001190-bbs2-0017" title="EbellM . Does donepezil help patients with moderate Alzheimer's dementia preserve their ability to function independently?. Evidence Based Practice2002. MohsR , DoodyR , MorrisJ , IeniJ , PerdomoC , PrattR , et al. Donepezil preserves activities of daily living in Alzheimer's disease patients: results from a one‐year placebo‐controlled functional survival study. Neurology2000;54(Suppl 3):A415. MohsR , DoodyR , MorrisJ , IeniJ , RogersS , PerdomoC , et al. Donepezil preserves functional status and improves cognition in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Journal of the American Geriatrics Society2000;48(8):S46. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled attrition study. Journal of the European College of Neuropsychopharmacology1999;9(Suppl 5):S328. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Quality Research in Dementia Conference; 2000 November 19‐22, London. 2000. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoC , et al. 312 Study Group. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients [Erratum]. Neurology2001; Vol. 57, issue 10:1942. [MEDLINE: http://www.lww.com] MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients. Neurology2001;57(3):481‐8. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illinois. 2000. [MEDLINE: SR‐HANDSRCH] PrattR , MohsR , DoodyR , MorrisJ , RogersS , IeniJ , et al. Donepezil preserves functional status in Alzheimer's disease patients results from a 1‐year prospective placebo controlled functional study. Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden2000:178. ">Mohs 2001</a>). </p> <p><a href="./references#CD001190-bbs2-0014" title="RobertP , LebertF , GoniS , TouchonJ , VincentS , ARIAL Study Investigators Collaborative Group. The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. Quality Research in Dementia; 19‐22 November, 2000, London. 2000. RobertPH , LebertF , GoniS , TouchonJ , ARIAL Study Investigators Collaborative Group. The impact of caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">Lebert 1999</a> was a large, multi‐centred trial designed to evaluate the stress on carers. </p> <p><a href="./references#CD001190-bbs2-0008" title="HommaA , TakedaM , ImaiY , UdakaF , HasegawaK , KameyamaM , et al. E2020 Study Group. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24‐week, multicenter, double‐blind, placebo‐controlled study in Japan. Dementia and Geriatric Cognitive Disorders2000; Vol. 11, issue 6:299‐313. ">Homma 2000</a> was a multicentre, phase III study carried out in Japan, funded by Eisai, with a similar protocol to the other Eisai phase III studies, except that only the lower dose of donepezil, 5 mg/day was tested and participants began with a lower dose for the first week. </p> <p><a href="./references#CD001190-bbs2-0017" title="EbellM . Does donepezil help patients with moderate Alzheimer's dementia preserve their ability to function independently?. Evidence Based Practice2002. MohsR , DoodyR , MorrisJ , IeniJ , PerdomoC , PrattR , et al. Donepezil preserves activities of daily living in Alzheimer's disease patients: results from a one‐year placebo‐controlled functional survival study. Neurology2000;54(Suppl 3):A415. MohsR , DoodyR , MorrisJ , IeniJ , RogersS , PerdomoC , et al. Donepezil preserves functional status and improves cognition in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Journal of the American Geriatrics Society2000;48(8):S46. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled attrition study. Journal of the European College of Neuropsychopharmacology1999;9(Suppl 5):S328. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Quality Research in Dementia Conference; 2000 November 19‐22, London. 2000. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoC , et al. 312 Study Group. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients [Erratum]. Neurology2001; Vol. 57, issue 10:1942. [MEDLINE: http://www.lww.com] MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients. Neurology2001;57(3):481‐8. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illinois. 2000. [MEDLINE: SR‐HANDSRCH] PrattR , MohsR , DoodyR , MorrisJ , RogersS , IeniJ , et al. Donepezil preserves functional status in Alzheimer's disease patients results from a 1‐year prospective placebo controlled functional study. Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden2000:178. ">Mohs 2001</a> investigated the effect of donepezil on the preservation of function over a one‐year period. The inclusion and exclusion criteria were similar to the phase III studies, except for baseline MMSE, which was approximately 5 points lower on average, and for the requirement that participants had to be able to perform eight of 10 instrumental activities of daily living and five of six basic activities of daily living, each scored on a scale of 0 (no impairment ) to 3 (very severe impairment) to a level no greater than 2. The primary endpoint was time to clinically evident decline in function, as defined in the protocol. Participants reaching this endpoint left the trial and received open‐label donepezil treatment. It was not possible to include the results of this trial in the meta‐analyses due to the removal of participants from the study. The only outcome we could include was the number in each group reaching the primary endpoint. </p> <p><a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a> recruited patients with probable or possible Alzheimer's disease of moderate to severe severity. Causes of the dementia, other than Alzheimer's disease, had to be ruled out. Patients randomised to donepezil took 5 mg/day for 4 weeks, followed by 10 mg/day for 20 weeks if the higher dose was tolerated. The trial was supported by Pfizer Inc and Eisai Co Ltd. An economic evaluation of donepezil from <a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a> has been published. Data were collected at four time points, including baseline, during the randomised treatment period, on patient and carer health resource utilisation and costs. Details are described below. </p> </section> <section id="CD001190-sec-0071"> <h6 class="title">Studies published after 2001</h6> <p>The remaining 19 included studies were reported after 2001.</p> <p><a href="./references#CD001190-bbs2-0028" title="TuneL , TiseoP , HoffmanJ , PerdomoC , VotawJ , RogersS , et al. PET in AD: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer's disease: results of a 24‐week study. 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 February 23‐26 San Francisco. 2001. TuneL , TiseoPJ , IeniJ , PerdomoC , PrattRD , VotawJR , et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24‐week, double‐blind, placebo‐controlled study. American Journal of Geriatric Psychiatry2003;11(2):169‐77. TuneLE , TiseoPJ , HoffmanJM , PerdomoCA , VotowJR , RogersSL , et al. Functional brain activity in Alzheimer's disease. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐ June 4, Toronto. 1998:NR345. [MEDLINE: SR‐HANDSRCH] ">Tune 2003</a>, with only 28 participants, was primarily aimed at investigating brain glucose metabolism; <a href="./references#CD001190-bbs2-0025" title="Anon . No title. Eisai Inc. ">Study 205</a>, with 12 participants investigated the effect on visuospatial attention and <a href="./references#CD001190-bbs2-0026" title="Anon . No title. Eisai Inc. ">Study 306</a>, with 39 participants, investigated whether Apo E genotype predicted response to donepezil. <a href="./references#CD001190-bbs2-0013" title="Anon . No title. Eisai Inc. KrishnanKR , CharlesHC , DoraiswamyPM , MintzerJ , WeislerR , YuX , et al. Randomized, placebo‐controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. The American Journal of Psychiatry2003;160(11):2003‐11. ">Krishnan 2003</a>, with 67 participants, was primarily to investigate brain measurements. There is very little published information on these studies. </p> <p><a href="./references#CD001190-bbs2-0001" title="AD2000 Collaborative Group. Long‐term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double‐blind trial. Lancet2004;363:2105‐15. BenthamP , GrayR , HillR , SellwoodE , CourtneyC . Twelve week response to cholinesterase inhibitors dose not predict future benefit the AD2000 trial experience. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:337. LendonCL . Determination of responses to anticholinesterase therapy in the treatment of Alzheimer's disease. 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden: Abstract No 1287. 2002. RobertsN . A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease (AD2000). National Research Register2001. SchneiderLS . AD2000: donepezil in Alzheimer's disease. Lancet2004;363(9427):2100‐1. WaghrayS . AD2000 A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease. National Research Register2000. [MEDLINE: http://www.doh.gov.uk/nrr.htm] ">AD2000</a> randomised 566 people with Alzheimer's disease, with or without vascular dementia, to 12 weeks of 5 mg/day donepezil or placebo, and then re‐randomised them to donepezil (5 mg/day or 10 mg/day) or placebo for another 48 weeks of treatment. Thus the trial was partially of a cross‐over design, some participants changed treatments, others did not. In addition, suitable participants were randomised to aspirin or aspirin avoidance. This trial was carried out independently of the pharmaceutical company. An extensive description of and the results from <a href="./references#CD001190-bbs2-0001" title="AD2000 Collaborative Group. Long‐term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double‐blind trial. Lancet2004;363:2105‐15. BenthamP , GrayR , HillR , SellwoodE , CourtneyC . Twelve week response to cholinesterase inhibitors dose not predict future benefit the AD2000 trial experience. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:337. LendonCL . Determination of responses to anticholinesterase therapy in the treatment of Alzheimer's disease. 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden: Abstract No 1287. 2002. RobertsN . A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease (AD2000). National Research Register2001. SchneiderLS . AD2000: donepezil in Alzheimer's disease. Lancet2004;363(9427):2100‐1. WaghrayS . AD2000 A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease. National Research Register2000. [MEDLINE: http://www.doh.gov.uk/nrr.htm] ">AD2000</a> have been published. The trial was designed with the intention of recruiting 3000 people, but only 566 were randomised. When this UK‐based trial started in 2000 donepezil was not available on the National Health Service (NHS), but became available in 2001. This affected not only recruitment, but also the retention of participants because participants already randomised left the trial to benefit from open‐label prescription of donepezil. Any patient referred to a memory clinic was potentially eligible if they were diagnosed (according to DSM IV) with dementia of Alzheimer type with or without a coexisting diagnosis of vascular dementia (16% of participants were also diagnosed with vascular dementia). Only 86% (486/566) of participants randomised at baseline entered the second randomisation at 12 weeks. During the next 48 weeks of treatment 40% (193) of participants were lost to follow‐up, 32 died, 42 were admitted to institutional care, 62 stopped treatment and 57 withdrew to open‐label donepezil. The trial continued with a six‐week washout before beginning a further 48 weeks of treatment (no further randomisation), but only 194 out of 293 finishing the previous phase entered. After the second 48‐week phase there was a four‐week washout, another 48 weeks of treatment, four‐week washout and 48 weeks of treatment. In theory, treatment could continue for 204 weeks, but the loss of participants continued at a substantial rate. The two primary endpoints were entry to an institution, and loss of either two of four basic, or six of 11 instrumental activities on the BADLS. Secondary outcome measures were functional ability (BADLS), behavioural symptoms as assessed by the NPI, MMSE, psychological well‐being of the carer (GHQ‐30), and death from Alzheimer's disease. In addition, <a href="./references#CD001190-bbs2-0001" title="AD2000 Collaborative Group. Long‐term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double‐blind trial. Lancet2004;363:2105‐15. BenthamP , GrayR , HillR , SellwoodE , CourtneyC . Twelve week response to cholinesterase inhibitors dose not predict future benefit the AD2000 trial experience. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:337. LendonCL . Determination of responses to anticholinesterase therapy in the treatment of Alzheimer's disease. 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden: Abstract No 1287. 2002. RobertsN . A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease (AD2000). National Research Register2001. SchneiderLS . AD2000: donepezil in Alzheimer's disease. Lancet2004;363(9427):2100‐1. WaghrayS . AD2000 A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease. National Research Register2000. [MEDLINE: http://www.doh.gov.uk/nrr.htm] ">AD2000</a> assessed costs, including NHS, social services and private, from information provided by the carer and by the family doctor, and costed using national (UK) average unit costs for each item, for example a stay in hospital. </p> <p><a href="./references#CD001190-bbs2-0006" title="HegerlU , MerglR , HenkelV , GallinatJ , KotterG , Muller SiechenederF , et al. Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia. Journal of Clinical Psychopharmacology2003;23(2):214‐6. ">Hegerl 2003</a> was a small pilot study of 40 participants diagnosed with probable Alzheimer's disease according to DSM‐IV and NINCDS‐ADRDA, designed to investigate whether donepezil is associated with Parkinsonian effects in people with Alzheimer's disease, by assessing cognition and hand‐motor function. It was supported by Pfizer Inc. and Eisai Europe. </p> <p><a href="./references#CD001190-bbs2-0023" title="SchindlerR , Corey‐BloomJ , DoodyR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4‐7, 2004. 2004. SchindlerR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. Neurobiology of Aging2004;25(S2):195. ">Schindler 2004</a> was a small study of 31 participants with mild to moderate Alzheimer's disease, who were already taking 10 mg/day donepezil at baseline. The objective was to assess the safety and tolerability of higher doses of donepezil. In addition to the 10 mg/day that the participants were already taking, participants were randomised to either placebo or to a further dose of 5 mg /day increasing to 10 mg/day donepezil over 24 weeks. It was funded by Pfizer/Eisai. </p> <p><a href="./references#CD001190-bbs2-0024" title="SeltzerB , ZolnouniP , NunezM , GoldmanR , KumarD , IeniJ , et al. Erratum: efficacy of donepezil in early‐stage alzheimer disease: a randomized placebo‐controlled trial (Archives of Neurology (December 2004) 61 (1852‐1856)). Archives of Neurology2005;62(5):825. SeltzerB , ZolnouniP , NunezM , GoldmanR , KumarD , IeniJ , et al. Donepezil 402 Study Group. Efficacy of donepezil in early‐stage Alzheimer disease. Archives of Neurolology2004;61:1852‐6. ">Seltzer 2004</a>, a 24‐week, parallel‐group study of 10 mg/day donepezil compared with placebo, evaluated the efficacy of donepezil in participants with early‐stage Alzheimer's disease. The mean MMSE at baseline was 24. </p> <p><a href="./references#CD001190-bbs2-0030" title="BatsmanS , MinthonL , EerikssonS , KilanderL , Jansson‐BlixtC , WetterholmA , et al. Study design and baseline patients characteristics in a randomized controlled trial of the efficacy and tolerability of donepezil in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. ErikssonS , WinbladB , KilanderL , BatsmanS , Jansson‐BlixtC , WetterholmA , et al. Efficacy of donepezil on secondary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. JelicV , HaglundA , KowalskiJ , LangworthS , WinbladB . Donepezil treatment of severe Alzheimer's disease in nursing home settings. Dementia and Geriatric Cognitive Disorders2008;26(5):458‐46. KilanderL , WinbladB , MinthonL , BatsmanS , Jansson‐BlixtC , CronlundA , et al. Donepezil is well tolerated in patients with severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MarderK . Donepezil in patients with severe Alzheimer's disease: double‐blind parallel‐group, placebo controlled study. Current Neurology and Neuroscience Reports2006;6(5):364‐73. OpieLH . Donepezil for severe Alzheimer's disease. Lancet2006;368:361‐2. WinbladB . Donepezil for severe Alzheimer's disease ‐ author's reply. Lancet2006;368(9533):362. WinbladB . Severe Alzheimer's disease: benefits of donepezil therapy. International Psychogeriatrics2006;18(5):S25‐S31. WinbladB , KilanderL , ErikssonS , MinthonL , BåtsmanS , WetterholmA , et al. for the Severe Alzheimer’s Disease Study Group. Donepezil in patients with severe Alzheimer’s disease: double‐blind, parallel‐group, placebo‐controlled study. Lancet2006;367(9156):1057‐65. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansoon‐BlixtC , WetterholmA , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansson‐BlixtC , WetterholmAL , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. International Psychogeriatrics2005;18(S1):S25‐S31. ">Winblad 2006</a>, a placebo‐controlled, six‐month study conducted in Sweden and funded by Pfizer, was designed to investigate the efficacy of donepezil in people with severe Alzheimer's disease. The 241 participants were living in assisted‐care nursing homes. Their baseline MMSE was between 1 and 10 points. Participants were randomised to donepezil (5 mg/day for 30 days followed by up to 10 mg/day) or placebo. The primary outcomes were cognition, as assessed by the SIB, and activities of daily living. </p> <p><a href="./references#CD001190-bbs2-0002" title="BlackS , LiHL , McRaeT , RichardsonS . Treatment of severe Alzheimer's disease with donepezil: results from a 24‐week, multinational, randomized, double‐blind, placebo‐controlled trial. Neurology2006;66(5):A347. BlackS , LiHonglang , McRaeT , RichardsonS . Donepezil treatment of severe Alzheimer's disease: results from a 24‐week, multinational, randomized, double‐blind, placebo controlled trial. Poster Presented at the Geneva Springfield ConferenceApril 2006. BlackSE , DoodyR , LiH , McRaeT , JamborKM , XuY , et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology2007;69(5):459‐69. Pfizer . E2020‐A001‐315: a 24 week multinational RCT evaluating the efficacy and safety of donepezil in severe AD. www.marc.soton.ac.uk/Research%20Page.htm. RichardsonS . A 24 week, multicenter, randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of donepezil hydrochloride (E2020) in patients with severe Alzheimer's disease followed by a 12 week open‐label extension period. www.clinicaltrials.gov/ct/show/NCT000964732004. ">Black 2007</a>, a placebo‐controlled, 24‐week study conducted in Australia, Canada, France, the UK and the USA, and funded by Pfizer, was designed to investigate the efficacy of donepezil in people with severe Alzheimer's disease. The 343 participants were living in the community or in assisted‐care nursing homes. Their baseline MMSE was between 1 and 12 points. Participants were randomised to donepezil (5 mg/day for six weeks followed by up to 10 mg/day) or placebo. The primary outcomes were cognition as assessed by the SIB and CIBIC‐Plus. </p> <p><a href="./references#CD001190-bbs2-0009" title="HommaA , ArimotoI , KaidojiK , OhbayashiT , OzawaH . Treatment of severe Alzheimer's disease with donepezil: results from a 24 week, parallel, placebo‐controlled study in Japan. 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, July 2006. 2006. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24‐week, double‐blind, placebo‐controlled, randomized trial. Geriatric Cognitive Disorders2008;25(5):399‐407. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Long‐term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52‐week, open‐label, multicenter, extension study in Japan. Dementia and Geritatric Congitive Disorders2009;27(3):232‐9. ">Homma 2008</a>, sponsored by Eisai Ltd. Japan, was a placebo‐controlled, 24‐week trial to investigate two doses of donepezil, 5 mg/day and 10 mg/day, in Japanese people with severe Alzheimer's disease. </p> <p><a href="./references#CD001190-bbs2-0011" title="HowardRJ , JuszczakE , BallardCG , BenthamP Brown RG , BullockR , et al. CALM‐AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine2007;357(14):1382‐92. PelosiA . Donepezil is no more effective than placebo for agitation in people with Alzheimer's disease. Evidence‐Based Mental Health2008;11(3):84. ">Howard 2007</a>, sponsored by the Medical Research Council (MRC) UK, and the Alzheimer Society, was a placebo‐controlled, 12‐week trial of 10 mg/day donepezil, for people with severe Alzheimer's disease and significant agitation, a subgroup of the population of people with severe Alzheimer's disease. </p> <p><a href="./references#CD001190-bbs2-0016" title="KorczynAD . Comments on the article by Mazza et al. concerning Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study. European Journal of Neurology2007;14(9):e9. MazzaM , CapuanoA , BriaAP , MazzaS . Letter to the editor. European Journal of Neurology2007;14(9):e10. MazzaM , CapuanoA , BriaP , MazzaS . Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study. European Journal of Neurology2006;13(9):981‐85. ">Mazza 2006</a> was a small, 24‐week trial, not industry‐sponsored, designed to compare <i>Ginkgo biloba</i> with donepezil and placebo in mild to moderate Alzheimer's disease. They reported only some of the results. </p> <p><a href="./references#CD001190-bbs2-0018" title="MoraesW , PoyaresD , Sukys‐ClaudinoL , GuilleminaultC , TufikS . Donepezil improves obstructive sleep apnoea in Alzheimer disease: a double‐blind, placebo‐controlled study. Chest2008;133(3):677‐83. MoraesW , Sukys‐ClaudinoL , PoyaresD , GuilleminaultC , TufikS . Donepezil improves oxygen desaturation in patients with alzheimer's disease and obstructive sleep apnoea. Sleep Medicine2006;7(S47):368. ">Moraes 2006a</a> was a small, 12‐week trial of people with sleep apnoea and Alzheimer's disease, investigating the effect of donepezil on polysomnography outcomes. Cognition was a secondary outcome. </p> <p><a href="./references#CD001190-bbs2-0019" title="MoraesW dos S , PoyaresDR , GuilleminaultC , RamosLR , BertolucciPH , TufikS . The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double‐blind placebo‐controlled study. Sleep2006;29(2):199‐205. ">Moraes 2006b</a> was a small, 26‐week trial studying the effect of donepezil on rapid eye movement (REM) sleep in Alzheimer's disease, with cognition as a secondary outcome. </p> <p><a href="./references#CD001190-bbs2-0015" title="Maher‐EdwardsG , DixonR , HunterJ , GoldM , HoptonG , JacobsG , et al. SB‐742457 and donepezil in Alzheimer's disease: a randomized, placebo‐controlled study. International Journal of Geriatric Psychiatry2011;26(5):536‐44. Maher‐EdwardsG , Zvartau‐HindM , DaviesJ , AlexanderK , SchronenJ , BoswellD , et al. Effects of 6‐month monotherapy treatment with the 5HT6 receptor antagonist SB 742457 or donepezil in subjects with mild‐to‐moderate Alzheimer's disease. Alzheimer's Association International Conference, Paris, France. 2011. ">Maher‐Edwards 2011</a> was a small, exploratory study (n = 130) of 24 weeks' duration with three treatment arms, donepezil (10 mg/day), SB‐742457 and placebo. </p> <p><a href="./references#CD001190-bbs2-0004" title="CummingsJL , GeldmacherD , FarlowM , SabbaghM , ChristensenD , BetzP . High‐dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. CNS Neuroscience &amp; Therapeutics2013;19(5):294‐301. DoodyRS , GeldmacherDS , FarlowMR , SunY , MolineM , MackellJ . Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate‐to‐severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dementia and Geriatric Cognitive Disorders2012;33(2‐3):164‐73. DoodyRS , RamosH , FaisonW , ZouH . Efficacy and safety of donepezil 23 mg/d vs. donepezil 10 mg/d in patients with moderate to severe Alzheimer's disease: impact of concomitant memantine use. Journal of the American Geriatrics Society 2011 Annual Scientific meeting of the American Geriatrics Society, National Harbor, MD, USA2011. FarlowM , RichardsonS , MackellJ , SunY . Long‐term safety and tolerability of donepezil 23 MG in patients with moderate‐to‐severe Alzheimer's disease: an 18‐month analysis. Alzheimer's and Dementia 2011 Alzheimer's Association International Conference, Paris, France. 2011. FarlowM , VelosoF , MolineM , YardleyJ , Brand‐SchieberE , BibbianiF , et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurology2011;11:57. FarlowMR , SallowayS , TariotPN , YardleyJ , MolineML , WangQ , et al. Effectiveness and tolerability of high‐dose (23 mg/d) versus standard‐dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24‐week, randomized, double‐blind study. Clinical Therapeutics2010;32(7):1234‐51. FerrisS , CummingsJ , ChristensenD , DoodyR , FarlowM , SabbaghM , et al. Donepezil 23 MG/D for moderate to severe Alzheimer's disease: assessing subdomains of the Severe Impairment Battery. Journal of Nutrition, Health and Aging 5th Conference Clinical Trials on Alzheimer's Disease, Monte Carlo, Monaco. 2012. FerrisS , CummingsJ , ChristensenD , DoodyR , FarlowM , SabbaghM , et al. Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimer's Research &amp; Therapy2013;5:12. FerrisS , MacKellJ , BaiZ , SunY . Effect of donepezil 23 mg/day on language function in patients with moderate‐to‐severe Alzheimer's disease (AD): subgroup analysis of united states (U.S.)‐based patients. Alzheimer's Association International Conference 2012 Vancouver, BC Canada. 2012. FerrisSH , SchmittFA , SaxtonJ , RichardsonS , MackellJ , SunY , et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimer's Research &amp; Therapy2011;3(3):22. HanS‐H , LeeJ‐H , KimSY , ParkKW , ChenC , TripathiM , et al. Donepezil 23 mg in Asian patients with moderate‐to‐severe Alzheimer's disease. Acta Neurologica Scandinavica2017;135(2):252‐56. SabbaghM , CummingsJ , ChristensenD , DoodyR , FarlowM , LiuL , et al. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatrics2013;13:56. SabbaghM , CummingsJ , ChristensenD , DoodyR , FarlowM , MacKellJ , et al. Evaluating the cognitive effects of donepezil 23 MG/D in moderate and severe Alzheimer's disease: a patient subgroup analysis. Journal of Nutrition, Health and Aging 5th Conference Clinical Trials on Alzheimer's Disease, Monte Carlo, Monaco. 2012. SabbaghM , HanS , KimS , NaH‐R , LeeJ‐H , KandiahN , et al. Clinical recommendations for the use of donepezil 23 mg in moderate‐to‐severe Alzheimer's disease in the Asia‐Pacific region. Dementia and Geriatric Cognitive Disorders Extra2016;6:382‐95. TariotP , SallowayS , YardleyJ , MackellJ , MolineM . Long‐term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease. BMC Research Notes2012;5:283. TariotP , YardleyJ , MolineM , Brand‐SchieberE , ZouH , TimothyH , et al. Long‐term safety and tolerability of high dose donepezil (23 mg/day) in moderate to severe Alzheimer's disease: a 12‐month open‐label study. Neuropsychopharmacology 49th Annual Conference of the American College of Neuropsychopharmacology, Miami Beach, FL, USA. 2010. ">Farlow 2010</a> and <a href="./references#CD001190-bbs2-0010" title="HommaA , AtarashiH , KubotaN , NakaiK , TakaseT . Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in Japanese patients with severe Alzheimer's disease: a randomized, double‐blind trial. Journal of Alzheimer's disease2016;52(1):345‐57. ">Homma 2016</a> were parallel‐group studies of 24 weeks' duration designed to compare donepezil (10 mg/day) with a slow‐release formulation of donepezil (23 mg/day). </p> <p><a href="./references#CD001190-bbs2-0012" title="JiaJP , WeiCB , JiaLF , TangY , LiangJH , ZhouAH , et al. Efficacy and safety of donepezil in Chinese patients with severe Alzheimer's disease: a randomized controlled trial. Journal of Alzheimer's disease2017;56(4):1495‐504. ">Jia 2017</a>, sponsored by Eisai China was a placebo‐controlled, 24‐week trial to investigate donepezil, 10 mg/day, in Chinese people with severe Alzheimer's disease. </p> </section> </section> <section id="CD001190-sec-0072"> <h5 class="title">Outcomes</h5> <p>The studies examined cognition, functional and behavioural symptoms, and global effects, as well as the safety and tolerability of donepezil. Apart from the outcomes related to safety or adverse effects, the included studies measured all the outcomes for the effectiveness of donepezil by questionnaires or psychometric tests and used different types of instruments to measure each outcome. We have summarised the details of the outcomes measured and reported in each trial in <a href="#CD001190-tbl-0006">Table 2</a>. </p> <p>In all studies assessments were carried out at more than one time point between the base line assessment and the reported end‐point. </p> <p>Details of adverse events were ascertained by the questioning of each patient at each assessment. Serious adverse events were reported immediately. </p> </section> </section> <section id="CD001190-sec-0073"> <h4 class="title">Excluded studies</h4> <p>These are listed in <a href="./references#CD001190-sec-0187" title="">Characteristics of excluded studies</a>. We excluded the greatest number of studies because the control was another drug and not placebo, or because the study was open label. </p> </section> </section> <section id="CD001190-sec-0074"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD001190-fig-0002">Figure 2</a> and <a href="#CD001190-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD001190-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD001190-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD001190-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD001190-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD001190-sec-0075"> <h4 class="title">Allocation</h4> <p>We considered all studies sponsored by Eisai Inc. and Pfizer Inc. to be at low risk of bias for randomisation and allocation concealment. Of the independent studies, most had a low risk of bias with clearly described procedures. </p> </section> <section id="CD001190-sec-0076"> <h4 class="title">Blinding</h4> <p>We considered most studies to be at low risk of bias. All studies were described as double‐blinded and were either placebo‐controlled or compared different doses of donepezil. Most studies described the interventions as having identical appearance and taste. Nearly all studies described a computer‐generated randomisation process, and most studies described the placebo and interventions as having identical appearance and taste, but only six studies described the blinding of the assessors. </p> </section> <section id="CD001190-sec-0077"> <h4 class="title">Incomplete outcome data</h4> <p>We considered most studies to be at low risk of bias.The number of dropouts was usually small, that is, less than 20%, except for <a href="./references#CD001190-bbs2-0017" title="EbellM . Does donepezil help patients with moderate Alzheimer's dementia preserve their ability to function independently?. Evidence Based Practice2002. MohsR , DoodyR , MorrisJ , IeniJ , PerdomoC , PrattR , et al. Donepezil preserves activities of daily living in Alzheimer's disease patients: results from a one‐year placebo‐controlled functional survival study. Neurology2000;54(Suppl 3):A415. MohsR , DoodyR , MorrisJ , IeniJ , RogersS , PerdomoC , et al. Donepezil preserves functional status and improves cognition in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Journal of the American Geriatrics Society2000;48(8):S46. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled attrition study. Journal of the European College of Neuropsychopharmacology1999;9(Suppl 5):S328. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Quality Research in Dementia Conference; 2000 November 19‐22, London. 2000. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoC , et al. 312 Study Group. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients [Erratum]. Neurology2001; Vol. 57, issue 10:1942. [MEDLINE: http://www.lww.com] MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients. Neurology2001;57(3):481‐8. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illinois. 2000. [MEDLINE: SR‐HANDSRCH] PrattR , MohsR , DoodyR , MorrisJ , RogersS , IeniJ , et al. Donepezil preserves functional status in Alzheimer's disease patients results from a 1‐year prospective placebo controlled functional study. Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden2000:178. ">Mohs 2001</a>, and <a href="./references#CD001190-bbs2-0001" title="AD2000 Collaborative Group. Long‐term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double‐blind trial. Lancet2004;363:2105‐15. BenthamP , GrayR , HillR , SellwoodE , CourtneyC . Twelve week response to cholinesterase inhibitors dose not predict future benefit the AD2000 trial experience. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:337. LendonCL . Determination of responses to anticholinesterase therapy in the treatment of Alzheimer's disease. 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden: Abstract No 1287. 2002. RobertsN . A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease (AD2000). National Research Register2001. SchneiderLS . AD2000: donepezil in Alzheimer's disease. Lancet2004;363(9427):2100‐1. WaghrayS . AD2000 A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease. National Research Register2000. [MEDLINE: http://www.doh.gov.uk/nrr.htm] ">AD2000</a>. </p> <p>The primary endpoint for <a href="./references#CD001190-bbs2-0017" title="EbellM . Does donepezil help patients with moderate Alzheimer's dementia preserve their ability to function independently?. Evidence Based Practice2002. MohsR , DoodyR , MorrisJ , IeniJ , PerdomoC , PrattR , et al. Donepezil preserves activities of daily living in Alzheimer's disease patients: results from a one‐year placebo‐controlled functional survival study. Neurology2000;54(Suppl 3):A415. MohsR , DoodyR , MorrisJ , IeniJ , RogersS , PerdomoC , et al. Donepezil preserves functional status and improves cognition in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Journal of the American Geriatrics Society2000;48(8):S46. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled attrition study. Journal of the European College of Neuropsychopharmacology1999;9(Suppl 5):S328. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Quality Research in Dementia Conference; 2000 November 19‐22, London. 2000. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoC , et al. 312 Study Group. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients [Erratum]. Neurology2001; Vol. 57, issue 10:1942. [MEDLINE: http://www.lww.com] MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients. Neurology2001;57(3):481‐8. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illinois. 2000. [MEDLINE: SR‐HANDSRCH] PrattR , MohsR , DoodyR , MorrisJ , RogersS , IeniJ , et al. Donepezil preserves functional status in Alzheimer's disease patients results from a 1‐year prospective placebo controlled functional study. Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden2000:178. ">Mohs 2001</a> was time to clinically evident decline in function, as defined in the protocol. Participants reaching this endpoint left the trial and received open‐label donepezil treatment. It was not possible to include most of the results of this trial in the meta‐analyses owing to the withdrawal of participants. It was possible to consider the time to clinically evident decline in function, but other outcomes would be biased by the risk of differential dropout related to treatment allocation. </p> <p>In order to compare the different methods of dealing with missing assessments, we conducted meta analyses where possible on two populations of participants, the ITT population and the completers' population in order to compare the results. The results from the analyses of the completers' population did not cause us to change our conclusions. </p> </section> <section id="CD001190-sec-0078"> <h4 class="title">Selective reporting</h4> <p>We considered most studies to be at low risk of bias.Twenty‐three of the 30 included studies reported all outcomes according to the outcomes identified in the methods section. There was insufficient information to assess the risk in the other seven studies. </p> </section> <section id="CD001190-sec-0079"> <h4 class="title">Other potential sources of bias</h4> <p>We considered some studies to be at high risk of bias.There are serious concerns about the methodological quality of <a href="./references#CD001190-bbs2-0014" title="RobertP , LebertF , GoniS , TouchonJ , VincentS , ARIAL Study Investigators Collaborative Group. The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. Quality Research in Dementia; 19‐22 November, 2000, London. 2000. RobertPH , LebertF , GoniS , TouchonJ , ARIAL Study Investigators Collaborative Group. The impact of caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">Lebert 1999</a>. There is limited information available as this trial has never been published except in conference proceedings. These proceedings report that five participants took the wrong treatment. </p> <p>Participants were withdrawn from <a href="./references#CD001190-bbs2-0017" title="EbellM . Does donepezil help patients with moderate Alzheimer's dementia preserve their ability to function independently?. Evidence Based Practice2002. MohsR , DoodyR , MorrisJ , IeniJ , PerdomoC , PrattR , et al. Donepezil preserves activities of daily living in Alzheimer's disease patients: results from a one‐year placebo‐controlled functional survival study. Neurology2000;54(Suppl 3):A415. MohsR , DoodyR , MorrisJ , IeniJ , RogersS , PerdomoC , et al. Donepezil preserves functional status and improves cognition in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Journal of the American Geriatrics Society2000;48(8):S46. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled attrition study. Journal of the European College of Neuropsychopharmacology1999;9(Suppl 5):S328. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Quality Research in Dementia Conference; 2000 November 19‐22, London. 2000. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoC , et al. 312 Study Group. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients [Erratum]. Neurology2001; Vol. 57, issue 10:1942. [MEDLINE: http://www.lww.com] MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients. Neurology2001;57(3):481‐8. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illinois. 2000. [MEDLINE: SR‐HANDSRCH] PrattR , MohsR , DoodyR , MorrisJ , RogersS , IeniJ , et al. Donepezil preserves functional status in Alzheimer's disease patients results from a 1‐year prospective placebo controlled functional study. Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden2000:178. ">Mohs 2001</a> if they met criteria of clinically evident decline in functional status. </p> <p>Participants were withdrawn from <a href="./references#CD001190-bbs2-0024" title="SeltzerB , ZolnouniP , NunezM , GoldmanR , KumarD , IeniJ , et al. Erratum: efficacy of donepezil in early‐stage alzheimer disease: a randomized placebo‐controlled trial (Archives of Neurology (December 2004) 61 (1852‐1856)). Archives of Neurology2005;62(5):825. SeltzerB , ZolnouniP , NunezM , GoldmanR , KumarD , IeniJ , et al. Donepezil 402 Study Group. Efficacy of donepezil in early‐stage Alzheimer disease. Archives of Neurolology2004;61:1852‐6. ">Seltzer 2004</a> if they could not tolerate the 10 mg dose. </p> </section> </section> <section id="CD001190-sec-0080"> <h3 class="title" id="CD001190-sec-0080">Effects of interventions</h3> <p>See: <a href="./full#CD001190-tbl-0001"><b>Summary of findings for the main comparison</b> Donepezil 10 mg/day compared with placebo for dementia due to Alzheimer's disease</a>; <a href="./full#CD001190-tbl-0002"><b>Summary of findings 2</b> Donepezil 23 mg/day compared with donepezil 10 mg/day for dementia due to Alzheimer's disease</a>; <a href="./full#CD001190-tbl-0003"><b>Summary of findings 3</b> Donepezil 10 mg/day compared with donepezil 5 mg/day for dementia due to Alzheimer's disease</a>; <a href="./full#CD001190-tbl-0004"><b>Summary of findings 4</b> Donepezil 10 mg/day compared with placebo for people with severe dementia due to Alzheimer's disease</a> </p> <p>There are 30 included studies, 21 of which reported results in sufficient detail for analysis. Nine studies contributed limited data or no data. <a href="./references#CD001190-bbs2-0013" title="Anon . No title. Eisai Inc. KrishnanKR , CharlesHC , DoraiswamyPM , MintzerJ , WeislerR , YuX , et al. Randomized, placebo‐controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. The American Journal of Psychiatry2003;160(11):2003‐11. ">Krishnan 2003</a> , <a href="./references#CD001190-bbs2-0025" title="Anon . No title. Eisai Inc. ">Study 205</a>, <a href="./references#CD001190-bbs2-0016" title="KorczynAD . Comments on the article by Mazza et al. concerning Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study. European Journal of Neurology2007;14(9):e9. MazzaM , CapuanoA , BriaAP , MazzaS . Letter to the editor. European Journal of Neurology2007;14(9):e10. MazzaM , CapuanoA , BriaP , MazzaS . Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study. European Journal of Neurology2006;13(9):981‐85. ">Mazza 2006</a>, <a href="./references#CD001190-bbs2-0018" title="MoraesW , PoyaresD , Sukys‐ClaudinoL , GuilleminaultC , TufikS . Donepezil improves obstructive sleep apnoea in Alzheimer disease: a double‐blind, placebo‐controlled study. Chest2008;133(3):677‐83. MoraesW , Sukys‐ClaudinoL , PoyaresD , GuilleminaultC , TufikS . Donepezil improves oxygen desaturation in patients with alzheimer's disease and obstructive sleep apnoea. Sleep Medicine2006;7(S47):368. ">Moraes 2006a</a>, <a href="./references#CD001190-bbs2-0019" title="MoraesW dos S , PoyaresDR , GuilleminaultC , RamosLR , BertolucciPH , TufikS . The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double‐blind placebo‐controlled study. Sleep2006;29(2):199‐205. ">Moraes 2006b</a> contributed a tiny amount of data or no data . Detailed results have been published from <a href="./references#CD001190-bbs2-0001" title="AD2000 Collaborative Group. Long‐term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double‐blind trial. Lancet2004;363:2105‐15. BenthamP , GrayR , HillR , SellwoodE , CourtneyC . Twelve week response to cholinesterase inhibitors dose not predict future benefit the AD2000 trial experience. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:337. LendonCL . Determination of responses to anticholinesterase therapy in the treatment of Alzheimer's disease. 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden: Abstract No 1287. 2002. RobertsN . A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease (AD2000). National Research Register2001. SchneiderLS . AD2000: donepezil in Alzheimer's disease. Lancet2004;363(9427):2100‐1. WaghrayS . AD2000 A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease. National Research Register2000. [MEDLINE: http://www.doh.gov.uk/nrr.htm] ">AD2000</a> but few are reported in this review as they are difficult to interpret due to the second randomisation three months after baseline, and the high percentage of participants leaving the trial early. Extraction for the meta‐analyses and interpretation of the published results is not straight forward due to the complex design of the study and the form in which results were reported. The results from <a href="./references#CD001190-bbs2-0014" title="RobertP , LebertF , GoniS , TouchonJ , VincentS , ARIAL Study Investigators Collaborative Group. The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. Quality Research in Dementia; 19‐22 November, 2000, London. 2000. RobertPH , LebertF , GoniS , TouchonJ , ARIAL Study Investigators Collaborative Group. The impact of caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">Lebert 1999</a> and <a href="./references#CD001190-bbs2-0006" title="HegerlU , MerglR , HenkelV , GallinatJ , KotterG , Muller SiechenederF , et al. Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia. Journal of Clinical Psychopharmacology2003;23(2):214‐6. ">Hegerl 2003</a> were not published with sufficient detail to allow extraction of the data for the meta‐analyses. We have serious concerns about the methodological quality of <a href="./references#CD001190-bbs2-0014" title="RobertP , LebertF , GoniS , TouchonJ , VincentS , ARIAL Study Investigators Collaborative Group. The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. Quality Research in Dementia; 19‐22 November, 2000, London. 2000. RobertPH , LebertF , GoniS , TouchonJ , ARIAL Study Investigators Collaborative Group. The impact of caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">Lebert 1999</a>. <a href="./references#CD001190-bbs2-0023" title="SchindlerR , Corey‐BloomJ , DoodyR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4‐7, 2004. 2004. SchindlerR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. Neurobiology of Aging2004;25(S2):195. ">Schindler 2004</a> published data on the number of adverse events only. </p> <p>The older studies included participants with mild to moderate Alzheimer's disease, mean baseline MMSE ranging from 17 to 22, but more recent studies have been including participants with more severe Alzheimer's disease. <a href="./references#CD001190-bbs2-0027" title="SteinmanMA , CovinskyKE , TariotPN , CummingsJL , KatzIR , MintzerJ , et al. Donepezil for nursing home patients with dementia: a reinterpretation of the evidence. Journal of the American Geriatrics Society2003;51(1):132‐33. TariotP , CummingsJL , KatzIR , PerdomoCA , WhalenE , SovelMA , et al. Donepezil was well‐tolerated and enhanced cognition in nursing home patients with Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. TariotP , PerdomoCA , WhalenE , SovelMA , SchamEM . Age is not a barrier to donepezil treatment of Alzheimer's disease in the long‐term care setting. International Psychogeriatrics1999;11(Supplement 1):134. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomised, double‐blind, placebo‐controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2003;51(1):133‐4. ">Tariot 2001</a>, <a href="./references#CD001190-bbs2-0002" title="BlackS , LiHL , McRaeT , RichardsonS . Treatment of severe Alzheimer's disease with donepezil: results from a 24‐week, multinational, randomized, double‐blind, placebo‐controlled trial. Neurology2006;66(5):A347. BlackS , LiHonglang , McRaeT , RichardsonS . Donepezil treatment of severe Alzheimer's disease: results from a 24‐week, multinational, randomized, double‐blind, placebo controlled trial. Poster Presented at the Geneva Springfield ConferenceApril 2006. BlackSE , DoodyR , LiH , McRaeT , JamborKM , XuY , et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology2007;69(5):459‐69. Pfizer . E2020‐A001‐315: a 24 week multinational RCT evaluating the efficacy and safety of donepezil in severe AD. www.marc.soton.ac.uk/Research%20Page.htm. RichardsonS . A 24 week, multicenter, randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of donepezil hydrochloride (E2020) in patients with severe Alzheimer's disease followed by a 12 week open‐label extension period. www.clinicaltrials.gov/ct/show/NCT000964732004. ">Black 2007</a>, <a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a>, <a href="./references#CD001190-bbs2-0009" title="HommaA , ArimotoI , KaidojiK , OhbayashiT , OzawaH . Treatment of severe Alzheimer's disease with donepezil: results from a 24 week, parallel, placebo‐controlled study in Japan. 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, July 2006. 2006. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24‐week, double‐blind, placebo‐controlled, randomized trial. Geriatric Cognitive Disorders2008;25(5):399‐407. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Long‐term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52‐week, open‐label, multicenter, extension study in Japan. Dementia and Geritatric Congitive Disorders2009;27(3):232‐9. ">Homma 2008</a>, <a href="./references#CD001190-bbs2-0011" title="HowardRJ , JuszczakE , BallardCG , BenthamP Brown RG , BullockR , et al. CALM‐AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine2007;357(14):1382‐92. PelosiA . Donepezil is no more effective than placebo for agitation in people with Alzheimer's disease. Evidence‐Based Mental Health2008;11(3):84. ">Howard 2007</a>, <a href="./references#CD001190-bbs2-0012" title="JiaJP , WeiCB , JiaLF , TangY , LiangJH , ZhouAH , et al. Efficacy and safety of donepezil in Chinese patients with severe Alzheimer's disease: a randomized controlled trial. Journal of Alzheimer's disease2017;56(4):1495‐504. ">Jia 2017</a> and <a href="./references#CD001190-bbs2-0030" title="BatsmanS , MinthonL , EerikssonS , KilanderL , Jansson‐BlixtC , WetterholmA , et al. Study design and baseline patients characteristics in a randomized controlled trial of the efficacy and tolerability of donepezil in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. ErikssonS , WinbladB , KilanderL , BatsmanS , Jansson‐BlixtC , WetterholmA , et al. Efficacy of donepezil on secondary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. JelicV , HaglundA , KowalskiJ , LangworthS , WinbladB . Donepezil treatment of severe Alzheimer's disease in nursing home settings. Dementia and Geriatric Cognitive Disorders2008;26(5):458‐46. KilanderL , WinbladB , MinthonL , BatsmanS , Jansson‐BlixtC , CronlundA , et al. Donepezil is well tolerated in patients with severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MarderK . Donepezil in patients with severe Alzheimer's disease: double‐blind parallel‐group, placebo controlled study. Current Neurology and Neuroscience Reports2006;6(5):364‐73. OpieLH . Donepezil for severe Alzheimer's disease. Lancet2006;368:361‐2. WinbladB . Donepezil for severe Alzheimer's disease ‐ author's reply. Lancet2006;368(9533):362. WinbladB . Severe Alzheimer's disease: benefits of donepezil therapy. International Psychogeriatrics2006;18(5):S25‐S31. WinbladB , KilanderL , ErikssonS , MinthonL , BåtsmanS , WetterholmA , et al. for the Severe Alzheimer’s Disease Study Group. Donepezil in patients with severe Alzheimer’s disease: double‐blind, parallel‐group, placebo‐controlled study. Lancet2006;367(9156):1057‐65. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansoon‐BlixtC , WetterholmA , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansson‐BlixtC , WetterholmAL , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. International Psychogeriatrics2005;18(S1):S25‐S31. ">Winblad 2006</a> have mean baseline MMSE ranging from 6 to 14. We have reported the results of <a href="./references#CD001190-bbs2-0011" title="HowardRJ , JuszczakE , BallardCG , BenthamP Brown RG , BullockR , et al. CALM‐AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine2007;357(14):1382‐92. PelosiA . Donepezil is no more effective than placebo for agitation in people with Alzheimer's disease. Evidence‐Based Mental Health2008;11(3):84. ">Howard 2007</a> separately, as the included participants were suffering with severe agitation, and thus were a subset of the total population of people with severe Alzheimer's disease. We have combined the results of the other studies with studies of the mild to moderate group and, in addition, we reported separately the results of <a href="./references#CD001190-bbs2-0002" title="BlackS , LiHL , McRaeT , RichardsonS . Treatment of severe Alzheimer's disease with donepezil: results from a 24‐week, multinational, randomized, double‐blind, placebo‐controlled trial. Neurology2006;66(5):A347. BlackS , LiHonglang , McRaeT , RichardsonS . Donepezil treatment of severe Alzheimer's disease: results from a 24‐week, multinational, randomized, double‐blind, placebo controlled trial. Poster Presented at the Geneva Springfield ConferenceApril 2006. BlackSE , DoodyR , LiH , McRaeT , JamborKM , XuY , et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology2007;69(5):459‐69. Pfizer . E2020‐A001‐315: a 24 week multinational RCT evaluating the efficacy and safety of donepezil in severe AD. www.marc.soton.ac.uk/Research%20Page.htm. RichardsonS . A 24 week, multicenter, randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of donepezil hydrochloride (E2020) in patients with severe Alzheimer's disease followed by a 12 week open‐label extension period. www.clinicaltrials.gov/ct/show/NCT000964732004. ">Black 2007</a>, <a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a>, <a href="./references#CD001190-bbs2-0009" title="HommaA , ArimotoI , KaidojiK , OhbayashiT , OzawaH . Treatment of severe Alzheimer's disease with donepezil: results from a 24 week, parallel, placebo‐controlled study in Japan. 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, July 2006. 2006. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24‐week, double‐blind, placebo‐controlled, randomized trial. Geriatric Cognitive Disorders2008;25(5):399‐407. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Long‐term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52‐week, open‐label, multicenter, extension study in Japan. Dementia and Geritatric Congitive Disorders2009;27(3):232‐9. ">Homma 2008</a>, <a href="./references#CD001190-bbs2-0011" title="HowardRJ , JuszczakE , BallardCG , BenthamP Brown RG , BullockR , et al. CALM‐AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine2007;357(14):1382‐92. PelosiA . Donepezil is no more effective than placebo for agitation in people with Alzheimer's disease. Evidence‐Based Mental Health2008;11(3):84. ">Howard 2007</a>, <a href="./references#CD001190-bbs2-0012" title="JiaJP , WeiCB , JiaLF , TangY , LiangJH , ZhouAH , et al. Efficacy and safety of donepezil in Chinese patients with severe Alzheimer's disease: a randomized controlled trial. Journal of Alzheimer's disease2017;56(4):1495‐504. ">Jia 2017</a> and <a href="./references#CD001190-bbs2-0030" title="BatsmanS , MinthonL , EerikssonS , KilanderL , Jansson‐BlixtC , WetterholmA , et al. Study design and baseline patients characteristics in a randomized controlled trial of the efficacy and tolerability of donepezil in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. ErikssonS , WinbladB , KilanderL , BatsmanS , Jansson‐BlixtC , WetterholmA , et al. Efficacy of donepezil on secondary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. JelicV , HaglundA , KowalskiJ , LangworthS , WinbladB . Donepezil treatment of severe Alzheimer's disease in nursing home settings. Dementia and Geriatric Cognitive Disorders2008;26(5):458‐46. KilanderL , WinbladB , MinthonL , BatsmanS , Jansson‐BlixtC , CronlundA , et al. Donepezil is well tolerated in patients with severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MarderK . Donepezil in patients with severe Alzheimer's disease: double‐blind parallel‐group, placebo controlled study. Current Neurology and Neuroscience Reports2006;6(5):364‐73. OpieLH . Donepezil for severe Alzheimer's disease. Lancet2006;368:361‐2. WinbladB . Donepezil for severe Alzheimer's disease ‐ author's reply. Lancet2006;368(9533):362. WinbladB . Severe Alzheimer's disease: benefits of donepezil therapy. International Psychogeriatrics2006;18(5):S25‐S31. WinbladB , KilanderL , ErikssonS , MinthonL , BåtsmanS , WetterholmA , et al. for the Severe Alzheimer’s Disease Study Group. Donepezil in patients with severe Alzheimer’s disease: double‐blind, parallel‐group, placebo‐controlled study. Lancet2006;367(9156):1057‐65. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansoon‐BlixtC , WetterholmA , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansson‐BlixtC , WetterholmAL , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. International Psychogeriatrics2005;18(S1):S25‐S31. ">Winblad 2006</a>, the six studies that included only participants with severe or moderately severe dementia. </p> <p>We have reported the main objective of each study in <a href="#CD001190-tbl-0007">Table 3</a>. Nineteen studies examined the cognitive, functional and global effects of donepezil. We analysed the results for treatment groups taking 5 mg/day and 10 mg/day of donepezil separately. Phase II dose‐finding studies had also used doses less than 5 mg/day, but donepezil is not prescribed at less than 5 mg/day and therefore we did not carry out meta‐analyses for the treatment groups where dose was less than 5 mg/day. </p> <p>We analysed results after treatment periods of 12, 24 to 26, and 52 weeks separately.</p> <p>Where data are available we have reported meta‐analyses on the ITT population, where LOCF assessments were incorporated when assessments were missing, and on the completers' population. The results appear similar, suggesting no differential dropout between the treatment groups. Models were fitted using fixed effects. There is evidence of heterogeneity between the studies for a few meta‐analyses. We rated outcomes as moderate quality, downgraded one level due to the risk of bias due to lack of information on allocation concealment and on the blinding of outcome assessment for some of the studies. Twenty‐two of the 30 studies did not describe allocation concealment and blinding of outcome, and 17 of the 30 studies did not describe blinding of the intervention. </p> <p>The rating scales and cognitive tests differ in the direction representing improvement, or fewer symptoms: </p> <p> <ul id="CD001190-list-0004"> <li> <p>a decrease in score indicates improvement with the Alzheimer's Disease Assessment Scale‐Cognitive (ADAS‐Cog), Activities of Daily Living (ADL), Behavioural Pathology in Alzheimer's Disease Rating Scale (BEHAVE‐AD), Clinical Dementia Rating scale (CDR), Clinician's Interview‐Based Impression of Change scale (CIBIC‐Plus), Cohen‐Mansfield Agitation Inventory (CMAI), Chrichton Scale (CMCS), Gottfries, Brane and Steen scale (GBS), Neuropsychiatric Instrument (NPI), Neuropsychiatric Inventory Distress scale (NPI‐D), and Syndrom Kurz Test (SKT); </p> </li> <li> <p>an increase in score shows improvement for the Alzheimer's Disease Cooperative Study‐Activities of Daily Living Scale (severe version) (ADCS‐ADL‐sev), Disability Assessment for Dementia (DAD), Mini Mental State Examination (MMSE), Progressive Deterioration Scale (PDS), Quality of Life scale (QoL), and Severe Impairment Battery (SIB). (See <a href="./appendices#CD001190-sec-0163">Appendix 2</a> for more information about tests and rating scales.) </p> </li> </ul> </p> <section id="CD001190-sec-0081"> <h4 class="title">Comparison of donepezil (10 mg/day) with placebo</h4> <section id="CD001190-sec-0082"> <h5 class="title">Cognitive function</h5> <p>The meta‐analysis, using mean differences (MDs) revealed a benefit on cognitive function as measured by the ADAS‐Cog test score for donepezil compared with placebo at 24 to 26 weeks (MD ‐2.67 , 95% CI ‐3.31 to ‐2.02, P &lt; 0.00001, 5 studies, 1130 participants, ITT analysis; <a href="./references#CD001190-fig-0004" title="">Analysis 1.1</a>). </p> <p>The MMSE showed similar results in favour of donepezil at 24 to 26 weeks compared with placebo (MD 1.05, 95% CI 0.73 to 1.37, P &lt; 0.00001, 7 studies, 1757 participants, ITT analysis; <a href="./references#CD001190-fig-0005" title="">Analysis 1.2</a>). </p> <p>The SIB showed similar results in favour of donepezil at 24 to 26 weeks compared with placebo (MD 5.92, 95% CI 4.53 to 7.31, P &lt; 0.00001, 5 studies, 1348 participants, ITT analysis; <a href="./references#CD001190-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD001190-sec-0083"> <h5 class="title">Activities of daily living</h5> <p>The meta‐analysis, using MDs revealed a benefit on activities of daily living as measured by the ADCS‐ADL‐sev test score for donepezil compared with placebo at 24 to 26 weeks (MD 1.03 , 95% CI 0.21 to 1.85, P = 0.01, 3 studies, 733 participants, ITT analysis; <a href="./references#CD001190-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD001190-sec-0084"> <h5 class="title">Global assessment</h5> <p>We dichotomised the seven‐point CIBIC‐Plus scale, or the Clinician's Global Impression of Change (CGIC) by counting those showing no change or decline against those showing improvement. There was benefit associated with donepezil (276/834), compared with placebo (173/840), at 24 to 26 weeks (OR 1.92, 95% CI 1.54 to 2.39, P &lt; 0.00001, 6 studies, 1674 participants, ITT analysis; <a href="./references#CD001190-fig-0008" title="">Analysis 1.5</a>). </p> <p>We also used mean differences to analyse the CDR sum of boxes, measuring both cognitive function and aspects of everyday functioning together in a single score. It shows a benefit for donepezil compared with placebo at 24 to 26 weeks, (MD ‐0.53, 95% CI ‐0.73 to ‐0.33, P &lt; 0.00001, 3 studies, 1028 participants, ITT analysis; <a href="./references#CD001190-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD001190-sec-0085"> <h5 class="title">Behavioural symptoms</h5> <p>Four studies (MD ‐1.62, 95% CI ‐3.43 to 0.19, P = 0.08, 4 studies, 1035 participants, ITT analysis; <a href="./references#CD001190-fig-0011" title="">Analysis 1.8</a>), assessed behavioural symptoms using the NPI, and one study (MD 0.40, 95% CI ‐1.28 to 2.08, P = 0.64, 194 participants, ITT analysis; <a href="./references#CD001190-fig-0010" title="">Analysis 1.7</a>) using the BEHAVE‐AD score. There was no difference between donepezil and placebo at 24 to 26 weeks for either score. </p> </section> <section id="CD001190-sec-0086"> <h5 class="title">Withdrawals before the end of treatment</h5> <p>The meta‐analysis of withdrawals before the end of treatment showed a benefit in favour of placebo (282/1401) compared with donepezil (348/1445) at 24 to 26 weeks (OR 1.25, 95% CI 1.05 to 1.50, P = 0.0013, 12 studies, 2846 participants, ITT analysis; <a href="./references#CD001190-fig-0013" title="">Analysis 1.10</a>). </p> </section> <section id="CD001190-sec-0087"> <h5 class="title">Adverse events</h5> <p>The meta‐analysis of numbers of participants with at least one adverse event before the end of treatment showed a benefit in favour of placebo (793/1226) compared with donepezil (913/1274) at 24 to 26 weeks (OR 1.59, 95% CI 1.31 to 1.95, P &lt; 0.00001, 10 studies, 2500 participants, ITT analysis; <a href="./references#CD001190-fig-0014" title="">Analysis 1.11</a>). </p> </section> <section id="CD001190-sec-0088"> <h5 class="title">Quality of life</h5> <p>The meta‐analysis, using MDs showed no difference for QoL between donepezil 10 mg/day compared with placebo at 24 weeks (MD ‐2.79, 95% CI ‐8.15 to 2.56, P = 0.31, 2 studies, 815 participants, ITT analysis; <a href="./references#CD001190-fig-0012" title="">Analysis 1.9</a>). </p> </section> </section> <section id="CD001190-sec-0089"> <h4 class="title">Comparison of donepezil (5 mg/day and 10 mg/day) with placebo</h4> <section id="CD001190-sec-0090"> <h5 class="title">Cognitive function</h5> <p>The meta‐analyses, using MDs, revealed a benefit on cognitive function as measured by ADAS‐Cog test scores for the lower‐dose and higher‐dose donepezil compared with placebo at 12, and 24 to 26 weeks. </p> <p> <ul id="CD001190-list-0005"> <li> <p>5 mg/day donepezil at 12 weeks (MD ‐2.27, 95% CI ‐3.16 to ‐1.39, P &lt; 0.00001, 3 studies, 488 participants, ITT analysis; <a href="./references#CD001190-fig-0016" title="">Analysis 2.2</a>) </p> </li> <li> <p>10 mg/day donepezil at 12 weeks (MD ‐2.99, 95% CI ‐3.99 to ‐1.99, P &lt; 0.00001, 5 studies, 459 participants, ITT analysis; <a href="./references#CD001190-fig-0016" title="">Analysis 2.2</a>) </p> </li> <li> <p>5 mg/day donepezil at 24 weeks (MD ‐2.01, 95% CI ‐2.69 to ‐1.34, P &lt; 0.00001, 3 studies, 1089 participants, ITT analysis; <a href="./references#CD001190-fig-0016" title="">Analysis 2.2</a>) </p> </li> <li> <p>10 mg/day donepezil at 24 weeks (MD ‐2.67, 95% CI ‐3.31 to ‐2.02, P &lt; 0.00001, 5 studies, 1130 participants, ITT analysis; <a href="./references#CD001190-fig-0016" title="">Analysis 2.2</a>) </p> </li> </ul> </p> <p>The MMSE showed similar results in favour of the lower‐dose and higher‐dose donepezil compared with placebo at 12, 24 to 26, and 52 weeks. </p> <p> <ul id="CD001190-list-0006"> <li> <p>5 mg/day donepezil at 12 weeks (MD 0.92, 95% CI 0.32 to 1.53, P = 0.003, 2 studies, 382 participants, ITT analysis; <a href="./references#CD001190-fig-0018" title="">Analysis 2.4</a> ) </p> </li> <li> <p>10 mg/day donepezil at 12 weeks (MD 1.19, 95% CI 0.61 to 1.77, P &lt; 0.0001, 2 studies, 511 participants, ITT analysis; <a href="./references#CD001190-fig-0018" title="">Analysis 2.4</a> ) </p> </li> <li> <p>5 mg/day donepezil at 24 weeks (MD 1.22, 95% CI 0.54 to 1.90, P = 0.0004, 2 studies, 358 participants, ITT analysis; <a href="./references#CD001190-fig-0018" title="">Analysis 2.4</a> ) </p> </li> <li> <p>10 mg/day donepezil at 24 weeks (MD 1.05, 95% CI 0.73 to 1.37, P &lt; 0.000001, 7 studies, 1757 participants, ITT analysis; <a href="./references#CD001190-fig-0018" title="">Analysis 2.4</a> ) </p> </li> <li> <p>10 mg/day donepezil at 52 weeks (MD 1.70, 95% CI 0.81 to 2.59, P = 0.0002, 1 study, 272 participants, ITT analysis; <a href="./references#CD001190-fig-0018" title="">Analysis 2.4</a> ) </p> </li> </ul> </p> <p>The meta‐analyses, using MDs, revealed a benefit on cognitive function as measured by SIB test scores for the lower‐dose and higher‐dose donepezil compared with placebo at 24 to 26 weeks. </p> <p> <ul id="CD001190-list-0007"> <li> <p>5 mg/day donepezil at 24 weeks (MD 6.70, 95% CI 3.66 to 9.74, P &lt; 0.0001, 1 study, 198 participants, ITT analysis; <a href="./references#CD001190-fig-0019" title="">Analysis 2.5</a> ) </p> </li> <li> <p>10 mg/day donepezil at 24 weeks (MD 5.92, 95% CI 4.53 to 7.31, P &lt; 0.000001, 5 studies, 1348 participants, ITT analysis; <a href="./references#CD001190-fig-0019" title="">Analysis 2.5</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0091"> <h5 class="title">Activities of daily living</h5> <p>The <a href="./references#CD001190-bbs2-0029" title="EngedalK , SoininenH , VerheyF , WaldemarG , WinbladB , WimoA , et al. Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000; Vol. 10, issue Suppl 3:S368. [MEDLINE: SR‐HANDSRCH] MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a one year, double‐blind, randomized trial. Journal of the American Geriatrics Society2001; Vol. 49, issue 4:S131. MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. Donepezil reduces the time caregivers spend providing care: results of a one‐year, double‐blind, randomized trial in patients with mild to moderate Alzheimer's disease. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23‐26, San Francisco2001. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Long term benefits of donepezil on ADLs in AD patients. Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:171. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Donepezil Nordic Study Group. Response to donepezil is not predicted by apolipoprotein E genotype and/or gender. World Alzheimer Congress; 2000 July 9‐13, Washington. 2000. WaldemarG , WinbladB , EngedalK , SoininenH , Donepezil Nordic Study Group et al. Benefits of donepezil on cognition, function and/or neuropsychiatric symptoms in patients with Alzheimers disease over one year. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WaldemarG , WinbladB , EngedalK , SoininenHS , VerheyFR , WimoA , et al. Donepezil Nordic Study Group. Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year. Neurology2000;54(Suppl 3):A470. WimoA . Erratum: an economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial (Dementia and Geriatric Cognitive Disorders (2003) 15 (44‐54)). Dementia and Geriatric Cognitive Disorders2003; Vol. 16, issue 2:102. WimoA , WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , et al. Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial. Dementia and Geriatric Cognitive Disorders2003;15(1):44‐54. WimoA , WinbladB , MasteyV . An economic evaluation of donepezil in mild to moderate Alzheimers disease: results of a one‐year, double‐blind, randomized trial. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WimoA , WinbladB , MasteyV , HaglundA , HertzmanP , MiceliR , et al. An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one‐year, double‐blind, randomized trial. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illionois. 2000. [MEDLINE: SR‐HANDSRCH] WinbladB . Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:164. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , WetterholmAL , ZhangR , HaglundA , SubbiahP . Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. International Psychogeriatrics1999;11(Supplement 1):138. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. A 1‐year, randomized, placebo‐controlled study of donepezil in patients with mild to moderate AD. Neurology2001;57(3):489‐95. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. Donepezil enhances global function and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. Quality Research in Dementia Conference; 2000 Nov 19‐22, London. 2000. WinbladB , WimoA , EngedalK , SoininenH , VerheyF , WaldemarG , et al. 3‐year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia and Geriatric Cognitive Disorders2006;21(5‐6):353‐63. ">Winblad 2001</a> was the only study to assess activities of daily living using the PDS scale. 10 mg/day donepezil showed benefit compared with placebo at 52 weeks (MD 3.80, 95% CI 1.70 to 5.90, P = 0.0004, 1 study, 276 participants, ITT analysis; <a href="./references#CD001190-fig-0029" title="">Analysis 2.15</a>). </p> <p>Two other studies assessed activities of daily living, <a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a> (using the DAD, Instrumental ADL and Physical Self‐maintenance Scale (PSMS)) and <a href="./references#CD001190-bbs2-0008" title="HommaA , TakedaM , ImaiY , UdakaF , HasegawaK , KameyamaM , et al. E2020 Study Group. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24‐week, multicenter, double‐blind, placebo‐controlled study in Japan. Dementia and Geriatric Cognitive Disorders2000; Vol. 11, issue 6:299‐313. ">Homma 2000</a> (CMCS). There was evidence of benefit of donepezil at 12 and 24 weeks. </p> <p> <ul id="CD001190-list-0008"> <li> <p>5 mg/day donepezil at 24 weeks (completers' analysis, MD ‐2.42, 95% CI ‐4.32 to ‐0.52, P = 0.01, 1 study, 228 participants, <a href="./references#CD001190-fig-0026" title="">Analysis 2.12</a>) (CMCS) </p> </li> <li> <p>10 mg/day donepezil at 12 weeks (completers' analysis, MD 4.83, 95% CI 1.35 to 8.31, P = 0.007, 1 study, 254 participants, <a href="./references#CD001190-fig-0027" title="">Analysis 2.13</a>) (DAD) </p> </li> <li> <p>10 mg/day donepezil at 24 weeks (completers' analysis, MD 8.00, 95% CI 3.61 to 12.39, P = 0.0004, 1 study, 247 participants, <a href="./references#CD001190-fig-0027" title="">Analysis 2.13</a>) (DAD) </p> </li> <li> <p>10 mg/day donepezil at 12 weeks (completers' analysis, MD ‐4.31, 95% CI ‐7.72 to ‐0.90, P = 0.01, 1 study, 250 participants, <a href="./references#CD001190-fig-0036" title="">Analysis 2.22</a> ) (IADL) </p> </li> <li> <p>10 mg/day donepezil at 24 weeks (completers' analysis, MD ‐6.32, 95% CI ‐10.02 to ‐2.62, P = 0.0008, 1 study, 243 participants, <a href="./references#CD001190-fig-0036" title="">Analysis 2.22</a>) (IADL) </p> </li> </ul> </p> <p><a href="./references#CD001190-bbs2-0030" title="BatsmanS , MinthonL , EerikssonS , KilanderL , Jansson‐BlixtC , WetterholmA , et al. Study design and baseline patients characteristics in a randomized controlled trial of the efficacy and tolerability of donepezil in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. ErikssonS , WinbladB , KilanderL , BatsmanS , Jansson‐BlixtC , WetterholmA , et al. Efficacy of donepezil on secondary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. JelicV , HaglundA , KowalskiJ , LangworthS , WinbladB . Donepezil treatment of severe Alzheimer's disease in nursing home settings. Dementia and Geriatric Cognitive Disorders2008;26(5):458‐46. KilanderL , WinbladB , MinthonL , BatsmanS , Jansson‐BlixtC , CronlundA , et al. Donepezil is well tolerated in patients with severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MarderK . Donepezil in patients with severe Alzheimer's disease: double‐blind parallel‐group, placebo controlled study. Current Neurology and Neuroscience Reports2006;6(5):364‐73. OpieLH . Donepezil for severe Alzheimer's disease. Lancet2006;368:361‐2. WinbladB . Donepezil for severe Alzheimer's disease ‐ author's reply. Lancet2006;368(9533):362. WinbladB . Severe Alzheimer's disease: benefits of donepezil therapy. International Psychogeriatrics2006;18(5):S25‐S31. WinbladB , KilanderL , ErikssonS , MinthonL , BåtsmanS , WetterholmA , et al. for the Severe Alzheimer’s Disease Study Group. Donepezil in patients with severe Alzheimer’s disease: double‐blind, parallel‐group, placebo‐controlled study. Lancet2006;367(9156):1057‐65. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansoon‐BlixtC , WetterholmA , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansson‐BlixtC , WetterholmAL , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. International Psychogeriatrics2005;18(S1):S25‐S31. ">Winblad 2006</a>, <a href="./references#CD001190-bbs2-0009" title="HommaA , ArimotoI , KaidojiK , OhbayashiT , OzawaH . Treatment of severe Alzheimer's disease with donepezil: results from a 24 week, parallel, placebo‐controlled study in Japan. 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, July 2006. 2006. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24‐week, double‐blind, placebo‐controlled, randomized trial. Geriatric Cognitive Disorders2008;25(5):399‐407. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Long‐term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52‐week, open‐label, multicenter, extension study in Japan. Dementia and Geritatric Congitive Disorders2009;27(3):232‐9. ">Homma 2008</a> and <a href="./references#CD001190-bbs2-0002" title="BlackS , LiHL , McRaeT , RichardsonS . Treatment of severe Alzheimer's disease with donepezil: results from a 24‐week, multinational, randomized, double‐blind, placebo‐controlled trial. Neurology2006;66(5):A347. BlackS , LiHonglang , McRaeT , RichardsonS . Donepezil treatment of severe Alzheimer's disease: results from a 24‐week, multinational, randomized, double‐blind, placebo controlled trial. Poster Presented at the Geneva Springfield ConferenceApril 2006. BlackSE , DoodyR , LiH , McRaeT , JamborKM , XuY , et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology2007;69(5):459‐69. Pfizer . E2020‐A001‐315: a 24 week multinational RCT evaluating the efficacy and safety of donepezil in severe AD. www.marc.soton.ac.uk/Research%20Page.htm. RichardsonS . A 24 week, multicenter, randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of donepezil hydrochloride (E2020) in patients with severe Alzheimer's disease followed by a 12 week open‐label extension period. www.clinicaltrials.gov/ct/show/NCT000964732004. ">Black 2007</a> used the ADCS‐ADL‐severe scale. There was evidence of benefit of donepezil. </p> <p>10 mg/day donepezil at 24 weeks (MD 1.03, 95% CI 0.21 to 1.85, P = 0.01, 3 studies, 733 participants, ITT analysis; <a href="./references#CD001190-fig-0028" title="">Analysis 2.14</a>). </p> <p>The primary endpoint of <a href="./references#CD001190-bbs2-0017" title="EbellM . Does donepezil help patients with moderate Alzheimer's dementia preserve their ability to function independently?. Evidence Based Practice2002. MohsR , DoodyR , MorrisJ , IeniJ , PerdomoC , PrattR , et al. Donepezil preserves activities of daily living in Alzheimer's disease patients: results from a one‐year placebo‐controlled functional survival study. Neurology2000;54(Suppl 3):A415. MohsR , DoodyR , MorrisJ , IeniJ , RogersS , PerdomoC , et al. Donepezil preserves functional status and improves cognition in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Journal of the American Geriatrics Society2000;48(8):S46. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled attrition study. Journal of the European College of Neuropsychopharmacology1999;9(Suppl 5):S328. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Quality Research in Dementia Conference; 2000 November 19‐22, London. 2000. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoC , et al. 312 Study Group. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients [Erratum]. Neurology2001; Vol. 57, issue 10:1942. [MEDLINE: http://www.lww.com] MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients. Neurology2001;57(3):481‐8. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illinois. 2000. [MEDLINE: SR‐HANDSRCH] PrattR , MohsR , DoodyR , MorrisJ , RogersS , IeniJ , et al. Donepezil preserves functional status in Alzheimer's disease patients results from a 1‐year prospective placebo controlled functional study. Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden2000:178. ">Mohs 2001</a> was time to clinically evident decline in function, as defined in the protocol. There was evidence of benefit of donepezil 10 mg/day (84/207) compared with placebo (116/206) at 54 weeks (OR 0.53, 95% CI 0.36 to 0.78, P = 0.001, 1 study, 413 participants; <a href="./references#CD001190-fig-0030" title="">Analysis 2.16</a>). </p> </section> <section id="CD001190-sec-0092"> <h5 class="title">Global assessment</h5> <p>We dichotomised the seven‐point CIBIC‐Plus scale, measuring global clinical state, counting those showing no change or decline, against those showing improvement, and we analysed the results using the OR. There are benefits associated with 5 mg/day and 10 mg/day donepezil compared with placebo at 12, and 24 to 26 weeks, as shown by the ITT analyses. </p> <p> <ul id="CD001190-list-0009"> <li> <p>5 mg/day donepezil at 12 weeks (49/153 donepezil, 27/150 placebo) (OR 2.10, 95% CI 1.25 to 3.53, P = 0.005, 1 study, 303 participants, ITT analysis; <a href="./references#CD001190-fig-0021" title="">Analysis 2.7</a>) </p> </li> <li> <p>10 mg/day donepezil at 12 weeks (58/152 donepezil, 27/150 placebo) (OR 2.70, 95% CI 1.64 to 4.46, P = 0.0001, 1 study, 302 participants, ITT analysis; <a href="./references#CD001190-fig-0021" title="">Analysis 2.7</a>) </p> </li> <li> <p>5 mg/day donepezil at 24 weeks (187/633 donepezil, 102/640 placebo) (OR 2.20, 95% CI 1.69 to 2.87, P &lt; 0.00001, 4 studies, 1273 participants, ITT analysis; <a href="./references#CD001190-fig-0021" title="">Analysis 2.7</a>) </p> </li> <li> <p>10 mg/day donepezil at 24 weeks (276/834 donepezil, 173/840 placebo) (OR 1.92, 95% CI 1.54 to 2.39, P &lt; 0.00001, 6 studies, 1674 participants, ITT analysis; <a href="./references#CD001190-fig-0021" title="">Analysis 2.7</a>) </p> </li> </ul> </p> <p>The GBS and Mental Function Impairment Scale (MENFIS) are both global assessment scales. Only two studies used these scales, the <a href="./references#CD001190-bbs2-0029" title="EngedalK , SoininenH , VerheyF , WaldemarG , WinbladB , WimoA , et al. Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000; Vol. 10, issue Suppl 3:S368. [MEDLINE: SR‐HANDSRCH] MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a one year, double‐blind, randomized trial. Journal of the American Geriatrics Society2001; Vol. 49, issue 4:S131. MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. Donepezil reduces the time caregivers spend providing care: results of a one‐year, double‐blind, randomized trial in patients with mild to moderate Alzheimer's disease. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23‐26, San Francisco2001. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Long term benefits of donepezil on ADLs in AD patients. Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:171. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Donepezil Nordic Study Group. Response to donepezil is not predicted by apolipoprotein E genotype and/or gender. World Alzheimer Congress; 2000 July 9‐13, Washington. 2000. WaldemarG , WinbladB , EngedalK , SoininenH , Donepezil Nordic Study Group et al. Benefits of donepezil on cognition, function and/or neuropsychiatric symptoms in patients with Alzheimers disease over one year. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WaldemarG , WinbladB , EngedalK , SoininenHS , VerheyFR , WimoA , et al. Donepezil Nordic Study Group. Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year. Neurology2000;54(Suppl 3):A470. WimoA . Erratum: an economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial (Dementia and Geriatric Cognitive Disorders (2003) 15 (44‐54)). Dementia and Geriatric Cognitive Disorders2003; Vol. 16, issue 2:102. WimoA , WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , et al. Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial. Dementia and Geriatric Cognitive Disorders2003;15(1):44‐54. WimoA , WinbladB , MasteyV . An economic evaluation of donepezil in mild to moderate Alzheimers disease: results of a one‐year, double‐blind, randomized trial. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WimoA , WinbladB , MasteyV , HaglundA , HertzmanP , MiceliR , et al. An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one‐year, double‐blind, randomized trial. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illionois. 2000. [MEDLINE: SR‐HANDSRCH] WinbladB . Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:164. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , WetterholmAL , ZhangR , HaglundA , SubbiahP . Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. International Psychogeriatrics1999;11(Supplement 1):138. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. A 1‐year, randomized, placebo‐controlled study of donepezil in patients with mild to moderate AD. Neurology2001;57(3):489‐95. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. Donepezil enhances global function and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. Quality Research in Dementia Conference; 2000 Nov 19‐22, London. 2000. WinbladB , WimoA , EngedalK , SoininenH , VerheyF , WaldemarG , et al. 3‐year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia and Geriatric Cognitive Disorders2006;21(5‐6):353‐63. ">Winblad 2001</a> used the GBS and <a href="./references#CD001190-bbs2-0008" title="HommaA , TakedaM , ImaiY , UdakaF , HasegawaK , KameyamaM , et al. E2020 Study Group. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24‐week, multicenter, double‐blind, placebo‐controlled study in Japan. Dementia and Geriatric Cognitive Disorders2000; Vol. 11, issue 6:299‐313. ">Homma 2000</a> used the MENFIS. There was some evidence of benefit associated with donepezil (completers). </p> <p> <ul id="CD001190-list-0010"> <li> <p>5 mg/day donepezil at 24 weeks (completers, MD ‐2.56, 95%CI ‐4.27 to ‐0.85, P = 0.003, 1 study, 228 participants, <a href="./references#CD001190-fig-0024" title="">Analysis 2.10</a>) </p> </li> <li> <p>10 mg/day donepezil at 52 weeks (completers, MD ‐6.01, 95%CI ‐11.93 to ‐0.09, P = 0.05, 1 study, 190 participants, <a href="./references#CD001190-fig-0024" title="">Analysis 2.10</a> ) </p> </li> </ul> </p> <p>We also analysed the CDR‐SB using MDs. This measures both cognitive function and aspects of everyday functioning together in a single score, and showed a benefit with 5 mg/day and 10 mg/day of donepezil compared with placebo at 12 weeks, and 10 mg/day of donepezil compared with placebo at 24 weeks, but there was no difference between donepezil 5 mg/day and placebo at 12 weeks. </p> <p> <ul id="CD001190-list-0011"> <li> <p>5 mg/day donepezil at 12 weeks (MD ‐0.02, 95% CI ‐0.25 to 0.21, P = 0.86, 3 studies, 487 participants, ITT analysis; <a href="./references#CD001190-fig-0023" title="">Analysis 2.9</a>) </p> </li> <li> <p>10 mg/day donepezil at 12 weeks (MD ‐0.23, 95% CI ‐0.47 to 0.00, P = 0.05, 4 studies, 559 participants, ITT analysis; <a href="./references#CD001190-fig-0023" title="">Analysis 2.9</a>) </p> </li> <li> <p>5 mg/day donepezil at 24 weeks (MD ‐0.51, 95% CI ‐0.70 to ‐0.32, P &lt; 0.00001, 3 studies, 1093 participants, ITT analysis; <a href="./references#CD001190-fig-0023" title="">Analysis 2.9</a>) </p> </li> <li> <p>10 mg/day donepezil at 24 weeks (MD ‐0.53, 95% CI ‐0.73 to ‐0.33, P &lt; 0.00001, 3 studies, 1028 participants, ITT analysis; <a href="./references#CD001190-fig-0023" title="">Analysis 2.9</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0093"> <h5 class="title">Behavioural symptoms</h5> <p><a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a>, <a href="./references#CD001190-bbs2-0028" title="TuneL , TiseoP , HoffmanJ , PerdomoC , VotawJ , RogersS , et al. PET in AD: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer's disease: results of a 24‐week study. 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 February 23‐26 San Francisco. 2001. TuneL , TiseoPJ , IeniJ , PerdomoC , PrattRD , VotawJR , et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24‐week, double‐blind, placebo‐controlled study. American Journal of Geriatric Psychiatry2003;11(2):169‐77. TuneLE , TiseoPJ , HoffmanJM , PerdomoCA , VotowJR , RogersSL , et al. Functional brain activity in Alzheimer's disease. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐ June 4, Toronto. 1998:NR345. [MEDLINE: SR‐HANDSRCH] ">Tune 2003</a>, <a href="./references#CD001190-bbs2-0030" title="BatsmanS , MinthonL , EerikssonS , KilanderL , Jansson‐BlixtC , WetterholmA , et al. Study design and baseline patients characteristics in a randomized controlled trial of the efficacy and tolerability of donepezil in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. ErikssonS , WinbladB , KilanderL , BatsmanS , Jansson‐BlixtC , WetterholmA , et al. Efficacy of donepezil on secondary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. JelicV , HaglundA , KowalskiJ , LangworthS , WinbladB . Donepezil treatment of severe Alzheimer's disease in nursing home settings. Dementia and Geriatric Cognitive Disorders2008;26(5):458‐46. KilanderL , WinbladB , MinthonL , BatsmanS , Jansson‐BlixtC , CronlundA , et al. Donepezil is well tolerated in patients with severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MarderK . Donepezil in patients with severe Alzheimer's disease: double‐blind parallel‐group, placebo controlled study. Current Neurology and Neuroscience Reports2006;6(5):364‐73. OpieLH . Donepezil for severe Alzheimer's disease. Lancet2006;368:361‐2. WinbladB . Donepezil for severe Alzheimer's disease ‐ author's reply. Lancet2006;368(9533):362. WinbladB . Severe Alzheimer's disease: benefits of donepezil therapy. International Psychogeriatrics2006;18(5):S25‐S31. WinbladB , KilanderL , ErikssonS , MinthonL , BåtsmanS , WetterholmA , et al. for the Severe Alzheimer’s Disease Study Group. Donepezil in patients with severe Alzheimer’s disease: double‐blind, parallel‐group, placebo‐controlled study. Lancet2006;367(9156):1057‐65. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansoon‐BlixtC , WetterholmA , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansson‐BlixtC , WetterholmAL , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. International Psychogeriatrics2005;18(S1):S25‐S31. ">Winblad 2006</a>, <a href="./references#CD001190-bbs2-0002" title="BlackS , LiHL , McRaeT , RichardsonS . Treatment of severe Alzheimer's disease with donepezil: results from a 24‐week, multinational, randomized, double‐blind, placebo‐controlled trial. Neurology2006;66(5):A347. BlackS , LiHonglang , McRaeT , RichardsonS . Donepezil treatment of severe Alzheimer's disease: results from a 24‐week, multinational, randomized, double‐blind, placebo controlled trial. Poster Presented at the Geneva Springfield ConferenceApril 2006. BlackSE , DoodyR , LiH , McRaeT , JamborKM , XuY , et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology2007;69(5):459‐69. Pfizer . E2020‐A001‐315: a 24 week multinational RCT evaluating the efficacy and safety of donepezil in severe AD. www.marc.soton.ac.uk/Research%20Page.htm. RichardsonS . A 24 week, multicenter, randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of donepezil hydrochloride (E2020) in patients with severe Alzheimer's disease followed by a 12 week open‐label extension period. www.clinicaltrials.gov/ct/show/NCT000964732004. ">Black 2007</a> and <a href="./references#CD001190-bbs2-0027" title="SteinmanMA , CovinskyKE , TariotPN , CummingsJL , KatzIR , MintzerJ , et al. Donepezil for nursing home patients with dementia: a reinterpretation of the evidence. Journal of the American Geriatrics Society2003;51(1):132‐33. TariotP , CummingsJL , KatzIR , PerdomoCA , WhalenE , SovelMA , et al. Donepezil was well‐tolerated and enhanced cognition in nursing home patients with Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. TariotP , PerdomoCA , WhalenE , SovelMA , SchamEM . Age is not a barrier to donepezil treatment of Alzheimer's disease in the long‐term care setting. International Psychogeriatrics1999;11(Supplement 1):134. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomised, double‐blind, placebo‐controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2003;51(1):133‐4. ">Tariot 2001</a> assessed behavioural disturbance (NPI‐TOTAL), and there was no evidence of benefit. </p> <p> <ul id="CD001190-list-0012"> <li> <p>10 mg/day donepezil at 12 weeks (MD ‐1.45, 95% CI ‐4.43 to 1.53, P = 0.34, 2 studies, 279 participants, ITT analysis; <a href="./references#CD001190-fig-0031" title="">Analysis 2.17</a>) </p> </li> <li> <p>10 mg/day donepezil at 24 weeks (MD ‐1.04, 95% CI ‐3.16 to 1.07, P = 0.33, 4 studies, 692 participants, ITT analysis; <a href="./references#CD001190-fig-0031" title="">Analysis 2.17</a>) </p> </li> </ul> </p> <p><a href="./references#CD001190-bbs2-0009" title="HommaA , ArimotoI , KaidojiK , OhbayashiT , OzawaH . Treatment of severe Alzheimer's disease with donepezil: results from a 24 week, parallel, placebo‐controlled study in Japan. 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, July 2006. 2006. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24‐week, double‐blind, placebo‐controlled, randomized trial. Geriatric Cognitive Disorders2008;25(5):399‐407. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Long‐term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52‐week, open‐label, multicenter, extension study in Japan. Dementia and Geritatric Congitive Disorders2009;27(3):232‐9. ">Homma 2008</a> assessed BEHAVE‐AD and there was no evidence of benefit of donepezil. </p> <p> <ul id="CD001190-list-0013"> <li> <p>5 mg/day donepezil at 24 weeks (MD 0.00, 95% CI ‐1.67 to 1.67, P = 1.0, 1 study, 198 participants, ITT analysis; <a href="./references#CD001190-fig-0032" title="">Analysis 2.18</a>) </p> </li> <li> <p>10 mg/day donepezil at 24 weeks (MD 0.40, 95% CI ‐1.28 to 2.08, P = 0.64, 1 study, 194 participants, ITT analysis; <a href="./references#CD001190-fig-0032" title="">Analysis 2.18</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0094"> <h5 class="title">Withdrawals before the end of treatment</h5> <p>Donepezil was judged to be fairly well tolerated. The meta‐analyses of withdrawals before the end of treatment, using the OR, showed benefit in withdrawals between the 5 mg/day group and the placebo group at 12 weeks in favour of placebo but not at 24 weeks, and for the 10 mg/day group at 12 and 24 weeks in favour of placebo but not at 52 weeks. </p> <p> <ul id="CD001190-list-0014"> <li> <p>5 mg/day donepezil at 12 weeks (70/543 donepezil, 40/536 placebo) (OR 1.81, 95% CI 1.22 to 2.68, P = 0.003, 4 studies, 1079 participants, ITT analysis; <a href="./references#CD001190-fig-0040" title="">Analysis 2.26</a>) </p> </li> <li> <p>10 mg/day at 12 weeks (29/184 donepezil, 13/178 placebo) (OR 2.31, 95% CI 1.21 to 4.40, P = 0.01, 2 studies, 362 participants, ITT analysis; <a href="./references#CD001190-fig-0040" title="">Analysis 2.26</a>) </p> </li> <li> <p>10 mg/day donepezil at 24 to 26 weeks (348/1445 donepezil, 282/1401 placebo) (OR 1.25, 95% CI 1.05 to 1.50, P = 0.013, 12 studies, 2846 participants, ITT analysis; <a href="./references#CD001190-fig-0040" title="">Analysis 2.26</a>). </p> </li> <li> <p>10 mg/day donepezil at 52 week (47/142 donepezil, 47/144 placebo) (OR 1.02, 95% CI 0.62 to 1.67, P = 0.93, 1 study, 286 participants, ITT analysis; <a href="./references#CD001190-fig-0040" title="">Analysis 2.26</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0095"> <h5 class="title">Dependency</h5> <p><a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a> assessed the time spent each day by the carer assisting with the activities of daily living but there was no evidence of a treatment effect. 10 mg/day donepezil at 24 weeks (MD ‐52.4, 95% CI ‐118.78 to 13.98, P = 0.12, 1 study, 221 participants, ITT analysis; <a href="./references#CD001190-fig-0038" title="">Analysis 2.24</a>). </p> </section> <section id="CD001190-sec-0096"> <h5 class="title">Withdrawals before the end of treatment due to adverse events</h5> <p>The meta‐analyses of withdrawals before the end of treatment due to adverse events, using the OR, showed differences in withdrawals between the 5 mg/day group and the placebo group at 12 weeks but not at 24 weeks, and for the 10 mg/day group at 12, and 24 to 26 weeks, but not at 52 weeks in favour of placebo. </p> <p> <ul id="CD001190-list-0015"> <li> <p>5 mg/day donepezil at 12 weeks (17/260 donepezil, 7/253 placebo) (OR 2.33, 95% CI 1.02 to 5.28, P = 0.04, 3 studies, 513 participants, ITT analysis; <a href="./references#CD001190-fig-0041" title="">Analysis 2.27</a>) </p> </li> <li> <p>5 mg/day donepezil at 24 weeks (43/662 donepezil, 55/673 placebo) (OR 0.78, 95% CI 0.52 to 1.18, P = 0.25, 4 studies, 1335 participants, ITT analysis; <a href="./references#CD001190-fig-0041" title="">Analysis 2.27</a>) </p> </li> <li> <p>10 mg/day at 12 weeks (16/184 donepezil, 43/178 placebo) (OR 3.45, 95% CI 1.40 to 8.50, P = 0.007, 3 studies, 362 participants, ITT analysis; <a href="./references#CD001190-fig-0041" title="">Analysis 2.27</a>) </p> </li> <li> <p>10 mg/day donepezil at 24 to 26 weeks (199/1431 donepezil, 121/1388 placebo) (OR 1.68, 95% CI 1.33 to 2.12, P &lt; 0.00001, 11 studies, 2819 participants, ITT analysis; <a href="./references#CD001190-fig-0041" title="">Analysis 2.27</a>) </p> </li> <li> <p>10 mg/day donepezil at 52 weeks (10/142 donepezil, 9/144 placebo) (OR 1.14, 95% CI 0.45 to 2.88, P = 0.79, 1 study, 286 participants, ITT analysis; <a href="./references#CD001190-fig-0041" title="">Analysis 2.27</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0097"> <h5 class="title">Adverse events</h5> <p>The meta‐analyses of numbers of participants with at least one adverse event showed a difference between the 5 mg/day group and placebo in favour of placebo, at 24 to 26 weeks but not at 12 weeks, and a similar result for the 10 mg/day donepezil. </p> <p> <ul id="CD001190-list-0016"> <li> <p>5 mg/day donepezil at 12 weeks (106/157 donepezil, 106/153 placebo) (OR 1.08, 95% CI 0.70 to 1.67, P = 0.24, 3 studies, 513 participants, ITT analysis; <a href="./references#CD001190-fig-0042" title="">Analysis 2.28</a>) </p> </li> <li> <p>5 mg/day donepezil at 24 to 26 weeks (346/508 donepezil, 317/510 placebo) (OR 1.40, 95% CI 1.06 to 1.86, P = 0.02, 3 studies, 1018 participants, ITT analysis; <a href="./references#CD001190-fig-0042" title="">Analysis 2.28</a>) </p> </li> <li> <p>10 mg/day donepezil at 12 weeks (124/158 donepezil, 106/153 placebo) (OR 1.55, 95% CI 0.94 to 2.55, P = 0.09, 2 studies, 323 participants, ITT analysis; <a href="./references#CD001190-fig-0042" title="">Analysis 2.28</a>) </p> </li> <li> <p>10 mg/day at 24 to 26 weeks (913/1274 donepezil, 793/1226 placebo) (OR 1.59, 95% CI 1.30 to 1.94, P &lt; 0.000001, 10 studies, 2500 participants, ITT analysis; <a href="./references#CD001190-fig-0042" title="">Analysis 2.28</a>) </p> </li> <li> <p>10 mg/day donepezil at 52 weeks (116/142 donepezil, 109/144 placebo) (OR 1.43, 95% CI 0.81 to 2.51, P = 0.22, 1 study, 286 participants, ITT analysis; <a href="./references#CD001190-fig-0042" title="">Analysis 2.28</a>) </p> </li> </ul> </p> <p>The studies reported 53 different causes of adverse events. The causes of adverse events seen more frequently in the 10 mg/day dose group than in the 5 mg/day group or placebo group included nausea, vomiting and diarrhoea. These were mostly mild and transient, but occasionally moderately severe. There were differences, in favour of placebo, compared with donepezil, usually the 10 mg/day dose, for several causes of adverse events. </p> <section id="CD001190-sec-0098"> <h6 class="title">Anorexia</h6> <p> <ul id="CD001190-list-0017"> <li> <p>10 mg/day donepezil 24 to 26 weeks (67/962 donepezil, 21/969 placebo) (OR 3.01 95% CI 1.96 to 4.62, P &lt; 0.00001, 6 studies, 1931 participants, ITT analysis; <a href="./references#CD001190-fig-0049" title="">Analysis 2.35</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0099"> <h6 class="title">Diarrhoea</h6> <p> <ul id="CD001190-list-0018"> <li> <p>5 mg/day donepezil at 12 weeks (14/197 donepezil, 5/193 placebo) (OR 2.64 95% CI 1.05 to 6.63, P = 0.04, 2 studies, 390 participants, ITT analysis; <a href="./references#CD001190-fig-0061" title="">Analysis 2.47</a>) </p> </li> <li> <p>10 mg/day donepezil at 12 weeks (21/158 donepezil, 4/153 placebo) (OR 4.22 95% CI 1.87 to 9.54, P = 0.0005, 1 study, 311 participants; <a href="./references#CD001190-fig-0061" title="">Analysis 2.47</a>) </p> </li> <li> <p>5 mg/day donepezil at 24 to 26 weeks (53/662 donepezil, 30/672 placebo) (OR 1.85 95% CI 1.19 to 2.89, P = 0.007, 4 studies, 1334 participants, ITT analysis; <a href="./references#CD001190-fig-0061" title="">Analysis 2.47</a>) </p> </li> <li> <p>10 mg/day donepezil at 24 to 26 weeks (166/1330 donepezil, 60/1292 placebo) (OR 2.69 95% CI 2.05 to 3.55, P &lt; 0.00001, 9 studies, 2622 participants, ITT analysis; <a href="./references#CD001190-fig-0061" title="">Analysis 2.47</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0100"> <h6 class="title">Dizziness</h6> <p> <ul id="CD001190-list-0019"> <li> <p>10 mg/day donepezil at 24 to 26 weeks (68/930 donepezil, 38/900 placebo) (OR 1.77 95% CI 1.19 to 2.63, P = 0.004, 6 studies, 1830 participants, ITT analysis; <a href="./references#CD001190-fig-0062" title="">Analysis 2.48</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0101"> <h6 class="title">Fatigue</h6> <p> <ul id="CD001190-list-0020"> <li> <p>10 mg/day donepezil at 24 to 26 weeks (12/157 donepezil, 3/162 placebo) (OR 3.63, 95% CI 1.29 to 10.21, P = 0.01, 1 study, 319 participants, ITT analysis; <a href="./references#CD001190-fig-0065" title="">Analysis 2.51</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0102"> <h6 class="title">Hallucinations</h6> <p> <ul id="CD001190-list-0021"> <li> <p>10 mg/day donepezil at 24 to 26 weeks (8/128 donepezil, 1/120 placebo) (OR 4.68, 95% CI 1.24 to 17.66, P = 0.02, 1 study, 248 participants, ITT analysis; <a href="./references#CD001190-fig-0070" title="">Analysis 2.56</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0103"> <h6 class="title">Insomnia</h6> <p> <ul id="CD001190-list-0022"> <li> <p>10 mg/day donepezil at 12 weeks (28/158 donepezil, 8/153 placebo) (OR 3.38, 95% CI 1.69 to 6.76, P = 0.0006, 1 study, 311 participants, ITT analysis; <a href="./references#CD001190-fig-0076" title="">Analysis 2.62</a>) </p> </li> <li> <p>10 mg/day donepezil at 24 to 26 weeks (39/546 donepezil, 15/497 placebo) (OR 2.40, 95% CI 1.38 to 4.15, P = 0.002, 3 studies, 1043 participants, ITT analysis; <a href="./references#CD001190-fig-0076" title="">Analysis 2.62</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0104"> <h6 class="title">Muscle cramp</h6> <p> <ul id="CD001190-list-0023"> <li> <p>5 mg/day donepezil at 24 to 26 weeks (9/154 donepezil, 1/162 placebo) (OR 5.48, 95% CI 1.56 to 19.27, P = 0.008, 1 study, 316 participants, ITT analysis; <a href="./references#CD001190-fig-0079" title="">Analysis 2.65</a>) </p> </li> <li> <p>10 mg/day donepezil at 24 to 26 weeks (12/157 donepezil, 1/162 placebo) (OR 6.00, 95% CI 1.98 to 18.18, P = 0.002, 1 study, 319 participants, ITT analysis; <a href="./references#CD001190-fig-0079" title="">Analysis 2.65</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0105"> <h6 class="title">Nausea</h6> <p> <ul id="CD001190-list-0024"> <li> <p>10 mg/day donepezil at 12 weeks (34/158 donepezil, 12/153 placebo) (OR 2.95, 95% CI 1.58 to 5.51, P = 0.0007, 1 study, 311 participants, ITT analysis; <a href="./references#CD001190-fig-0080" title="">Analysis 2.66</a>) </p> </li> <li> <p>10 mg/day donepezil at 24 to 26 weeks (144/1120 donepezil, 46/1064 placebo) (OR 3.06, 95% CI 2.26 to 4.14, P &lt; 0.00001, 8 studies, 2184 participants, ITT analysis; <a href="./references#CD001190-fig-0080" title="">Analysis 2.66</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0106"> <h6 class="title">Peripheral oedema</h6> <p> <ul id="CD001190-list-0025"> <li> <p>10 mg/day donepezil at 24 to 26 weeks (25/103 donepezil, 14/105 placebo) (OR 2.04, 95% CI 1.02 to 4.09, P = 0.04, 1 study, 208 participants, ITT analysis; <a href="./references#CD001190-fig-0082" title="">Analysis 2.68</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0107"> <h6 class="title">Tremor</h6> <p> <ul id="CD001190-list-0026"> <li> <p>10 mg/day donepezil at 24 to 26 weeks (8/103 donepezil, 2/105 placebo) (OR 3.58, 95% CI 1.01 to 12.71, P = 0.05, 1 study, 208 participants, ITT analysis; <a href="./references#CD001190-fig-0091" title="">Analysis 2.77</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0108"> <h6 class="title">Vertigo</h6> <p> <ul id="CD001190-list-0027"> <li> <p>10 mg/day donepezil at 52 weeks (11/142 donepezil, 3/144 placebo) (OR 3.36, 95% CI 1.15 to 9.82, P = 0.03, 1 study, 286 participants, ITT analysis; <a href="./references#CD001190-fig-0094" title="">Analysis 2.80</a> ) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0109"> <h6 class="title">Vomiting</h6> <p> <ul id="CD001190-list-0028"> <li> <p>10 mg/day donepezil at 24 to 26 weeks (109/949 donepezil, 43/959 placebo) (OR 2.65, 95% CI 1.90 to 3.70, P &lt; 0.00001, 6 studies, 1908 participants, <a href="./references#CD001190-fig-0088" title="">Analysis 2.74</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0110"> <h6 class="title">Weight loss</h6> <p> <ul id="CD001190-list-0029"> <li> <p>10 mg/day donepezil at 24 to 26 weeks (34/404 donepezil, 19/407 placebo) (OR 1.90, 95% CI 1.08 to 3.35, P = 0.03, 3 studies, 811 participants, ITT analysis; <a href="./references#CD001190-fig-0095" title="">Analysis 2.81</a>) </p> </li> </ul> </p> <p>There were significant differences between numbers suffering adverse events in the donepezil group compared with the placebo group in favour of donepezil at 12 weeks but not at 24 weeks for the following causes. </p> </section> <section id="CD001190-sec-0111"> <h6 class="title">Increased cough</h6> <p> <ul id="CD001190-list-0030"> <li> <p>5 mg/day donepezil at 12 weeks (2/157 donepezil, 8/153 placebo) (OR 0.28 95% CI 0.08 to 1.00, P = 0.05, 1 study, 310 participants, ITT analysis; <a href="./references#CD001190-fig-0077" title="">Analysis 2.63</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0112"> <h6 class="title">Peripheral oedema</h6> <p> <ul id="CD001190-list-0031"> <li> <p>5 mg/day donepezil at 12 weeks (1/157 donepezil, 8/153 placebo) (OR 0.20, 95% CI 0.05 to 0.74, P = 0.02, 1 study, 310 participants, ITT analysis; <a href="./references#CD001190-fig-0082" title="">Analysis 2.68</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0113"> <h6 class="title">Urinary tract infection</h6> <p> <ul id="CD001190-list-0032"> <li> <p>5 mg/day donepezil at 12 weeks (10/157 donepezil, 20/153 placebo) (OR 0.47, 95% CI 0.22 to 0.99, P = 0.05, 1 study, 310 participants, ITT analysis; <a href="./references#CD001190-fig-0093" title="">Analysis 2.79</a>) </p> </li> <li> <p>10 mg/day donepezil at 12 weeks (6/158 donepezil, 20/153 placebo) (OR 0.30, 95% CI 0.13 to 0.67, P = 0.003, 1 study, 311 participants, ITT analysis; <a href="./references#CD001190-fig-0093" title="">Analysis 2.79</a>) </p> </li> </ul> </p> <p>The <a href="./references#CD001190-bbs2-0029" title="EngedalK , SoininenH , VerheyF , WaldemarG , WinbladB , WimoA , et al. Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000; Vol. 10, issue Suppl 3:S368. [MEDLINE: SR‐HANDSRCH] MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a one year, double‐blind, randomized trial. Journal of the American Geriatrics Society2001; Vol. 49, issue 4:S131. MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. Donepezil reduces the time caregivers spend providing care: results of a one‐year, double‐blind, randomized trial in patients with mild to moderate Alzheimer's disease. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23‐26, San Francisco2001. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Long term benefits of donepezil on ADLs in AD patients. Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:171. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Donepezil Nordic Study Group. Response to donepezil is not predicted by apolipoprotein E genotype and/or gender. World Alzheimer Congress; 2000 July 9‐13, Washington. 2000. WaldemarG , WinbladB , EngedalK , SoininenH , Donepezil Nordic Study Group et al. Benefits of donepezil on cognition, function and/or neuropsychiatric symptoms in patients with Alzheimers disease over one year. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WaldemarG , WinbladB , EngedalK , SoininenHS , VerheyFR , WimoA , et al. Donepezil Nordic Study Group. Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year. Neurology2000;54(Suppl 3):A470. WimoA . Erratum: an economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial (Dementia and Geriatric Cognitive Disorders (2003) 15 (44‐54)). Dementia and Geriatric Cognitive Disorders2003; Vol. 16, issue 2:102. WimoA , WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , et al. Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial. Dementia and Geriatric Cognitive Disorders2003;15(1):44‐54. WimoA , WinbladB , MasteyV . An economic evaluation of donepezil in mild to moderate Alzheimers disease: results of a one‐year, double‐blind, randomized trial. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WimoA , WinbladB , MasteyV , HaglundA , HertzmanP , MiceliR , et al. An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one‐year, double‐blind, randomized trial. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illionois. 2000. [MEDLINE: SR‐HANDSRCH] WinbladB . Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:164. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , WetterholmAL , ZhangR , HaglundA , SubbiahP . Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. International Psychogeriatrics1999;11(Supplement 1):138. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. A 1‐year, randomized, placebo‐controlled study of donepezil in patients with mild to moderate AD. Neurology2001;57(3):489‐95. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. Donepezil enhances global function and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. Quality Research in Dementia Conference; 2000 Nov 19‐22, London. 2000. WinbladB , WimoA , EngedalK , SoininenH , VerheyF , WaldemarG , et al. 3‐year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia and Geriatric Cognitive Disorders2006;21(5‐6):353‐63. ">Winblad 2001</a> reported only causes of adverse events suffered by more than 5% of participants receiving donepezil. </p> </section> </section> <section id="CD001190-sec-0114"> <h5 class="title">Serious adverse events</h5> <p>The meta‐analyses of numbers of participants with at least one serious adverse event showed no difference between the 5 mg/day group and placebo, and the 10 mg/day group and placebo, at 12, and 24 to 26 weeks, and a difference at 52 weeks in favour of placebo. </p> <p> <ul id="CD001190-list-0033"> <li> <p>5 mg/day donepezil at 12 weeks (6/157 donepezil, 7/153 placebo) (OR 0.83, 95% CI 0.27 to 2.51, P = 0.74, 1 study 310 participants, <a href="./references#CD001190-fig-0097" title="">Analysis 2.83</a>) </p> </li> <li> <p>5 mg/day donepezil at 24 weeks (35/526 donepezil, 49/541 placebo) (ITT analysis; OR 0.76, 95% CI 0.49 to 1.18, P = 0.22, 3 studies, 1067 participants, ITT analysis; <a href="./references#CD001190-fig-0097" title="">Analysis 2.83</a> ) </p> </li> <li> <p>10 mg/day donepezil at 12 weeks (6/158 donepezil, 7/153 placebo) (OR 0.82, 95% CI 0.27 to 2.50, P = 0.73, 1 study, 311 participants, ITT analysis; <a href="./references#CD001190-fig-0097" title="">Analysis 2.83</a> ) </p> </li> <li> <p>10 mg/day donepezil at 24 to 26 weeks (148/1301 donepezil, 161/1298 placebo) (OR 0.90, 95% CI 0.71 to 1.14, P = 0.38, 9 studies, 2599 participants, ITT analysis; <a href="./references#CD001190-fig-0097" title="">Analysis 2.83</a>) </p> </li> <li> <p>10 mg/day donepezil at 52 weeks (35/142 donepezil, 20/144 placebo) (OR 1.99, 95% CI 1.11 to 3.59, P = 0.02, 1 study, 286 participants, ITT analysis; <a href="./references#CD001190-fig-0097" title="">Analysis 2.83</a> ) </p> </li> </ul> </p> <section id="CD001190-sec-0115"> <h6 class="title">Deaths</h6> <p>The meta‐analyses of numbers of deaths showed no difference between the 5 mg/day group and placebo, and the 10 mg/day group and placebo, at 12, 24 to 26 weeks and at 52 weeks. </p> <p> <ul id="CD001190-list-0034"> <li> <p>5 mg/day donepezil at 12 weeks (1/260 donepezil, 1/253 placebo) (OR 0.96, 95% CI 0.06 to 15.29, P = 0.97, 3 studies, 513 participants, ITT analysis; <a href="./references#CD001190-fig-0096" title="">Analysis 2.82</a>) </p> </li> <li> <p>5 mg/day donepezil at 24 weeks (4/662 donepezil, 4/672 placebo) (OR 1.02, 95% CI 0.25 to 4.10, P = 0.98, 4 studies, 1334 participants, ITT analysis; <a href="./references#CD001190-fig-0096" title="">Analysis 2.82</a>) </p> </li> <li> <p>10 mg/day donepezil at 12 weeks (0/158 donepezil, 1/153 placebo) (OR 0.13, 95% CI 0.00 to 6.60, P = 0.31, 1 study, 311 participants, ITT analysis; <a href="./references#CD001190-fig-0096" title="">Analysis 2.82</a>) </p> </li> <li> <p>10 mg/day donepezil at 24 to 26 weeks (32/1445 donepezil, 41/1402 placebo) (OR 0.74, 95% CI 0.46 to 1.19, P = 0.21, 12 studies, 2847 participants, ITT analysis; <a href="./references#CD001190-fig-0096" title="">Analysis 2.82</a>) </p> </li> <li> <p>10 mg/day donepezil at 52 weeks (4/142 donepezil, 3/144 placebo) (OR 1.36, 95% CI 0.30 to 6.07, P = 0.69, 1 study, 286 participants, ITT analysis; <a href="./references#CD001190-fig-0096" title="">Analysis 2.82</a>) </p> </li> </ul> </p> </section> </section> <section id="CD001190-sec-0116"> <h5 class="title">Quality of life</h5> <p>There was no evidence of any benefit associated with donepezil in the patient‐rated Quality‐of‐Life scale at doses of either 5 mg/day or 10 mg/day compared with placebo at 12 or 24 weeks. </p> <p> <ul id="CD001190-list-0035"> <li> <p>5 mg/day donepezil at 12 weeks (MD 1.18, 95% CI ‐3.04 to 5.40, P = 0.58, 4 studies, 1127 participants, ITT analysis; <a href="./references#CD001190-fig-0034" title="">Analysis 2.20</a>) </p> </li> <li> <p>10 mg/day donepezil at 12 weeks (MD 1.16, 95% CI ‐3.20 to 5.52, P = 0.60, 4 studies, 1031 participants, ITT analysis; <a href="./references#CD001190-fig-0034" title="">Analysis 2.20</a>) </p> </li> <li> <p>5 mg/day donepezil at 24 weeks (MD 2.26, 95% CI ‐3.64 to 8.16, P = 0.45, 2 studies, 681 participants, ITT analysis; <a href="./references#CD001190-fig-0034" title="">Analysis 2.20</a>) </p> </li> <li> <p>10 mg/day donepezil at 24 weeks (MD ‐1.17, 95% CI ‐7.26 to 4.91, P = 0.71, 2 studies, 645 participants, ITT analysis; <a href="./references#CD001190-fig-0034" title="">Analysis 2.20</a>). </p> </li> </ul> </p> <section id="CD001190-sec-0117"> <h6 class="title">Carer stress</h6> <p><a href="./references#CD001190-bbs2-0014" title="RobertP , LebertF , GoniS , TouchonJ , VincentS , ARIAL Study Investigators Collaborative Group. The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. Quality Research in Dementia; 19‐22 November, 2000, London. 2000. RobertPH , LebertF , GoniS , TouchonJ , ARIAL Study Investigators Collaborative Group. The impact of caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">Lebert 1999</a> assessed the stress on carers but reported the results without any measure of precision. </p> </section> </section> </section> <section id="CD001190-sec-0118"> <h4 class="title">Comparison of donepezil (10 mg/day) with placebo (patient and carer health resource utilisation) </h4> <p><a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a> and <a href="./references#CD001190-bbs2-0029" title="EngedalK , SoininenH , VerheyF , WaldemarG , WinbladB , WimoA , et al. Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000; Vol. 10, issue Suppl 3:S368. [MEDLINE: SR‐HANDSRCH] MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a one year, double‐blind, randomized trial. Journal of the American Geriatrics Society2001; Vol. 49, issue 4:S131. MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. Donepezil reduces the time caregivers spend providing care: results of a one‐year, double‐blind, randomized trial in patients with mild to moderate Alzheimer's disease. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23‐26, San Francisco2001. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Long term benefits of donepezil on ADLs in AD patients. Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:171. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Donepezil Nordic Study Group. Response to donepezil is not predicted by apolipoprotein E genotype and/or gender. World Alzheimer Congress; 2000 July 9‐13, Washington. 2000. WaldemarG , WinbladB , EngedalK , SoininenH , Donepezil Nordic Study Group et al. Benefits of donepezil on cognition, function and/or neuropsychiatric symptoms in patients with Alzheimers disease over one year. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WaldemarG , WinbladB , EngedalK , SoininenHS , VerheyFR , WimoA , et al. Donepezil Nordic Study Group. Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year. Neurology2000;54(Suppl 3):A470. WimoA . Erratum: an economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial (Dementia and Geriatric Cognitive Disorders (2003) 15 (44‐54)). Dementia and Geriatric Cognitive Disorders2003; Vol. 16, issue 2:102. WimoA , WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , et al. Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial. Dementia and Geriatric Cognitive Disorders2003;15(1):44‐54. WimoA , WinbladB , MasteyV . An economic evaluation of donepezil in mild to moderate Alzheimers disease: results of a one‐year, double‐blind, randomized trial. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WimoA , WinbladB , MasteyV , HaglundA , HertzmanP , MiceliR , et al. An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one‐year, double‐blind, randomized trial. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illionois. 2000. [MEDLINE: SR‐HANDSRCH] WinbladB . Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:164. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , WetterholmAL , ZhangR , HaglundA , SubbiahP . Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. International Psychogeriatrics1999;11(Supplement 1):138. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. A 1‐year, randomized, placebo‐controlled study of donepezil in patients with mild to moderate AD. Neurology2001;57(3):489‐95. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. Donepezil enhances global function and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. Quality Research in Dementia Conference; 2000 Nov 19‐22, London. 2000. WinbladB , WimoA , EngedalK , SoininenH , VerheyF , WaldemarG , et al. 3‐year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia and Geriatric Cognitive Disorders2006;21(5‐6):353‐63. ">Winblad 2001</a> assessed this outcome. We did not pool the studies as we did not consider the outcomes to be comparable across studies. Many items were assessed and reported separately, and total costs were reported. There were no significant differences between donepezil and placebo apart from total carer costs (counselling, visits to physician and medication) in favour of placebo (MD 31.00, 95% CI 7.22 to 54.78, P = 0.01, one study, 289 participants; <a href="./references#CD001190-fig-0100" title="">Analysis 3.3</a>). </p> </section> <section id="CD001190-sec-0119"> <h4 class="title">Comparison of donepezil 5 mg/day with donepezil 10 mg/day</h4> <p>The phase III studies were designed not only to compare donepezil with placebo, but also to compare two doses, 5 mg/day and 10 mg/day. We pooled results from the three 26‐week studies, <a href="./references#CD001190-bbs2-0009" title="HommaA , ArimotoI , KaidojiK , OhbayashiT , OzawaH . Treatment of severe Alzheimer's disease with donepezil: results from a 24 week, parallel, placebo‐controlled study in Japan. 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, July 2006. 2006. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24‐week, double‐blind, placebo‐controlled, randomized trial. Geriatric Cognitive Disorders2008;25(5):399‐407. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Long‐term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52‐week, open‐label, multicenter, extension study in Japan. Dementia and Geritatric Congitive Disorders2009;27(3):232‐9. ">Homma 2008</a>, <a href="./references#CD001190-bbs2-0022" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. Erratum: a 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613‐620)). Neurology2001; Vol. 57, issue 11:2153. FriedhoffLT , RogersL . Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease ‐ results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston. Neurology1997;48(3):A100. FriedhoffLT , RogersSL . Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17, Vienna, Austria1997. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis. European Journal of Neurology1997;4(Suppl 1):S9. RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyR , MohsR , FriedhoffLT . E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30‐week phase III trial. Neurology1996;46:A217 S14.001 ARI‐8. RogersSL , DoodyR , MohsR , FriedhoffT , Donepezil Study Group. E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30‐week trial. Unpublished paper1996b. RogersSL , FarlowMR , DoodyRS , MohsR , FriedhoffLT , Donepezil Study Group. A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998;50(1):136‐45. RogersSL , FriedhoffLT , FarlowMR , DoodyRS , MohsR . Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply]. Neurology1999; Vol. 52, issue 1:218‐19. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego1997. ">Rogers 1998b</a> and <a href="./references#CD001190-bbs2-0003" title="BayerAJ , RossorM , HeckerJ , GauthierS , BurnsA , PetiteH , et al. International Donepezil Study Group. Donepezil improves functional activity in patients with Alzheimer's disease. 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12‐16, Glasgow, Scotland. 1998. [MEDLINE: SR‐HANDSRCH] BurnsA , GauthierS , PerdomoC . Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(8):806‐12. BurnsA , RossorM , HeckerJ , GauthierS , PetitH , MöllerH‐J , et al. International Donepezil Study Group. The effects of donepezil in Alzheimer's disease ‐ results from a multinational trial. Dementia and Geriatric Cognitive Disorders1999;10(3):237‐44. GauthierS , RosserM , HeckerJ , PetiteH , RogersS , MohrE , et al. Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐June 4, Toronto, Canada1998. [MEDLINE: SR‐HANDSRCH] GauthierS , RossorM , HeckerJ . Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 15‐18 1998. PrattRD , GauthierS , BurnsA , PerdomoCA . Donepezil provides long‐term clinical benefits for patients with Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington. 2000. ">Burns 1999</a>. </p> <section id="CD001190-sec-0120"> <h5 class="title">Cognitive function</h5> <p>There was a significant difference in favour of the 10 mg group for ADAS‐Cog (MD ‐1.05, 95% CI ‐1.80 to ‐0.30, P = 0.006, 2 studies, 818 participants, ITT analysis; <a href="./references#CD001190-fig-0163" title="">Analysis 7.1</a>), but no difference between the groups for MMSE (MD 0.15, 95% CI ‐0.55 to 0.85, P = 0.67, 1 study, 303 participants, ITT analysis; <a href="./references#CD001190-fig-0164" title="">Analysis 7.2</a>), or SIB (MD 2.20, 95% CI ‐1.00 to 5.40, P = 0.18, 1 study, 188 participants, ITT analysis; <a href="./references#CD001190-fig-0165" title="">Analysis 7.3</a>). </p> </section> <section id="CD001190-sec-0121"> <h5 class="title">Quality of life</h5> <p>There was a difference in favour of the 5 mg/day group for quality of life (MD ‐8.33, 95% CI ‐16.23 to ‐0.43, P = 0.04, 1 study, 302 participants; <a href="./references#CD001190-fig-0170" title="">Analysis 7.8</a>). </p> </section> <section id="CD001190-sec-0122"> <h5 class="title">Global assessment</h5> <p>There was no difference between the 10 mg/day and 5 mg/day groups at 24 to 26 weeks for the global assessment using CIBIC‐plus (OR 1.26, 95% CI 0.94 to 1.67, P = 0.12, 3 studies, 981 participants, ITT analysis; <a href="./references#CD001190-fig-0167" title="">Analysis 7.5</a>), or CDR‐SB (MD ‐0.08, 95% CI ‐0.29 to 0.14, P = 0.48, 2 studies, 824 participants, ITT analysis; <a href="./references#CD001190-fig-0168" title="">Analysis 7.6</a>). </p> </section> <section id="CD001190-sec-0123"> <h5 class="title">Behavioural symptoms</h5> <p>There was no difference between the 10 mg/day and 5 mg/day groups at 24 to 26 weeks for the BEHAVE‐AD (MD 0.40, 95% CI ‐1.27 to 2.07, 1 study, 198 participants, ITT analysis; <a href="./references#CD001190-fig-0169" title="">Analysis 7.7</a>). </p> </section> <section id="CD001190-sec-0124"> <h5 class="title">Withdrawals before the end of treatment</h5> <p>The meta‐analyses of withdrawals before the end of treatment at 24 to 26 weeks, using the OR, showed differences in withdrawals in favour of the 5 mg/day group (143/526 10 mg/day, 96/526 5 mg/day) (OR 1.67, 95% CI 1.24 to 2.23, P = 0.0006, 3 studies, 1052 participants, ITT analysis; <a href="./references#CD001190-fig-0171" title="">Analysis 7.9</a>). </p> </section> <section id="CD001190-sec-0125"> <h5 class="title">Withdrawals before the end of treatment due to adverse events</h5> <p>The meta‐analyses of withdrawals before the end of treatment at 24 to 26 weeks, due to an adverse event, using the OR, show that there was a difference in favour of the 5 mg/day group (89/526 10 mg/day, 41/526 5 mg/day) (OR 2.41 95% CI 1.63 to 3.57, P &lt; 0.0001, 3 studies, 1052 participants, ITT analysis; <a href="./references#CD001190-fig-0172" title="">Analysis 7.10</a>). </p> </section> <section id="CD001190-sec-0126"> <h5 class="title">Adverse events</h5> <p>The meta‐analyses of the total number of participants who suffered at least one adverse event showed a difference in favour of the 5 mg/day group (314/369 10 mg/day, 292/372 5 mg/day) (OR 1.56, 95% CI 1.07 to 2.28, P = 0.02, 2 studies,741, ITT analysis; <a href="./references#CD001190-fig-0173" title="">Analysis 7.11</a>). </p> <p>There were significant differences, in favour of 5 mg/day, compared with 10 mg/day, for several causes of adverse events. The adverse events seen more frequently in the 10 mg/day group than in the 5 mg/day group were anorexia, nausea, diarrhoea, rhinitis and vomiting. </p> <p> <ul id="CD001190-list-0036"> <li> <p>Anorexia: (39/526 10 mg/day, 15/526 5 mg/day) (OR 2.72, 95% CI 1.48 to 5.00, P = 0.001, 3 studies, 1052 participants, ITT analysis; <a href="./references#CD001190-fig-0174" title="">Analysis 7.12</a>) </p> </li> <li> <p>Diarrhoea: (80/526 10 mg/day, 48/526 5 mg/day) (OR 1.78 ,95% CI 1.22 to 2.61, P = 0.003, 3 studies, 1052 participants, ITT analysis; <a href="./references#CD001190-fig-0176" title="">Analysis 7.14</a>) </p> </li> <li> <p>Nausea: (92/430 10 mg/day, 26/425 5 mg/day) (OR 4.22, 95% CI 2.67 to 6.70, P &lt; 0.00001, 2 studies, 855 participants, ITT analysis; <a href="./references#CD001190-fig-0182" title="">Analysis 7.20</a>) </p> </li> <li> <p>Rhinitis: (9/157 10 mg/day, 1/154 5 mg/day) (OR 9.30, 95% CI 1.16 to 74.35, P = 0.04, 1 study, 311 participants, ITT analysis; <a href="./references#CD001190-fig-0183" title="">Analysis 7.21</a>) </p> </li> <li> <p>Vomiting: (73/526 10 mg/day, 24/526 5 mg/day) (OR 3.40, 95% CI 2.10 to 5.48, P &lt; 0.00001, 3 studies, 1052 participants, ITT analysis; <a href="./references#CD001190-fig-0184" title="">Analysis 7.22</a>) </p> </li> </ul> </p> </section> </section> <section id="CD001190-sec-0127"> <h4 class="title">Comparison of donepezil (15‐20 mg/day) with donepezil (10 mg/day)</h4> <p><a href="./references#CD001190-bbs2-0023" title="SchindlerR , Corey‐BloomJ , DoodyR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4‐7, 2004. 2004. SchindlerR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. Neurobiology of Aging2004;25(S2):195. ">Schindler 2004</a> reported the number of adverse events in 26 weeks of treatment when participants already taking 10 mg/day of donepezil were randomised to either placebo or a further 5 mg/day or 10 mg/day of donepezil. There was no difference between treatment and placebo (that is, between 15‐20 mg/day and 10 mg/day) (6/16 15‐20 mg/day, 4/15 10 mg/day) (OR 1.65, 95% CI 0.36 to 7.60, P = 0.52, 1 study, 31 participants, ITT analysis; <a href="./references#CD001190-fig-0145" title="">Analysis 5.1</a>). <a href="./references#CD001190-bbs2-0023" title="SchindlerR , Corey‐BloomJ , DoodyR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4‐7, 2004. 2004. SchindlerR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. Neurobiology of Aging2004;25(S2):195. ">Schindler 2004</a> did not assess cognitive function. </p> </section> <section id="CD001190-sec-0128"> <h4 class="title">Comparison of donepezil (10 mg/day) with placebo at 12 weeks for participants with severe agitation </h4> <p>One study included participants with severe agitation, <a href="./references#CD001190-bbs2-0011" title="HowardRJ , JuszczakE , BallardCG , BenthamP Brown RG , BullockR , et al. CALM‐AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine2007;357(14):1382‐92. PelosiA . Donepezil is no more effective than placebo for agitation in people with Alzheimer's disease. Evidence‐Based Mental Health2008;11(3):84. ">Howard 2007</a>. There was no difference between donepezil (13/128), and placebo (19/131) for withdrawals before end of treatment (OR 0.67, 95% CI 0.31 to 1.41, P = 0.29, 1 study, 259 participants, <a href="./references#CD001190-fig-0149" title="">Analysis 6.4</a>), CMAI (MD 0.18, 95% CI ‐4.23 to 4.59, P = 0.94 , 1 study 221 participants, <a href="./references#CD001190-fig-0146" title="">Analysis 6.1</a>), NPI (MD 0.10, 95% CI ‐3.78 to 3.98, P = 0.96, 1 study, 201 participants, <a href="./references#CD001190-fig-0147" title="">Analysis 6.2</a>), and NPI‐carer distress (MD ‐0.45, 95% CI ‐2.06 to 1.16, P = 0.58, 1 study, 200 participants, <a href="./references#CD001190-fig-0148" title="">Analysis 6.3</a>). The SIB and MMSE were also outcomes but less than half of the participants were able to complete these assessments. </p> </section> <section id="CD001190-sec-0129"> <h4 class="title"><i>Comparison of donepezil (23 mg/day) with donepezil (10 mg/day)</i> </h4> <section id="CD001190-sec-0130"> <h5 class="title">Cognitive Function</h5> <p>There was no significant difference between the 23 mg group and the 10 mg group for SIB (MD 1.05, 95% CI ‐0.15 to 2.25, P = 0.09, 2 studies, 1704 participants, ITT analysis; <a href="./references#CD001190-fig-0106" title="">Analysis 4.1</a>), and there was no difference between the groups for the MMSE (MD 0.20, 95% CI ‐0.33 to 0.73, P = 0.46, 1 study, 1370 participants, ITT analysis; <a href="./references#CD001190-fig-0107" title="">Analysis 4.2</a>). </p> </section> <section id="CD001190-sec-0131"> <h5 class="title">Activities of daily living</h5> <p>There was no difference between the groups for the ADCS‐ADL‐sev (MD 0.0, 95% CI ‐1.18 to 1.18, 1 study, 1369 participants, ITT analysis; <a href="./references#CD001190-fig-0108" title="">Analysis 4.3</a>). </p> </section> <section id="CD001190-sec-0132"> <h5 class="title">Global assessment</h5> <p>There was no difference between the groups for the CIBIC‐plus (OR 0.99, 95% CI 0.78 to 1.26, P = 0.93, 2 studies, 1704 participants, ITT analysis; <a href="./references#CD001190-fig-0109" title="">Analysis 4.4</a>). </p> </section> <section id="CD001190-sec-0133"> <h5 class="title">Withdrawals before the end of treatment</h5> <p>The meta‐analysis of withdrawals before the end of treatment at 24 to 26 weeks, using the OR, showed a significant difference in withdrawals in favour of the 10 mg/day group (112/652), compared with the 23 mg/day group (348/1166), (OR 2.02, 95% CI 1.59 to 2.57, P &lt; 0.00001, 2 studies, 1818 participants, ITT analysis; <a href="./references#CD001190-fig-0110" title="">Analysis 4.5</a>). </p> </section> <section id="CD001190-sec-0134"> <h5 class="title">Withdrawals before the end of treatment due to adverse events</h5> <p>The meta‐analysis of withdrawals before the end of treatment due to adverse events at 24 to 26 weeks, using the OR, showed a significant difference in withdrawals in favour of the 10 mg/day group (54/652) compared with the 23 mg group (215/1166), (OR 2.51, 95% CI 1.83 to 3.45, P &lt; 0.00001, 2 studies, 1818 participants, ITT analysis; <a href="./references#CD001190-fig-0111" title="">Analysis 4.6</a>). </p> </section> <section id="CD001190-sec-0135"> <h5 class="title">Adverse events</h5> <p>The meta‐analyses of the total number of participants who suffered at least one adverse event showed a significant difference in favour of the 10 mg/day group (398/637), compared with the 23 mg/day group (844/1148) at 24 to 26 weeks, (OR 1.65, 95% CI 1.34 to 2.03, P &lt; 0.0001, 1 study, 1785 participants, ITT analysis; <a href="./references#CD001190-fig-0112" title="">Analysis 4.7</a>). </p> <p>There was no difference between the groups for the numbers of participants who suffered a serious adverse event at 24 to 26 weeks (103/1148 23 mg/day, 59/637 10 mg/day) (OR 0.99, 95% CI 0.71 to 1.38, P = 0.94. 2 studies, 1785 participants, ITT analysis; <a href="./references#CD001190-fig-0113" title="">Analysis 4.8</a>). </p> <p>There were significant differences, in favour of 10 mg/day, compared with 23 mg/day, for several causes of adverse events. The adverse events seen more frequently in the 23 mg/day dose group than in the 105 mg/day group were asthenia, anorexia, contusion, nausea, vomiting and diarrhoea, fatigue and bradycardia. </p> <p> <ul id="CD001190-list-0037"> <li> <p>Anorexia: (51/963 23 mg/day, 8/471 10 mg/day) (OR 3.24, 95% CI 1.52 to 6.88, P = 0.002, 1 study, 1434 participants, ITT analysis; <a href="./references#CD001190-fig-0116" title="">Analysis 4.11</a>) </p> </li> <li> <p>Asthenia: (20/963 23 mg/day, 3/471 10 mg/day) (OR 3.31, 95% CI 0.98 to 11.19, P = 0.05, 1 study, 1434 participants, ITT analysis; <a href="./references#CD001190-fig-0114" title="">Analysis 4.9</a>) </p> </li> <li> <p>Bradycardia: (27/963 23 mg/day, 3/471 10 mg/day) (OR 4.50, 95% CI 1.36 to 14.91, P = 0.01, 1 study, 1434 participants, ITT analysis; <a href="./references#CD001190-fig-0127" title="">Analysis 4.22</a>) </p> </li> <li> <p>Contusion: (34/1148 23 mg/day, 5/63710 mg/day) (OR 4.9997, 95% CI 1.88 to 13.26, P = 0.001, 2 studies, 1785 participants, ITT analysis; <a href="./references#CD001190-fig-0115" title="">Analysis 4.10</a>) </p> </li> <li> <p>Diarrhoea: (94/1148 23 mg/day, 30/637 10 mg/day) (OR 1.76, 95% CI 1.15 to 2.68, P = 0.009, 2 studies, 1785 participants, ITT analysis; <a href="./references#CD001190-fig-0117" title="">Analysis 4.12</a>) </p> </li> <li> <p>Fatigue: (23/963 23 mg/day, 4/471 10 mg/day) (OR 2.86, 95% CI 0.98 to 8.31, P = 0.05, 1 study, 1434 participants, ITT analysis; <a href="./references#CD001190-fig-0119" title="">Analysis 4.14</a>) </p> </li> <li> <p>Nausea: (123/1148 23 mg/day, 21/637 10 mg/day) (OR 3.36, 95% CI 2.09 to 5.42, P &lt; 0.00001, 2 studies, 1785 participants, ITT analysis; <a href="./references#CD001190-fig-0122" title="">Analysis 4.17</a>) </p> </li> <li> <p>Vomiting: (105/1148 23 mg/day, 16/637 10 mg/day) (OR 3.88, 95% CI 2.27 to 6.65, P &lt; 0.00001, 2 studies, 1785 participants, ITT analysis; <a href="./references#CD001190-fig-0123" title="">Analysis 4.18</a>) </p> </li> </ul> </p> <section id="CD001190-sec-0136"> <h6 class="title">Deaths</h6> <p>There was no difference between the groups for the numbers of participants who died before end of treatment at 24 to 26 weeks (8/1148 23 mg/day, 6/637 10 mg/day) (OR 0.69, 95% CI 0.24 to 1.95, P = 0.48, 2 studies, 1785 participants, ITT analysis; <a href="./references#CD001190-fig-0132" title="">Analysis 4.27</a>). </p> </section> </section> </section> <section id="CD001190-sec-0137"> <h4 class="title">Comparison of donepezil (5 mg/day and 10 mg/day) with placebo in participants with severe dementia </h4> <section id="CD001190-sec-0138"> <h5 class="title">Cognitive function</h5> <p>The MMSE, using MDs, showed a benefit on cognitive function in favour of the higher‐dose donepezil compared with placebo at 24 weeks. </p> <p> <ul id="CD001190-list-0038"> <li> <p>10 mg/day donepezil at 24 weeks (MD 0.97, 95% CI 0.56 to 1.38, P = &lt;0.00001, 4 studies, 1102 participants, ITT analysis; <a href="./references#CD001190-fig-0193" title="">Analysis 8.1</a>) </p> </li> </ul> </p> <p>The meta‐analyses, using MDs, revealed a benefit on cognitive function as measured by SIB test scores for the lower‐dose and higher‐dose donepezil compared with placebo at 24 weeks. </p> <p> <ul id="CD001190-list-0039"> <li> <p>5 mg/day donepezil at 24 weeks (MD 6.70, 95% CI 3.66 to 9.74, P &lt; 0.0001, 1 study, 198 participants, ITT analysis; <a href="./references#CD001190-fig-0194" title="">Analysis 8.2</a>) </p> </li> <li> <p>10 mg/day donepezil at 24 weeks (MD 5.92, 95% CI 4.53 to 7.31, P &lt; 0.00001, 5 studies, 1348 participants, ITT analysis; <a href="./references#CD001190-fig-0194" title="">Analysis 8.2</a>). </p> </li> </ul> </p> </section> <section id="CD001190-sec-0139"> <h5 class="title">Activities of daily living</h5> <p><a href="./references#CD001190-bbs2-0030" title="BatsmanS , MinthonL , EerikssonS , KilanderL , Jansson‐BlixtC , WetterholmA , et al. Study design and baseline patients characteristics in a randomized controlled trial of the efficacy and tolerability of donepezil in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. ErikssonS , WinbladB , KilanderL , BatsmanS , Jansson‐BlixtC , WetterholmA , et al. Efficacy of donepezil on secondary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. JelicV , HaglundA , KowalskiJ , LangworthS , WinbladB . Donepezil treatment of severe Alzheimer's disease in nursing home settings. Dementia and Geriatric Cognitive Disorders2008;26(5):458‐46. KilanderL , WinbladB , MinthonL , BatsmanS , Jansson‐BlixtC , CronlundA , et al. Donepezil is well tolerated in patients with severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MarderK . Donepezil in patients with severe Alzheimer's disease: double‐blind parallel‐group, placebo controlled study. Current Neurology and Neuroscience Reports2006;6(5):364‐73. OpieLH . Donepezil for severe Alzheimer's disease. Lancet2006;368:361‐2. WinbladB . Donepezil for severe Alzheimer's disease ‐ author's reply. Lancet2006;368(9533):362. WinbladB . Severe Alzheimer's disease: benefits of donepezil therapy. International Psychogeriatrics2006;18(5):S25‐S31. WinbladB , KilanderL , ErikssonS , MinthonL , BåtsmanS , WetterholmA , et al. for the Severe Alzheimer’s Disease Study Group. Donepezil in patients with severe Alzheimer’s disease: double‐blind, parallel‐group, placebo‐controlled study. Lancet2006;367(9156):1057‐65. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansoon‐BlixtC , WetterholmA , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansson‐BlixtC , WetterholmAL , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. International Psychogeriatrics2005;18(S1):S25‐S31. ">Winblad 2006</a>, <a href="./references#CD001190-bbs2-0009" title="HommaA , ArimotoI , KaidojiK , OhbayashiT , OzawaH . Treatment of severe Alzheimer's disease with donepezil: results from a 24 week, parallel, placebo‐controlled study in Japan. 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, July 2006. 2006. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24‐week, double‐blind, placebo‐controlled, randomized trial. Geriatric Cognitive Disorders2008;25(5):399‐407. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Long‐term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52‐week, open‐label, multicenter, extension study in Japan. Dementia and Geritatric Congitive Disorders2009;27(3):232‐9. ">Homma 2008</a> and <a href="./references#CD001190-bbs2-0002" title="BlackS , LiHL , McRaeT , RichardsonS . Treatment of severe Alzheimer's disease with donepezil: results from a 24‐week, multinational, randomized, double‐blind, placebo‐controlled trial. Neurology2006;66(5):A347. BlackS , LiHonglang , McRaeT , RichardsonS . Donepezil treatment of severe Alzheimer's disease: results from a 24‐week, multinational, randomized, double‐blind, placebo controlled trial. Poster Presented at the Geneva Springfield ConferenceApril 2006. BlackSE , DoodyR , LiH , McRaeT , JamborKM , XuY , et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology2007;69(5):459‐69. Pfizer . E2020‐A001‐315: a 24 week multinational RCT evaluating the efficacy and safety of donepezil in severe AD. www.marc.soton.ac.uk/Research%20Page.htm. RichardsonS . A 24 week, multicenter, randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of donepezil hydrochloride (E2020) in patients with severe Alzheimer's disease followed by a 12 week open‐label extension period. www.clinicaltrials.gov/ct/show/NCT000964732004. ">Black 2007</a> used the ADCS‐ADL‐severe scale. There was evidence of benefit of 10 mg/day donepezil at 24 weeks (MD 1.03, 95% CI 0.21 to 1.85, P = 0.01, 3 studies, 733 participants, ITT analysis; <a href="./references#CD001190-fig-0196" title="">Analysis 8.4</a>), but not for 5 mg/day at 24 weeks (MD 1.00, 95% CI ‐0.54 to 2.54, P = 0.20, 1 study, 198 participants, ITT analysis; <a href="./references#CD001190-fig-0196" title="">Analysis 8.4</a>). </p> </section> <section id="CD001190-sec-0140"> <h5 class="title">Dependency</h5> <p><a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a> assessed the time spent each day by the carer assisting with the activities of daily living but there was no evidence of a treatment effect. 10 mg/day donepezil at 24 weeks (MD ‐52.4, 95% CI ‐118.78 to 13.98, P = 0.12, 1 study, 221 participants, ITT analysis; <a href="./references#CD001190-fig-0199" title="">Analysis 8.7</a>). </p> </section> <section id="CD001190-sec-0141"> <h5 class="title">Global assessment</h5> <p>We dichotomised the seven‐point CIBIC‐Plus scale, measuring global clinical state, counting those showing no change or decline, against those showing improvement, and analysed the results using the OR. There were benefits associated with 10 mg/day donepezil compared with placebo at 24 weeks as shown by the ITT analyses, but not with 5 mg/day. </p> <p> <ul id="CD001190-list-0040"> <li> <p>5 mg/day donepezil at 24 weeks (31/96 donepezil, 24/102 placebo) (OR 1.54, 95% CI 0.83 to 2.87, P = 0.17, 1 study, 198 participants, ITT analysis; <a href="./references#CD001190-fig-0195" title="">Analysis 8.3</a>) </p> </li> <li> <p>10 mg/day donepezil at 24 weeks (151/379 donepezil, 103/376 placebo) (OR 1.78, 95% CI 1.31 to 2.43, P = 0.0002, 3 studies, 755 participants, ITT analysis; <a href="./references#CD001190-fig-0195" title="">Analysis 8.3</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0142"> <h5 class="title">Behavioural symptoms</h5> <p><a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a>, <a href="./references#CD001190-bbs2-0030" title="BatsmanS , MinthonL , EerikssonS , KilanderL , Jansson‐BlixtC , WetterholmA , et al. Study design and baseline patients characteristics in a randomized controlled trial of the efficacy and tolerability of donepezil in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. ErikssonS , WinbladB , KilanderL , BatsmanS , Jansson‐BlixtC , WetterholmA , et al. Efficacy of donepezil on secondary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. JelicV , HaglundA , KowalskiJ , LangworthS , WinbladB . Donepezil treatment of severe Alzheimer's disease in nursing home settings. Dementia and Geriatric Cognitive Disorders2008;26(5):458‐46. KilanderL , WinbladB , MinthonL , BatsmanS , Jansson‐BlixtC , CronlundA , et al. Donepezil is well tolerated in patients with severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MarderK . Donepezil in patients with severe Alzheimer's disease: double‐blind parallel‐group, placebo controlled study. Current Neurology and Neuroscience Reports2006;6(5):364‐73. OpieLH . Donepezil for severe Alzheimer's disease. Lancet2006;368:361‐2. WinbladB . Donepezil for severe Alzheimer's disease ‐ author's reply. Lancet2006;368(9533):362. WinbladB . Severe Alzheimer's disease: benefits of donepezil therapy. International Psychogeriatrics2006;18(5):S25‐S31. WinbladB , KilanderL , ErikssonS , MinthonL , BåtsmanS , WetterholmA , et al. for the Severe Alzheimer’s Disease Study Group. Donepezil in patients with severe Alzheimer’s disease: double‐blind, parallel‐group, placebo‐controlled study. Lancet2006;367(9156):1057‐65. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansoon‐BlixtC , WetterholmA , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansson‐BlixtC , WetterholmAL , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. International Psychogeriatrics2005;18(S1):S25‐S31. ">Winblad 2006</a>, and <a href="./references#CD001190-bbs2-0002" title="BlackS , LiHL , McRaeT , RichardsonS . Treatment of severe Alzheimer's disease with donepezil: results from a 24‐week, multinational, randomized, double‐blind, placebo‐controlled trial. Neurology2006;66(5):A347. BlackS , LiHonglang , McRaeT , RichardsonS . Donepezil treatment of severe Alzheimer's disease: results from a 24‐week, multinational, randomized, double‐blind, placebo controlled trial. Poster Presented at the Geneva Springfield ConferenceApril 2006. BlackSE , DoodyR , LiH , McRaeT , JamborKM , XuY , et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology2007;69(5):459‐69. Pfizer . E2020‐A001‐315: a 24 week multinational RCT evaluating the efficacy and safety of donepezil in severe AD. www.marc.soton.ac.uk/Research%20Page.htm. RichardsonS . A 24 week, multicenter, randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of donepezil hydrochloride (E2020) in patients with severe Alzheimer's disease followed by a 12 week open‐label extension period. www.clinicaltrials.gov/ct/show/NCT000964732004. ">Black 2007</a> assessed behavioural disturbance (NPI‐TOTAL), and there was evidence of benefit of donepezil 10 mg/day at 24 weeks. </p> <p> <ul id="CD001190-list-0041"> <li> <p>10 mg/day donepezil at 24 weeks (MD ‐2.18, 95% CI ‐4.11 to ‐0.25, P = 0.03, 3 studies, 827 participants, ITT analysis; <a href="./references#CD001190-fig-0198" title="">Analysis 8.6</a>) </p> </li> </ul> </p> <p><a href="./references#CD001190-bbs2-0009" title="HommaA , ArimotoI , KaidojiK , OhbayashiT , OzawaH . Treatment of severe Alzheimer's disease with donepezil: results from a 24 week, parallel, placebo‐controlled study in Japan. 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, July 2006. 2006. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24‐week, double‐blind, placebo‐controlled, randomized trial. Geriatric Cognitive Disorders2008;25(5):399‐407. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Long‐term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52‐week, open‐label, multicenter, extension study in Japan. Dementia and Geritatric Congitive Disorders2009;27(3):232‐9. ">Homma 2008</a> assessed BEHAVE‐AD and there was no evidence of benefit of donepezil. </p> <p> <ul id="CD001190-list-0042"> <li> <p>5 mg/day donepezil at 24 weeks (MD 0.00, 95% CI ‐1.67 to 1.67, P = 1.00, 1 study, 198 participants, ITT analysis; <a href="./references#CD001190-fig-0197" title="">Analysis 8.5</a>) </p> </li> <li> <p>10 mg/day donepezil at 24 weeks (MD 0.40, 95% C I ‐1.28 to 2.08, P = 0.64, 1 study, 194 participants, ITT analysis; <a href="./references#CD001190-fig-0197" title="">Analysis 8.5</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0143"> <h5 class="title">Withdrawals before the end of treatment</h5> <p>The meta‐analyses of withdrawals before the end of treatment, using the OR, showed significant differences in withdrawals between the 10 mg/day group and the placebo group in favour of placebo at 24 weeks, but not for the 5 mg/day group. </p> <p> <ul id="CD001190-list-0043"> <li> <p>5 mg/day donepezil at 24 weeks (13/101 donepezil, 19/105 placebo) (OR 0.67, 95% CI 0.32 to 1.43, P = 0.30, 1 study, 206 participants, ITT analysis; <a href="./references#CD001190-fig-0200" title="">Analysis 8.8</a>). </p> </li> <li> <p>10 mg/day donepezil at 24 weeks (164/701 donepezil, 130/695 placebo) (OR 1.32, 95% CI 1.02 to 1.71, P = 0.04, 5 studies, 1396 participants, ITT analysis; <a href="./references#CD001190-fig-0200" title="">Analysis 8.8</a>). </p> </li> </ul> </p> </section> <section id="CD001190-sec-0144"> <h5 class="title">Withdrawals before the end of treatment due to adverse events</h5> <p>The meta‐analyses of withdrawals before the end of treatment due to adverse events, using the OR, showed significant differences in withdrawals between the 10 mg/day group at 24 weeks in favour of placebo, but not for the 5 mg/day group. </p> <p> <ul id="CD001190-list-0044"> <li> <p>5 mg/day donepezil at 24 weeks (8/101 donepezil, 11/105 placebo) (OR 0.74, 95% CI 0.29 to 1.89, P = 0.53, 1 study, 206 participants, ITT analysis; <a href="./references#CD001190-fig-0201" title="">Analysis 8.9</a>). </p> </li> <li> <p>10 mg/day donepezil at 24 weeks (93/701 donepezil, 55/695 placebo) (OR 1.72, 95% CI 1.23 to 2.42, P = 0.002, 5 studies, 1396 participants, ITT analysis; <a href="./references#CD001190-fig-0201" title="">Analysis 8.9</a>). </p> </li> </ul> </p> </section> <section id="CD001190-sec-0145"> <h5 class="title">Adverse events</h5> <p>The meta‐analyses of numbers of participants with at least one adverse event showed a significant difference between the 10 mg/day group and placebo in favour of placebo, at 24 weeks but not for the 5 mg/day donepezil. </p> <p> <ul id="CD001190-list-0045"> <li> <p>5 mg/day donepezil at 24 weeks(79/101 donepezil, 77/105 placebo) (OR 1.30, 95% CI 0.69 to 2.46, P = 0.41, 1 study, 206 participants, ITT analysis; <a href="./references#CD001190-fig-0202" title="">Analysis 8.10</a>). </p> </li> <li> <p>10 mg/day at 24 weeks (487/701 donepezil, 328/695 placebo) (OR 1.59, 95% CI 1.23 to 2.05, P = 0.0003, 5 studies, 1396 participants, ITT analysis; <a href="./references#CD001190-fig-0202" title="">Analysis 8.10</a>) </p> </li> </ul> </p> <p>The included studies reported 32 different causes of adverse events. The causes of adverse events seen more frequently in the 10 mg/day dose group than in the 5 mg/day group or placebo group included nausea, vomiting and diarrhoea. These were mostly mild and transient, but occasionally moderately severe. There were significant differences, in favour of placebo, compared with donepezil, usually the 10 mg/day dose, for several causes of adverse events. </p> <p> <ul id="CD001190-list-0046"> <li> <p>Anexoria: 10 mg/day donepezil 24 weeks (26/429 donepezil, 141/428 placebo) (OR 2.32 95% CI 1.20 to 4.48, P = 0.01, 3 studies, 857 participants, ITT analysis; <a href="./references#CD001190-fig-0206" title="">Analysis 8.14</a>) </p> </li> <li> <p>Arthralgia: 10 mg/day donepezil 24 weeks (10/144 donepezil, 2/146 placebo) (OR 4.06 95% CI 1.28 to 12.86, P = 0.02, 1 study, 290 participants, ITT analysis; <a href="./references#CD001190-fig-0208" title="">Analysis 8.16</a>) </p> </li> <li> <p>Diarrhoea: 10 mg/day donepezil at 24 weeks (60/701 donepezil, 20/694placebo) (OR 2.57 95% CI 1.65 to 4.01, P &lt; 0.0001, 5 studies, 1395 participants, ITT analysis; <a href="./references#CD001190-fig-0217" title="">Analysis 8.25</a>) </p> </li> <li> <p>Hallucinations: 10 mg/day donepezil at 24 weeks (8/128 donepezil, 1/120 placebo) (OR 4.68, 95% CI 1.24 to 17.66, P = 0.02, 1 study, 248 participants, ITT analysis; <a href="./references#CD001190-fig-0222" title="">Analysis 8.30</a>) </p> </li> <li> <p>Headache: 10 mg/day donepezil at 24 weeks (17/144 donepezil, 6/146 placebo) (OR 2.86, 95% CI 1.22 to 6.69, P = 0.02, 1 study, 290 participants, ITT analysis; <a href="./references#CD001190-fig-0229" title="">Analysis 8.37</a>) </p> </li> <li> <p>Insomnia: 10 mg/day donepezil at 24 weeks (12/176 donepezil, 4/167 placebo) (OR 2.70, 95% CI 0.99 to 7.35, P = 0.05, 1 study, 343 participants, ITT analysis; <a href="./references#CD001190-fig-0225" title="">Analysis 8.33</a>) </p> </li> <li> <p>Nausea: 10 mg/day donepezil at 24 weeks (31/424 donepezil, 14/404 placebo) (OR 2.11, 95% CI 1.16 to 3.85, P = 0.01, 3 studies, 828 participants, ITT analysis; <a href="./references#CD001190-fig-0227" title="">Analysis 8.35</a>) </p> </li> <li> <p>Restlessness: 5 mg/day donepezil at 24 weeks (6/101 donepezil, 1/105 placebo) (OR 4.54, 95% CI 1.01 to 20.41, P = 0.05, 1 study, 206 participants, ITT analysis; <a href="./references#CD001190-fig-0228" title="">Analysis 8.36</a>) </p> </li> <li> <p>Vomiting: 10 mg/day donepezil at 24 weeks (35/416 donepezil, 15/418 placebo) (OR 2.42, 95% CI 1.37 to 4.31, P = 0.002, 3 studies, 834 participants, ITT analysis; <a href="./references#CD001190-fig-0231" title="">Analysis 8.39</a>) </p> </li> </ul> </p> </section> <section id="CD001190-sec-0146"> <h5 class="title">Serious adverse events</h5> <p>The meta‐analyses of numbers of participants with at least one serious adverse event showed no difference between the 5 mg/day group and placebo, and the 10 mg/day group and placebo, at 24 weeks. </p> <p> <ul id="CD001190-list-0047"> <li> <p>5 mg/day donepezil at 24 weeks(12/101 donepezil, 15/105 placebo) (OR 0.81, 95% CI 0.36 to 1.82, P = 0.61, 1 study, 206 participants, ITT analysis; <a href="./references#CD001190-fig-0236" title="">Analysis 8.44</a>). </p> </li> <li> <p>10 mg/day at 24 weeks (90/701 donepezil, 107/695 placebo) (OR 0.80, 95% CI 0.59 to 1.08, P = 0.14, 5 studies, 1396 participants, ITT analysis; <a href="./references#CD001190-fig-0236" title="">Analysis 8.44</a>) </p> </li> </ul> </p> <section id="CD001190-sec-0147"> <h6 class="title">Deaths</h6> <p>The meta‐analyses of numbers of deaths before end of treatment at 24 weeks showed no difference between the 5 mg/day group and placebo, and the 10 mg/day group and placebo, at 24 weeks. </p> <p> <ul id="CD001190-list-0048"> <li> <p>5 mg/day donepezil at 24 weeks (2/101 donepezil, 1/105 placebo) (OR 2.04, 95% CI 0.21 to 19.83, P = 0.54, 1 study, 206 participants, ITT analysis; <a href="./references#CD001190-fig-0235" title="">Analysis 8.43</a>). </p> </li> <li> <p>10 mg/day at 24 weeks (24/701 donepezil, 31/695 placebo) (OR 0.71, 95% CI 0.41 to 1.25, P = 0.24, 5 studies, 1396 participants, ITT analysis; <a href="./references#CD001190-fig-0235" title="">Analysis 8.43</a> </p> </li> </ul> </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001190-sec-0148" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001190-sec-0148">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001190-sec-0216">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001190-sec-0148"></div> <section id="CD001190-sec-0149"> <h3 class="title" id="CD001190-sec-0149">Summary of main results</h3> <p>The main findings of the review were as follows.</p> <p> <ul id="CD001190-list-0049"> <li> <p>The currently recommended dose of donepezil (10 mg/day) has benefits compared with placebo at 26 weeks for cognitive function, activities of daily living and the clinician‐rated global impression scales. We found no difference for behavioural symptoms or quality of life. Participants on donepezil were more likely to experience adverse events (OR of 1.6) or to withdraw from the trial before the end. </p> </li> <li> <p>Participants on a lower dose of 5 mg/day were less likely to experience adverse events or to withdraw from the trial compared with participants on 10 mg/day. The higher dose showed some benefit for cognitive function, but not for activities of daily living and clinician‐related global impression compared with the lower dose. </p> </li> <li> <p>A higher dose of 23 mg/day from a slow‐release formulation had no benefits for cognitive function, activities of daily living and clinician‐rated global impression scales compared with the 10 mg/day dose, but participants on the higher dose were more likely to experience adverse events or to withdraw from the trial compared with participants on the lower dose. </p> </li> <li> <p>Four studies only included participants with severe or moderately severe dementia. The results from these four studies reported similar results to the studies that included only participants with mild to moderate dementia. </p> </li> </ul> </p> <section id="CD001190-sec-0150"> <h4 class="title">Outcomes</h4> <p>The included studies used three cognitive tests. The MMSE and the ADAS‐Cog assess similar domains and the results of the meta‐analyses were similar. The results from five studies showed that 10 mg daily of donepezil improved cognitive function of participants with mild to moderate probable Alzheimer's disease treated over a period of 24 to 26 weeks by 1.1 points on the MMSE (range 0 to 30) and by 2.7 points on the ADAS‐Cog (range 0 to 70), when compared with placebo. The results from five studies showed that 10 mg/day of donepezil improved cognitive function of participants with moderately severe to severe probable Alzheimer's disease treated over a period of 24 weeks by 5.9 points on the SIB (range 0 to 100) when compared with placebo. </p> <p>Three studies assessed the effect of 10 mg/day donepezil on activities of daily living using the ADCS‐ADL‐sev scale (range 0 to 54). Donepezil showed a benefit of 1.0 points compared with placebo. </p> <p>When we dichotomised the results of the clinician‐rated global impression measures to compare the number of participants who showed no change or whose condition had deteriorated with the number who had improved, the 10 mg/day donepezil group was significantly better than the placebo group at 24 to 26 weeks. </p> <p>There was very little evidence on the effect of donepezil on behavioural problems, which only five studies assessed. In none of the studies did the participants suffer from more than mild problems at baseline. We found no evidence that donepezil affects patient‐rated quality of life measured on the scale chosen for these studies. <a href="./references#CD001190-bbs2-0014" title="RobertP , LebertF , GoniS , TouchonJ , VincentS , ARIAL Study Investigators Collaborative Group. The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. Quality Research in Dementia; 19‐22 November, 2000, London. 2000. RobertPH , LebertF , GoniS , TouchonJ , ARIAL Study Investigators Collaborative Group. The impact of caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">Lebert 1999</a> assessed stress on carers but reported the results without any measure of precision and so we have not included them in this review. </p> </section> <section id="CD001190-sec-0151"> <h4 class="title">Adverse effects</h4> <p>Donepezil appears to have a low incidence of serious side effects. The earlier studies (<a href="./references#CD001190-bbs2-0021" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. PrattRD , PerdomoCA , IeniJK . Long‐term safety and tolerability of donepezil: results from a phase iii extension trial of patients with mild to moderately severe Alzheimer's disease. European Journal of Neurology1999;6(Suppl 3):116. [MEDLINE: SR‐HANDSRCH] RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyRS , MohsRC , FriedhoffLT , the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine1998;158:1021‐31. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego. 1997. ">Rogers 1998a</a>; <a href="./references#CD001190-bbs2-0022" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. Erratum: a 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613‐620)). Neurology2001; Vol. 57, issue 11:2153. FriedhoffLT , RogersL . Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease ‐ results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston. Neurology1997;48(3):A100. FriedhoffLT , RogersSL . Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17, Vienna, Austria1997. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis. European Journal of Neurology1997;4(Suppl 1):S9. RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyR , MohsR , FriedhoffLT . E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30‐week phase III trial. Neurology1996;46:A217 S14.001 ARI‐8. RogersSL , DoodyR , MohsR , FriedhoffT , Donepezil Study Group. E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30‐week trial. Unpublished paper1996b. RogersSL , FarlowMR , DoodyRS , MohsR , FriedhoffLT , Donepezil Study Group. A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998;50(1):136‐45. RogersSL , FriedhoffLT , FarlowMR , DoodyRS , MohsR . Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply]. Neurology1999; Vol. 52, issue 1:218‐19. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego1997. ">Rogers 1998b</a>; <a href="./references#CD001190-bbs2-0003" title="BayerAJ , RossorM , HeckerJ , GauthierS , BurnsA , PetiteH , et al. International Donepezil Study Group. Donepezil improves functional activity in patients with Alzheimer's disease. 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12‐16, Glasgow, Scotland. 1998. [MEDLINE: SR‐HANDSRCH] BurnsA , GauthierS , PerdomoC . Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(8):806‐12. BurnsA , RossorM , HeckerJ , GauthierS , PetitH , MöllerH‐J , et al. International Donepezil Study Group. The effects of donepezil in Alzheimer's disease ‐ results from a multinational trial. Dementia and Geriatric Cognitive Disorders1999;10(3):237‐44. GauthierS , RosserM , HeckerJ , PetiteH , RogersS , MohrE , et al. Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐June 4, Toronto, Canada1998. [MEDLINE: SR‐HANDSRCH] GauthierS , RossorM , HeckerJ . Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 15‐18 1998. PrattRD , GauthierS , BurnsA , PerdomoCA . Donepezil provides long‐term clinical benefits for patients with Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington. 2000. ">Burns 1999</a>) used a short titration period of one week on 5 mg/day before proceeding to the 10 mg/day dose but later studies used a four‐week titration period, as recommended by the pharmaceutical company in the prescribing information. There were significantly more total dropouts and dropouts due to adverse events from the 10 mg/day group than from the placebo or 5 mg/day groups, and therefore side effects remain a clinical issue. </p> </section> </section> <section id="CD001190-sec-0152"> <h3 class="title" id="CD001190-sec-0152">Overall completeness and applicability of evidence</h3> <p>We were able to include evidence from both published and unpublished studies in this systematic review. Most of the studies were sponsored by the pharmaceutical industry. The participants had mainly mild to moderate dementia due to Alzheimer's disease. In six studies participants were included with a MMSE less than 12. These participants were excluded from most of the other included studies. When these results are added to the meta‐analyses the results appear very similar to those of participants with mild to moderate dementia. Although the MMSE measurements are in a different part of the MMSE scale, the treatment effect is very similar to the other studies. In the studies of people with severe dementia, the SIB was also used to assess cognitive function, a scale designed for use with people with severe dementia. There is no evidence of a different rate of withdrawals or rates of adverse events from the studies of participants with severe dementia, compared with the studies of participants with mild to moderate dementia. The death rate is higher for participants with severe dementia compared to the participants with mild to moderate dementia, but this reflects the greater age of the people in the severe stage of dementia compared with the milder stages. There is no difference between the death rates for the treatment and placebo groups. </p> <p>The main limitation in the completeness and applicability of the evidence was the lack of long‐term data beyond 26 weeks. One study reported data at 52 weeks. There were relatively few data on outcomes important to patients and carers, such as quality of life. </p> </section> <section id="CD001190-sec-0153"> <h3 class="title" id="CD001190-sec-0153">Quality of the evidence</h3> <p>The quality of the evidence at 26 weeks is moderate for most outcomes.</p> <p>In terms of measuring outcomes and statistical analysis, the donepezil studies have essentially followed the relevant FDA guidance. The results reported are on an ITT basis, based on the participants' last assessments during the double‐blind phase (so‐called Last Observation Carried Forward LOCF analysis). As participants who did not complete the trial would, on average, show a further decline by the end of the double‐blind phase, this substitution of the LOCF is likely to enhance the final outcome. This effect is of significance when large numbers drop out and when there is differential dropout across the treatment groups. In these studies the latter effect applies to the 10 mg/day donepezil group, where there is a slightly greater dropout rate compared with placebo (27% compared with 21%), which is probably related to treatment. However, we have reported the results from the analysis of the ITT and completers' data, and found that the loss of participants from the studies did not alter our conclusions. </p> </section> <section id="CD001190-sec-0154"> <h3 class="title" id="CD001190-sec-0154">Potential biases in the review process</h3> <p>One review extracted the data and the same review author checked them. This was considered adequate when the previous versions of the review were written as the reviewer is a professional statistician. There have been no errors in data extraction reported. </p> </section> <section id="CD001190-sec-0155"> <h3 class="title" id="CD001190-sec-0155">Agreements and disagreements with other studies or reviews</h3> <p>The most recent systematic reviews of cholinesterase inhibitors have included all three cholinesterase inhibitors, donepezil, rivastigmine and galantamine, in the review. <a href="./references#CD001190-bbs2-0146" title="TanC‐C , YuJ‐T , WangH‐F , TanM‐S , MengX‐F , WangC , et al. Efficacy and safety of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease: a systematic review and meta‐analysis. Journal of Alzheimer's Disease2014;41:615‐31. [DOI: 10.3233/JAD‐132690] ">Tan 2014</a> included all three cholinesterase inhibitors and reported results for each separately. <a href="./references#CD001190-bbs2-0146" title="TanC‐C , YuJ‐T , WangH‐F , TanM‐S , MengX‐F , WangC , et al. Efficacy and safety of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease: a systematic review and meta‐analysis. Journal of Alzheimer's Disease2014;41:615‐31. [DOI: 10.3233/JAD‐132690] ">Tan 2014</a> included 10 studies comparing donepezil 10 mg/day with placebo and reported a treatment effect as measured on the ADAS‐Cog of MD ‐2.48 (95% CI ‐3.23 to ‐1.73, 4 studies), which is comparable to the treatment effect reported in this review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001190-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for searches conducted in January 2015, November 2016 and May 2017" data-id="CD001190-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram for searches conducted in January 2015, November 2016 and May 2017</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD001190-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD001190-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 1 ADAS‐Cog (change from baseline at 24‐26 weeks) ITT‐LOCF." data-id="CD001190-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 1 ADAS‐Cog (change from baseline at 24‐26 weeks) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 2 MMSE (change from baseline at 24‐26 weeks) ITT‐LOCF." data-id="CD001190-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 2 MMSE (change from baseline at 24‐26 weeks) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 3 SIB (change from baseline at 24‐26 weeks) ITT‐LOCF." data-id="CD001190-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 3 SIB (change from baseline at 24‐26 weeks) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 4 ADCS‐ADL‐severe (change from baseline at 24‐26 weeks) ITT‐LOCF." data-id="CD001190-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 4 ADCS‐ADL‐severe (change from baseline at 24‐26 weeks) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 5 CIBIC‐Plus or CGIC (numbers improved at 24‐26 weeks) ITT‐LOCF." data-id="CD001190-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 5 CIBIC‐Plus or CGIC (numbers improved at 24‐26 weeks) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 6 CDR‐SB (change from baseline at 24‐26 weeks) ITT‐LOCF." data-id="CD001190-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 6 CDR‐SB (change from baseline at 24‐26 weeks) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 7 BEHAVE‐AD (change from baseline at 24‐26 weeks) ITT‐LOCF." data-id="CD001190-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 7 BEHAVE‐AD (change from baseline at 24‐26 weeks) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 8 Behavioural disturbance (Total NPI ) (change from baseline at 24‐26 weeks) ITT‐LOCF." data-id="CD001190-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 8 Behavioural disturbance (Total NPI ) (change from baseline at 24‐26 weeks) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 9 QoL (participant‐rated quality of life at 24‐26 weeks) ITT‐LOCF." data-id="CD001190-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 9 QoL (participant‐rated quality of life at 24‐26 weeks) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 10 Total number of withdrawals before end of treatment at 24‐26 weeks." data-id="CD001190-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 10 Total number of withdrawals before end of treatment at 24‐26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 11 Total number of participants who suffered from at least one adverse event by 24‐26 weeks." data-id="CD001190-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Donepezil (10 mg/day) versus placebo, Outcome 11 Total number of participants who suffered from at least one adverse event by 24‐26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 1 ADAS‐COG (change from baseline) completers." data-id="CD001190-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 1 ADAS‐COG (change from baseline) completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 2 ADAS‐COG (change from baseline) ITT‐LOCF." data-id="CD001190-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 2 ADAS‐COG (change from baseline) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 3 MMSE (change from baseline) completers." data-id="CD001190-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 3 MMSE (change from baseline) completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 4 MMSE (change from baseline) ITT‐LOCF." data-id="CD001190-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 4 MMSE (change from baseline) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 5 SIB (change from baseline) ITT‐LOCF." data-id="CD001190-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 5 SIB (change from baseline) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 6 CIBIC‐plus or CGIC (numbers improved) completers." data-id="CD001190-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 6 CIBIC‐plus or CGIC (numbers improved) completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 7 CIBIC‐plus or CGIC (numbers improved) ITT‐LOCF." data-id="CD001190-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 7 CIBIC‐plus or CGIC (numbers improved) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 8 CDR‐SB (change from baseline) completers." data-id="CD001190-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 8 CDR‐SB (change from baseline) completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 9 CDR‐SB (change from baseline) ITT‐LOCF." data-id="CD001190-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 9 CDR‐SB (change from baseline) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 10 GBS or MENFIS ‐ global assessment completers." data-id="CD001190-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 10 GBS or MENFIS ‐ global assessment completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 11 GBS ‐ global assessment ITT‐LOCF." data-id="CD001190-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 11 GBS ‐ global assessment ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 12 ADL and IADL (CMCS) (change from baseline) completers." data-id="CD001190-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 12 ADL and IADL (CMCS) (change from baseline) completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 13 ADl and IADL (DAD) (change from baseline) completers." data-id="CD001190-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 13 ADl and IADL (DAD) (change from baseline) completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 14 ADCS‐ADL‐severe (change from baseline) ITT‐LOCF." data-id="CD001190-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 14 ADCS‐ADL‐severe (change from baseline) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 15 PDS ‐ progressive deterioration scale ITT‐LOCF." data-id="CD001190-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 15 PDS ‐ progressive deterioration scale ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 16 Total number meeting criterion for functional decline before end of treatment." data-id="CD001190-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 16 Total number meeting criterion for functional decline before end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 17 Behavioural disturbance (total NPI) (change from baseline) completers." data-id="CD001190-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 17 Behavioural disturbance (total NPI) (change from baseline) completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 18 BEHAVE‐AD (change from baseline) ITT‐LOCF." data-id="CD001190-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 18 BEHAVE‐AD (change from baseline) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 19 Behavioural disturbance (total NPI ) (change from baseline) ITT‐LOCF." data-id="CD001190-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 19 Behavioural disturbance (total NPI ) (change from baseline) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 20 QoL (participant‐rated quality of life) completers." data-id="CD001190-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 20 QoL (participant‐rated quality of life) completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 21 QoL (participant‐rated quality of life) ITT‐LOCF." data-id="CD001190-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 21 QoL (participant‐rated quality of life) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 22 IADL (change from baseline) completers." data-id="CD001190-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 22 IADL (change from baseline) completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 23 PSMS (change from baseline) completers." data-id="CD001190-fig-0037" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 23 PSMS (change from baseline) completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 24 Time (mins/day) spent by carer assisting in IADL and PSMS (change from baseline) LOCF." data-id="CD001190-fig-0038" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 24 Time (mins/day) spent by carer assisting in IADL and PSMS (change from baseline) LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 25 Total number who enter long‐term institutional care before end of treatment." data-id="CD001190-fig-0039" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 25 Total number who enter long‐term institutional care before end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 26 Total number of withdrawals before end of treatment." data-id="CD001190-fig-0040" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 26 Total number of withdrawals before end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 27 Total number of participants who withdrew due to an adverse event." data-id="CD001190-fig-0041" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 27 Total number of participants who withdrew due to an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 28 Total number of participants who suffered from at least one adverse event." data-id="CD001190-fig-0042" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.28</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 28 Total number of participants who suffered from at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 29 Total number of participants who suffered from abdominal pain." data-id="CD001190-fig-0043" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.29</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 29 Total number of participants who suffered from abdominal pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 30 Total number of participants who suffered from abnormal gait." data-id="CD001190-fig-0044" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.30</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 30 Total number of participants who suffered from abnormal gait. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 31 Total number of participants who suffered from abnormal dreams." data-id="CD001190-fig-0045" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.31</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 31 Total number of participants who suffered from abnormal dreams. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 32 Total number of participants who suffered from accidental fall." data-id="CD001190-fig-0046" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.32</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 32 Total number of participants who suffered from accidental fall. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 33 Total number of participants who suffered from accidental injury." data-id="CD001190-fig-0047" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.33</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 33 Total number of participants who suffered from accidental injury. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 34 Total number of participants who suffered from agitation." data-id="CD001190-fig-0048" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.34</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 34 Total number of participants who suffered from agitation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 35 Total number of participants who suffered from anorexia." data-id="CD001190-fig-0049" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.35</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 35 Total number of participants who suffered from anorexia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 36 Total number of participants who suffered from anxiety." data-id="CD001190-fig-0050" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.36</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 36 Total number of participants who suffered from anxiety. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 37 Total number of participants who suffered from arthralgia." data-id="CD001190-fig-0051" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.37</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 37 Total number of participants who suffered from arthralgia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 38 Total number of participants who suffered from asthenia." data-id="CD001190-fig-0052" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.38</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 38 Total number of participants who suffered from asthenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 39 Total number of participants who suffered from back pain." data-id="CD001190-fig-0053" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.39</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 39 Total number of participants who suffered from back pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 40 Total number of participants who suffered from cold syndrome." data-id="CD001190-fig-0054" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.40</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 40 Total number of participants who suffered from cold syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 41 Total number of participants who suffered from confusion." data-id="CD001190-fig-0055" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.41</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 41 Total number of participants who suffered from confusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 42 Total number of participants who suffered from conjunctivitis." data-id="CD001190-fig-0056" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.42</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 42 Total number of participants who suffered from conjunctivitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 43 Total number of participants who suffered from constipation." data-id="CD001190-fig-0057" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.43</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 43 Total number of participants who suffered from constipation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 44 Total number of participants who suffered from contusion." data-id="CD001190-fig-0058" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.44</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 44 Total number of participants who suffered from contusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-44.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-45" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-45.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 45 Total number of participants who suffered from cystitis." data-id="CD001190-fig-0059" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-45.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.45</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 45 Total number of participants who suffered from cystitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-45.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-46" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-46.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 46 Total number of participants who suffered from depression." data-id="CD001190-fig-0060" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-46.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.46</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 46 Total number of participants who suffered from depression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-46.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-47" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-47.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 47 Total number of participants who suffered from diarrhoea." data-id="CD001190-fig-0061" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-47.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.47</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 47 Total number of participants who suffered from diarrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-47.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-48" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-48.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 48 Total number of participants who suffered from dizziness." data-id="CD001190-fig-0062" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-48.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.48</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 48 Total number of participants who suffered from dizziness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-48.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-49" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-49.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 49 Total number of participants who suffered from ecchymosis." data-id="CD001190-fig-0063" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-49.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.49</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 49 Total number of participants who suffered from ecchymosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-49.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-50" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-50.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 50 Total number of participants who suffered from eczema." data-id="CD001190-fig-0064" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-50.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.50</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 50 Total number of participants who suffered from eczema. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-50.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-51" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-51.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 51 Total number of participants who suffered from fatigue." data-id="CD001190-fig-0065" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-51.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.51</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 51 Total number of participants who suffered from fatigue. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-51.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-52" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-52.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 52 Total number of participants who suffered from fever." data-id="CD001190-fig-0066" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-52.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.52</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 52 Total number of participants who suffered from fever. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-52.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-53" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-53.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 53 Total number of participants who suffered from fracture." data-id="CD001190-fig-0067" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-53.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.53</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 53 Total number of participants who suffered from fracture. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-53.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-54" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-54.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 54 Total number of participants who suffered from gastroenteritis." data-id="CD001190-fig-0068" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-54.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.54</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 54 Total number of participants who suffered from gastroenteritis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-54.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-55" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-55.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 55 Total number of participants who suffered from haemorrhage." data-id="CD001190-fig-0069" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-55.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.55</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 55 Total number of participants who suffered from haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-55.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-56" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-56.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 56 Total number of participants who suffered from hallucinations." data-id="CD001190-fig-0070" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-56.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.56</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 56 Total number of participants who suffered from hallucinations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-56.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-57" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-57.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 57 Total number of participants who suffered from headache." data-id="CD001190-fig-0071" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-57.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.57</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 57 Total number of participants who suffered from headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-57.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-58" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-58.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 58 Total number of participants who suffered from hostility." data-id="CD001190-fig-0072" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-58.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.58</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 58 Total number of participants who suffered from hostility. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-58.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-59" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-59.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 59 Total number of participants who suffered from loss of appetite." data-id="CD001190-fig-0073" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-59.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.59</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 59 Total number of participants who suffered from loss of appetite. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-59.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-60" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-60.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 60 Total number of participants who suffered from infection." data-id="CD001190-fig-0074" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-60.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.60</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 60 Total number of participants who suffered from infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-60.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-61" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-61.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 61 Total number of participants who suffered from inflammation of upper airway." data-id="CD001190-fig-0075" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-61.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.61</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 61 Total number of participants who suffered from inflammation of upper airway. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-61.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-62" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-62.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 62 Total number of participants who suffered from insomnia." data-id="CD001190-fig-0076" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-62.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.62</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 62 Total number of participants who suffered from insomnia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-62.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-63" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-63.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 63 Total number of participants who suffered from increased cough." data-id="CD001190-fig-0077" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-63.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.63</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 63 Total number of participants who suffered from increased cough. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-63.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-64" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-64.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 64 Total number of participants who suffered from myasthenia." data-id="CD001190-fig-0078" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-64.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.64</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 64 Total number of participants who suffered from myasthenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-64.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-65" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-65.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 65 Total number of participants who suffered from muscle cramp." data-id="CD001190-fig-0079" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-65.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.65</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 65 Total number of participants who suffered from muscle cramp. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-65.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-66" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-66.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 66 Total number of participants who suffered from nausea." data-id="CD001190-fig-0080" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-66.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.66</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 66 Total number of participants who suffered from nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-66.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-67" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-67.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 67 Total number of participants who suffered from pain." data-id="CD001190-fig-0081" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-67.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.67</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 67 Total number of participants who suffered from pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-67.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-68" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-68.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 68 Total number of participants who suffered from peripheral oedema." data-id="CD001190-fig-0082" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-68.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.68</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 68 Total number of participants who suffered from peripheral oedema. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-68.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-69" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-69.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 69 Total number of participants who suffered from pneumonia." data-id="CD001190-fig-0083" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-69.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.69</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 69 Total number of participants who suffered from pneumonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-69.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-70" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-70.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 70 Total number of participants who suffered from rash." data-id="CD001190-fig-0084" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-70.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.70</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 70 Total number of participants who suffered from rash. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-70.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-71" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-71.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 71 Total number of participants who suffered from restlessness." data-id="CD001190-fig-0085" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-71.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.71</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 71 Total number of participants who suffered from restlessness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-71.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-72" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-72.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 72 Total number of participants who suffered from respiratory tract infection." data-id="CD001190-fig-0086" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-72.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.72</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 72 Total number of participants who suffered from respiratory tract infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-72.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-73" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-73.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 73 Total number of participants who suffered from rhinitis." data-id="CD001190-fig-0087" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-73.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.73</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 73 Total number of participants who suffered from rhinitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-73.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-74" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-74.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 74 Total number of participants who suffered from vomiting." data-id="CD001190-fig-0088" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-74.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.74</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 74 Total number of participants who suffered from vomiting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-74.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-75" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-75.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 75 Total number of participants who suffered from skin ulcer." data-id="CD001190-fig-0089" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-75.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.75</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 75 Total number of participants who suffered from skin ulcer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-75.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-76" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-76.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 76 Total number of participants who suffered from syncope." data-id="CD001190-fig-0090" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-76.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.76</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 76 Total number of participants who suffered from syncope. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-76.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-77" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-77.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 77 Total number of participants who suffered from tremor." data-id="CD001190-fig-0091" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-77.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.77</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 77 Total number of participants who suffered from tremor. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-77.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-78" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-78.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 78 Total number of participants who suffered from urinary incontinence." data-id="CD001190-fig-0092" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-78.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.78</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 78 Total number of participants who suffered from urinary incontinence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-78.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-79" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-79.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 79 Total number of participants who suffered from urinary tract infection." data-id="CD001190-fig-0093" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-79.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.79</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 79 Total number of participants who suffered from urinary tract infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-79.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-80" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-80.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 80 Total number of participants who suffered from vertigo." data-id="CD001190-fig-0094" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-80.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.80</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 80 Total number of participants who suffered from vertigo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-80.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-81" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-81.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 81 Total number of participants who suffered from weight loss." data-id="CD001190-fig-0095" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-81.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.81</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 81 Total number of participants who suffered from weight loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-81.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-82" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-82.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 82 total number of deaths before end of treatment." data-id="CD001190-fig-0096" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-82.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.82</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 82 total number of deaths before end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-82.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-002-83" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-002-83.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 83 Total number of participants who suffered from at least one serious adverse event." data-id="CD001190-fig-0097" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-83.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.83</div> <div class="figure-caption"> <p>Comparison 2 Donepezil (5 mg/day or 10 mg/day) versus placebo, Outcome 83 Total number of participants who suffered from at least one serious adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-002-83.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation), Outcome 1 Patient and carer health resource utilisation over 24 weeks (Australia, Canada, France)." data-id="CD001190-fig-0098" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation), Outcome 1 Patient and carer health resource utilisation over 24 weeks (Australia, Canada, France). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation), Outcome 2 Health resource cost/participant (CAD) over 24 weeks in 1998 (Australia, Canada, France)." data-id="CD001190-fig-0099" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation), Outcome 2 Health resource cost/participant (CAD) over 24 weeks in 1998 (Australia, Canada, France). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation), Outcome 3 Health resource cost/carer (CAD) over 24 weeks in 1998 (Australia, Canada, France)." data-id="CD001190-fig-0100" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation), Outcome 3 Health resource cost/carer (CAD) over 24 weeks in 1998 (Australia, Canada, France). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation), Outcome 4 Unpaid carer time cost (CAD) in 1998 (Australia, Canada, France)." data-id="CD001190-fig-0101" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation), Outcome 4 Unpaid carer time cost (CAD) in 1998 (Australia, Canada, France). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation), Outcome 5 Total cost to society (CAD) in 1998 (Australia, Canada, France)." data-id="CD001190-fig-0102" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation), Outcome 5 Total cost to society (CAD) in 1998 (Australia, Canada, France). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation), Outcome 6 Health resource cost/participant (USD) over one year in 1999 (northern Europe)." data-id="CD001190-fig-0103" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation), Outcome 6 Health resource cost/participant (USD) over one year in 1999 (northern Europe). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation), Outcome 7 Health resource cost/carer (USD) over one year in 1999 (northern Europe)." data-id="CD001190-fig-0104" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation), Outcome 7 Health resource cost/carer (USD) over one year in 1999 (northern Europe). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation), Outcome 8 Health resource cost/participant + carer (USD) over one year in 1999 (northern Europe)." data-id="CD001190-fig-0105" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation), Outcome 8 Health resource cost/participant + carer (USD) over one year in 1999 (northern Europe). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 1 SIB (change from baseline) at 24 weeks ITT‐LOCF." data-id="CD001190-fig-0106" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 1 SIB (change from baseline) at 24 weeks ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 2 MMSE (change from baseline at 24 weeks) ITT‐LOCF." data-id="CD001190-fig-0107" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 2 MMSE (change from baseline at 24 weeks) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 3 ADCS‐ADL‐sev (change from baseline) at 24 weeks ITT‐LOCF." data-id="CD001190-fig-0108" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 3 ADCS‐ADL‐sev (change from baseline) at 24 weeks ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 4 CIBIC‐plus (numbers improved) by end of treatment at 24 weeks." data-id="CD001190-fig-0109" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 4 CIBIC‐plus (numbers improved) by end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 5 total number of patients who withdrew before end of treatment at 24 weeks." data-id="CD001190-fig-0110" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 5 total number of patients who withdrew before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 6 total number of patients who withdrew due to an adverse event before end of treatment at 24 weeks." data-id="CD001190-fig-0111" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 6 total number of patients who withdrew due to an adverse event before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 7 total number of patients who suffered an adverse event before end of treatment at 24 weeks." data-id="CD001190-fig-0112" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 7 total number of patients who suffered an adverse event before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 8 total number of patients who suffered a serious adverse event before end of treatment at 24 weeks." data-id="CD001190-fig-0113" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 8 total number of patients who suffered a serious adverse event before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 9 total number of patients who suffered an adverse event of asthenia before end of treatment at 24 weeks." data-id="CD001190-fig-0114" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 9 total number of patients who suffered an adverse event of asthenia before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 10 total number of patients who suffered an adverse event of contusion before end of treatment at 24 weeks." data-id="CD001190-fig-0115" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 10 total number of patients who suffered an adverse event of contusion before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 11 total number of patients who suffered an adverse event of anorexia before end of treatment at 24 weeks." data-id="CD001190-fig-0116" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 11 total number of patients who suffered an adverse event of anorexia before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 12 total number of patients who suffered an adverse event of diarrhoea before end of treatment at 24 weeks." data-id="CD001190-fig-0117" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 12 total number of patients who suffered an adverse event of diarrhoea before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 13 total number of patients who suffered an adverse event of dizziness before end of treatment at 24 weeks." data-id="CD001190-fig-0118" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 13 total number of patients who suffered an adverse event of dizziness before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 14 total number of patients who suffered an adverse event of fatigue before end of treatment at 24 weeks." data-id="CD001190-fig-0119" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 14 total number of patients who suffered an adverse event of fatigue before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 15 total number of patients who suffered an adverse event of headache before end of treatment at 24 weeks." data-id="CD001190-fig-0120" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 15 total number of patients who suffered an adverse event of headache before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 16 total number of patients who suffered an adverse event of insomnia before end of treatment at 24 weeks." data-id="CD001190-fig-0121" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 16 total number of patients who suffered an adverse event of insomnia before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 17 total number of patients who suffered an adverse event of nausea before end of treatment at 24 weeks." data-id="CD001190-fig-0122" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 17 total number of patients who suffered an adverse event of nausea before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 18 total number of patients who suffered an adverse event of vomiting before end of treatment at 24 weeks." data-id="CD001190-fig-0123" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.18</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 18 total number of patients who suffered an adverse event of vomiting before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 19 total number of patients who suffered an adverse event of weight decrease before end of treatment at 24 weeks." data-id="CD001190-fig-0124" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.19</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 19 total number of patients who suffered an adverse event of weight decrease before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 20 total number of patients who suffered an adverse event of accidental fall before end of treatment at 24 weeks." data-id="CD001190-fig-0125" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.20</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 20 total number of patients who suffered an adverse event of accidental fall before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 21 total number of patients who suffered an adverse event of urinary tract infection before end of treatment at 24 weeks." data-id="CD001190-fig-0126" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.21</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 21 total number of patients who suffered an adverse event of urinary tract infection before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 22 total number of patients who suffered an adverse event of bradycardia and sinus bradycardia before end of treatment at 24 weeks." data-id="CD001190-fig-0127" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.22</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 22 total number of patients who suffered an adverse event of bradycardia and sinus bradycardia before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 23 total number of patients who suffered an adverse event of agitation before end of treatment at 24 weeks." data-id="CD001190-fig-0128" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.23</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 23 total number of patients who suffered an adverse event of agitation before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 24 total number of patients who suffered an adverse event of aggression before end of treatment at 24 weeks." data-id="CD001190-fig-0129" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.24</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 24 total number of patients who suffered an adverse event of aggression before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 25 total number of patients who suffered an adverse event of urinary incontinence before end of treatment at 24 weeks." data-id="CD001190-fig-0130" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.25</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 25 total number of patients who suffered an adverse event of urinary incontinence before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 26 total number of patients who suffered an adverse event of somnolence before end of treatment at 24 weeks." data-id="CD001190-fig-0131" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.26</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 26 total number of patients who suffered an adverse event of somnolence before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 27 total number of patients who died before end of treatment at 24 weeks." data-id="CD001190-fig-0132" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.27</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 27 total number of patients who died before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 28 total number of patients who suffered an adverse event of nasopharyngitis before end of treatment at 24 weeks." data-id="CD001190-fig-0133" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.28</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 28 total number of patients who suffered an adverse event of nasopharyngitis before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 29 total number of patients who suffered an adverse event of decreased appetite before end of treatment at 24 weeks." data-id="CD001190-fig-0134" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.29</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 29 total number of patients who suffered an adverse event of decreased appetite before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 30 total number of patients who suffered an adverse event of ECG QT prolonged before end of treatment at 24 weeks." data-id="CD001190-fig-0135" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.30</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 30 total number of patients who suffered an adverse event of ECG QT prolonged before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 31 total number of patients who suffered an adverse event of anger before end of treatment at 24 weeks." data-id="CD001190-fig-0136" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.31</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 31 total number of patients who suffered an adverse event of anger before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 32 total number of patients who suffered an adverse event of constipation before end of treatment at 24 weeks end of treatment." data-id="CD001190-fig-0137" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.32</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 32 total number of patients who suffered an adverse event of constipation before end of treatment at 24 weeks end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 33 total number of patients who suffered an adverse event of bronchitis before end of treatment at 24 weeks." data-id="CD001190-fig-0138" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.33</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 33 total number of patients who suffered an adverse event of bronchitis before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 34 total number of patients who suffered an adverse event of conjunctivitis before end of treatment at 24 weeks." data-id="CD001190-fig-0139" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.34</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 34 total number of patients who suffered an adverse event of conjunctivitis before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 35 total number of patients who suffered an adverse event of upper respiratory tract infection before end of treatment at 24 weeks." data-id="CD001190-fig-0140" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.35</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 35 total number of patients who suffered an adverse event of upper respiratory tract infection before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 36 total number of patients who suffered an adverse event of arthralgia before end of treatment at 24 weeks." data-id="CD001190-fig-0141" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.36</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 36 total number of patients who suffered an adverse event of arthralgia before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 37 total number of patients who suffered an adverse event of back pain before end of treatment at 24 weeks." data-id="CD001190-fig-0142" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.37</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 37 total number of patients who suffered an adverse event of back pain before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 38 total number of patients who suffered an adverse event of spinal compression fracture before end of treatment at 24 weeks." data-id="CD001190-fig-0143" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.38</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 38 total number of patients who suffered an adverse event of spinal compression fracture before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-004-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-004-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 39 total number of patients who suffered an adverse event of dermatitis contact before end of treatment at 24 weeks." data-id="CD001190-fig-0144" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.39</div> <div class="figure-caption"> <p>Comparison 4 Donepezil (23 mg/day) versus donepezil (10 mg/day), Outcome 39 total number of patients who suffered an adverse event of dermatitis contact before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-004-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Donepezil (15‐20 mg/day) versus donepezil (10 mg/day), Outcome 1 Number who suffered an adverse event before end of treatment at 26 weeks." data-id="CD001190-fig-0145" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Donepezil (15‐20 mg/day) versus donepezil (10 mg/day), Outcome 1 Number who suffered an adverse event before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 1 CMAI (change from baseline) completers." data-id="CD001190-fig-0146" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 1 CMAI (change from baseline) completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 2 NPI (change from baseline) completers." data-id="CD001190-fig-0147" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 2 NPI (change from baseline) completers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 3 NPI caregiver distress (change from baseline)." data-id="CD001190-fig-0148" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 3 NPI caregiver distress (change from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 4 Total number of withdrawals before end of treatment." data-id="CD001190-fig-0149" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 4 Total number of withdrawals before end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 5 Total number of participants who suffered from nausea." data-id="CD001190-fig-0150" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 5 Total number of participants who suffered from nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 6 Total number of participants who suffered from diarrhoea." data-id="CD001190-fig-0151" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 6 Total number of participants who suffered from diarrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 7 Total number of participants who suffered from rash." data-id="CD001190-fig-0152" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 7 Total number of participants who suffered from rash. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 8 Total number of participants who suffered from increased agitation." data-id="CD001190-fig-0153" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 8 Total number of participants who suffered from increased agitation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 9 Total number of participants who suffered from postural hypotension." data-id="CD001190-fig-0154" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 9 Total number of participants who suffered from postural hypotension. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 10 Total number of participants who suffered from a fall." data-id="CD001190-fig-0155" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 10 Total number of participants who suffered from a fall. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 11 Total number of participants who suffered from femoral fracture." data-id="CD001190-fig-0156" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 11 Total number of participants who suffered from femoral fracture. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 12 Total number of participants who suffered from a stroke." data-id="CD001190-fig-0157" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 12 Total number of participants who suffered from a stroke. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 13 Total number of participants who suffered from myocardial infarct." data-id="CD001190-fig-0158" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 13 Total number of participants who suffered from myocardial infarct. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0159"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 14 Total number of participants who suffered from urinary tract infection." data-id="CD001190-fig-0159" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 14 Total number of participants who suffered from urinary tract infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0159">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0160"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 15 Total number of participants who suffered from chest infection." data-id="CD001190-fig-0160" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.15</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 15 Total number of participants who suffered from chest infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0160">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0161"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 16 Total number of participants who suffered from seizure." data-id="CD001190-fig-0161" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.16</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 16 Total number of participants who suffered from seizure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0161">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0162"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-006-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-006-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 17 Total number of deaths." data-id="CD001190-fig-0162" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.17</div> <div class="figure-caption"> <p>Comparison 6 Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation, Outcome 17 Total number of deaths. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0162">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-006-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0163"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 1 ADAS‐Cog (change from baseline at 24 weeks) ITT‐LOCF." data-id="CD001190-fig-0163" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 1 ADAS‐Cog (change from baseline at 24 weeks) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0163">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0164"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 2 MMSE (change from baseline at 24 weeks) ITT‐LOCF." data-id="CD001190-fig-0164" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 2 MMSE (change from baseline at 24 weeks) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0164">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0165"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 3 SIB (change from baseline) at 24 weeks ITT‐LOCF." data-id="CD001190-fig-0165" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 3 SIB (change from baseline) at 24 weeks ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0165">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0166"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 4 ADCS‐ADL‐sev (change from baseline) at 24 weeks ITT‐LOCF." data-id="CD001190-fig-0166" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 4 ADCS‐ADL‐sev (change from baseline) at 24 weeks ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0166">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0167"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 5 CIBIC‐plus (numbers improved) by end of treatment at 26 weeks." data-id="CD001190-fig-0167" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 5 CIBIC‐plus (numbers improved) by end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0167">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0168"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 6 CDR‐SB (change from baseline at 24 weeks) ITT‐LOCF." data-id="CD001190-fig-0168" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 6 CDR‐SB (change from baseline at 24 weeks) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0168">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0169"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 7 BEHAVE‐AD (change from baseline) at 24 weeks ITT‐LOCF." data-id="CD001190-fig-0169" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 7 BEHAVE‐AD (change from baseline) at 24 weeks ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0169">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0170"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 8 QoL (change from baseline at 24 weeks) ITT‐LOCF." data-id="CD001190-fig-0170" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 8 QoL (change from baseline at 24 weeks) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0170">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0171"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 9 Total number of participants who withdrew before end of treatment at 26 weeks." data-id="CD001190-fig-0171" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 9 Total number of participants who withdrew before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0171">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0172"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 10 Total number of participants who withdrew due to an adverse event before end of treatment at 26 weeks." data-id="CD001190-fig-0172" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 10 Total number of participants who withdrew due to an adverse event before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0172">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0173"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 11 Total number of participants who suffered an adverse event before end of treatment at 26 weeks." data-id="CD001190-fig-0173" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.11</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 11 Total number of participants who suffered an adverse event before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0173">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0174"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 12 Total number of participants who suffered an adverse event of anorexia before end of treatment at 26 weeks." data-id="CD001190-fig-0174" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.12</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 12 Total number of participants who suffered an adverse event of anorexia before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0174">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0175"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 13 Total number of participants who suffered an adverse event of confusion before end of treatment at 26 weeks." data-id="CD001190-fig-0175" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.13</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 13 Total number of participants who suffered an adverse event of confusion before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0175">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0176"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 14 Total number of participants who suffered an adverse event of diarrhoea before end of treatment at 26 weeks." data-id="CD001190-fig-0176" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.14</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 14 Total number of participants who suffered an adverse event of diarrhoea before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0176">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0177"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 15 Total number of participants who suffered an adverse event of dizziness before end of treatment at 26 weeks." data-id="CD001190-fig-0177" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.15</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 15 Total number of participants who suffered an adverse event of dizziness before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0177">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0178"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 16 Total number of participants who suffered an adverse event of fatigue before end of treatment at 26 weeks." data-id="CD001190-fig-0178" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.16</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 16 Total number of participants who suffered an adverse event of fatigue before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0178">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0179"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 17 Total number of participants who suffered an adverse event of headache before end of treatment at 26 weeks." data-id="CD001190-fig-0179" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.17</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 17 Total number of participants who suffered an adverse event of headache before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0179">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0180"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 18 Total number of participants who suffered an adverse event of insomnia before end of treatment at 26 weeks." data-id="CD001190-fig-0180" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.18</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 18 Total number of participants who suffered an adverse event of insomnia before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0180">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0181"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 19 Total number of participants who suffered an adverse event of muscle cramp before end of treatment at 26 weeks." data-id="CD001190-fig-0181" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.19</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 19 Total number of participants who suffered an adverse event of muscle cramp before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0181">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0182"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 20 Total number of participants who suffered an adverse event of nausea before end of treatment at 26 weeks." data-id="CD001190-fig-0182" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.20</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 20 Total number of participants who suffered an adverse event of nausea before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0182">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0183"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 21 Total number of participants who suffered an adverse event of rhinitis before end of treatment at 26 weeks." data-id="CD001190-fig-0183" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.21</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 21 Total number of participants who suffered an adverse event of rhinitis before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0183">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0184"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 22 Total number of participants who suffered an adverse event of vomiting before end of treatment at 26 weeks." data-id="CD001190-fig-0184" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.22</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 22 Total number of participants who suffered an adverse event of vomiting before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0184">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0185"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 23 Total number of participants who suffered an adverse event of cold syndrome before end of treatment at 26 weeks." data-id="CD001190-fig-0185" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.23</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 23 Total number of participants who suffered an adverse event of cold syndrome before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0185">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0186"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 24 Total number of participants who suffered an adverse event of accidental fall before end of treatment at 26 weeks." data-id="CD001190-fig-0186" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.24</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 24 Total number of participants who suffered an adverse event of accidental fall before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0186">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0187"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 25 Total number of participants who suffered an adverse event of respiratory tract infection before end of treatment at 26 weeks." data-id="CD001190-fig-0187" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.25</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 25 Total number of participants who suffered an adverse event of respiratory tract infection before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0187">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0188"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 26 Total number of participants who suffered an adverse event of constipation before end of treatment at 26 weeks." data-id="CD001190-fig-0188" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.26</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 26 Total number of participants who suffered an adverse event of constipation before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0188">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0189"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 27 Total number of participants who suffered an adverse event of fever before end of treatment at 26 weeks." data-id="CD001190-fig-0189" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.27</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 27 Total number of participants who suffered an adverse event of fever before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0189">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0190"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 28 Total number of participants who suffered an adverse event of loss of appetite before end of treatment at 26 weeks." data-id="CD001190-fig-0190" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.28</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 28 Total number of participants who suffered an adverse event of loss of appetite before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0190">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0191"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 29 Total number of participants who suffered an adverse event of bruising before end of treatment at 26 weeks." data-id="CD001190-fig-0191" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.29</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 29 Total number of participants who suffered an adverse event of bruising before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0191">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0192"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-007-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-007-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 30 Total number of participants who suffered an adverse event of restlessness before end of treatment at 26 weeks." data-id="CD001190-fig-0192" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.30</div> <div class="figure-caption"> <p>Comparison 7 Donepezil (10 mg/day) versus donepezil (5 mg/day), Outcome 30 Total number of participants who suffered an adverse event of restlessness before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0192">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-007-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0193"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 1 MMSE (change from baseline) ITT‐LOCF." data-id="CD001190-fig-0193" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 1 MMSE (change from baseline) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0193">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0194"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 2 SIB (change from baseline) ITT‐LOCF." data-id="CD001190-fig-0194" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 2 SIB (change from baseline) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0194">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0195"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 3 CIBIC‐Plus or CGIC (numbers improved) ITT‐LOCF." data-id="CD001190-fig-0195" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 3 CIBIC‐Plus or CGIC (numbers improved) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0195">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0196"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 4 ADCS‐ADL‐severe (change from baseline) ITT‐LOCF." data-id="CD001190-fig-0196" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 4 ADCS‐ADL‐severe (change from baseline) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0196">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0197"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 5 BEHAVE‐AD (change from baseline) ITT‐LOCF." data-id="CD001190-fig-0197" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 5 BEHAVE‐AD (change from baseline) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0197">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0198"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 6 Behavioural disturbance (total NPI ) (change from baseline) ITT‐LOCF." data-id="CD001190-fig-0198" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 6 Behavioural disturbance (total NPI ) (change from baseline) ITT‐LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0198">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0199"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 7 Time (mins/day) spent by carer assisting in IADL and PSMS (change from baseline) LOCF." data-id="CD001190-fig-0199" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 7 Time (mins/day) spent by carer assisting in IADL and PSMS (change from baseline) LOCF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0199">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0200"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 8 Total number of withdrawals before end of treatment." data-id="CD001190-fig-0200" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 8 Total number of withdrawals before end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0200">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0201"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 9 Total number of participants who withdrew due to an adverse event." data-id="CD001190-fig-0201" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 9 Total number of participants who withdrew due to an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0201">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0202"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 10 Total number of participants who suffered from at least one adverse event." data-id="CD001190-fig-0202" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 10 Total number of participants who suffered from at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0202">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0203"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 11 Total number of participants who suffered from abdominal pain." data-id="CD001190-fig-0203" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.11</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 11 Total number of participants who suffered from abdominal pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0203">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0204"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 12 Total number of participants who suffered from accidental fall." data-id="CD001190-fig-0204" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.12</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 12 Total number of participants who suffered from accidental fall. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0204">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0205"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 13 Total number of participants who suffered from accidental injury." data-id="CD001190-fig-0205" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.13</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 13 Total number of participants who suffered from accidental injury. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0205">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0206"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 14 Total number of participants who suffered from anorexia." data-id="CD001190-fig-0206" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.14</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 14 Total number of participants who suffered from anorexia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0206">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0207"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 15 Total number of participants who suffered from anxiety." data-id="CD001190-fig-0207" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.15</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 15 Total number of participants who suffered from anxiety. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0207">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0208"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 16 Total number of participants who suffered from arthralgia." data-id="CD001190-fig-0208" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.16</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 16 Total number of participants who suffered from arthralgia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0208">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0209"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 17 Total number of participants who suffered from asthenia." data-id="CD001190-fig-0209" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.17</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 17 Total number of participants who suffered from asthenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0209">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0210"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 18 Total number of participants who suffered from back pain." data-id="CD001190-fig-0210" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.18</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 18 Total number of participants who suffered from back pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0210">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0211"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 19 Total number of participants who suffered from cold syndrome." data-id="CD001190-fig-0211" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.19</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 19 Total number of participants who suffered from cold syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0211">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0212"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 20 Total number of participants who suffered from confusion." data-id="CD001190-fig-0212" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.20</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 20 Total number of participants who suffered from confusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0212">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0213"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 21 Total number of participants who suffered from constipation." data-id="CD001190-fig-0213" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.21</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 21 Total number of participants who suffered from constipation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0213">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0214"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 22 Total number of participants who suffered from contusion." data-id="CD001190-fig-0214" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.22</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 22 Total number of participants who suffered from contusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0214">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0215"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 23 Total number of participants who suffered from cystitis." data-id="CD001190-fig-0215" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.23</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 23 Total number of participants who suffered from cystitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0215">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0216"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 24 Total number of participants who suffered from depression." data-id="CD001190-fig-0216" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.24</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 24 Total number of participants who suffered from depression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0216">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0217"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 25 Total number of participants who suffered from diarrhoea." data-id="CD001190-fig-0217" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.25</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 25 Total number of participants who suffered from diarrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0217">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0218"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 26 Total number of participants who suffered from dizziness." data-id="CD001190-fig-0218" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.26</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 26 Total number of participants who suffered from dizziness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0218">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0219"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 27 Total number of participants who suffered from fever." data-id="CD001190-fig-0219" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.27</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 27 Total number of participants who suffered from fever. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0219">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0220"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 28 Total number of participants who suffered from fracture." data-id="CD001190-fig-0220" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.28</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 28 Total number of participants who suffered from fracture. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0220">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0221"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 29 Total number of participants who suffered from gastroenteritis." data-id="CD001190-fig-0221" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.29</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 29 Total number of participants who suffered from gastroenteritis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0221">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0222"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 30 Total number of participants who suffered from hallucinations." data-id="CD001190-fig-0222" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.30</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 30 Total number of participants who suffered from hallucinations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0222">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0223"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 31 Total number of participants who suffered from pneumonia." data-id="CD001190-fig-0223" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.31</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 31 Total number of participants who suffered from pneumonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0223">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0224"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 32 Total number of participants who suffered from hostility." data-id="CD001190-fig-0224" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.32</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 32 Total number of participants who suffered from hostility. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0224">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0225"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 33 Total number of participants who suffered from insomnia." data-id="CD001190-fig-0225" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.33</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 33 Total number of participants who suffered from insomnia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0225">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0226"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 34 Total number of participants who suffered from loss of appetite." data-id="CD001190-fig-0226" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.34</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 34 Total number of participants who suffered from loss of appetite. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0226">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0227"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 35 Total number of participants who suffered from nausea." data-id="CD001190-fig-0227" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.35</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 35 Total number of participants who suffered from nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0227">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0228"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 36 Total number of participants who suffered from restlessness." data-id="CD001190-fig-0228" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.36</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 36 Total number of participants who suffered from restlessness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0228">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0229"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 37 Total number of participants who suffered from headache." data-id="CD001190-fig-0229" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.37</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 37 Total number of participants who suffered from headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0229">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0230"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 38 Total number of participants who suffered from respiratory tract infection." data-id="CD001190-fig-0230" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.38</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 38 Total number of participants who suffered from respiratory tract infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0230">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0231"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 39 Total number of participants who suffered from vomiting." data-id="CD001190-fig-0231" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.39</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 39 Total number of participants who suffered from vomiting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0231">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0232"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 40 Total number of participants who suffered from urinary incontinence." data-id="CD001190-fig-0232" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.40</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 40 Total number of participants who suffered from urinary incontinence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0232">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0233"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 41 Total number of participants who suffered from urinary tract infection." data-id="CD001190-fig-0233" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.41</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 41 Total number of participants who suffered from urinary tract infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0233">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0234"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 42 Total number of participants who suffered from weight loss." data-id="CD001190-fig-0234" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.42</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 42 Total number of participants who suffered from weight loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0234">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0235"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 43 Total number of deaths before end of treatment." data-id="CD001190-fig-0235" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.43</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 43 Total number of deaths before end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0235">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001190-fig-0236"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/urn:x-wiley:14651858:media:CD001190:CD001190-CMP-008-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_t/tCD001190-CMP-008-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 44 Total number of participants who suffered from at least one serious adverse event." data-id="CD001190-fig-0236" src="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.44</div> <div class="figure-caption"> <p>Comparison 8 Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia, Outcome 44 Total number of participants who suffered from at least one serious adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-fig-0236">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/media/CDSR/CD001190/image_n/nCD001190-CMP-008-44.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001190-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Donepezil 10 mg/day compared with placebo for dementia due to Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Donepezil 10 mg/day compared with placebo for dementia due to Alzheimer's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with Alzheimer's disease </p> <p><b>Settings:</b> worldwide </p> <p><b>Intervention:</b> donepezil 10 mg/day for 24 to 26 weeks </p> <p><b>Comparison:</b> placebo for 24 to 26 weeks </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Donepezil 10 mg/day</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 26 weeks using ADAS‐Cog)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil group was 2.67 lower (3.31 to 2.02 lower) than in the placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1130<br/> (5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADAS‐Cog score has a maximum of 70 points, the lower score in the donepezil group indicates greater improvement </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 26 weeks using MMSE)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil group was 1.05 higher (0.73 to 1.37 higher) than in the placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1757<br/> (7 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE has a maximum score of 30 points, a lower score indicates greater impairment. Treatment effect was in favour of donepezil. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Activities of daily living</b> (change from baseline at 26 weeks measured using the ADCS)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention group was<br/> 1.03 higher (0.21 to 1.85 higher) than in the placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>733<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher score indicates greater improvement.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinician‐rated global impression tests</b> </p> <p>(improved compared with baseline, measured using CIBIC‐plus at 24‐26 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>331 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>487 per 1000 (432 to 542)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.92</b> (1.54 to 2.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1674<br/> (6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behavioural symptoms</b> </p> <p>(change from baseline at 26 weeks measured using the NPI)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean score in the intervention group was 1.62 lower ( 3.43 lower to 0.19 higher) than in the placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1035</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A lower score indicates greater improvement. There was no significant difference between the 2 groups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment</b> </p> <p>(as measured by withdrawals from trial before end of treatment at 26 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>248 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>291 per 1000 (256 to 331)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.25</b> (1.05 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2846</p> <p>(12 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals were significantly more frequent in the donepezil group compared with placebo group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incidence of adverse events</b> </p> <p>(at least one adverse event by 26 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>780 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>849 per 1000 (822 to 874)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.59</b> (1.31 to 1.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2500 (10 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were significantly more frequent in the donepezil group compared with placebo group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life of participants</b> </p> <p>(change from baseline at 26 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean score was 2.79 lower (8.15 lower to 2.56 higher) than in the placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>815 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A higher svcore indicates greater improvement.There was no significant difference between the 2 groups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The <b>assumed risk is the weighted average across studies</b> . The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ADAS‐Cog</b> : Alzheimer's Disease Assessment Scale‐Cognitive; <b>ADCS</b> : Alzheimer's Disease Cooperative Study; <b>CI:</b> confidence interval; <b>CIBIC</b> : Clinician's Interview‐Based Impression of Change; <b>MMSE</b> : Mini‐Mental State Examination; <b>NPI</b> : Neuropsychiatric Inventory; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>All statistics are based on the analyses of the intention to treat last observation carried forward (ITT‐LOCF) population. Although using the ITT population in the analyses for studies in degenerative conditions can be criticised as substitution of the LOCF when a patients is lost before end point may enhance the outcome, in this review the results of the analyses of the population who completed the study were similar to the ITT results and did not alter our conclusions.<br/> <sup>2</sup>Downgraded one level due to the risk of bias due to lack of information on allocation concealment and on the blinding of outcome assessment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Donepezil 10 mg/day compared with placebo for dementia due to Alzheimer's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001190-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Donepezil 23 mg/day compared with donepezil 10 mg/day for dementia due to Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Donepezil 23 mg/day compared with donepezil 10 mg/day for dementia due to Alzheimer's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with Alzheimer's disease </p> <p><b>Settings:</b> worldwide </p> <p><b>Intervention:</b> donepezil 23 mg/day for 24 weeks </p> <p><b>Comparison:</b> donepezil 10 mg/day for 24 weeks </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Donepezil 10 mg/day</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Donepezil 23 mg/day</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 24 weeks using SIB)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil 23 mg/day group was 1.05 higher (0.15 lower to 2.25 higher) than in the donepezil 10 mg/day group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1704</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SIB has a maximum score of 100 points, a lower score indicates greater impairment.There was no significant difference between the 2 groups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 24 weeks using MMSE)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil 23 mg/day group was 0.20 higher (0.33 lower to 0.73 higher) than in the donepezil 10 mg/day group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1370</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE has a maximum score of 30 points, a lower score indicates greater impairment. There was no significant difference between the 2 groups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Activities of daily living</b> </p> <p>(change from baseline at 24 weeks using the ADCS‐ADL‐sev)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil 23 mg/day group was 0 higher (1.18 lower to 1.18 higher) than in the donepezil 10 mg/day group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1396</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between the 2 groups</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinician‐rated global impression test</b> </p> <p>(improved compared with baseline assessed using CIBIC‐plus at 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>212 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>210 per 1000</b><br/> (173 to 253) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.99</b> (0.78 to 1.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1704<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between the 2 groups</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment</b> </p> <p>(as measured by withdrawals from trial before end of treatment at 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>172 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b><br/> (248 to 348) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.02</b> (1.59 to 2.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1818<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of adverse events</b> </p> <p>(at least one adverse event by 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>624 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>732 per 1000</b><br/> (690 to 771) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.65</b> (1.34 to 2.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1785<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ADCS‐ADL‐sev</b> : Alzheimer's Disease Cooperative Study‐Activities of Daily Living Scale (severe version); <b>CI:</b> confidence interval; <b>CIBIC</b> : Clinician's Interview‐Based Impression of Change; <b>MMSE</b> : Mini‐Mental State Examination; <b>OR:</b> odds ratio; <b>SIB</b>: Severe Impairment Battery </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>All statistics are based on the analyses of the intention to treat last observation carried forward (ITT‐LOCF) population. Although using the ITT population in the analyses for studies in degenerative conditions can be criticised as substitution of the LOCF when a patients is lost before end point may enhance the outcome, in this review the results of the analyses of the population who completed the study were similar to the ITT results and did not alter our conclusions.<br/> <sup>2</sup>Downgraded one level due to the risk of bias due to lack of information on the blinding of outcome assessment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Donepezil 23 mg/day compared with donepezil 10 mg/day for dementia due to Alzheimer's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001190-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Donepezil 10 mg/day compared with donepezil 5 mg/day for dementia due to Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Donepezil 10 mg/day compared with donepezil 5 mg/day for dementia due to Alzheimer's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with Alzheimer's disease </p> <p><b>Settings</b>: worldwide </p> <p><b>Intervention</b>: donepezil 10 mg/day </p> <p><b>Comparison:</b> *donepezil 5 mg/day </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Donepezil 5 mg/day</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Donepezil 10 mg/day</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 24 weeks using ADAS‐Cog)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil 10 mg/day group was 1.05 lower (1.80 lower to 0.30 lower) than in the donepezil 5 mg/day group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>818<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADAS‐Cog score has a maximum of 70 points, the lower score in the donepezil 10 mg/day group indicates greater improvement </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 24 weeks using MMSE)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil 10 mg/day group was 0.15 higher (‐0.55 to 0.85 higher) than in the donepezil 5 mg/day group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE has a maximum score of 30 points, a lower score indicates greater impairment.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinician‐rated global impression test</b> </p> <p>(improved compared with baseline assessed using CIBIC‐plus at 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>246 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>291 per 1000</b><br/> (235 to 353) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.26</b> (0.94 to 1.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>981 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment</b> </p> <p>(as measured by withdrawals from trial before end of treatment at 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>183 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>272 per 1000</b><br/> (217 to 333) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.67</b> (1.24 to 2.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1052</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of adverse events</b> </p> <p>(at least one adverse event by 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>785per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>851 per 1000</b><br/> (796 to 893) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.56</b> (1.07 to 2.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>741 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ADAS‐Cog</b> : Alzheimer's Disease Assessment Scale‐Cognitive; <b>CI:</b> confidence interval; <b>CIBIC</b> : Clinician's Interview‐Based Impression of Change; <b>MMSE</b> : Mini‐Mental State Examination; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>All statistics are based on the analyses of the intention to treat last observation carried forward (ITT‐LOCF) population. Although using the ITT population in the analyses for studies in degenerative conditions can be criticised as substitution of the LOCF when a patients is lost before end point may enhance the outcome, in this review the results of the analyses of the population who completed the study were similar to the ITT results and did not alter our conclusions.<br/> <sup>2</sup>Downgraded one level due to the risk of bias due to lack of information on the blinding of outcome assessment and of blinding of participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Donepezil 10 mg/day compared with donepezil 5 mg/day for dementia due to Alzheimer's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001190-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Donepezil 10 mg/day compared with placebo for people with severe dementia due to Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Donepezil 10 mg/day compared with placebo for people with severe dementia due to Alzheimer's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with severe Alzheimer's disease </p> <p><b>Settings</b>: worldwide </p> <p><b>Intervention:</b> donepezil 10 mg/day for 24 weeks </p> <p><b>Comparison</b>: placebo for 24 weeks </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Donepezil 10 mg/day</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 26 weeks using MMSE)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil group was 0.97 higher (0.56 higher to 1.38 higher) than in the placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1102<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE has a maximum score of 30 points, a lower score indicates greater impairment. Treatment effect was in favour of donepezil. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 24 weeks using SIB)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil 10 mg/day group was 5.92 higher (4.53 higher to 7.31 higher) than in the placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1348</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SIB has a maximum score of 100 points, a lower score indicates greater impairment.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinician‐rated global impression tests</b> </p> <p>(improved compared with baseline, measured using CIBIC‐Plus at 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>274 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>402 per 1000</b><br/> (331 to 478) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.78 (1.31 to 2.43)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>755 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Activities of daily living</b> </p> <p>(change from baseline at 24 weeks using the ADCS‐ADL‐sev)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the donepezil 10 mg/day group was 1.03 higher 0.21 higher to 1.85 higher) than in the placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>733<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher score indicates greater improvement.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment</b> </p> <p>(as measured by withdrawals from trial before end of treatment at 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>187 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>233 per 1000</b><br/> (190 to 282) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.32</b> (1.02 to 1.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1396</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals significantly more frequent in the donepezil group compared with placebo group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of adverse events</b> </p> <p>(at least one adverse event by 24 weeks)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>616 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>718 per 1000</b><br/> (664 to 767) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.59</b> (1.23 to 2.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1396</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events significantly more frequent in the donepezil group compared with placebo group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ADCS‐ADL‐sev</b> : Alzheimer's Disease Cooperative Study‐Activities of Daily Living Scale (severe version); <b>CI:</b> confidence interval; <b>CIBIC</b> : Clinician's Interview‐Based Impression of Change; <b>MMSE</b> : Mini‐Mental State Examination; <b>OR:</b> odds ratio; <b>SIB</b>: Severe Impairment Battery </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>All statistics are based on the analyses of the intention to treat last observation carried forward (ITT‐LOCF) population. Although using the ITT population in the analyses for studies in degenerative conditions can be criticised as substitution of the LOCF when a patients is lost before end point may enhance the outcome, in this review the results of the analyses of the population who completed the study were similar to the ITT results and did not alter our conclusions.<br/> <sup>2</sup> Downgraded one level due to the risk of bias due to lack of information on allocation concealment and on the blinding of outcome assessment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Donepezil 10 mg/day compared with placebo for people with severe dementia due to Alzheimer's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001190-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of included studies at baseline</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration (weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age<br/> (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% female</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean MMSE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose mg/day donepezil</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Phase</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0007" title="HommaA , ImaiY , HariguchiS , HasegawaK , KameyamaM , NishimuraT . Late phase II clinical study of acetyl cholinesterase inhibitor E2020 in patients with Alzheimer‐type dementia. Clinical Evaluation1998;26(2):251‐84. ">Homma 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3, 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0008" title="HommaA , TakedaM , ImaiY , UdakaF , HasegawaK , KameyamaM , et al. E2020 Study Group. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24‐week, multicenter, double‐blind, placebo‐controlled study in Japan. Dementia and Geriatric Cognitive Disorders2000; Vol. 11, issue 6:299‐313. ">Homma 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0020" title="FriedhoffLT , IeniJR , RogersSL , PrattRD . Donepezil provides long‐term clinical benefits for patients with Alzheimer's Disease. Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum;1998 July 12‐16, Glasgow, Scotland1998:ABSTRACT REF: PW11017. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Correlation between the clinical efficacy of donepezil HCL (E2020) and red blood cell (RBC) acetylcholinesterase (ACHE) inhibition in patients with Alzheimer's disease. Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5‐8, San Diego. UK: Medical Education Network, 1997; Vol. 2:6‐7. RogersS , PerdomoC , FriedhoffL . Clinical benefits are maintained during long‐term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 September 30‐October 4, Venice1995a. [MEDLINE: SR‐HANDSRCH] RogersSL , DoodyRS , PrattRD , IeniJR . Long‐term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open‐label study. European Neuropsychopharmacology2000; Vol. 10, issue 3:195‐203. RogersSL , FriedhoffLT . E2020 improves cognition and quality of life in patients with mild to moderate Alzheimers Disease: results of a phase II trial. Proceedings of the 46th Annual meeting of the American Academy of Neurology. 1994 May 1‐7, Washington DC1994; Vol. 44, issue Suppl 2:A165. RogersSL , Friedhoff LT and the Donepezil Study Group. The Efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double‐blind, placebo‐controlled trial. Dementia1996;7:293‐303. ">Rogers 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1, 3, 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0028" title="TuneL , TiseoP , HoffmanJ , PerdomoC , VotawJ , RogersS , et al. PET in AD: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer's disease: results of a 24‐week study. 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 February 23‐26 San Francisco. 2001. TuneL , TiseoPJ , IeniJ , PerdomoC , PrattRD , VotawJR , et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24‐week, double‐blind, placebo‐controlled study. American Journal of Geriatric Psychiatry2003;11(2):169‐77. TuneLE , TiseoPJ , HoffmanJM , PerdomoCA , VotowJR , RogersSL , et al. Functional brain activity in Alzheimer's disease. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐ June 4, Toronto. 1998:NR345. [MEDLINE: SR‐HANDSRCH] ">Tune 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0013" title="Anon . No title. Eisai Inc. KrishnanKR , CharlesHC , DoraiswamyPM , MintzerJ , WeislerR , YuX , et al. Randomized, placebo‐controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. The American Journal of Psychiatry2003;160(11):2003‐11. ">Krishnan 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0025" title="Anon . No title. Eisai Inc. ">Study 205</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0021" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. PrattRD , PerdomoCA , IeniJK . Long‐term safety and tolerability of donepezil: results from a phase iii extension trial of patients with mild to moderately severe Alzheimer's disease. European Journal of Neurology1999;6(Suppl 3):116. [MEDLINE: SR‐HANDSRCH] RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyRS , MohsRC , FriedhoffLT , the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine1998;158:1021‐31. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego. 1997. ">Rogers 1998a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5, 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0022" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. Erratum: a 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613‐620)). Neurology2001; Vol. 57, issue 11:2153. FriedhoffLT , RogersL . Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease ‐ results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston. Neurology1997;48(3):A100. FriedhoffLT , RogersSL . Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17, Vienna, Austria1997. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis. European Journal of Neurology1997;4(Suppl 1):S9. RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyR , MohsR , FriedhoffLT . E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30‐week phase III trial. Neurology1996;46:A217 S14.001 ARI‐8. RogersSL , DoodyR , MohsR , FriedhoffT , Donepezil Study Group. E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30‐week trial. Unpublished paper1996b. RogersSL , FarlowMR , DoodyRS , MohsR , FriedhoffLT , Donepezil Study Group. A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998;50(1):136‐45. RogersSL , FriedhoffLT , FarlowMR , DoodyRS , MohsR . Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply]. Neurology1999; Vol. 52, issue 1:218‐19. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego1997. ">Rogers 1998b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5, 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0003" title="BayerAJ , RossorM , HeckerJ , GauthierS , BurnsA , PetiteH , et al. International Donepezil Study Group. Donepezil improves functional activity in patients with Alzheimer's disease. 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12‐16, Glasgow, Scotland. 1998. [MEDLINE: SR‐HANDSRCH] BurnsA , GauthierS , PerdomoC . Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(8):806‐12. BurnsA , RossorM , HeckerJ , GauthierS , PetitH , MöllerH‐J , et al. International Donepezil Study Group. The effects of donepezil in Alzheimer's disease ‐ results from a multinational trial. Dementia and Geriatric Cognitive Disorders1999;10(3):237‐44. GauthierS , RosserM , HeckerJ , PetiteH , RogersS , MohrE , et al. Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐June 4, Toronto, Canada1998. [MEDLINE: SR‐HANDSRCH] GauthierS , RossorM , HeckerJ . Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 15‐18 1998. PrattRD , GauthierS , BurnsA , PerdomoCA . Donepezil provides long‐term clinical benefits for patients with Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington. 2000. ">Burns 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5, 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0026" title="Anon . No title. Eisai Inc. ">Study 306</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0027" title="SteinmanMA , CovinskyKE , TariotPN , CummingsJL , KatzIR , MintzerJ , et al. Donepezil for nursing home patients with dementia: a reinterpretation of the evidence. Journal of the American Geriatrics Society2003;51(1):132‐33. TariotP , CummingsJL , KatzIR , PerdomoCA , WhalenE , SovelMA , et al. Donepezil was well‐tolerated and enhanced cognition in nursing home patients with Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. TariotP , PerdomoCA , WhalenE , SovelMA , SchamEM . Age is not a barrier to donepezil treatment of Alzheimer's disease in the long‐term care setting. International Psychogeriatrics1999;11(Supplement 1):134. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomised, double‐blind, placebo‐controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2003;51(1):133‐4. ">Tariot 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0017" title="EbellM . Does donepezil help patients with moderate Alzheimer's dementia preserve their ability to function independently?. Evidence Based Practice2002. MohsR , DoodyR , MorrisJ , IeniJ , PerdomoC , PrattR , et al. Donepezil preserves activities of daily living in Alzheimer's disease patients: results from a one‐year placebo‐controlled functional survival study. Neurology2000;54(Suppl 3):A415. MohsR , DoodyR , MorrisJ , IeniJ , RogersS , PerdomoC , et al. Donepezil preserves functional status and improves cognition in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Journal of the American Geriatrics Society2000;48(8):S46. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled attrition study. Journal of the European College of Neuropsychopharmacology1999;9(Suppl 5):S328. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Quality Research in Dementia Conference; 2000 November 19‐22, London. 2000. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoC , et al. 312 Study Group. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients [Erratum]. Neurology2001; Vol. 57, issue 10:1942. [MEDLINE: http://www.lww.com] MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients. Neurology2001;57(3):481‐8. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illinois. 2000. [MEDLINE: SR‐HANDSRCH] PrattR , MohsR , DoodyR , MorrisJ , RogersS , IeniJ , et al. Donepezil preserves functional status in Alzheimer's disease patients results from a 1‐year prospective placebo controlled functional study. Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden2000:178. ">Mohs 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0002" title="BlackS , LiHL , McRaeT , RichardsonS . Treatment of severe Alzheimer's disease with donepezil: results from a 24‐week, multinational, randomized, double‐blind, placebo‐controlled trial. Neurology2006;66(5):A347. BlackS , LiHonglang , McRaeT , RichardsonS . Donepezil treatment of severe Alzheimer's disease: results from a 24‐week, multinational, randomized, double‐blind, placebo controlled trial. Poster Presented at the Geneva Springfield ConferenceApril 2006. BlackSE , DoodyR , LiH , McRaeT , JamborKM , XuY , et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology2007;69(5):459‐69. Pfizer . E2020‐A001‐315: a 24 week multinational RCT evaluating the efficacy and safety of donepezil in severe AD. www.marc.soton.ac.uk/Research%20Page.htm. RichardsonS . A 24 week, multicenter, randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of donepezil hydrochloride (E2020) in patients with severe Alzheimer's disease followed by a 12 week open‐label extension period. www.clinicaltrials.gov/ct/show/NCT000964732004. ">Black 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia, Canada, France, UK, USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0024" title="SeltzerB , ZolnouniP , NunezM , GoldmanR , KumarD , IeniJ , et al. Erratum: efficacy of donepezil in early‐stage alzheimer disease: a randomized placebo‐controlled trial (Archives of Neurology (December 2004) 61 (1852‐1856)). Archives of Neurology2005;62(5):825. SeltzerB , ZolnouniP , NunezM , GoldmanR , KumarD , IeniJ , et al. Donepezil 402 Study Group. Efficacy of donepezil in early‐stage Alzheimer disease. Archives of Neurolology2004;61:1852‐6. ">Seltzer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0001" title="AD2000 Collaborative Group. Long‐term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double‐blind trial. Lancet2004;363:2105‐15. BenthamP , GrayR , HillR , SellwoodE , CourtneyC . Twelve week response to cholinesterase inhibitors dose not predict future benefit the AD2000 trial experience. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:337. LendonCL . Determination of responses to anticholinesterase therapy in the treatment of Alzheimer's disease. 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden: Abstract No 1287. 2002. RobertsN . A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease (AD2000). National Research Register2001. SchneiderLS . AD2000: donepezil in Alzheimer's disease. Lancet2004;363(9427):2100‐1. WaghrayS . AD2000 A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease. National Research Register2000. [MEDLINE: http://www.doh.gov.uk/nrr.htm] ">AD2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5, 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0014" title="RobertP , LebertF , GoniS , TouchonJ , VincentS , ARIAL Study Investigators Collaborative Group. The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. Quality Research in Dementia; 19‐22 November, 2000, London. 2000. RobertPH , LebertF , GoniS , TouchonJ , ARIAL Study Investigators Collaborative Group. The impact of caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">Lebert 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0004" title="CummingsJL , GeldmacherD , FarlowM , SabbaghM , ChristensenD , BetzP . High‐dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. CNS Neuroscience &amp; Therapeutics2013;19(5):294‐301. DoodyRS , GeldmacherDS , FarlowMR , SunY , MolineM , MackellJ . Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate‐to‐severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dementia and Geriatric Cognitive Disorders2012;33(2‐3):164‐73. DoodyRS , RamosH , FaisonW , ZouH . Efficacy and safety of donepezil 23 mg/d vs. donepezil 10 mg/d in patients with moderate to severe Alzheimer's disease: impact of concomitant memantine use. Journal of the American Geriatrics Society 2011 Annual Scientific meeting of the American Geriatrics Society, National Harbor, MD, USA2011. FarlowM , RichardsonS , MackellJ , SunY . Long‐term safety and tolerability of donepezil 23 MG in patients with moderate‐to‐severe Alzheimer's disease: an 18‐month analysis. Alzheimer's and Dementia 2011 Alzheimer's Association International Conference, Paris, France. 2011. FarlowM , VelosoF , MolineM , YardleyJ , Brand‐SchieberE , BibbianiF , et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurology2011;11:57. FarlowMR , SallowayS , TariotPN , YardleyJ , MolineML , WangQ , et al. Effectiveness and tolerability of high‐dose (23 mg/d) versus standard‐dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24‐week, randomized, double‐blind study. Clinical Therapeutics2010;32(7):1234‐51. FerrisS , CummingsJ , ChristensenD , DoodyR , FarlowM , SabbaghM , et al. Donepezil 23 MG/D for moderate to severe Alzheimer's disease: assessing subdomains of the Severe Impairment Battery. Journal of Nutrition, Health and Aging 5th Conference Clinical Trials on Alzheimer's Disease, Monte Carlo, Monaco. 2012. FerrisS , CummingsJ , ChristensenD , DoodyR , FarlowM , SabbaghM , et al. Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimer's Research &amp; Therapy2013;5:12. FerrisS , MacKellJ , BaiZ , SunY . Effect of donepezil 23 mg/day on language function in patients with moderate‐to‐severe Alzheimer's disease (AD): subgroup analysis of united states (U.S.)‐based patients. Alzheimer's Association International Conference 2012 Vancouver, BC Canada. 2012. FerrisSH , SchmittFA , SaxtonJ , RichardsonS , MackellJ , SunY , et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimer's Research &amp; Therapy2011;3(3):22. HanS‐H , LeeJ‐H , KimSY , ParkKW , ChenC , TripathiM , et al. Donepezil 23 mg in Asian patients with moderate‐to‐severe Alzheimer's disease. Acta Neurologica Scandinavica2017;135(2):252‐56. SabbaghM , CummingsJ , ChristensenD , DoodyR , FarlowM , LiuL , et al. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatrics2013;13:56. SabbaghM , CummingsJ , ChristensenD , DoodyR , FarlowM , MacKellJ , et al. Evaluating the cognitive effects of donepezil 23 MG/D in moderate and severe Alzheimer's disease: a patient subgroup analysis. Journal of Nutrition, Health and Aging 5th Conference Clinical Trials on Alzheimer's Disease, Monte Carlo, Monaco. 2012. SabbaghM , HanS , KimS , NaH‐R , LeeJ‐H , KandiahN , et al. Clinical recommendations for the use of donepezil 23 mg in moderate‐to‐severe Alzheimer's disease in the Asia‐Pacific region. Dementia and Geriatric Cognitive Disorders Extra2016;6:382‐95. TariotP , SallowayS , YardleyJ , MackellJ , MolineM . Long‐term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease. BMC Research Notes2012;5:283. TariotP , YardleyJ , MolineM , Brand‐SchieberE , ZouH , TimothyH , et al. Long‐term safety and tolerability of high dose donepezil (23 mg/day) in moderate to severe Alzheimer's disease: a 12‐month open‐label study. Neuropsychopharmacology 49th Annual Conference of the American College of Neuropsychopharmacology, Miami Beach, FL, USA. 2010. ">Farlow 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10, 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia, Canada, France</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0006" title="HegerlU , MerglR , HenkelV , GallinatJ , KotterG , Muller SiechenederF , et al. Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia. Journal of Clinical Psychopharmacology2003;23(2):214‐6. ">Hegerl 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germany</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0009" title="HommaA , ArimotoI , KaidojiK , OhbayashiT , OzawaH . Treatment of severe Alzheimer's disease with donepezil: results from a 24 week, parallel, placebo‐controlled study in Japan. 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, July 2006. 2006. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24‐week, double‐blind, placebo‐controlled, randomized trial. Geriatric Cognitive Disorders2008;25(5):399‐407. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Long‐term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52‐week, open‐label, multicenter, extension study in Japan. Dementia and Geritatric Congitive Disorders2009;27(3):232‐9. ">Homma 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5, 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0010" title="HommaA , AtarashiH , KubotaN , NakaiK , TakaseT . Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in Japanese patients with severe Alzheimer's disease: a randomized, double‐blind trial. Journal of Alzheimer's disease2016;52(1):345‐57. ">Homma 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10, 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0012" title="JiaJP , WeiCB , JiaLF , TangY , LiangJH , ZhouAH , et al. Efficacy and safety of donepezil in Chinese patients with severe Alzheimer's disease: a randomized controlled trial. Journal of Alzheimer's disease2017;56(4):1495‐504. ">Jia 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0011" title="HowardRJ , JuszczakE , BallardCG , BenthamP Brown RG , BullockR , et al. CALM‐AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine2007;357(14):1382‐92. PelosiA . Donepezil is no more effective than placebo for agitation in people with Alzheimer's disease. Evidence‐Based Mental Health2008;11(3):84. ">Howard 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>England, UK</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0015" title="Maher‐EdwardsG , DixonR , HunterJ , GoldM , HoptonG , JacobsG , et al. SB‐742457 and donepezil in Alzheimer's disease: a randomized, placebo‐controlled study. International Journal of Geriatric Psychiatry2011;26(5):536‐44. Maher‐EdwardsG , Zvartau‐HindM , DaviesJ , AlexanderK , SchronenJ , BoswellD , et al. Effects of 6‐month monotherapy treatment with the 5HT6 receptor antagonist SB 742457 or donepezil in subjects with mild‐to‐moderate Alzheimer's disease. Alzheimer's Association International Conference, Paris, France. 2011. ">Maher‐Edwards 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Austria, Bulgaria, Chile, Estonia, Germany, The Russian Federation, Slovakia, UK</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0016" title="KorczynAD . Comments on the article by Mazza et al. concerning Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study. European Journal of Neurology2007;14(9):e9. MazzaM , CapuanoA , BriaAP , MazzaS . Letter to the editor. European Journal of Neurology2007;14(9):e10. MazzaM , CapuanoA , BriaP , MazzaS . Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study. European Journal of Neurology2006;13(9):981‐85. ">Mazza 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0018" title="MoraesW , PoyaresD , Sukys‐ClaudinoL , GuilleminaultC , TufikS . Donepezil improves obstructive sleep apnoea in Alzheimer disease: a double‐blind, placebo‐controlled study. Chest2008;133(3):677‐83. MoraesW , Sukys‐ClaudinoL , PoyaresD , GuilleminaultC , TufikS . Donepezil improves oxygen desaturation in patients with alzheimer's disease and obstructive sleep apnoea. Sleep Medicine2006;7(S47):368. ">Moraes 2006a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0019" title="MoraesW dos S , PoyaresDR , GuilleminaultC , RamosLR , BertolucciPH , TufikS . The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double‐blind placebo‐controlled study. Sleep2006;29(2):199‐205. ">Moraes 2006b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0029" title="EngedalK , SoininenH , VerheyF , WaldemarG , WinbladB , WimoA , et al. Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000; Vol. 10, issue Suppl 3:S368. [MEDLINE: SR‐HANDSRCH] MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a one year, double‐blind, randomized trial. Journal of the American Geriatrics Society2001; Vol. 49, issue 4:S131. MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. Donepezil reduces the time caregivers spend providing care: results of a one‐year, double‐blind, randomized trial in patients with mild to moderate Alzheimer's disease. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23‐26, San Francisco2001. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Long term benefits of donepezil on ADLs in AD patients. Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:171. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Donepezil Nordic Study Group. Response to donepezil is not predicted by apolipoprotein E genotype and/or gender. World Alzheimer Congress; 2000 July 9‐13, Washington. 2000. WaldemarG , WinbladB , EngedalK , SoininenH , Donepezil Nordic Study Group et al. Benefits of donepezil on cognition, function and/or neuropsychiatric symptoms in patients with Alzheimers disease over one year. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WaldemarG , WinbladB , EngedalK , SoininenHS , VerheyFR , WimoA , et al. Donepezil Nordic Study Group. Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year. Neurology2000;54(Suppl 3):A470. WimoA . Erratum: an economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial (Dementia and Geriatric Cognitive Disorders (2003) 15 (44‐54)). Dementia and Geriatric Cognitive Disorders2003; Vol. 16, issue 2:102. WimoA , WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , et al. Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial. Dementia and Geriatric Cognitive Disorders2003;15(1):44‐54. WimoA , WinbladB , MasteyV . An economic evaluation of donepezil in mild to moderate Alzheimers disease: results of a one‐year, double‐blind, randomized trial. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WimoA , WinbladB , MasteyV , HaglundA , HertzmanP , MiceliR , et al. An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one‐year, double‐blind, randomized trial. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illionois. 2000. [MEDLINE: SR‐HANDSRCH] WinbladB . Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:164. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , WetterholmAL , ZhangR , HaglundA , SubbiahP . Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. International Psychogeriatrics1999;11(Supplement 1):138. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. A 1‐year, randomized, placebo‐controlled study of donepezil in patients with mild to moderate AD. Neurology2001;57(3):489‐95. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. Donepezil enhances global function and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. Quality Research in Dementia Conference; 2000 Nov 19‐22, London. 2000. WinbladB , WimoA , EngedalK , SoininenH , VerheyF , WaldemarG , et al. 3‐year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia and Geriatric Cognitive Disorders2006;21(5‐6):353‐63. ">Winblad 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0023" title="SchindlerR , Corey‐BloomJ , DoodyR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4‐7, 2004. 2004. SchindlerR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. Neurobiology of Aging2004;25(S2):195. ">Schindler 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10,20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0030" title="BatsmanS , MinthonL , EerikssonS , KilanderL , Jansson‐BlixtC , WetterholmA , et al. Study design and baseline patients characteristics in a randomized controlled trial of the efficacy and tolerability of donepezil in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. ErikssonS , WinbladB , KilanderL , BatsmanS , Jansson‐BlixtC , WetterholmA , et al. Efficacy of donepezil on secondary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. JelicV , HaglundA , KowalskiJ , LangworthS , WinbladB . Donepezil treatment of severe Alzheimer's disease in nursing home settings. Dementia and Geriatric Cognitive Disorders2008;26(5):458‐46. KilanderL , WinbladB , MinthonL , BatsmanS , Jansson‐BlixtC , CronlundA , et al. Donepezil is well tolerated in patients with severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MarderK . Donepezil in patients with severe Alzheimer's disease: double‐blind parallel‐group, placebo controlled study. Current Neurology and Neuroscience Reports2006;6(5):364‐73. OpieLH . Donepezil for severe Alzheimer's disease. Lancet2006;368:361‐2. WinbladB . Donepezil for severe Alzheimer's disease ‐ author's reply. Lancet2006;368(9533):362. WinbladB . Severe Alzheimer's disease: benefits of donepezil therapy. International Psychogeriatrics2006;18(5):S25‐S31. WinbladB , KilanderL , ErikssonS , MinthonL , BåtsmanS , WetterholmA , et al. for the Severe Alzheimer’s Disease Study Group. Donepezil in patients with severe Alzheimer’s disease: double‐blind, parallel‐group, placebo‐controlled study. Lancet2006;367(9156):1057‐65. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansoon‐BlixtC , WetterholmA , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansson‐BlixtC , WetterholmAL , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. International Psychogeriatrics2005;18(S1):S25‐S31. ">Winblad 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sweden</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><b>MMSE</b>: Mini‐Mental State Examination </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of included studies at baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001190-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcome measures</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MMSE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ADAS‐Cog</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CDR‐SB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CIBIC‐plus</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0007" title="HommaA , ImaiY , HariguchiS , HasegawaK , KameyamaM , NishimuraT . Late phase II clinical study of acetyl cholinesterase inhibitor E2020 in patients with Alzheimer‐type dementia. Clinical Evaluation1998;26(2):251‐84. ">Homma 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MENFIS, Crichton, FGIR, GIR, OSR, GUR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0008" title="HommaA , TakedaM , ImaiY , UdakaF , HasegawaK , KameyamaM , et al. E2020 Study Group. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24‐week, multicenter, double‐blind, placebo‐controlled study in Japan. Dementia and Geriatric Cognitive Disorders2000; Vol. 11, issue 6:299‐313. ">Homma 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MENFIS, Japanese‐CGIC, Crichton</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0020" title="FriedhoffLT , IeniJR , RogersSL , PrattRD . Donepezil provides long‐term clinical benefits for patients with Alzheimer's Disease. Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum;1998 July 12‐16, Glasgow, Scotland1998:ABSTRACT REF: PW11017. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Correlation between the clinical efficacy of donepezil HCL (E2020) and red blood cell (RBC) acetylcholinesterase (ACHE) inhibition in patients with Alzheimer's disease. Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5‐8, San Diego. UK: Medical Education Network, 1997; Vol. 2:6‐7. RogersS , PerdomoC , FriedhoffL . Clinical benefits are maintained during long‐term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 September 30‐October 4, Venice1995a. [MEDLINE: SR‐HANDSRCH] RogersSL , DoodyRS , PrattRD , IeniJR . Long‐term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open‐label study. European Neuropsychopharmacology2000; Vol. 10, issue 3:195‐203. RogersSL , FriedhoffLT . E2020 improves cognition and quality of life in patients with mild to moderate Alzheimers Disease: results of a phase II trial. Proceedings of the 46th Annual meeting of the American Academy of Neurology. 1994 May 1‐7, Washington DC1994; Vol. 44, issue Suppl 2:A165. RogersSL , Friedhoff LT and the Donepezil Study Group. The Efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double‐blind, placebo‐controlled trial. Dementia1996;7:293‐303. ">Rogers 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0028" title="TuneL , TiseoP , HoffmanJ , PerdomoC , VotawJ , RogersS , et al. PET in AD: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer's disease: results of a 24‐week study. 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 February 23‐26 San Francisco. 2001. TuneL , TiseoPJ , IeniJ , PerdomoC , PrattRD , VotawJR , et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24‐week, double‐blind, placebo‐controlled study. American Journal of Geriatric Psychiatry2003;11(2):169‐77. TuneLE , TiseoPJ , HoffmanJM , PerdomoCA , VotowJR , RogersSL , et al. Functional brain activity in Alzheimer's disease. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐ June 4, Toronto. 1998:NR345. [MEDLINE: SR‐HANDSRCH] ">Tune 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI, functional brain activity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0013" title="Anon . No title. Eisai Inc. KrishnanKR , CharlesHC , DoraiswamyPM , MintzerJ , WeislerR , YuX , et al. Randomized, placebo‐controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. The American Journal of Psychiatry2003;160(11):2003‐11. ">Krishnan 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hippocampal volumes and brain concentrations of N‐acetylaspartate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0025" title="Anon . No title. Eisai Inc. ">Study 205</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0021" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. PrattRD , PerdomoCA , IeniJK . Long‐term safety and tolerability of donepezil: results from a phase iii extension trial of patients with mild to moderately severe Alzheimer's disease. European Journal of Neurology1999;6(Suppl 3):116. [MEDLINE: SR‐HANDSRCH] RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyRS , MohsRC , FriedhoffLT , the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine1998;158:1021‐31. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego. 1997. ">Rogers 1998a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0022" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. Erratum: a 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613‐620)). Neurology2001; Vol. 57, issue 11:2153. FriedhoffLT , RogersL . Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease ‐ results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston. Neurology1997;48(3):A100. FriedhoffLT , RogersSL . Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17, Vienna, Austria1997. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis. European Journal of Neurology1997;4(Suppl 1):S9. RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyR , MohsR , FriedhoffLT . E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30‐week phase III trial. Neurology1996;46:A217 S14.001 ARI‐8. RogersSL , DoodyR , MohsR , FriedhoffT , Donepezil Study Group. E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30‐week trial. Unpublished paper1996b. RogersSL , FarlowMR , DoodyRS , MohsR , FriedhoffLT , Donepezil Study Group. A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998;50(1):136‐45. RogersSL , FriedhoffLT , FarlowMR , DoodyRS , MohsR . Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply]. Neurology1999; Vol. 52, issue 1:218‐19. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego1997. ">Rogers 1998b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0003" title="BayerAJ , RossorM , HeckerJ , GauthierS , BurnsA , PetiteH , et al. International Donepezil Study Group. Donepezil improves functional activity in patients with Alzheimer's disease. 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12‐16, Glasgow, Scotland. 1998. [MEDLINE: SR‐HANDSRCH] BurnsA , GauthierS , PerdomoC . Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(8):806‐12. BurnsA , RossorM , HeckerJ , GauthierS , PetitH , MöllerH‐J , et al. International Donepezil Study Group. The effects of donepezil in Alzheimer's disease ‐ results from a multinational trial. Dementia and Geriatric Cognitive Disorders1999;10(3):237‐44. GauthierS , RosserM , HeckerJ , PetiteH , RogersS , MohrE , et al. Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐June 4, Toronto, Canada1998. [MEDLINE: SR‐HANDSRCH] GauthierS , RossorM , HeckerJ . Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 15‐18 1998. PrattRD , GauthierS , BurnsA , PerdomoCA . Donepezil provides long‐term clinical benefits for patients with Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington. 2000. ">Burns 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IDDD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0026" title="Anon . No title. Eisai Inc. ">Study 306</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0027" title="SteinmanMA , CovinskyKE , TariotPN , CummingsJL , KatzIR , MintzerJ , et al. Donepezil for nursing home patients with dementia: a reinterpretation of the evidence. Journal of the American Geriatrics Society2003;51(1):132‐33. TariotP , CummingsJL , KatzIR , PerdomoCA , WhalenE , SovelMA , et al. Donepezil was well‐tolerated and enhanced cognition in nursing home patients with Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. TariotP , PerdomoCA , WhalenE , SovelMA , SchamEM . Age is not a barrier to donepezil treatment of Alzheimer's disease in the long‐term care setting. International Psychogeriatrics1999;11(Supplement 1):134. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomised, double‐blind, placebo‐controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2003;51(1):133‐4. ">Tariot 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI‐NH</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0017" title="EbellM . Does donepezil help patients with moderate Alzheimer's dementia preserve their ability to function independently?. Evidence Based Practice2002. MohsR , DoodyR , MorrisJ , IeniJ , PerdomoC , PrattR , et al. Donepezil preserves activities of daily living in Alzheimer's disease patients: results from a one‐year placebo‐controlled functional survival study. Neurology2000;54(Suppl 3):A415. MohsR , DoodyR , MorrisJ , IeniJ , RogersS , PerdomoC , et al. Donepezil preserves functional status and improves cognition in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Journal of the American Geriatrics Society2000;48(8):S46. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled attrition study. Journal of the European College of Neuropsychopharmacology1999;9(Suppl 5):S328. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Quality Research in Dementia Conference; 2000 November 19‐22, London. 2000. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoC , et al. 312 Study Group. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients [Erratum]. Neurology2001; Vol. 57, issue 10:1942. [MEDLINE: http://www.lww.com] MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients. Neurology2001;57(3):481‐8. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illinois. 2000. [MEDLINE: SR‐HANDSRCH] PrattR , MohsR , DoodyR , MorrisJ , RogersS , IeniJ , et al. Donepezil preserves functional status in Alzheimer's disease patients results from a 1‐year prospective placebo controlled functional study. Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden2000:178. ">Mohs 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADFACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0002" title="BlackS , LiHL , McRaeT , RichardsonS . Treatment of severe Alzheimer's disease with donepezil: results from a 24‐week, multinational, randomized, double‐blind, placebo‐controlled trial. Neurology2006;66(5):A347. BlackS , LiHonglang , McRaeT , RichardsonS . Donepezil treatment of severe Alzheimer's disease: results from a 24‐week, multinational, randomized, double‐blind, placebo controlled trial. Poster Presented at the Geneva Springfield ConferenceApril 2006. BlackSE , DoodyR , LiH , McRaeT , JamborKM , XuY , et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology2007;69(5):459‐69. Pfizer . E2020‐A001‐315: a 24 week multinational RCT evaluating the efficacy and safety of donepezil in severe AD. www.marc.soton.ac.uk/Research%20Page.htm. RichardsonS . A 24 week, multicenter, randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of donepezil hydrochloride (E2020) in patients with severe Alzheimer's disease followed by a 12 week open‐label extension period. www.clinicaltrials.gov/ct/show/NCT000964732004. ">Black 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>x</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB, ADCS‐ADL‐sev, NPI, CBQ, RUSP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0024" title="SeltzerB , ZolnouniP , NunezM , GoldmanR , KumarD , IeniJ , et al. Erratum: efficacy of donepezil in early‐stage alzheimer disease: a randomized placebo‐controlled trial (Archives of Neurology (December 2004) 61 (1852‐1856)). Archives of Neurology2005;62(5):825. SeltzerB , ZolnouniP , NunezM , GoldmanR , KumarD , IeniJ , et al. Donepezil 402 Study Group. Efficacy of donepezil in early‐stage Alzheimer disease. Archives of Neurolology2004;61:1852‐6. ">Seltzer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMBT, apathy scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0001" title="AD2000 Collaborative Group. Long‐term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double‐blind trial. Lancet2004;363:2105‐15. BenthamP , GrayR , HillR , SellwoodE , CourtneyC . Twelve week response to cholinesterase inhibitors dose not predict future benefit the AD2000 trial experience. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:337. LendonCL . Determination of responses to anticholinesterase therapy in the treatment of Alzheimer's disease. 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden: Abstract No 1287. 2002. RobertsN . A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease (AD2000). National Research Register2001. SchneiderLS . AD2000: donepezil in Alzheimer's disease. Lancet2004;363(9427):2100‐1. WaghrayS . AD2000 A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease. National Research Register2000. [MEDLINE: http://www.doh.gov.uk/nrr.htm] ">AD2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>entry to institutional care, BADLS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0014" title="RobertP , LebertF , GoniS , TouchonJ , VincentS , ARIAL Study Investigators Collaborative Group. The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. Quality Research in Dementia; 19‐22 November, 2000, London. 2000. RobertPH , LebertF , GoniS , TouchonJ , ARIAL Study Investigators Collaborative Group. The impact of caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">Lebert 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI, BADLS, GHQ‐30, institutionalisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0004" title="CummingsJL , GeldmacherD , FarlowM , SabbaghM , ChristensenD , BetzP . High‐dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. CNS Neuroscience &amp; Therapeutics2013;19(5):294‐301. DoodyRS , GeldmacherDS , FarlowMR , SunY , MolineM , MackellJ . Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate‐to‐severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dementia and Geriatric Cognitive Disorders2012;33(2‐3):164‐73. DoodyRS , RamosH , FaisonW , ZouH . Efficacy and safety of donepezil 23 mg/d vs. donepezil 10 mg/d in patients with moderate to severe Alzheimer's disease: impact of concomitant memantine use. Journal of the American Geriatrics Society 2011 Annual Scientific meeting of the American Geriatrics Society, National Harbor, MD, USA2011. FarlowM , RichardsonS , MackellJ , SunY . Long‐term safety and tolerability of donepezil 23 MG in patients with moderate‐to‐severe Alzheimer's disease: an 18‐month analysis. Alzheimer's and Dementia 2011 Alzheimer's Association International Conference, Paris, France. 2011. FarlowM , VelosoF , MolineM , YardleyJ , Brand‐SchieberE , BibbianiF , et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurology2011;11:57. FarlowMR , SallowayS , TariotPN , YardleyJ , MolineML , WangQ , et al. Effectiveness and tolerability of high‐dose (23 mg/d) versus standard‐dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24‐week, randomized, double‐blind study. Clinical Therapeutics2010;32(7):1234‐51. FerrisS , CummingsJ , ChristensenD , DoodyR , FarlowM , SabbaghM , et al. Donepezil 23 MG/D for moderate to severe Alzheimer's disease: assessing subdomains of the Severe Impairment Battery. Journal of Nutrition, Health and Aging 5th Conference Clinical Trials on Alzheimer's Disease, Monte Carlo, Monaco. 2012. FerrisS , CummingsJ , ChristensenD , DoodyR , FarlowM , SabbaghM , et al. Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimer's Research &amp; Therapy2013;5:12. FerrisS , MacKellJ , BaiZ , SunY . Effect of donepezil 23 mg/day on language function in patients with moderate‐to‐severe Alzheimer's disease (AD): subgroup analysis of united states (U.S.)‐based patients. Alzheimer's Association International Conference 2012 Vancouver, BC Canada. 2012. FerrisSH , SchmittFA , SaxtonJ , RichardsonS , MackellJ , SunY , et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimer's Research &amp; Therapy2011;3(3):22. HanS‐H , LeeJ‐H , KimSY , ParkKW , ChenC , TripathiM , et al. Donepezil 23 mg in Asian patients with moderate‐to‐severe Alzheimer's disease. Acta Neurologica Scandinavica2017;135(2):252‐56. SabbaghM , CummingsJ , ChristensenD , DoodyR , FarlowM , LiuL , et al. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatrics2013;13:56. SabbaghM , CummingsJ , ChristensenD , DoodyR , FarlowM , MacKellJ , et al. Evaluating the cognitive effects of donepezil 23 MG/D in moderate and severe Alzheimer's disease: a patient subgroup analysis. Journal of Nutrition, Health and Aging 5th Conference Clinical Trials on Alzheimer's Disease, Monte Carlo, Monaco. 2012. SabbaghM , HanS , KimS , NaH‐R , LeeJ‐H , KandiahN , et al. Clinical recommendations for the use of donepezil 23 mg in moderate‐to‐severe Alzheimer's disease in the Asia‐Pacific region. Dementia and Geriatric Cognitive Disorders Extra2016;6:382‐95. TariotP , SallowayS , YardleyJ , MackellJ , MolineM . Long‐term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease. BMC Research Notes2012;5:283. TariotP , YardleyJ , MolineM , Brand‐SchieberE , ZouH , TimothyH , et al. Long‐term safety and tolerability of high dose donepezil (23 mg/day) in moderate to severe Alzheimer's disease: a 12‐month open‐label study. Neuropsychopharmacology 49th Annual Conference of the American College of Neuropsychopharmacology, Miami Beach, FL, USA. 2010. ">Farlow 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB, ADCS‐ADL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB, CIBIS, DAD, NPI, FRS, CSS, CAUST, SF‐36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0006" title="HegerlU , MerglR , HenkelV , GallinatJ , KotterG , Muller SiechenederF , et al. Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia. Journal of Clinical Psychopharmacology2003;23(2):214‐6. ">Hegerl 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hand‐motor function</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0009" title="HommaA , ArimotoI , KaidojiK , OhbayashiT , OzawaH . Treatment of severe Alzheimer's disease with donepezil: results from a 24 week, parallel, placebo‐controlled study in Japan. 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, July 2006. 2006. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24‐week, double‐blind, placebo‐controlled, randomized trial. Geriatric Cognitive Disorders2008;25(5):399‐407. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Long‐term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52‐week, open‐label, multicenter, extension study in Japan. Dementia and Geritatric Congitive Disorders2009;27(3):232‐9. ">Homma 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB, ADCS‐ADL‐sev, BEHAVE‐ADL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0010" title="HommaA , AtarashiH , KubotaN , NakaiK , TakaseT . Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in Japanese patients with severe Alzheimer's disease: a randomized, double‐blind trial. Journal of Alzheimer's disease2016;52(1):345‐57. ">Homma 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0012" title="JiaJP , WeiCB , JiaLF , TangY , LiangJH , ZhouAH , et al. Efficacy and safety of donepezil in Chinese patients with severe Alzheimer's disease: a randomized controlled trial. Journal of Alzheimer's disease2017;56(4):1495‐504. ">Jia 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0011" title="HowardRJ , JuszczakE , BallardCG , BenthamP Brown RG , BullockR , et al. CALM‐AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine2007;357(14):1382‐92. PelosiA . Donepezil is no more effective than placebo for agitation in people with Alzheimer's disease. Evidence‐Based Mental Health2008;11(3):84. ">Howard 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMAI, NPI NPI‐D SIB</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0015" title="Maher‐EdwardsG , DixonR , HunterJ , GoldM , HoptonG , JacobsG , et al. SB‐742457 and donepezil in Alzheimer's disease: a randomized, placebo‐controlled study. International Journal of Geriatric Psychiatry2011;26(5):536‐44. Maher‐EdwardsG , Zvartau‐HindM , DaviesJ , AlexanderK , SchronenJ , BoswellD , et al. Effects of 6‐month monotherapy treatment with the 5HT6 receptor antagonist SB 742457 or donepezil in subjects with mild‐to‐moderate Alzheimer's disease. Alzheimer's Association International Conference, Paris, France. 2011. ">Maher‐Edwards 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DAD, NPI, ACQLI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0016" title="KorczynAD . Comments on the article by Mazza et al. concerning Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study. European Journal of Neurology2007;14(9):e9. MazzaM , CapuanoA , BriaAP , MazzaS . Letter to the editor. European Journal of Neurology2007;14(9):e10. MazzaM , CapuanoA , BriaP , MazzaS . Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study. European Journal of Neurology2006;13(9):981‐85. ">Mazza 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SKT, CGIC</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0018" title="MoraesW , PoyaresD , Sukys‐ClaudinoL , GuilleminaultC , TufikS . Donepezil improves obstructive sleep apnoea in Alzheimer disease: a double‐blind, placebo‐controlled study. Chest2008;133(3):677‐83. MoraesW , Sukys‐ClaudinoL , PoyaresD , GuilleminaultC , TufikS . Donepezil improves oxygen desaturation in patients with alzheimer's disease and obstructive sleep apnoea. Sleep Medicine2006;7(S47):368. ">Moraes 2006a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0019" title="MoraesW dos S , PoyaresDR , GuilleminaultC , RamosLR , BertolucciPH , TufikS . The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double‐blind placebo‐controlled study. Sleep2006;29(2):199‐205. ">Moraes 2006b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0029" title="EngedalK , SoininenH , VerheyF , WaldemarG , WinbladB , WimoA , et al. Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000; Vol. 10, issue Suppl 3:S368. [MEDLINE: SR‐HANDSRCH] MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a one year, double‐blind, randomized trial. Journal of the American Geriatrics Society2001; Vol. 49, issue 4:S131. MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. Donepezil reduces the time caregivers spend providing care: results of a one‐year, double‐blind, randomized trial in patients with mild to moderate Alzheimer's disease. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23‐26, San Francisco2001. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Long term benefits of donepezil on ADLs in AD patients. Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:171. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Donepezil Nordic Study Group. Response to donepezil is not predicted by apolipoprotein E genotype and/or gender. World Alzheimer Congress; 2000 July 9‐13, Washington. 2000. WaldemarG , WinbladB , EngedalK , SoininenH , Donepezil Nordic Study Group et al. Benefits of donepezil on cognition, function and/or neuropsychiatric symptoms in patients with Alzheimers disease over one year. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WaldemarG , WinbladB , EngedalK , SoininenHS , VerheyFR , WimoA , et al. Donepezil Nordic Study Group. Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year. Neurology2000;54(Suppl 3):A470. WimoA . Erratum: an economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial (Dementia and Geriatric Cognitive Disorders (2003) 15 (44‐54)). Dementia and Geriatric Cognitive Disorders2003; Vol. 16, issue 2:102. WimoA , WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , et al. Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial. Dementia and Geriatric Cognitive Disorders2003;15(1):44‐54. WimoA , WinbladB , MasteyV . An economic evaluation of donepezil in mild to moderate Alzheimers disease: results of a one‐year, double‐blind, randomized trial. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WimoA , WinbladB , MasteyV , HaglundA , HertzmanP , MiceliR , et al. An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one‐year, double‐blind, randomized trial. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illionois. 2000. [MEDLINE: SR‐HANDSRCH] WinbladB . Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:164. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , WetterholmAL , ZhangR , HaglundA , SubbiahP . Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. International Psychogeriatrics1999;11(Supplement 1):138. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. A 1‐year, randomized, placebo‐controlled study of donepezil in patients with mild to moderate AD. Neurology2001;57(3):489‐95. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. Donepezil enhances global function and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. Quality Research in Dementia Conference; 2000 Nov 19‐22, London. 2000. WinbladB , WimoA , EngedalK , SoininenH , VerheyF , WaldemarG , et al. 3‐year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia and Geriatric Cognitive Disorders2006;21(5‐6):353‐63. ">Winblad 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GBS, PDS, NPI, GDS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0023" title="SchindlerR , Corey‐BloomJ , DoodyR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4‐7, 2004. 2004. SchindlerR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. Neurobiology of Aging2004;25(S2):195. ">Schindler 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TEAE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0030" title="BatsmanS , MinthonL , EerikssonS , KilanderL , Jansson‐BlixtC , WetterholmA , et al. Study design and baseline patients characteristics in a randomized controlled trial of the efficacy and tolerability of donepezil in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. ErikssonS , WinbladB , KilanderL , BatsmanS , Jansson‐BlixtC , WetterholmA , et al. Efficacy of donepezil on secondary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. JelicV , HaglundA , KowalskiJ , LangworthS , WinbladB . Donepezil treatment of severe Alzheimer's disease in nursing home settings. Dementia and Geriatric Cognitive Disorders2008;26(5):458‐46. KilanderL , WinbladB , MinthonL , BatsmanS , Jansson‐BlixtC , CronlundA , et al. Donepezil is well tolerated in patients with severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MarderK . Donepezil in patients with severe Alzheimer's disease: double‐blind parallel‐group, placebo controlled study. Current Neurology and Neuroscience Reports2006;6(5):364‐73. OpieLH . Donepezil for severe Alzheimer's disease. Lancet2006;368:361‐2. WinbladB . Donepezil for severe Alzheimer's disease ‐ author's reply. Lancet2006;368(9533):362. WinbladB . Severe Alzheimer's disease: benefits of donepezil therapy. International Psychogeriatrics2006;18(5):S25‐S31. WinbladB , KilanderL , ErikssonS , MinthonL , BåtsmanS , WetterholmA , et al. for the Severe Alzheimer’s Disease Study Group. Donepezil in patients with severe Alzheimer’s disease: double‐blind, parallel‐group, placebo‐controlled study. Lancet2006;367(9156):1057‐65. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansoon‐BlixtC , WetterholmA , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansson‐BlixtC , WetterholmAL , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. International Psychogeriatrics2005;18(S1):S25‐S31. ">Winblad 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADCS‐ADL‐sev, SIB, CGIC, NPI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The descriptions of the scales and tests appears in <a href="./appendices#CD001190-sec-0163">Appendix 2</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>ACQLI</b> : Alzheimer Carer's Quality of Life Instrument; <b>ADAS‐Cog</b> : Alzheimer's Disease Assessment Scale;<b>ADCS‐ADL‐sev</b> : Alzheimer's Disease Cooperative Study‐Activities of Daily Living Scale (severe version); <b>ADFACS</b> : AD Functional Assessment and Change Score; <b>ADL</b> : Activities of Daily Living; <b>aRSS</b> : abridged Relative's Stress Scale; <b>BADLS</b> : Bristol Activities of Daily Living Scale; <b>BEHAVE‐ADL</b> : Behavioural Pathology in Alzheimer's Disease Activities of Daily Living; <b>CAUST</b> : Canadian Utilization of Services Tracking; <b>CBQ</b> : Caregiver Burden Questionnaire; <b>CDR‐SB</b> : Clinical Dementia Scale, sum of boxes; <b>CGIC</b> : Clinician's Global Impression of Change; <b>CIBIC+</b> : Clinician's Interview‐Based Impression of Change;<b>CIBIS:</b> Clinician's Interview‐based Impression of Severity<b>, CMAI</b> : Cohen‐Mansfield Agitation Inventory; CSS: Caregiver Stress Scale, CMBT: Computerized Memory Battery Test, <b>DAD</b> : Disability Assessment for Dementia; FRS: Functional Rating Scale, <b>GBS</b> : Gottfries, Brane and Steen scale; <b>GDS</b> : Geriatric Depression Scale; <b>GHQ‐30</b> : General Health Questionnaire; <b>IDDD</b> : Interview for Deterioration in Daily living in Dementia scale; <b>MENFIS</b> : Mental Function Impairment Scale; <b>MMSE</b> : Mini Mental State Examination; <b>NOSGER</b> : Nurses' Observation Scale for Geriatric Patients; <b>NPI</b> : Neuropsychiatric Instrument; <b>NPI‐D</b> : Neuropsychiatric Inventory Distress scale; <b>NPI‐NH</b> : Neuropsychiatric Inventory Nursing Home version <b>PDS</b> : Progressive Deterioration Scale; <b>QoL</b> : Quality of Life; <b>RUSP</b> : Resources Utilisation for Severe Alzheimer's Disease Patients; <b>SF‐36</b> : Short Form ‐ 36; <b>SKT</b> : Syndrom Kurz Test; <b>SIB</b> : Severe Impairment Battery; <b>TEAE</b>: treatment‐emergent adverse event </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcome measures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001190-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Study objectives</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Objectives</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0001" title="AD2000 Collaborative Group. Long‐term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double‐blind trial. Lancet2004;363:2105‐15. BenthamP , GrayR , HillR , SellwoodE , CourtneyC . Twelve week response to cholinesterase inhibitors dose not predict future benefit the AD2000 trial experience. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:337. LendonCL . Determination of responses to anticholinesterase therapy in the treatment of Alzheimer's disease. 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20‐25, Stockholm, Sweden: Abstract No 1287. 2002. RobertsN . A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease (AD2000). National Research Register2001. SchneiderLS . AD2000: donepezil in Alzheimer's disease. Lancet2004;363(9427):2100‐1. WaghrayS . AD2000 A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease. National Research Register2000. [MEDLINE: http://www.doh.gov.uk/nrr.htm] ">AD2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"We aimed to determine whether donepezil produces worthwhile improvements in disability, dependency, behavioural and psychological symptoms, carers’ psychological wellbeing, or delay in institutionalisation. If so, which patients<br/> benefit, from what dose, and for how long?" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0002" title="BlackS , LiHL , McRaeT , RichardsonS . Treatment of severe Alzheimer's disease with donepezil: results from a 24‐week, multinational, randomized, double‐blind, placebo‐controlled trial. Neurology2006;66(5):A347. BlackS , LiHonglang , McRaeT , RichardsonS . Donepezil treatment of severe Alzheimer's disease: results from a 24‐week, multinational, randomized, double‐blind, placebo controlled trial. Poster Presented at the Geneva Springfield ConferenceApril 2006. BlackSE , DoodyR , LiH , McRaeT , JamborKM , XuY , et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology2007;69(5):459‐69. Pfizer . E2020‐A001‐315: a 24 week multinational RCT evaluating the efficacy and safety of donepezil in severe AD. www.marc.soton.ac.uk/Research%20Page.htm. RichardsonS . A 24 week, multicenter, randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of donepezil hydrochloride (E2020) in patients with severe Alzheimer's disease followed by a 12 week open‐label extension period. www.clinicaltrials.gov/ct/show/NCT000964732004. ">Black 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the safety and efficacy of donepezil for severe Alzheimer disease (AD)."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0003" title="BayerAJ , RossorM , HeckerJ , GauthierS , BurnsA , PetiteH , et al. International Donepezil Study Group. Donepezil improves functional activity in patients with Alzheimer's disease. 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12‐16, Glasgow, Scotland. 1998. [MEDLINE: SR‐HANDSRCH] BurnsA , GauthierS , PerdomoC . Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(8):806‐12. BurnsA , RossorM , HeckerJ , GauthierS , PetitH , MöllerH‐J , et al. International Donepezil Study Group. The effects of donepezil in Alzheimer's disease ‐ results from a multinational trial. Dementia and Geriatric Cognitive Disorders1999;10(3):237‐44. GauthierS , RosserM , HeckerJ , PetiteH , RogersS , MohrE , et al. Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐June 4, Toronto, Canada1998. [MEDLINE: SR‐HANDSRCH] GauthierS , RossorM , HeckerJ . Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 15‐18 1998. PrattRD , GauthierS , BurnsA , PerdomoCA . Donepezil provides long‐term clinical benefits for patients with Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington. 2000. ">Burns 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the efficacy and safety of once‐daily administration of donepezil at doses of 5 and 10 mg versus placebo in a large, multinational cohort of patients with mild‐moderately severe Alzheimer's disease" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0004" title="CummingsJL , GeldmacherD , FarlowM , SabbaghM , ChristensenD , BetzP . High‐dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. CNS Neuroscience &amp; Therapeutics2013;19(5):294‐301. DoodyRS , GeldmacherDS , FarlowMR , SunY , MolineM , MackellJ . Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate‐to‐severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dementia and Geriatric Cognitive Disorders2012;33(2‐3):164‐73. DoodyRS , RamosH , FaisonW , ZouH . Efficacy and safety of donepezil 23 mg/d vs. donepezil 10 mg/d in patients with moderate to severe Alzheimer's disease: impact of concomitant memantine use. Journal of the American Geriatrics Society 2011 Annual Scientific meeting of the American Geriatrics Society, National Harbor, MD, USA2011. FarlowM , RichardsonS , MackellJ , SunY . Long‐term safety and tolerability of donepezil 23 MG in patients with moderate‐to‐severe Alzheimer's disease: an 18‐month analysis. Alzheimer's and Dementia 2011 Alzheimer's Association International Conference, Paris, France. 2011. FarlowM , VelosoF , MolineM , YardleyJ , Brand‐SchieberE , BibbianiF , et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurology2011;11:57. FarlowMR , SallowayS , TariotPN , YardleyJ , MolineML , WangQ , et al. Effectiveness and tolerability of high‐dose (23 mg/d) versus standard‐dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24‐week, randomized, double‐blind study. Clinical Therapeutics2010;32(7):1234‐51. FerrisS , CummingsJ , ChristensenD , DoodyR , FarlowM , SabbaghM , et al. Donepezil 23 MG/D for moderate to severe Alzheimer's disease: assessing subdomains of the Severe Impairment Battery. Journal of Nutrition, Health and Aging 5th Conference Clinical Trials on Alzheimer's Disease, Monte Carlo, Monaco. 2012. FerrisS , CummingsJ , ChristensenD , DoodyR , FarlowM , SabbaghM , et al. Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimer's Research &amp; Therapy2013;5:12. FerrisS , MacKellJ , BaiZ , SunY . Effect of donepezil 23 mg/day on language function in patients with moderate‐to‐severe Alzheimer's disease (AD): subgroup analysis of united states (U.S.)‐based patients. Alzheimer's Association International Conference 2012 Vancouver, BC Canada. 2012. FerrisSH , SchmittFA , SaxtonJ , RichardsonS , MackellJ , SunY , et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimer's Research &amp; Therapy2011;3(3):22. HanS‐H , LeeJ‐H , KimSY , ParkKW , ChenC , TripathiM , et al. Donepezil 23 mg in Asian patients with moderate‐to‐severe Alzheimer's disease. Acta Neurologica Scandinavica2017;135(2):252‐56. SabbaghM , CummingsJ , ChristensenD , DoodyR , FarlowM , LiuL , et al. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatrics2013;13:56. SabbaghM , CummingsJ , ChristensenD , DoodyR , FarlowM , MacKellJ , et al. Evaluating the cognitive effects of donepezil 23 MG/D in moderate and severe Alzheimer's disease: a patient subgroup analysis. Journal of Nutrition, Health and Aging 5th Conference Clinical Trials on Alzheimer's Disease, Monte Carlo, Monaco. 2012. SabbaghM , HanS , KimS , NaH‐R , LeeJ‐H , KandiahN , et al. Clinical recommendations for the use of donepezil 23 mg in moderate‐to‐severe Alzheimer's disease in the Asia‐Pacific region. Dementia and Geriatric Cognitive Disorders Extra2016;6:382‐95. TariotP , SallowayS , YardleyJ , MackellJ , MolineM . Long‐term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease. BMC Research Notes2012;5:283. TariotP , YardleyJ , MolineM , Brand‐SchieberE , ZouH , TimothyH , et al. Long‐term safety and tolerability of high dose donepezil (23 mg/day) in moderate to severe Alzheimer's disease: a 12‐month open‐label study. Neuropsychopharmacology 49th Annual Conference of the American College of Neuropsychopharmacology, Miami Beach, FL, USA. 2010. ">Farlow 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"The objective of this study was to compare the effectiveness and safety profile of high‐dose donepezil (23 mg/day) and standard dose donepezil (10 mg/day) in patients with moderate to severe AD" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0005" title="FeldmanH . Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:59. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). European Journal of Neurology2002;9(Suppl 2):34. FeldmanH , GauthierS , HeckerJ , VellasB , EmirB , MasteyV , et al. and the Donepezil Study Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.. Journal of the American Geriatrics Society2003;51:737‐44. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , EmirB , et al. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden. 2002:285. FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , XuY , et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology2004;63(4):644‐50. FeldmanH , GauthierS , HeckerJ , VellasB , IeniJ , XuY , et al. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097. 2005. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5‐8, Stockholm2000:174. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001; Vol. 57, issue 4:613‐20. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Group. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology2000; Vol. 54, issue Suppl 3:A469. FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. GauthierS . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate‐to‐severe Alzheimer's disease, and impact on caregiver burden. Geriatrics and Aging2004;7(5):34‐6. GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , McGillPS . Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. The 8th conference on Alzheimer's disease and related disorders, July 20‐25, 2002, Stockholm, Sweden2002:277. GauthierS , FeldmanH , HeckerJ , VellasB , EmirB , SubbiahP , The Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2002;18(6):347‐54. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. GauthierS , FeldmanH , HeckerJ , VellasB , SubbiahP , WhalenE . Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S359. [MEDLINE: SR‐HANDSRCH] GauthierS , FeldmanH , VellasB , SubbiahP . Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society2000; Vol. 48, issue 8:S2. HeckerJ , FotiD , GauthierS , VellasB , SubbiahP , WhalenE . Benefits of donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington DC2000. LuckmannR . Donepezil improved the clinical state and quality of life in moderate‐to‐severe Alzheimer disease. ACP‐Journal‐Club2002; Vol. 136, issue 2:59. PanissetM , FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , et al. Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ShahSN , FeldmanH , GauthierS , HeckerJ , VellasB , HuxM , et al. PfizerInc , NewYork , NY , USA . Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease. Neurobiology of Aging2004;25(S2):208. VellasB , FeldmanH , GauthierS , HeckerJ , SubbiahP , WhalenE , et al. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington2000. ">Feldman 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To investigate the efficacy and safety of donepezil in patients with moderate to severe AD" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0006" title="HegerlU , MerglR , HenkelV , GallinatJ , KotterG , Muller SiechenederF , et al. Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia. Journal of Clinical Psychopharmacology2003;23(2):214‐6. ">Hegerl 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the effects of donepezil on hand motor function in patients with mild‐moderate AD" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0007" title="HommaA , ImaiY , HariguchiS , HasegawaK , KameyamaM , NishimuraT . Late phase II clinical study of acetyl cholinesterase inhibitor E2020 in patients with Alzheimer‐type dementia. Clinical Evaluation1998;26(2):251‐84. ">Homma 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate efficacy, safety and the optimal dose of E2020 in patients with mild to moderate Alzheimer‐type dementia" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0008" title="HommaA , TakedaM , ImaiY , UdakaF , HasegawaK , KameyamaM , et al. E2020 Study Group. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24‐week, multicenter, double‐blind, placebo‐controlled study in Japan. Dementia and Geriatric Cognitive Disorders2000; Vol. 11, issue 6:299‐313. ">Homma 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the efficacy and safety of donepezil hydrochloride (donepezil) at 5mg/day in patients with mild to moderately Alzheimer's disease for 24 weeks" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0009" title="HommaA , ArimotoI , KaidojiK , OhbayashiT , OzawaH . Treatment of severe Alzheimer's disease with donepezil: results from a 24 week, parallel, placebo‐controlled study in Japan. 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, July 2006. 2006. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24‐week, double‐blind, placebo‐controlled, randomized trial. Geriatric Cognitive Disorders2008;25(5):399‐407. HommaA , ImaiY , TagoH , AsadaT , ShigetaM , IwamotoT , et al. Long‐term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52‐week, open‐label, multicenter, extension study in Japan. Dementia and Geritatric Congitive Disorders2009;27(3):232‐9. ">Homma 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"A 24‐week, randomized, parallel‐group, double‐blind placebo‐controlled study was conducted to evaluate the efficacy and tolerability of donepezil in severe Alzheimer’s disease (AD)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0010" title="HommaA , AtarashiH , KubotaN , NakaiK , TakaseT . Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in Japanese patients with severe Alzheimer's disease: a randomized, double‐blind trial. Journal of Alzheimer's disease2016;52(1):345‐57. ">Homma 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To demonstrate the superiority of SR 23 mg/day donepezil over IR 10 mg/day donepezil in Japanese patients with<br/> severe AD (SAD)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0011" title="HowardRJ , JuszczakE , BallardCG , BenthamP Brown RG , BullockR , et al. CALM‐AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine2007;357(14):1382‐92. PelosiA . Donepezil is no more effective than placebo for agitation in people with Alzheimer's disease. Evidence‐Based Mental Health2008;11(3):84. ">Howard 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"The primary question was whether donepezil is better than placebo in the management of agitation that is inappropriate for, or has not responded to, a psychosocial treatment." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0012" title="JiaJP , WeiCB , JiaLF , TangY , LiangJH , ZhouAH , et al. Efficacy and safety of donepezil in Chinese patients with severe Alzheimer's disease: a randomized controlled trial. Journal of Alzheimer's disease2017;56(4):1495‐504. ">Jia 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To examine the effects of donepezil on N‐acetylaspartate concentration and hippocampal volume in patients with mild‐moderate AD" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0013" title="Anon . No title. Eisai Inc. KrishnanKR , CharlesHC , DoraiswamyPM , MintzerJ , WeislerR , YuX , et al. Randomized, placebo‐controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. The American Journal of Psychiatry2003;160(11):2003‐11. ">Krishnan 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"The authors examined the effect of the acetylcholinesterase inhibitor donepezil on magnetic resonance markers<br/> of neurodegeneration in Alzheimer’s disease." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0014" title="RobertP , LebertF , GoniS , TouchonJ , VincentS , ARIAL Study Investigators Collaborative Group. The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. Quality Research in Dementia; 19‐22 November, 2000, London. 2000. RobertPH , LebertF , GoniS , TouchonJ , ARIAL Study Investigators Collaborative Group. The impact of caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">Lebert 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD2000 is a large, simple, ‘real‐life’ trial that aims to produce reliable evidence on the value of donepezil (Aricept®) in routine practice </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0015" title="Maher‐EdwardsG , DixonR , HunterJ , GoldM , HoptonG , JacobsG , et al. SB‐742457 and donepezil in Alzheimer's disease: a randomized, placebo‐controlled study. International Journal of Geriatric Psychiatry2011;26(5):536‐44. Maher‐EdwardsG , Zvartau‐HindM , DaviesJ , AlexanderK , SchronenJ , BoswellD , et al. Effects of 6‐month monotherapy treatment with the 5HT6 receptor antagonist SB 742457 or donepezil in subjects with mild‐to‐moderate Alzheimer's disease. Alzheimer's Association International Conference, Paris, France. 2011. ">Maher‐Edwards 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"This exploratory study was designed to estimate the effects of donepezil and SB‐742457 in a current day setting and population using a study design similar to those employed in two pivotal studies with donepezil (<a href="./references#CD001190-bbs2-0022" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. Erratum: a 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613‐620)). Neurology2001; Vol. 57, issue 11:2153. FriedhoffLT , RogersL . Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease ‐ results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston. Neurology1997;48(3):A100. FriedhoffLT , RogersSL . Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17, Vienna, Austria1997. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis. European Journal of Neurology1997;4(Suppl 1):S9. RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyR , MohsR , FriedhoffLT . E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30‐week phase III trial. Neurology1996;46:A217 S14.001 ARI‐8. RogersSL , DoodyR , MohsR , FriedhoffT , Donepezil Study Group. E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30‐week trial. Unpublished paper1996b. RogersSL , FarlowMR , DoodyRS , MohsR , FriedhoffLT , Donepezil Study Group. A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998;50(1):136‐45. RogersSL , FriedhoffLT , FarlowMR , DoodyRS , MohsR . Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply]. Neurology1999; Vol. 52, issue 1:218‐19. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego1997. ">Rogers 1998b</a>, <a href="./references#CD001190-bbs2-0003" title="BayerAJ , RossorM , HeckerJ , GauthierS , BurnsA , PetiteH , et al. International Donepezil Study Group. Donepezil improves functional activity in patients with Alzheimer's disease. 21st Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12‐16, Glasgow, Scotland. 1998. [MEDLINE: SR‐HANDSRCH] BurnsA , GauthierS , PerdomoC . Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(8):806‐12. BurnsA , RossorM , HeckerJ , GauthierS , PetitH , MöllerH‐J , et al. International Donepezil Study Group. The effects of donepezil in Alzheimer's disease ‐ results from a multinational trial. Dementia and Geriatric Cognitive Disorders1999;10(3):237‐44. GauthierS , RosserM , HeckerJ , PetiteH , RogersS , MohrE , et al. Donepezil produces both clinical global and cognitive test improvement in patients with Alzheimer's disease. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐June 4, Toronto, Canada1998. [MEDLINE: SR‐HANDSRCH] GauthierS , RossorM , HeckerJ . Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Poster presentation at 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 15‐18 1998. PrattRD , GauthierS , BurnsA , PerdomoCA . Donepezil provides long‐term clinical benefits for patients with Alzheimers disease. Proceedings of the World Alzheimer Congress; 2000 Jul 9‐13, Washington. 2000. ">Burns 1999</a>)" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0016" title="KorczynAD . Comments on the article by Mazza et al. concerning Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study. European Journal of Neurology2007;14(9):e9. MazzaM , CapuanoA , BriaAP , MazzaS . Letter to the editor. European Journal of Neurology2007;14(9):e10. MazzaM , CapuanoA , BriaP , MazzaS . Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study. European Journal of Neurology2006;13(9):981‐85. ">Mazza 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To assess the efficacy of Ginkgo biloba special extract in patients with dementia of the Alzheimer type in slowing down the disease's progression and patient's cognitive impairment compared with donepezil and placebo" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0017" title="EbellM . Does donepezil help patients with moderate Alzheimer's dementia preserve their ability to function independently?. Evidence Based Practice2002. MohsR , DoodyR , MorrisJ , IeniJ , PerdomoC , PrattR , et al. Donepezil preserves activities of daily living in Alzheimer's disease patients: results from a one‐year placebo‐controlled functional survival study. Neurology2000;54(Suppl 3):A415. MohsR , DoodyR , MorrisJ , IeniJ , RogersS , PerdomoC , et al. Donepezil preserves functional status and improves cognition in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Journal of the American Geriatrics Society2000;48(8):S46. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled attrition study. Journal of the European College of Neuropsychopharmacology1999;9(Suppl 5):S328. MohsR , DoodyR , MorrisJ , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1‐year prospective placebo‐controlled study. Quality Research in Dementia Conference; 2000 November 19‐22, London. 2000. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoC , et al. 312 Study Group. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients [Erratum]. Neurology2001; Vol. 57, issue 10:1942. [MEDLINE: http://www.lww.com] MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. A 1‐year, placebo‐controlled preservation of function survival study of donepezil in AD patients. Neurology2001;57(3):481‐8. MohsRC , DoodyRS , MorrisJC , IeniJR , RogersSL , PerdomoCA , et al. Donepezil preserves functional status in Alzheimer's disease. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illinois. 2000. [MEDLINE: SR‐HANDSRCH] PrattR , MohsR , DoodyR , MorrisJ , RogersS , IeniJ , et al. Donepezil preserves functional status in Alzheimer's disease patients results from a 1‐year prospective placebo controlled functional study. Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden2000:178. ">Mohs 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To examine the effects of donepezil compared with placebo on the preservation of function in<br/> patients with AD over a 1‐year period" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0018" title="MoraesW , PoyaresD , Sukys‐ClaudinoL , GuilleminaultC , TufikS . Donepezil improves obstructive sleep apnoea in Alzheimer disease: a double‐blind, placebo‐controlled study. Chest2008;133(3):677‐83. MoraesW , Sukys‐ClaudinoL , PoyaresD , GuilleminaultC , TufikS . Donepezil improves oxygen desaturation in patients with alzheimer's disease and obstructive sleep apnoea. Sleep Medicine2006;7(S47):368. ">Moraes 2006a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"This study evaluates the effects of donepezil on obstructive sleep apnea in patients with<br/> Alzheimer disease." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0019" title="MoraesW dos S , PoyaresDR , GuilleminaultC , RamosLR , BertolucciPH , TufikS . The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double‐blind placebo‐controlled study. Sleep2006;29(2):199‐205. ">Moraes 2006b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Examine the effects of donepezil on sleep and rapid eye movement (REM) sleep electroencephalogram (EEG) in patients with Alzheimer disease, using polysomnography" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0020" title="FriedhoffLT , IeniJR , RogersSL , PrattRD . Donepezil provides long‐term clinical benefits for patients with Alzheimer's Disease. Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum;1998 July 12‐16, Glasgow, Scotland1998:ABSTRACT REF: PW11017. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Correlation between the clinical efficacy of donepezil HCL (E2020) and red blood cell (RBC) acetylcholinesterase (ACHE) inhibition in patients with Alzheimer's disease. Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5‐8, San Diego. UK: Medical Education Network, 1997; Vol. 2:6‐7. RogersS , PerdomoC , FriedhoffL . Clinical benefits are maintained during long‐term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 September 30‐October 4, Venice1995a. [MEDLINE: SR‐HANDSRCH] RogersSL , DoodyRS , PrattRD , IeniJR . Long‐term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open‐label study. European Neuropsychopharmacology2000; Vol. 10, issue 3:195‐203. RogersSL , FriedhoffLT . E2020 improves cognition and quality of life in patients with mild to moderate Alzheimers Disease: results of a phase II trial. Proceedings of the 46th Annual meeting of the American Academy of Neurology. 1994 May 1‐7, Washington DC1994; Vol. 44, issue Suppl 2:A165. RogersSL , Friedhoff LT and the Donepezil Study Group. The Efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double‐blind, placebo‐controlled trial. Dementia1996;7:293‐303. ">Rogers 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the efficacy and safety of donepezil in patients with mild to moderately severe Alzheimer's disease and to examine the relationships between plasma donepezil concentration, red blood cell acetylcholinesterase activity and clinical response" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0021" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. PrattRD , PerdomoCA , IeniJK . Long‐term safety and tolerability of donepezil: results from a phase iii extension trial of patients with mild to moderately severe Alzheimer's disease. European Journal of Neurology1999;6(Suppl 3):116. [MEDLINE: SR‐HANDSRCH] RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyRS , MohsRC , FriedhoffLT , the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine1998;158:1021‐31. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego. 1997. ">Rogers 1998a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"The present phase I11 study was undertaken to further evaluate the efficacy and safety of donepezil at dosage levels of 5 and 10 mg/d versus placebo in patients with mild to moderate AD" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0022" title="DoodyRS , GeldmacherDS , GordonB , PerdomoCA , PrattRD , Donepezil Study Group. Open‐label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology2001;58(3):427‐33. FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE , Donepezil MSAD Study Investigators Group. Erratum: a 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease (Neurology (2001) 57 (613‐620)). Neurology2001; Vol. 57, issue 11:2153. FriedhoffLT , RogersL . Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease ‐ results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston. Neurology1997;48(3):A100. FriedhoffLT , RogersSL . Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17, Vienna, Austria1997. [MEDLINE: SR‐HANDSRCH] FriedhoffLT , RogersSL . Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis. European Journal of Neurology1997;4(Suppl 1):S9. RogersSL . Donepezil new clinical trials support long term use. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:133. RogersSL , DoodyR , MohsR , FriedhoffLT . E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30‐week phase III trial. Neurology1996;46:A217 S14.001 ARI‐8. RogersSL , DoodyR , MohsR , FriedhoffT , Donepezil Study Group. E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's disease. Results of a 30‐week trial. Unpublished paper1996b. RogersSL , FarlowMR , DoodyRS , MohsR , FriedhoffLT , Donepezil Study Group. A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998;50(1):136‐45. RogersSL , FriedhoffLT , FarlowMR , DoodyRS , MohsR . Efficacy of donepezil in Alzheimer's disease: fact or artifact? [Reply]. Neurology1999; Vol. 52, issue 1:218‐19. RogersSL , MohsRC , FriedhoffLT . Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from phase III trials. American Psychiatric Association 150th Annual Meeting, San Diego1997. ">Rogers 1998b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"This phase 3 study was 1 of 2 pivotal trials undertaken to establish the efficacy and safety of using donepezil in patients with mild to moderately severe Alzheimer disease" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0023" title="SchindlerR , Corey‐BloomJ , DoodyR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4‐7, 2004. 2004. SchindlerR , ZhangR , IeniJR , LiH . Donepezil is safe and well tolerated in Alzheimer's disease patients, at doses of up to 20 mg/day. Neurobiology of Aging2004;25(S2):195. ">Schindler 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To determine the safety and tolerability of treatment with 15 or 20 mg/day donepezil in mild to moderate AD" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0024" title="SeltzerB , ZolnouniP , NunezM , GoldmanR , KumarD , IeniJ , et al. Erratum: efficacy of donepezil in early‐stage alzheimer disease: a randomized placebo‐controlled trial (Archives of Neurology (December 2004) 61 (1852‐1856)). Archives of Neurology2005;62(5):825. SeltzerB , ZolnouniP , NunezM , GoldmanR , KumarD , IeniJ , et al. Donepezil 402 Study Group. Efficacy of donepezil in early‐stage Alzheimer disease. Archives of Neurolology2004;61:1852‐6. ">Seltzer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the efficacy of donepezil in patients with early‐stage Alzheimer disease"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0025" title="Anon . No title. Eisai Inc. ">Study 205</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the effect of donepezil on visuospatial attention in Alzheimer's disease patients" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0026" title="Anon . No title. Eisai Inc. ">Study 306</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the utility of APo‐E subtype in predicting response to treatment with donepezil in Alzheimer's disease patients" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0027" title="SteinmanMA , CovinskyKE , TariotPN , CummingsJL , KatzIR , MintzerJ , et al. Donepezil for nursing home patients with dementia: a reinterpretation of the evidence. Journal of the American Geriatrics Society2003;51(1):132‐33. TariotP , CummingsJL , KatzIR , PerdomoCA , WhalenE , SovelMA , et al. Donepezil was well‐tolerated and enhanced cognition in nursing home patients with Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. TariotP , PerdomoCA , WhalenE , SovelMA , SchamEM . Age is not a barrier to donepezil treatment of Alzheimer's disease in the long‐term care setting. International Psychogeriatrics1999;11(Supplement 1):134. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomised, double‐blind, placebo‐controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2003;51(1):133‐4. ">Tariot 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the safety and efficacy of donepezil in the management of patients with Alzheimer’s disease (AD) residing in nursing home facilities." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0028" title="TuneL , TiseoP , HoffmanJ , PerdomoC , VotawJ , RogersS , et al. PET in AD: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer's disease: results of a 24‐week study. 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 February 23‐26 San Francisco. 2001. TuneL , TiseoPJ , IeniJ , PerdomoC , PrattRD , VotawJR , et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24‐week, double‐blind, placebo‐controlled study. American Journal of Geriatric Psychiatry2003;11(2):169‐77. TuneLE , TiseoPJ , HoffmanJM , PerdomoCA , VotowJR , RogersSL , et al. Functional brain activity in Alzheimer's disease. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐ June 4, Toronto. 1998:NR345. [MEDLINE: SR‐HANDSRCH] ">Tune 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"This study evaluated the effects of donepezil on functional brain activity in patients with AD." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0029" title="EngedalK , SoininenH , VerheyF , WaldemarG , WinbladB , WimoA , et al. Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease. Journal of the European College of Neuropsychopharmacology2000; Vol. 10, issue Suppl 3:S368. [MEDLINE: SR‐HANDSRCH] MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a one year, double‐blind, randomized trial. Journal of the American Geriatrics Society2001; Vol. 49, issue 4:S131. MasteyV , WimoA , WinbladB , HaglundA , JacobsonL , MiceliR , et al. Donepezil reduces the time caregivers spend providing care: results of a one‐year, double‐blind, randomized trial in patients with mild to moderate Alzheimer's disease. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23‐26, San Francisco2001. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Long term benefits of donepezil on ADLs in AD patients. Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:171. SoininenH , WinbladB , EngedalK , VerheyF , WaldemarG , WimoA , et al. Donepezil Nordic Study Group. Response to donepezil is not predicted by apolipoprotein E genotype and/or gender. World Alzheimer Congress; 2000 July 9‐13, Washington. 2000. WaldemarG , WinbladB , EngedalK , SoininenH , Donepezil Nordic Study Group et al. Benefits of donepezil on cognition, function and/or neuropsychiatric symptoms in patients with Alzheimers disease over one year. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WaldemarG , WinbladB , EngedalK , SoininenHS , VerheyFR , WimoA , et al. Donepezil Nordic Study Group. Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year. Neurology2000;54(Suppl 3):A470. WimoA . Erratum: an economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial (Dementia and Geriatric Cognitive Disorders (2003) 15 (44‐54)). Dementia and Geriatric Cognitive Disorders2003; Vol. 16, issue 2:102. WimoA , WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , et al. Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1‐year, double‐blind, randomized trial. Dementia and Geriatric Cognitive Disorders2003;15(1):44‐54. WimoA , WinbladB , MasteyV . An economic evaluation of donepezil in mild to moderate Alzheimers disease: results of a one‐year, double‐blind, randomized trial. World Alzheimer Congress; 2000 July 9‐13, Washington DC. 2000. WimoA , WinbladB , MasteyV , HaglundA , HertzmanP , MiceliR , et al. An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one‐year, double‐blind, randomized trial. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18, Chicago, Illionois. 2000. [MEDLINE: SR‐HANDSRCH] WinbladB . Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5‐8, Stockholm. 2000:164. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , WetterholmAL , ZhangR , HaglundA , SubbiahP . Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. International Psychogeriatrics1999;11(Supplement 1):138. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. A 1‐year, randomized, placebo‐controlled study of donepezil in patients with mild to moderate AD. Neurology2001;57(3):489‐95. WinbladB , EngedalK , SoininenH , VerheyF , WaldemarG , WimoA , et al. Donepezil enhances global function and activities of daily living compared with placebo in a one‐year, double‐blind trial in patients with mild to moderate Alzheimer's disease. Quality Research in Dementia Conference; 2000 Nov 19‐22, London. 2000. WinbladB , WimoA , EngedalK , SoininenH , VerheyF , WaldemarG , et al. 3‐year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dementia and Geriatric Cognitive Disorders2006;21(5‐6):353‐63. ">Winblad 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"To evaluate the long‐term clinical efficacy and safety of donepezil versus placebo over 1 year in patients with mild to moderate AD." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001190-bbs2-0030" title="BatsmanS , MinthonL , EerikssonS , KilanderL , Jansson‐BlixtC , WetterholmA , et al. Study design and baseline patients characteristics in a randomized controlled trial of the efficacy and tolerability of donepezil in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. ErikssonS , WinbladB , KilanderL , BatsmanS , Jansson‐BlixtC , WetterholmA , et al. Efficacy of donepezil on secondary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. JelicV , HaglundA , KowalskiJ , LangworthS , WinbladB . Donepezil treatment of severe Alzheimer's disease in nursing home settings. Dementia and Geriatric Cognitive Disorders2008;26(5):458‐46. KilanderL , WinbladB , MinthonL , BatsmanS , Jansson‐BlixtC , CronlundA , et al. Donepezil is well tolerated in patients with severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. MarderK . Donepezil in patients with severe Alzheimer's disease: double‐blind parallel‐group, placebo controlled study. Current Neurology and Neuroscience Reports2006;6(5):364‐73. OpieLH . Donepezil for severe Alzheimer's disease. Lancet2006;368:361‐2. WinbladB . Donepezil for severe Alzheimer's disease ‐ author's reply. Lancet2006;368(9533):362. WinbladB . Severe Alzheimer's disease: benefits of donepezil therapy. International Psychogeriatrics2006;18(5):S25‐S31. WinbladB , KilanderL , ErikssonS , MinthonL , BåtsmanS , WetterholmA , et al. for the Severe Alzheimer’s Disease Study Group. Donepezil in patients with severe Alzheimer’s disease: double‐blind, parallel‐group, placebo‐controlled study. Lancet2006;367(9156):1057‐65. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansoon‐BlixtC , WetterholmA , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. IPA 12th International Congress, Stockholm, Sweden, 20‐24 September 2005. 2005. WinbladB , MinthonL , ErikssonS , BatsmanS , Jansson‐BlixtC , WetterholmAL , et al. Efficacy of donepezil on primary end points in a randomized, double‐blind placebo‐controlled study in severe Alzheimer's disease. International Psychogeriatrics2005;18(S1):S25‐S31. ">Winblad 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Our aim was to assess the eff ect of donepezil on cognition and activities of daily living in patients with severe Alzheimer’s disease living in nursing homes ran by trained staff ." </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p><b>AD</b> : Alzheimer's disease; <b>SAD</b> : severe Alzheimer's disease;; <b>REM:</b> rapid eye movement </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Study objectives</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/full#CD001190-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001190-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Donepezil (10 mg/day) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ADAS‐Cog (change from baseline at 24‐26 weeks) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.67 [‐3.31, ‐2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 MMSE (change from baseline at 24‐26 weeks) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 donepezil (10 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.73, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 SIB (change from baseline at 24‐26 weeks) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 donepezil (10 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.92 [4.53, 7.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 ADCS‐ADL‐severe (change from baseline at 24‐26 weeks) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 donepezil (10 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.21, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 CIBIC‐Plus or CGIC (numbers improved at 24‐26 weeks) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [1.54, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 CDR‐SB (change from baseline at 24‐26 weeks) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐0.73, ‐0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 BEHAVE‐AD (change from baseline at 24‐26 weeks) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 donepezil (10 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.4 [‐1.28, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Behavioural disturbance (Total NPI ) (change from baseline at 24‐26 weeks) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 donepezil (10 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.62 [‐3.43, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 QoL (participant‐rated quality of life at 24‐26 weeks) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>815</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.79 [‐8.15, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Total number of withdrawals before end of treatment at 24‐26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.05, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Total number of participants who suffered from at least one adverse event by 24‐26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.31, 1.95]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Donepezil (10 mg/day) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001190-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Donepezil (5 mg/day or 10 mg/day) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ADAS‐COG (change from baseline) completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.15 [‐2.69, ‐1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.02 [‐2.77, ‐1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.45 [‐3.01, ‐1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.81 [‐3.55, ‐2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 ADAS‐COG (change from baseline) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.27 [‐3.16, ‐1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.01 [‐2.69, ‐1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.99 [‐3.99, ‐1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.67 [‐3.31, ‐2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 MMSE (change from baseline) completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.61, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.64, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.90, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.90, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [0.53, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 MMSE (change from baseline) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 donepezil (5 mg/d) at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.32, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 donepezil (5 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.54, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 donepezil (10 mg/d) at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.61, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 donepezil (10 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.73, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 donepezil (10 mg/d) at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.81, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 SIB (change from baseline) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 donepezil (5 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.7 [3.66, 9.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 donepezil (10 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.92 [4.53, 7.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 CIBIC‐plus or CGIC (numbers improved) completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.93 [2.20, 7.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [1.40, 4.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 CIBIC‐plus or CGIC (numbers improved) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [1.25, 3.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [1.69, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [1.64, 4.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [1.54, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 CDR‐SB (change from baseline) completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.38, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐0.80, ‐0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.43, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.56 [‐0.83, ‐0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 CDR‐SB (change from baseline) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.25, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1093</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.51 [‐0.70, ‐0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.47, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐0.73, ‐0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 GBS or MENFIS ‐ global assessment completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.56 [‐4.27, ‐0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.08 [‐4.15, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.16 [‐6.85, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.01 [‐11.93, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 GBS ‐ global assessment ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.26 [‐7.38, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 ADL and IADL (CMCS) (change from baseline) completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 donepezil (5 mg/day) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.42 [‐4.32, ‐0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 ADl and IADL (DAD) (change from baseline) completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.83 [1.35, 8.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.0 [3.61, 12.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 ADCS‐ADL‐severe (change from baseline) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 donepezil (5 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐0.54, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 donepezil (10 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.21, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 PDS ‐ progressive deterioration scale ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 donepezil ( 10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [1.70, 5.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Total number meeting criterion for functional decline before end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 donepezil (10 mg/day) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.36, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Behavioural disturbance (total NPI) (change from baseline) completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.45 [‐4.43, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.04 [‐3.16, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 BEHAVE‐AD (change from baseline) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 donepezil (5 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐1.67, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 donepezil (10 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.4 [‐1.28, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Behavioural disturbance (total NPI ) (change from baseline) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 donepezil (10 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.62 [‐3.43, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 QoL (participant‐rated quality of life) completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [‐3.04, 5.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [‐3.64, 8.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1031</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [‐3.20, 5.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.17 [‐7.26, 4.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 QoL (participant‐rated quality of life) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [‐3.81, 9.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [‐4.60, 6.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.40 [‐15.72, ‐1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>815</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.79 [‐8.15, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 IADL (change from baseline) completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.31 [‐7.72, ‐0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.32 [‐10.02, ‐2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 PSMS (change from baseline) completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐1.17, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.88 [‐1.77, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Time (mins/day) spent by carer assisting in IADL and PSMS (change from baseline) LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐52.4 [‐118.78, 13.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Total number who enter long‐term institutional care before end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 donepezil (10 mg/d) at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.10, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Total number of withdrawals before end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.22, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.66, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.31 [1.21, 4.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.05, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.5 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.62, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Total number of participants who withdrew due to an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [1.02, 5.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.52, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.45 [1.40, 8.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [1.33, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.5 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.45, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Total number of participants who suffered from at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.70, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.06, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.94, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.30, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.5 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.81, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Total number of participants who suffered from abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.53, 4.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.11, 3.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.31, 3.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.58, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.5 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.12, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Total number of participants who suffered from abnormal gait <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.63, 3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Total number of participants who suffered from abnormal dreams <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 donepezil (10 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.49 [0.71, 218.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Total number of participants who suffered from accidental fall <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.40, 3.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.58, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Total number of participants who suffered from accidental injury <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.32, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.36, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.3 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.87, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Total number of participants who suffered from agitation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.23, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.36, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.3 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.60, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Total number of participants who suffered from anorexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.61, 6.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.88, 4.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [0.81, 6.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.01 [1.96, 4.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Total number of participants who suffered from anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.28, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.2 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.84, 4.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Total number of participants who suffered from arthralgia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.62, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Total number of participants who suffered from asthenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.95, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.2 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [0.82, 6.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 Total number of participants who suffered from back pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.87, 3.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 Total number of participants who suffered from cold syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.30, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.86, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.25, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.54, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 Total number of participants who suffered from confusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.61, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1045</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.57, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.3 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.15, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 Total number of participants who suffered from conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.72, 5.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 Total number of participants who suffered from constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.73, 5.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.41, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.3 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.24, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 Total number of participants who suffered from contusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.41, 7.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.22, 5.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45 Total number of participants who suffered from cystitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.50, 4.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46 Total number of participants who suffered from depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.54, 4.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.2 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.69, 3.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47 Total number of participants who suffered from diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [1.05, 6.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.19, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.22 [1.87, 9.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [2.05, 3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.5 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.41, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48 Total number of participants who suffered from dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.55, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>861</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.82, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.60, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1830</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.19, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.5 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.55, 4.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49 Total number of participants who suffered from ecchymosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.55, 4.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50 Total number of participants who suffered from eczema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.23 [0.75, 70.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51 Total number of participants who suffered from fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.20, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [0.81, 8.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.60, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.63 [1.29, 10.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52 Total number of participants who suffered from fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.53, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.58, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53 Total number of participants who suffered from fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.05, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.49, 5.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.3 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.54, 4.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54 Total number of participants who suffered from gastroenteritis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.24, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55 Total number of participants who suffered from haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.35, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">56 Total number of participants who suffered from hallucinations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.68 [1.24, 17.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">57 Total number of participants who suffered from headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.71, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.66, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.71, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.88, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.5 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.51, 3.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58 Total number of participants who suffered from hostility <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.58, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.2 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.16, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">59 Total number of participants who suffered from loss of appetite <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.51, 14.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [0.40, 12.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60 Total number of participants who suffered from infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.76, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61 Total number of participants who suffered from inflammation of upper airway <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.25, 8.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">62 Total number of participants who suffered from insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.67, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.85, 3.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.38 [1.69, 6.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1043</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [1.38, 4.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.5 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.63, 3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">63 Total number of participants who suffered from increased cough <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.08, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.2 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.11, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.3 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.56, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">64 Total number of participants who suffered from myasthenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.54, 7.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">65 Total number of participants who suffered from muscle cramp <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.53, 4.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.48 [1.56, 19.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.76, 5.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.00 [1.98, 18.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">66 Total number of participants who suffered from nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.70, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.74, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [1.58, 5.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.06 [2.26, 4.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.5 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.59, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">67 Total number of participants who suffered from pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.56, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.2 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.93, 4.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.3 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.64, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">68 Total number of participants who suffered from peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.05, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.2 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.15, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.3 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [1.02, 4.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">69 Total number of participants who suffered from pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.65, 4.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">70 Total number of participants who suffered from rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.37, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">71 Total number of participants who suffered from restlessness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.44, 5.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [0.22, 20.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">72 Total number of participants who suffered from respiratory tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.45, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.29, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.24, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.50, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">73 Total number of participants who suffered from rhinitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.45, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.05, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.24, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.75, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">74 Total number of participants who suffered from vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.22, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.68, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.53, 3.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.65 [1.90, 3.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">75 Total number of participants who suffered from skin ulcer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>75.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.56, 4.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">76 Total number of participants who suffered from syncope <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.1 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.27 [0.75, 6.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">77 Total number of participants who suffered from tremor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>77.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.58 [1.01, 12.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">78 Total number of participants who suffered from urinary incontinence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>78.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.31 [0.79, 6.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">79 Total number of participants who suffered from urinary tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>79.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.22, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>79.2 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.13, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>79.3 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.59, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>79.4 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.31, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">80 Total number of participants who suffered from vertigo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>80.1 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.36 [1.15, 9.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">81 Total number of participants who suffered from weight loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>81.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.19, 4.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>81.2 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.48 [0.74, 8.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>81.3 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [1.08, 3.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">82 total number of deaths before end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>82.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.06, 15.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>82.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.25, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>82.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.00, 6.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>82.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.46, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>82.5 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.30, 6.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">83 Total number of participants who suffered from at least one serious adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>83.1 donepezil (5 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.27, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>83.2 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.49, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>83.3 donepezil (10 mg/d) vs placebo at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.27, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>83.4 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.71, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>83.5 donepezil (10 mg/d) vs placebo at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.11, 3.59]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Donepezil (5 mg/day or 10 mg/day) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001190-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Patient and carer health resource utilisation over 24 weeks (Australia, Canada, France) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 In‐home nursing visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐2.61, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Other healthcare professional visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐2.98, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Day hospital visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.70, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 AD‐related physician visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.71, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 AD‐related medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.53, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Residential care days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.9 [‐17.12, 3.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Respite care days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.9 [‐0.36, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Day centre visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐4.90, 3.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9 In‐home nursing visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐2.61, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10 Home help visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.5 [‐9.73, 14.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11 Meal delivery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.90 [‐12.46, 6.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12 Carer ‐ counselling visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.4 [‐0.28, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13 Carer‐related physician visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐0.21, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14 Unpaid carer time (total hours)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐34.0 [‐191.45, 123.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Health resource cost/participant (CAD) over 24 weeks in 1998 (Australia, Canada, France) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 In‐home nursing care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>22.00 [‐118.50, 162.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Other healthcare professional services</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐103.00 [‐243.15, 37.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Day hospital use</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐74.71, 72.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 AD‐related physician services</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.0 [‐42.21, 12.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 AD‐related medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>25.0 [‐5.59, 55.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Acute‐care hospital stays</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>22.00 [‐118.50, 162.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 In‐home nursing care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐22.00 [‐206.26, 162.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Residential care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐595.0 [‐1604.31, 414.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 Respite care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>86.0 [‐37.07, 209.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 Day centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐34.0 [‐311.05, 243.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11 Home help</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>112.0 [‐524.20, 748.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12 Meal delivery service</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐41.0 [‐169.68, 87.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13 Total cost including cost of donepezil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>34.0 [‐641.33, 709.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Health resource cost/carer (CAD) over 24 weeks in 1998 (Australia, Canada, France) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Counseling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>25.00 [‐26.81, 76.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Physician visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.0 [‐6.05, 36.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.0 [‐27.26, 11.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Total carer costs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>31.0 [7.22, 54.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Unpaid carer time cost (CAD) in 1998 (Australia, Canada, France) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Total cost to society (CAD) in 1998 (Australia, Canada, France) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Health resource cost/participant (USD) over one year in 1999 (northern Europe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>MD (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Total participant direct costs including cost of donepezil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>MD (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>291.0 [‐2645.03, 3227.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Health resource cost/carer (USD) over one year in 1999 (northern Europe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>MD (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Total carer direct medical costs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>MD (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>355.0 [‐84.03, 794.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Total carer time costs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>MD (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1033.0 [‐1765.83, 3831.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Health resource cost/participant + carer (USD) over one year in 1999 (northern Europe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>MD (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Total participant and carer costs including cost of donepezil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>MD (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1097.0 [‐3052.24, 5246.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Donepezil (10 mg/day) versus placebo (patient and carer health resource utilisation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001190-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Donepezil (23 mg/day) versus donepezil (10 mg/day)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 SIB (change from baseline) at 24 weeks ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [‐0.15, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 MMSE (change from baseline at 24 weeks) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.33, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 ADCS‐ADL‐sev (change from baseline) at 24 weeks ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐1.18, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 CIBIC‐plus (numbers improved) by end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.78, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 total number of patients who withdrew before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.59, 2.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 total number of patients who withdrew due to an adverse event before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.51 [1.83, 3.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 total number of patients who suffered an adverse event before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.34, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 total number of patients who suffered a serious adverse event before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.71, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 total number of patients who suffered an adverse event of asthenia before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.31 [0.98, 11.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 total number of patients who suffered an adverse event of contusion before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.99 [1.88, 13.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 total number of patients who suffered an adverse event of anorexia before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.24 [1.52, 6.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 total number of patients who suffered an adverse event of diarrhoea before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.15, 2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 total number of patients who suffered an adverse event of dizziness before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.82, 2.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 total number of patients who suffered an adverse event of fatigue before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [0.98, 8.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 total number of patients who suffered an adverse event of headache before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.74, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 total number of patients who suffered an adverse event of insomnia before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.67, 2.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 total number of patients who suffered an adverse event of nausea before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.36 [2.09, 5.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 total number of patients who suffered an adverse event of vomiting before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.88 [2.27, 6.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 total number of patients who suffered an adverse event of weight decrease before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [1.12, 3.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 total number of patients who suffered an adverse event of accidental fall before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.60, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 total number of patients who suffered an adverse event of urinary tract infection before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.62, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 total number of patients who suffered an adverse event of bradycardia and sinus bradycardia before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.5 [1.36, 14.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 total number of patients who suffered an adverse event of agitation before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.58, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 total number of patients who suffered an adverse event of aggression before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.53, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 total number of patients who suffered an adverse event of urinary incontinence before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.80, 4.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 total number of patients who suffered an adverse event of somnolence before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [0.97, 6.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 total number of patients who died before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.24, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 total number of patients who suffered an adverse event of nasopharyngitis before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.83, 3.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 total number of patients who suffered an adverse event of decreased appetite before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [1.00, 6.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 total number of patients who suffered an adverse event of ECG QT prolonged before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.39, 4.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 total number of patients who suffered an adverse event of anger before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.67, 4.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 total number of patients who suffered an adverse event of constipation before end of treatment at 24 weeks end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.22, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 total number of patients who suffered an adverse event of bronchitis before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [0.44, 11.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 total number of patients who suffered an adverse event of conjunctivitis before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.15 [0.56, 184.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 total number of patients who suffered an adverse event of upper respiratory tract infection before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.26, 5.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 total number of patients who suffered an adverse event of arthralgia before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.65 [0.40, 32.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 total number of patients who suffered an adverse event of back pain before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.33, 10.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 total number of patients who suffered an adverse event of spinal compression fracture before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.26 [0.44, 154.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 total number of patients who suffered an adverse event of dermatitis contact before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.08, 2.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Donepezil (23 mg/day) versus donepezil (10 mg/day)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001190-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Donepezil (15‐20 mg/day) versus donepezil (10 mg/day)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number who suffered an adverse event before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.36, 7.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Donepezil (15‐20 mg/day) versus donepezil (10 mg/day)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001190-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 CMAI (change from baseline) completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐4.23, 4.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 NPI (change from baseline) completers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.1 [‐3.78, 3.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 NPI caregiver distress (change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐2.06, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total number of withdrawals before end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.31, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Total number of participants who suffered from nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.32, 30.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Total number of participants who suffered from diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.20 [0.25, 109.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Total number of participants who suffered from rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.18, 23.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Total number of participants who suffered from increased agitation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.11, 4.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Total number of participants who suffered from postural hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Total number of participants who suffered from a fall <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.14, 7.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Total number of participants who suffered from femoral fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.20 [0.25, 109.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Total number of participants who suffered from a stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [0.12, 76.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Total number of participants who suffered from myocardial infarct <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [0.12, 76.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Total number of participants who suffered from urinary tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.11, 4.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Total number of participants who suffered from chest infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.06, 16.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Total number of participants who suffered from seizure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.11, 4.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Total number of deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.17, 3.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Donepezil (10 mg/day) versus placebo at 12 weeks for people with AD with severe agitation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001190-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Donepezil (10 mg/day) versus donepezil (5 mg/day)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ADAS‐Cog (change from baseline at 24 weeks) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.05 [‐1.80, ‐0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 MMSE (change from baseline at 24 weeks) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.55, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 SIB (change from baseline) at 24 weeks ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.2 [‐1.00, 5.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 ADCS‐ADL‐sev (change from baseline) at 24 weeks ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 CIBIC‐plus (numbers improved) by end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.94, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 CDR‐SB (change from baseline at 24 weeks) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.29, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 BEHAVE‐AD (change from baseline) at 24 weeks ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 QoL (change from baseline at 24 weeks) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.33 [‐16.23, ‐0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Total number of participants who withdrew before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.24, 2.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Total number of participants who withdrew due to an adverse event before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.41 [1.63, 3.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Total number of participants who suffered an adverse event before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>741</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.07, 2.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Total number of participants who suffered an adverse event of anorexia before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.72 [1.48, 5.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Total number of participants who suffered an adverse event of confusion before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.41, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Total number of participants who suffered an adverse event of diarrhoea before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.22, 2.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Total number of participants who suffered an adverse event of dizziness before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.83, 2.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Total number of participants who suffered an adverse event of fatigue before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.60, 3.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Total number of participants who suffered an adverse event of headache before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.73, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Total number of participants who suffered an adverse event of insomnia before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.61, 2.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Total number of participants who suffered an adverse event of muscle cramp before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.55, 3.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Total number of participants who suffered an adverse event of nausea before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.22 [2.67, 6.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Total number of participants who suffered an adverse event of rhinitis before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.30 [1.16, 74.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Total number of participants who suffered an adverse event of vomiting before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.40 [2.10, 5.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Total number of participants who suffered an adverse event of cold syndrome before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.49, 2.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Total number of participants who suffered an adverse event of accidental fall before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.29, 2.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Total number of participants who suffered an adverse event of respiratory tract infection before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.29, 2.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Total number of participants who suffered an adverse event of constipation before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.20, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Total number of participants who suffered an adverse event of fever before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [0.42, 7.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Total number of participants who suffered an adverse event of loss of appetite before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.22, 3.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Total number of participants who suffered an adverse event of bruising before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.14, 2.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Total number of participants who suffered an adverse event of restlessness before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.07, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Donepezil (10 mg/day) versus donepezil (5 mg/day)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001190-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 MMSE (change from baseline) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 donepezil (10 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.56, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 SIB (change from baseline) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 donepezil (5 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.7 [3.66, 9.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 donepezil (10 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.92 [4.53, 7.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 CIBIC‐Plus or CGIC (numbers improved) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.83, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.31, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 ADCS‐ADL‐severe (change from baseline) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 donepezil (5 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐0.54, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 donepezil (10 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.21, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 BEHAVE‐AD (change from baseline) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 donepezil (5 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐1.67, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 donepezil (10 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.4 [‐1.28, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Behavioural disturbance (total NPI ) (change from baseline) ITT‐LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 donepezil (10 mg/d) at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.18 [‐4.11, ‐0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Time (mins/day) spent by carer assisting in IADL and PSMS (change from baseline) LOCF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐52.4 [‐118.78, 13.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Total number of withdrawals before end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 donepezil ( 5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.32, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.02, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Total number of participants who withdrew due to an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 donepezil ( 5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.29, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [1.23, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Total number of participants who suffered from at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.69, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.23, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Total number of participants who suffered from abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.36, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Total number of participants who suffered from accidental fall <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.40, 3.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.58, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Total number of participants who suffered from accidental injury <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.46, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Total number of participants who suffered from anorexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.05, 5.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [1.20, 4.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Total number of participants who suffered from anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.28, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Total number of participants who suffered from arthralgia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.06 [1.28, 12.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Total number of participants who suffered from asthenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.59, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Total number of participants who suffered from back pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.63, 4.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Total number of participants who suffered from cold syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.55, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.54, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Total number of participants who suffered from confusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.43, 3.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Total number of participants who suffered from constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [0.66, 6.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.41, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Total number of participants who suffered from contusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.41, 7.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.22, 5.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Total number of participants who suffered from cystitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.50, 4.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Total number of participants who suffered from depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.54, 4.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Total number of participants who suffered from diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 donepezil ( 5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.45, 5.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [1.65, 4.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Total number of participants who suffered from dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.69, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Total number of participants who suffered from fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [0.40, 20.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.32 [0.85, 21.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Total number of participants who suffered from fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.49, 5.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Total number of participants who suffered from gastroenteritis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.24, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Total number of participants who suffered from hallucinations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.68 [1.24, 17.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Total number of participants who suffered from pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.65, 4.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Total number of participants who suffered from hostility <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.58, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Total number of participants who suffered from insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [0.99, 7.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Total number of participants who suffered from loss of appetite <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.51, 14.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [0.40, 12.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Total number of participants who suffered from nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [1.16, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Total number of participants who suffered from restlessness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.54 [1.01, 20.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [0.22, 20.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Total number of participants who suffered from headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [1.22, 6.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Total number of participants who suffered from respiratory tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.29, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.50, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 Total number of participants who suffered from vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.35, 3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [1.37, 4.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 Total number of participants who suffered from urinary incontinence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.31 [0.79, 6.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 Total number of participants who suffered from urinary tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.55, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 Total number of participants who suffered from weight loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.69, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 Total number of deaths before end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1 donepezil ( 5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.21, 19.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.41, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 Total number of participants who suffered from at least one serious adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.1 donepezil (5 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.36, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.2 donepezil (10 mg/d) vs placebo at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.59, 1.08]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Donepezil (5 mg/day or 10 mg/day) versus placebo for people with severe dementia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001190.pub3/references#CD001190-tbl-0015">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001190.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001190-note-0018">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001190-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001190-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001190-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD001190-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD001190-note-0007">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD001190-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD001190-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001190-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001190\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001190\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001190\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001190\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001190\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001190\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001190\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001190\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001190.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001190.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001190.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001190.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001190.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714478468"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001190.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714478472"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001190.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6fa74ea99377',t:'MTc0MDcxNDQ3OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 